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 i 
ABSTRACT 
 
The peptide hormone, ghrelin, exerts its physiological effects through a G-protein-coupled 
receptor called the ghrelin-R. The ghrelin-R displays a high degree of constitutive activity, 
signalling through the inositol phosphate pathway in the absence of bound agonist.  
 
TMs III and VI have been reported to be central to the activation of Family A GPCRs, with 
interactions between the two helices stabilising the ground state. During activation 
conformational rearrangements result in these interactions being broken, with new contacts 
forming and stabilising the active state. Investigation of the ghrelin-R constitutive activity 
gives an insight into the mechanisms involved in receptor activation. In this study the role of 
specific individual residues in the ghrelin-R has been investigated and the effect of disrupting 
or introducing intramolecular interactions was addressed. Site-directed mutagenesis and 
functional assays revealed that ghrelin-R constitutive activity can be increased and decreased 
with mutation of residues within the TM domains, specifically TMs III, VI and VII.  
 
The extracellular loops have been found to be involved in ligand binding and activation in a 
number of Family A GPCRs. The residues within ECL2 of the ghrelin-R were systematically 
mutated to alanine to determine their role. In particular, one residue, Asn196, was identified 
as being critical in ghrelin-R function and may be forming stabilising interactions which 
maintain ghrelin-R constitutive activity.   
 
The data presented in this thesis provide an insight into the structure and function of the 
ghrelin-R and the underlying molecular mechanisms of ghrelin-R constitutive activity. 
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 iii 
ABBREVIATIONS 
 
Throughout this thesis, abbreviations are used as recommended by the Journal of Biological 
Chemistry. In addition, the following abbreviations have been used: 
 
5-HT  5-hydroxytryptamine  
7TM  seven transmembrane  
A2AR  A2A adenosine receptor 
AC  adenylyl cyclase 
ACTH  adrenocorticotrophin hormone 
AgRP  Agouti-related peptide 
ARC  arcuate nucleus 
AT1aR Angiotensin II type 1a receptor 
AVP  [arginine
8
]vasopressin 
BRET bioluminescence resonance energy transfer 
bRho  bovine rhodopsin 
BSA  bovine serum albumin 
C5aR  C5a anaphylatoxin chemotactic receptor 
CAM  constitutively active mutation 
cAMP cyclic 3‟, 5‟-adenosine monophosphate 
CART cocaine and amphetamine-regulated transcript 
CB1 receptor cannabinoid receptor 1 
CB2 receptor cannabinoid receptor 2 
CRE  cAMP responsive element 
CREB  cAMP responsive element binding protein 
D1R dopamine receptor 1 
D2R dopamine receptor 2 
D4R dopamine receptor 4 
DAG  1,2-diacylglycerol 
DMEM Dulbecco‟s modified Eagle‟s medium 
ECL   extracellular loop 
ELISA enzyme-linked immunosorbent assay 
ERK1/2 extracellular regulated protein kinase 1/2 
FBS  foetal bovine serum 
FFAR  free fatty acid receptor 
FRET fluorescence resonance energy transfer 
FSHR follicle-stimulating hormone receptor 
GABA  γ-aminobutyric acid 
GABAbR GABAb receptor 
GAP  GTPase activating protein 
GED GTPase effector domain 
GEF guanine nucleotide exchange factor 
GFP  green-fluorescent protein 
GH  growth hormone 
ghrelin-R ghrelin receptor 
GHRH-R  growth hormone-releasing hormone receptor 
GHS  growth hormone secretagogue 
GHS-R1a growth hormone secretagogue receptor 1a (ghrelin-R) 
GHS-R1b growth hormone secretagogue receptor 1b 
 iv 
GnRHR gonadotropin-releasing hormone receptor 
GOAT ghrelin O-acyltransferase 
GPCR  G-protein-coupled receptor 
G-protein guanine nucleotide binding protein 
GRK G-protein-coupled receptor kinase 
GαCT C-terminal synthetic peptide of transducin 
Gαt transducin 
H1R histamine receptor 1 
H2R histamine receptor 2 
H4R histamine receptor 4 
HA Haemagglutinin 
HEK human embryonic kidney 
HRP horse radish peroxidase 
ICL  Intracellular loop 
InsP  inositol phosphate 
InsP2  inositol diphosphate 
InsP3 inositol 1,4,5-trisphosphate 
LB  luria broth 
LHR  luteinising hormone receptor 
mAChR muscarinic acetylcholine receptor 
MAP  mitogen activated protein 
MC4R  melanocortin 4 receptor 
MSH  melanocyte-stimulating hormone 
NPY   neuropeptide Y 
NT-R  neurotensin receptor 
OPD O-phenlyenediamine dihydrochloride 
OR opioid receptor 
P2Y1 purinoceptor P2Y1 
P2Y6 purinoceptor P2Y6 
PAF platelet activating factor  
PAGE polyacrylimide-gel-electrophoresis 
PBS  phosphate-buffered saline 
PCR   polymerase chain reaction 
PDL  poly-D-lysine 
PEI  polyethylenimine 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PKA  protein kinase A 
PKC  protein kinase C 
PLC  phospholipase C 
POMC  proopiomelanocortin 
PTHR parathyroid hormone receptor 
PWS Prader-Willi syndrome 
RAMP receptor activity-modifying protein 
RGS regulators of G-protein specificity 
rho rho small GTPase 
Rho rhodopsin 
RTK receptor tyrosine kinase  
SDS  sodium dodecyl-sulphate 
SP-analogue [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P 
SST somatostatin 
T4L T4 lysozyme 
TBE  tris-borate-EDTA buffer 
 v 
TBS  tris-buffered saline 
TM  transmembrane 
TRHR  thyrotropin releasing hormone receptor 
TSHR  thyroid-stimulating hormone receptor 
UBD  ubiquitin binding domain 
V1aR  vasopressin 1a receptor 
V2R  vasopressin 2 receptor 
VPAC vasoactive intestinal polypeptide/pituitary adenylate cyclase activating peptide 
WT wild-type 
α1aAR  α1a adrenoceptor 
α1bAR  α1b adrenoceptor 
α2AR  α2 adrenergic receptor  
β1AR  β1 adrenergic receptor 
β2AR  β2 adrenergic receptor 
 
 vi 
TABLE OF CONTENTS 
 
Chapter 1. Introduction ...................................................................................... 1 
1.1 G-Protein-Coupled Receptors .......................................................................................... 1 
1.1.1 GPCR Structure and Classification ........................................................................... 1 
1.2 G-proteins ......................................................................................................................... 6 
1.3 GPCR activation and intracellular signalling ................................................................... 7 
1.3.1 Key residues and motifs in Family A GPCRs ........................................................... 9 
1.3.2 Models of receptor activation .................................................................................. 10 
1.3.3 Classical signalling pathways .................................................................................. 14 
1.3.4 Non-classical/G-protein-independent signalling pathways ..................................... 14 
1.4 Constitutive GPCR activity ............................................................................................ 16 
1.5 Ligand classes and binding ............................................................................................. 18 
1.5.1 Agonists ................................................................................................................... 20 
1.5.2 Antagonists .............................................................................................................. 20 
1.5.3 Inverse agonists ....................................................................................................... 21 
1.6 Allosteric modulation ..................................................................................................... 22 
1.7 GPCR oligomerisation .................................................................................................... 23 
1.8 Post-translational modifications ..................................................................................... 26 
1.8.1 Phosphorylation ....................................................................................................... 26 
1.8.2 Glycosylation ........................................................................................................... 26 
1.8.3 Palmitoylation .......................................................................................................... 27 
1.8.4 Ubiquitination .......................................................................................................... 27 
1.9 GPCR regulation ............................................................................................................ 28 
1.10 Ghrelin: an acylated peptide hormone .......................................................................... 30 
1.10.1 The discovery of ghrelin ........................................................................................ 31 
1.10.2 Ghrelin processing ................................................................................................. 31 
1.10.3 Ghrelin physiology and pathology ........................................................................ 33 
1.11 The ghrelin receptor ..................................................................................................... 36 
1.11.1 The ghrelin-R displays high constitutive activity .................................................. 38 
1.11.2 Alternative receptors for ghrelin ........................................................................... 39 
1.12 Aims of this study ......................................................................................................... 40 
Chapter 2. Materials and Methods .................................................................. 41 
2.1 Materials ......................................................................................................................... 41 
2.1.1 Antibodies ................................................................................................................ 41 
2.1.2 Cell culture reagents ................................................................................................ 41 
2.1.3 Molecular biology reagents ..................................................................................... 41 
2.1.4 Oligonucleotides ...................................................................................................... 41 
2.1.5 Peptide ligands ......................................................................................................... 42 
2.1.6 Plamid expression vectors ....................................................................................... 42 
2.1.7 Radiochemicals ........................................................................................................ 42 
2.1.8 Substrates ................................................................................................................. 42 
2.2 Methods .......................................................................................................................... 42 
2.2.1 Polymerase chain reaction (PCR) ............................................................................ 42 
2.2.2 Site-directed mutagenesis ........................................................................................ 44 
2.2.3 Restriction enzyme digests ...................................................................................... 44 
2.2.4 Agarose gel electrophoresis ..................................................................................... 44 
2.2.5 Agarose gel cDNA purification ............................................................................... 45 
2.2.6 Ligation of cDNA .................................................................................................... 45 
2.2.7 Transformation ........................................................................................................ 45 
2.2.8 Plasmid cDNA preparation ...................................................................................... 45 
 vii 
2.2.9 Automated fluorescent DNA sequencing ................................................................ 46 
2.2.10 Cell culture ............................................................................................................ 46 
2.2.11 PEI transfections .................................................................................................... 46 
2.2.12 Inositol phosphate accumulation assays ................................................................ 46 
2.2.13 Harvesting and preparation of cell membranes ..................................................... 47 
2.2.14 Protein Assays ....................................................................................................... 47 
2.2.15 Radioligand binding assays ................................................................................... 48 
2.2.16 Enzyme-linked immunosorbant assay (ELISA) .................................................... 48 
Chapter 3. The Ghrelin-R: Epitope Tagging, Constitutive Activity and 
Family A Conserved Residues .......................................................................... 49 
3.1 The ghrelin-R haemagglutinin epitope tag ..................................................................... 49 
3.1.1 Introduction ............................................................................................................. 49 
3.1.2 Results ..................................................................................................................... 50 
3.2 The ghrelin-R displays high constitutive activity ........................................................... 61 
3.2.1 Introduction ............................................................................................................. 61 
3.2.2 Results ..................................................................................................................... 61 
3.3 Functional importance of residues conserved in Family A GPCRs ............................... 68 
3.3.1 Introduction ............................................................................................................. 68 
3.3.2 Results ..................................................................................................................... 68 
3.4 Discussion ....................................................................................................................... 76 
3.4.1 The ghrelin-R haemagglutinin epitope tag .............................................................. 76 
3.4.2 The ghrelin-R displays high constitutive activity .................................................... 79 
3.4.3 Functional importance of residues conserved in Family A GPCRs ........................ 80 
Chapter 4. Mechanisms of Ghrelin-R Activation .......................................... 86 
4.1 Introduction .................................................................................................................... 86 
4.2 Results ............................................................................................................................ 87 
4.2.1 The role of the highly conserved ERY motif .......................................................... 91 
4.2.2 Further analysis of the ERY motif ........................................................................... 91 
4.2.3 The role of residue 6.30 in ghrelin-R function ...................................................... 101 
4.2.4 Investigation of further stabilising interactions ..................................................... 109 
4.2.5 The role of residue 5.58
 
in ghrelin-R activity ........................................................ 120 
4.2.6 Investigation of the rotamer toggle switch in the ghrelin-R .................................. 126 
4.2.7 The role of the highly conserved NPxxY motif in ghrelin-R activity ................... 138 
4.3 Discussion ..................................................................................................................... 141 
4.3.1 The role of the ERY motif in ghrelin-R activity ................................................... 142 
4.3.2 Investigation of „ionic lock‟ interactions within the ghrelin-R ............................. 146 
4.3.3 Investigation of further stabilising interactions ..................................................... 151 
4.3.4 The role of residue Tyr
5.58
 in ghrelin-R activity .................................................... 158 
4.3.5 Investigation of the rotamer toggle switch in the ghrelin-R .................................. 160 
4.3.6 The role of the highly conserved NPxxY motif in ghrelin-R function .................. 165 
Chapter 5. Ghrelin Receptor Constitutive Activity: The Role of 
Hydrophobic and Polar Residues Within the Transmembrane Domains  171 
5.1 Introduction .................................................................................................................. 171 
5.2 Results .......................................................................................................................... 172 
5.2.1 The role of the conserved hydrophobic residues
 
in ghrelin-R function................. 172 
5.2.2 Investigation of the conserved hydrophobic residues using an inverse agonist .... 186 
5.2.3 The role of polar residues in TMIII of the ghrelin-R ............................................ 191 
5.2.4 Investigation of polar residues using an inverse agonist ....................................... 197 
5.3 Discussion ..................................................................................................................... 200 
5.3.1 The role of the conserved hydrophobic residues in ghrelin-R function ................ 200 
5.3.2 The role of polar residues in TMIII of the ghrelin-R ............................................ 207 
 viii 
Chapter 6. The Role of ECL2 and Extracellular Residues in Ghrelin-R 
Function ............................................................................................................ 210 
6.1 Introduction .................................................................................................................. 210 
6.2 Results .......................................................................................................................... 212 
6.2.1 ECL2 alanine scanning mutagenesis study ........................................................... 212 
6.2.2 Extended ECL2 mutagenesis study ....................................................................... 221 
6.2.3 Investigation of the role of residues at the extracellular face of TMVI ................ 236 
6.3 Discussion ..................................................................................................................... 247 
6.3.1 Alanine scanning mutagenesis of ECL2 of the ghrelin-R ..................................... 247 
6.3.2 The role of Cys116
(3.25)
 and Cys198
(C)
 .................................................................. 249 
6.3.3 Asn188 and Thr190: A potential glycosylation motif ........................................... 251 
6.3.4 The role of key ECL2 residues in ghrelin-R function ........................................... 253 
6.3.5 The role of Phe203
(C+5)
 and Ala204
(C+6)
 in ghrelin-R function ............................. 257 
6.3.6 Investigation of the role of residues at the extracellular face of TMVI ................ 261 
Chapter 7. Summary, Conclusions and Future Work ................................. 264 
7.1 Summary and Conclusions ........................................................................................... 264 
7.2 Future Work .................................................................................................................. 267 
Chapter 8. References ..................................................................................... 270 
Chapter 9. Appendix ....................................................................................... 295 
 
 
 1 
CHAPTER 1. 
INTRODUCTION 
 
1.1 G-Protein-Coupled Receptors 
G-protein-coupled receptors (GPCRs) are seven transmembrane (TM) helix proteins 
responsible for the majority of signal transduction that occurs across cell membranes. 
Members of the GPCR superfamily are activated by a broad range of ligands from biogenic 
amines, peptides, glycoproteins, lipids, nucleotides and ions to proteases and, in the case of 
the opsins, light (Kolakowski, 1994). With approximately 2 % of genes within the human 
genome encoding GPCRs (more than 800 identified), they comprise the largest family of 
proteins (Fredriksson et al., 2003; Klco et al., 2005; Perez et al., 2005). The diverse role of 
GPCRs in regulating physiological processes makes the receptor superfamily a major 
pharmaceutical target; almost 60 % of approved drugs target GPCRs (Muller, 2000). In 
addition, mutations that occur within the receptors are responsible for many human diseases, 
increasing the importance of GPCR research to the pharmaceutical industry.    
 
1.1.1 GPCR Structure and Classification 
GPCRs have a common molecular architecture, consisting of seven membrane-spanning α-
helices, connected by alternating intracellular loops (ICLs) and extracellular loops (ECLs), 
with an extracellular amino terminus (N-terminus) and an intracellular carboxyl terminus (C-
terminus) (Fig 1.1). Resolved to 2.8 Å, by X-ray crystallography in the year 2000, the crystal 
structure of ground-state, retinal bound, bovine rhodopsin (bRho) advanced understanding of 
the complex structure of GPCRs. The crystal structure confirmed the presence of the 7TM 
domains and identified an intracellular amphipathic eighth helix (HelixVIII), lying almost 
perpendicular to TMVII, and parallel to the plasma membrane. HelixVIII follows the 
conserved NPxxY motif at the C-terminal end of TMVII and ends at palmitoylated double 
cysteine residues, Cys322 and Cys323 (Palczewski et al., 2000) (Fig 1.2). This first crystal 
structure, along with subsequent advances and refinements, identified the helices as being 
irregular, with a number displaying tilts relative to the membrane, kinked architecture, or a 
mixture of α- and 310 helices (Palczewski et al., 2000; Okada et al., 2001a; Riek et al., 2001; 
Teller et al., 2001; Krebs et al., 2003).  
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Figure 1.1 Schematic representation of a typical Family A GPCR: The 7TM helical 
domains of the receptor are connected by alternating intracellular and extracellular loops. 
Glycosylation sites are often found at the N-terminus and within the ECLs. An intramolecular 
disulphide bond is found between TMIII and ECL2. The HelixVIII region is frequently 
palmitoylated at conserved cysteine residues, anchoring the receptor C-terminus to the 
membrane, and essentially creating a fourth intracellular loop. 
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The TM helices are bent or tilted in relation to each other and to the plasma membrane. TMI, 
TMIV, TMVI and TMVII have been shown to be bent due to the presence of α-helix-
disrupting proline residues, with TMVI having a significant “kink” at Pro267(6.50) in Rho, but 
all of the helices having a certain amount of curving (Palczewski et al., 2000; Krebs et al., 
2003). Glycine, serine, threonine and cysteine have also been shown to induce irregularities 
within helices as a result of their hydrogen bonding capabilities (Teller et al., 2001). Each 
helix was determined to be at a different plane within the plasma membrane. TMIV, TMVI 
and TMVII were observed to be almost parallel to the membrane plane, whereas TMs I, II, V 
and particularly III, are tilted in relation to the plasma membrane (Krebs et al., 2003) (Fig 
1.2). 
 
Crystallization of GPCRs has proved difficult due to the flexibility of GPCRs and the 
negative effect that the detergents, used in purification processes, have on receptor stability 
within the membrane. The high availability of bRho, from rod cells, contributed to the 
crystallization of this Family A GPCR (Filipek et al., 2003). Since the crystal structure of 
bRho was determined in the year 2000, a number of Family A GPCR crystal structures have 
been resolved. The structure of the β2 adrenergic receptor (β2AR) (Cherezov et al., 2007; 
Rasmussen et al., 2007), the A2A adenosine receptor (A2AR) (Jaakola et al., 2008), the β1 
adrenergic receptor (β1AR) (Warne et al., 2008), the squid rhodopsin (Murakami et al., 2008), 
and bovine opsin (Park et al., 2008; Scheerer et al., 2008) have all been determined in recent 
years, substantially enhancing knowledge of Family A GPCRs.  
 
The structure of the β2AR was resolved to 3.4/3.7 Ǻ, bound to an inverse agonist, carazolol, 
and in complex with a Fab5 antibody fragment, replacing ICL3 (Rasmussen et al., 2007). In 
the same year, the crystal structure of a β2AR-T4 lysozyme complex, also bound to carazolol, 
was resolved to 2.4 Å (Cherezov et al., 2007). The structures revealed a number of key 
differences to the bRho structure, principally, weaker interactions at the cytoplasmic ends of 
TMIII and TMVI, possibly explaining the constitutive activity of the β2AR and giving more 
detailed insights into the structural basis of ligand-independent activation. Despite being 
bound to an inverse agonist, the cytoplasmic segments of the β2AR have a more open 
arrangement than that seen for Rho. The ionic lock, found between Arg
3.50
 and Glu
6.30
 at the 
cytoplasmic ends of TMs III and VI in Rho (Palczewski et al., 2000), and suggested from 
site-directed mutagenesis studies to occur in a number of Family A GPCRs (Ballesteros et al., 
2001; Greasley et al., 2002; Shapiro et al., 2002; Springael et al., 2007) is not present in the 
β2AR crystal structures (Cherezov et al., 2007; Rasmussen et al., 2007). The β2AR structures 
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Figure 1.2 Crystal structure of bRho resolved to 2.8 Å: The 7TM domains and HelixVIII 
of bRho viewed (a) through the membrane and (b) from the extracellular side. The 
anticlockwise arrangement of the helices can be seen and retinal is represented within the 
binding pocket (white). TMI (light blue), TMII (purple), TMIII (blue), TMIV (pink), TMV 
(turquoise), TMVI (green), TMVII (orange) and HelixVIII (brown) (Palczewski et al., 
2000). 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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more closely resemble that of opsin, in which Arg
3.50
 and Glu
6.30
 form new stabilising 
interactions with TMs V and VI (Park et al., 2008). 
 
Despite a common structural topology, GPCRs within the superfamily share very little overall 
sequence similarity. The TM domains of GPCRs display the greatest sequence homology 
(Kobilka, 2007), whereas both the ICL and ECL regions have low homology, even amongst 
receptors from the same receptor family (Lawson et al., 2004). The N-terminal domains have 
been shown to have the greatest sequence diversity (Kobilka, 2007). Based on receptor 
sequence homology, and the presence of various conserved residues and motifs, GPCRs can 
be divided into three major (Family A, Family B and Family C) and three minor (Families D, 
E and F) subfamilies, which encompass all vertebrate and invertebrate receptors (Kolakowski, 
1994). Human GPCRs can be further subdivided into five classes; rhodopsin-like (class A), 
secretin-like (class B), glutamate (class C), adhesion and frizzled/taste2 (Fredriksson et al., 
2003). 
 
Family A (rhodopsin/β2-adrenergic receptor-like) is the largest GPCR subfamily, representing 
approximately 90 % of all GPCRs. Given the size of the family and the diversity of 
endogenous ligands, it is not surprising that there is low overall sequence homology amongst 
members of Family A. There are however a number of highly conserved residues and motifs 
which provide important structural and functional roles. These include two cysteine residues, 
located at the top of TMIII and within ECL2, that form a stabilising intramolecular disulphide 
bond; the D/ERY motif at the cytoplasmic end of TMIII, that is important for maintaining the 
ground state and for receptor activation and the NPxxY motif in TMVII, which is involved in 
a number of intramolecular interactions, both in the inactive (R) and active (R*) state. A 
residue numbering system was introduced by Ballesteros and Weinstein to enable direct 
comparison between members of Family A. The most conserved residue in each helix was 
assigned the number 50 and each helix numbered 1-7. Amino acids are then numbered 
according to their position within the helix, relative to the most conserved residue. For 
example, the arginine of the D/ERY motif in TMIII is the most conserved residue within this 
helix and is therefore numbered Arg
3.50
. The aspartate/glutamate to the N-terminal side of 
Arg
3.50
 is Asp/Glu
3.49
, and the tyrosine to the C-terminal side is Tyr
3.51
 (Ballesteros et al., 
1992) (conserved residues discussed further in Chapter 3).  
 
Family B receptors are the glucagon-like/secretin-like receptors and are characterised by a 
large N-terminus, compared to Family A GPCRs. The N-termini contain a number of cysteine 
 6 
residues that form intramolecular disulphide bonds and the N-terminus is extensively 
involved in ligand binding in this receptor class. Family C receptors are the metabotropic 
neurotransmitter-related receptors and generally have a larger N-terminus than either the 
Family A or B receptors (~600 amino acids). The large N-terminal domains of Family C 
receptors have been implicated in dimerisation, which is essential for Family C GPCR 
function (section 1.7). There are members of all three families that contain the two highly 
conserved cysteine residues at the top of TMIII and ECL2, that form the disulphide bond, but 
apart from this common feature there are no other conserved residues within all three families 
(Gether, 2000).  
 
The three minor GPCR subfamilies are Family D (Ste2 receptors) and Family E (Ste3 
receptors), which are the yeast pheromone receptors and Family F receptors which are present 
only in the amoeba Dictyostelium discoideum (Gether, 2000).  
 
1.2 G-proteins 
GPCRs signal via membrane-associated, heterotrimeric guanine nucleotide binding proteins 
(G-proteins) which consist of an α-, β- and γ-subunit. G-proteins can be grouped into four 
main subtypes, Gq/11, Gi, Gs and G12/13 depending on the α-subunit present (Wess, 1997). 
There are sixteen α-subunits, five β-subunits and fourteen γ-subunits currently identified 
(Milligan et al., 2006).  
 
All G-proteins are activated by their GPCRs in essentially the same way despite the diversity 
of G-protein subtypes provided by the variety of subunits. After a ligand binds to a GPCR the 
conformational changes that occur within the receptor allow the α-subunit of the G-protein to 
couple to the GPCR. The conformational changes increase the affinity of the receptor for the 
G-protein and the rearrangement of the cytoplasmic ends of TMs III and VI allow the C-
terminal end of the G-protein to couple to the receptor. It is known that the sites of G-protein 
interaction are located within ICL2, ICL3, the C-terminal domain and within a G-protein 
binding pocket located between the TM helices (Hill-Eubanks et al., 1996). Activation of the 
GPCR exposes key residues to the G-protein that are otherwise protected from interaction 
with the G-protein in the inactive receptor state. The crystal structure of opsin in the G-protein 
interacting conformation was resolved using the opsin protein and 11 amino acids that made 
up a synthetic peptide derived from the C-terminus of the Gα subunit of transducin (GαCT). 
The crystal structure shows the interaction between Arg
3.50
 of the D/ERY motif and the tip of 
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GαCT (Scheerer et al., 2008). It has been noted that some GPCRs pre-couple to their target 
G-proteins and therefore do not require the same agonist-induced conformational 
rearrangements suggesting that other mechanisms must be involved (Zezula et al., 2008). 
Despite the common G-protein binding and activation mechanisms, the specific interactions 
vary between receptors and G-protein subtypes, explaining why GPCRs can only activate a 
limited subset of G-proteins, and thus dictates receptor-G-protein specificity (Wess, 1997). 
Residue 5.58 in TMV is one residue that has been found to be involved in the selectivity of 
receptor-G-protein interactions. Located at the cytoplasmic interface of TMV and ICL3, 5.58 
can dictate G-protein subtype interactions depending on the amino acid located at this locus 
(discussed further in Chapter 4) (Biebermann et al., 1998; Erlenbach et al., 1998). 
 
The coupling of a G-protein to its GPCR causes the exchange of GDP, bound to the G-protein 
α-subunit, for GTP, thus activating the G-protein. This, in turn, allows the α-GTP complex to 
dissociate from the GPCR and from the G-protein βγ-subunits. The α-GTP and the βγ-
subunits are then free to interact with their specific target proteins and initiate down-stream 
signalling cascades (Fig 1.3). The intrinsic GTPase activity of the α-subunit leads to 
hydrolysis of the GTP to GDP and allows re-association of the α- and the βγ-subunits at the 
plasma membrane (Rens-Domiano et al., 1995). Although the Gα subunit possesses high 
GTPase activity, a family of GTPase activating proteins (GAPs) called regulators of G-protein 
signalling (RGS) proteins act as regulators of signalling by increasing the GTPase activity of 
the Gα subunit (Ross et al., 2000) (Fig 1.3).  
 
1.3 GPCR activation and intracellular signalling 
Ligand binding to GPCRs results in the activation of the receptor and the initiation of 
subsequent intracellular signalling cascades. GPCR activation involves the disruption of the 
stabilising interactions that maintain the receptor in the R state in the absence of bound 
agonist. Conformational changes occurring within the helical bundle after agonist binding, 
result in the formation of the R* conformation, which is capable of binding G-proteins. A 
common mechanism is believed to occur in all GPCRs, despite profound differences in 
agonists and in the G-proteins that are targeted. It is now accepted that activation of Family A 
GPCRs requires the inward movement of the extracellular end of TMVI, towards TMIII, 
resulting in the movement of the cytoplasmic end of TMVI away from TMIII, and thus 
revealing a G-protein binding cavity. This movement has been demonstrated using spin
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Figure 1.3 The G-protein cycle: Activation of a GPCR (R) by agonist (A) leads to 
association of a heterotrimeric G-protein. GDP is exchanged for GTP at the α-subunit to 
produce an active G-protein. The βγ-subunits dissociate from the α-subunit and all dissociate 
from the receptor. The α-GTP and βγ-subunits are then able to activate or inhibit target 
effector molecules leading to signal transduction via second messengers within the cell. The 
intrinsic GTPase activity of the α-subunit, accelerated by a GAP such as an RGS protein, 
hydrolyses GTP to GDP with the release of inorganic phosphate. The α- and βγ-subunits are 
then able to re-associate (Image adapted from Rens-Domiano et al., 1995; Milligan et al., 
2006). 
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labelling (Farrens et al., 1996; Hubbell et al., 2003), fluorescent probes  (Gether et al., 1997; 
Jensen et al., 2000), cysteine cross-linking (Ward et al., 2003; Han et al., 2005) and metal-ion 
site engineering (Elling et al., 1997; Elling et al., 2006) and is termed the „global toggle 
switch‟ (Elling et al., 2006; Schwartz et al., 2006).  
 
1.3.1 Key residues and motifs in Family A GPCRs 
Key activation motifs and residues are highly conserved throughout Family A GPCRs. The 
„global toggle switch‟ supports the movement of TMVI in a “see-saw-like” manner around a 
conserved TM proline (Pro
6.50
) allowing the association of G-proteins and other signalling 
molecules (Elling et al., 2006). Trp
6.48 
of the CWxP motif found in TMVI is highly conserved 
(71 %) in Family A GPCRs (Mirzadegan et al., 2003). Trp
6.48
 is thought to act as a rotamer 
toggle switch, modulating the proline-induced kink within TMVI. Upon receptor activation 
Trp
6.48 
undergoes a conformational rearrangement, releasing interactions with TMVII and 
forming new interactions with TMs III and V. The altered conformation of Trp
6.48 
and the 
neighbouring Cys
6.47 
allows for a decrease in the bend-angle of the proline-induced kink, 
straightening TMVI and moving the cytoplasmic end of TMVI away from TMIII (Shi et al., 
2002b; Ruprecht et al., 2004; Schwartz et al., 2006)  
 
The highly conserved D/ERY motif at the bottom of TMIII has been shown to play a 
significant role in maintaining the ground state of GPCRs (Sheikh et al., 1996). The arginine 
(Arg
3.50
) residue of the D/ERY motif is highly conserved (96 %) in Family A GPCRs 
(Mirzadegan et al., 2003). Arg
3.50 
forms a salt bridge interaction with the neighbouring 
aspartate/glutamate (Asp/Glu
3.49
) residue. Protonation of the aspartate/glutamate residue 
found at position 3.49 results in a disruption of the ionic interaction with Arg
3.50
 (Arnis et al., 
1994: Scheer et al., 1996). The interaction is broken upon receptor activation, with both 
Glu
3.49 
and Arg
3.50 
forming new contacts (Park et al., 2008). A network of hydrogen bonds 
known as the “ionic lock” has been proposed to form between the D/ERY motif in TMIII and 
residues within TMVI in certain members of the GPCR superfamily. This ionic interaction 
acts to constrain TMIII and TMVI at their cytoplasmic ends, maintaining the inactive state of 
the receptor in the absence of an agonist. Mutagenesis studies carried out on the β2AR 
demonstrated that Arg
3.50 
not only interacts with Asp
3.49
, but also with a residue at the 
intracellular face of TMVI, Glu
6.30
, via an interhelical ionic bond (Ballesteros et al., 2001). It 
has been predicted, for some GPCRs, that the inactive receptor is constrained by interactions 
between the Asp/Glu
3.49
, Arg
3.50 
and Glu
6.30
 along with other TMVI residues, and that 
activation involves the breaking of these interactions. Mutation of these critical residues can 
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lead to conformational changes that allow the active receptor conformation to be adopted in 
the absence of agonist, thus inducing constitutive activity (Alewijnse et al., 2000; Ballesteros 
et al., 2001). The identification of constitutively active mutations (CAMs) and mutations that 
decrease constitutive activity has aided investigation of the intramolecular interactions 
involved in activation of GPCRs. The crystal structure of bRho demonstrates the presence of 
the ionic lock interaction between TMs III and VI (Palczewski et al., 2000) however, in all of 
the other Family A GPCR crystal structures resolved to date, the Arg
3.50
 and Glu
6.30
 side 
chains are too far apart for the interaction to occur (Cherezov et al., 2007; Rasmussen et al., 
2007; Jaakola et al., 2008; Warne et al., 2008) (Fig 1.4). However all of these structures were 
obtained from GPCRs occupied by inverse agonists, which might affect an „ionic lock-like‟ 
interaction. There is the additional complication of the T4L and Fab fragment in the β2AR 
crystal structures, which may have affected interactions at the cytoplasmic ends of the TM 
helices allowing residual constitutive activity in the presence of the inverse agonist, carazolol 
(Cherezov et al., 2007; Rasmussen et al., 2007; Audet et al., 2008) or may disrupt 
intramolecular interactions by themselves interacting with TM residues (Rosenbaum et al., 
2007). In the β2AR (Cherezov et al., 2007; Rasmussen et al., 2007), the A2AR (Jaakola et al., 
2008) and the β1AR (Warne et al., 2008), other interactions have been found to occur which 
stabilise the inactive receptor conformation. These interactions are discussed further in 
Chapter 4.    
 
Other interactions are known to stabilise the R* state of Family A GPCRs. An interaction 
occurs between Asn
7.49
 of the NPxxY motif and Asp
2.50
 in TMII, upon receptor activation. 
Asn
1.50
, Asp
2.50
 and Asn
7.49
 have been shown to participate in a network of hydrogen bonds 
with water molecules in Family A GPCRs. In the 5 hydroxytryptamine receptor 2A 
(5HT2AR), as well as other Family A receptors, a hydrogen bond network between Tyr
7.53
,  
Asn
1.50
 , Asp
2.50
 and Asn
7.49
 acts to stabilise the TMVII orientation (Konvicka et al., 1998). 
Asn
7.49
 appears to act as an on/off switch, changing conformation after agonist binding, 
stabilising the R* state (Govaerts et al., 2001; Urizar et al., 2005) (Chapter 4).  
 
1.3.2 Models of receptor activation 
Pharmacological models have been proposed to explain the signalling of GPCRs after ligand 
binding. Based on the laws of mass action a number of models have been described. Initially, 
the two-state model was proposed for receptor activation, whereby receptors exist in dynamic 
equilibrium between the R and R* states (Clark, 1937). 
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Figure 1.4 Crystal structure of Rho, the β2AR-T4L and β2AR-Fab, the β1AR and the 
A2AR: In the Rho crystal structure Arg
3.50
 and Glu
6.30 
are close enough to interact, producing 
the ionic lock and stabilising the inactive receptor conformation by maintaining the 
cytoplasmic ends of TMs III and VI in close proximity, preventing G-protein coupling. In the 
other crystal structures, Arg
3.50
 and Glu
6.30
 are too far apart for an ionic interaction to occur. 
Green is the A2AR, pink is Rho, blue is the β2AR and orange is the β1AR. (Image taken from 
Rosenbaum et al., 2009) 
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The actions of agonists and inverse agonists stabilise the R* and R receptor conformations, 
respectively. The ternary complex model is an extension of the two-state model and proposes 
equilibrium between R and inactive agonist-bound receptor (AR), agonist-bound receptor 
coupled to G-protein (ARG) and the receptor coupled to G-protein (RG) (De Lean et al., 
1980). With the discovery of naturally constitutively active receptors and CAMs, this model 
had to be adapted, producing the extended ternary complex (ETC) model (Samama et al., 
1993) and the cubic ternary complex (CTC) model (Weiss et al., 1996) both of which take 
into account the ligand-independent activation of receptors and subsequent activation of 
associated G-proteins (Fig 1.5). 
 
The ETC model describes the action of agonists, antagonists and inverse agonists on receptor 
activation, and takes into account the constitutive activity observed for a number of GPCRs 
(Fig 1.5 (a)). Six receptor species are proposed to exist at equilibrium; R, R*, R*G, AR, AR* 
and AR*G. The equilibrium constant, J, determines the equilibrium between R and R*. βJ 
defines the allosteric effect of the ligand (A) on J and the ability of A to activate the receptor. 
The constant, M, defines the affinity of R* for the G-protein (G), and αM the affinity of the 
activated ligand-bound (AR*) receptor for G. The equilibrium constant K is the affinity of the 
ligand for the receptor, in the active state (βK) and the active G-protein-bound state (αβK). 
Agonists have a high affinity for R* and therefore exhibit positive efficacy and increase both 
α and β, increasing the population of R* due to a shift in equilibrium. Classical antagonists do 
not alter the equilibrium, being neutral, and therefore do not influence the populations of R or 
R*. Inverse agonists, presenting negative efficacy, have a higher affinity for R and decrease α 
and β, favouring the inactive conformations. The ETC does not however take into account the 
coupling of G-proteins to inactive receptors. The CTC model was proposed to include 
inactive GPCRs coupling to G-proteins, which has since been proven experimentally 
(Monczor et al., 2003) (Fig 1.5 (b)). 
 
A limitation of the CTC model is that it assumes that a receptor can exist in two states with 
respect to the activation of G-proteins; active or inactive. In fact, GPCRs appear to 
demonstrate much more complex behaviour, existing in a possibly limitless number of 
conformations. These theories lead to the proposal of the probabilistic model, whereby 
receptor conformations are influenced, not only by the type of ligand, but by the efficacy of 
the ligands. Therefore, different receptor conformations are more or less likely to be adopted, 
depending on the binding of ligands, the ligand efficacy and the binding of G-proteins, as well 
as other influencing factors such as accessory proteins and GPCR oligomers (Kenakin, 1995).      
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Figure 1.5 Extended ternary complex model and cubic ternary complex model of 
receptor activation: (a) The ETC model shows the equilibrium between six receptor species, 
R, R*, AR*, AR, R*G and AR*G. K represents the association constant of the receptor and 
ligand, J represents the equilibrium constant between the active and inactive receptor states 
and M represents the constant between the active states and G-protein-coupled states. (b) The 
CTC model builds on the ETC model to incorporate the ability of an inactive receptor to 
couple to a G-protein (Images adapted from Weiss et al., 1996). 
(a) 
 
 
 
 
 
 
 
 
(b) 
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1.3.3 Classical signalling pathways 
Activation of G-proteins results in the initiation of intracellular signalling cascades. Three 
classical signalling cascades have been identified for members of the GPCR superfamily. 
These involve the activation or inhibition of adenylyl cyclase (AC) and the activation of 
phospholipase C (PLC) (Fig 1.6).  
 
1.3.3.1 The adenylyl cyclase signalling pathway 
The Gαs and Gαi G-proteins couple to AC and act to stimulate or inhibit AC respectively. AC 
regulates the intracellular concentrations of cyclic 3‟, 5‟-adenosine monophosphate (cAMP) 
as the activation of AC induces the synthesis of cAMP from ATP within the cell. cAMP, the 
second messenger, then activates cAMP-dependent protein kinases, specifically protein kinase 
A (PKA). The protein kinases catalyse the phosphorylation of serine or threonine residues on 
other target proteins to activate or inhibit enzymes, transcription factors or ion channels and 
thus initiate a response within the cell (Rang, 2003). Gαi activation results in inhibition of AC 
and a subsequent reduction in PKA activity.     
 
1.3.3.2 The phospholipase C signalling pathway 
The Gαq and Gα11 G-proteins activate PLCβ which hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) to the second messengers inositol 1,4,5-trisphosphate (InsP3) and 1,2-
diacylglycerol (DAG). InsP3 acts to modulate intracellular calcium concentrations, primarily 
by its effect on the InsP3 receptor, but also on plasma membrane and endoplasmic reticulum 
calcium channels. Ca
2+
 binds to the intracellular calcium receptor, calmodulin, producing a 
complex that is then able to activate the calmodulin pathway, bringing about cellular 
responses (Means et al., 1980). Increased intracellular calcium causes protein kinase C (PKC) 
to accumulate at the plasma membrane. DAG then activates PKC, which results in the 
initiation of further signalling cascades by its effect on target proteins, enzymes and 
transcription factors. 
 
1.3.4 Non-classical/G-protein-independent signalling pathways 
As well as the G-protein-dependent pathways, GPCRs can activate G-protein-independent 
pathways such as the mitogen activated protein (MAP) kinase pathway and the small 
GTPases. The activation of alternative signalling cascades raises the question of the name 
„GPCR‟ and has prompted the use of the term 7TM receptor in a number of instances to 
incorporate G-protein-independent signalling. 
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Figure 1.6 Intracellular signalling through GPCRs: G-proteins are activated by GPCRs after ligand binding resulting in the initiation of 
intracellular signalling cascades. The Gα subunit of the G-protein dictates the signalling pathway. Gαs and Gαi activate or inhibit AC 
respectively, leading to increases/decreases in the cAMP concentration within the cell. Gαq/11 G-proteins activate PLCβ which in turn promotes 
the hydrolysis of PIP2 to DAG and InsP3. InsP3 causes a release of Ca
2+
 from intracellular stores and DAG activates PKC. The second messenger 
signalling cascades result in activation or inhibition of enzymes and transcription factors which regulate gene transcription and result in various 
biological responses (Image adapted from Marinissen et al., 2001). 
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1.3.4.1 Activation of MAP kinase pathways 
Many GPCRs have been shown to interact with and activate members of the MAP kinase 
family. The three major pathways involve extracellular signal-related kinase 1/2 (ERK1/2), 
Jun-kinase and p38 (Luttrell et al., 1999). The interactions can involve typical G-protein 
second messenger production pathways, transactivation of receptor tyrosine kinases (RTKs) 
or an interaction of the receptor with other proteins, such as β-arrestin (Gurevich et al., 2006; 
Charest et al., 2007). It has been found that RTKs can be „transactivated‟ by GPCRs, where 
activation of the GPCR initiates tyrosine phosphorylation of RTKs and results in activation of 
ERK1/2 (Daub et al., 1997). β-arrestin was shown to be important in G-protein-independent 
angiotensin II-stimulated ERK1/2 activation, through the angiotensin II type 1 receptor 
(AT1R) (Seta et al., 2002). β-arrestin may act by initiating the assembly of the proteins 
involved in the MAP kinase signalling cascade into intracellular compartments, therefore 
directing the GPCR signalling pathways away from the G-protein-mediated production of 
second messengers and enhancing the efficiency of signalling to other pathways (Pierce et al., 
2001).  
 
1.3.4.2 Activation of small G-proteins  
GPCRs are also known to activate rho family GTPases which are small, monomeric G-
proteins (Bhattacharya et al., 2004). The rho family are regulators of a number of important 
processes that occur in all eukaryotic cells. The rho G-proteins are themselves regulated by 
signals that originate from many classes of receptors present at the cell surface and by other 
regulatory proteins (Kjoller et al., 1999). Many of the GPCRs that can activate rho-dependant 
pathways are coupled to Gαq (Sah et al., 2000).  However Gαq does not interact with rho or 
the rho guanine nucleotide-exchange factors (GEFs) directly (Kjoller et al., 1999; Sah et al., 
2000). Gα12/13 G-proteins interact with rhoA directly, and many GPCRs that can couple to 
Gα12/13 also couple to Gαq suggesting a mechanism by which Gαq-coupled receptors can 
activate rhoA (Meyer et al., 1999). Roles for rho, related to GPCRs, include inhibition of 
internalisation of the m1 muscarinic acetylcholine receptor (mAChR), and the m2 mAChR 
(Sah et al., 2000). 
 
1.4 Constitutive GPCR activity 
Receptors exist in a dynamic equilibrium between the R and the R* states in the absence of 
ligands. This is known as the two-state activation model (De Lean et al., 1980; Leff, 1995) 
(section 1.3.2). In receptors that display a high degree of constitutive activity, the bias is 
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toward the R* state resulting in receptor activation in the absence of bound agonist. 
Consequently, constitutively active receptors are able to adopt a structure that can activate G-
proteins spontaneously (Parnot et al., 2002). 
 
Following the cloning of GPCRs, it was observed that recombinant expression in cultured 
cells at high levels could result in increased basal signalling. Following this, constitutively 
active receptors were identified after the observations that CAMs of GPCRs resulted in 
agonist-independent activation. By introducing CAMs into GPCRs, the interactions that 
constrain the inactive receptor can be abolished. CAMs can therefore be used to investigate 
the intramolecular interactions that dictate the active or inactive state of the receptor (Parnot 
et al., 2002). After the evidence from CAMs and the development of more sensitive assays, 
able to detect agonist-independent activity even when at low levels, it became apparent that a 
number of wild-type (WT) GPCRs from Families A, B and C, display significant levels of 
constitutive activity (Seifert et al., 2002; Smit et al., 2007).  
 
The β2AR has been extensively studied and found to demonstrate a significant level of 
constitutive activity (Gotze et al., 1994) which has been determined to be of importance to the 
physiological functioning of the receptor (Seifert et al., 2002). WT constitutively active 
receptors have a broad number of physiological roles and could potentially act as “signalling 
set points” to counteract inhibitory mechanisms (Holst et al., 2004b). It is however often 
difficult to determine and accurately assess constitutive activity in vitro as over-expression of 
receptors often results in a detectable increase in basal signalling that is not measurable in 
native systems (Holst et al., 2004b). In contrast however, it is difficult to ensure total absence 
of endogenous agonists in native systems, and therefore, these systems do not necessarily 
make measuring GPCR constitutive activity easier than recombinant systems. Constitutive 
activity can also be particularly hard to detect and measure in certain cellular systems due to 
the inverse agonistic allosteric effects of sodium ions on receptor function (Milligan, 2003). 
 
Many disease states are caused by naturally occurring CAMs within GPCRs. These may 
either be gain-of-function mutations or deleterious mutations, resulting in inhibition of 
cellular processes (Parnot et al., 2002). In the thyroid-stimulating hormone receptor (TSHR), 
CAMs (D619G and A623I) were identified as being responsible for hyperthyroidism (Parma 
et al., 1993), and a CAM in Rho (G90D) was found in people suffering from congenital night 
blindness (Rao et al., 1994). In WT constitutively active receptors, mutations can result in a 
loss of basal signalling. A naturally occurring alanine to glutamate (A204E) mutation in the 
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ghrelin receptor (ghrelin-R) produces a functional receptor able to bind ghrelin and signal, but 
which lacks any constitutive activity resulting in short stature (Pantel et al., 2006) or obesity 
(Wang et al., 2004), again illustrating the physiological importance of the ligand-independent 
signalling.   
 
1.5 Ligand classes and binding 
The diversity of GPCRs is dictated by the wide range of endogenous ligands that are able to 
activate members of this receptor superfamily and require GPCRs to mediate physiological 
processes. GPCR ligands can be divided into five basic subtypes and each of these ligand 
classes bind to their receptors in a different manner (Fig 1.7); (i) Small biogenic amines (such 
as acetylcholine) and nucleotides bind to sites located deep within the TM helical bundle; (ii) 
peptide ligands bind to both the hydrophobic core created by the TM helices and to the 
extracellular domains; (iii) the small ligands Ca
2+, glutamate and neurotransmitters such as γ-
aminobutyric acid (GABA) bind to the N-terminus and cause conformational rearrangements 
which allow the N-terminal domain to interact with the TM domains and ECLs, resulting in 
receptor activation; (iv) large ligands such as the glycoprotein hormones are known to bind to 
the extracellular regions, specifically the N-terminus; (v) protease ligands, such as thrombin, 
bind to the N-terminal domain and cleave it, allowing the truncated N-terminus to interact 
with the TM domains and with the ECLs. In this manner, the N-terminus functions as a 
„tethered ligand‟.  
 
The binding sites of Family A GPCRs vary considerably with the type of ligand that activates 
the receptor, although the ECLs, N-terminus and the extracellular ends of the TM helices can 
all participate in formation of the binding cavity. Since the βAR (which bind diffusible 
ligands) crystal structures were resolved, various comparisons have been made between these 
and the binding site of Rho, which forms a covalent bond with 11-cis retinal within the 
binding pocket. In Rho (and opsin) a β-hairpin is formed by ECL2 which projects into the 
ligand binding crevice and forms a closed „cap-like‟ structure, along with the N-terminus, 
protecting retinal from the extracellular environment (Palczewski et al., 2000). In contrast, 
ECL2 of the β1AR and β2AR contains a short α-helical section stabilised by a second 
disulphide bond, and the loop adopts a more exposed conformation, allowing the diffusion of 
ligands into, and out of, the binding pocket (Cherezov et al., 2007). 
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Figure 1.7 Representation of ligand binding to GPCRs: (i) Binding of amine ligands 
within the TM helices, (ii) peptide binding sites are found both within the TM helices, and 
within the extracellular regions, (iii) small neurotransmitters and ions bind to the N-terminus, 
(iv) glycoproteins bind to the characteristically large N-terminal domain and (v) the action of 
the protease on the thrombin receptor, where the N-terminal domain is cleaved and 
subsequently acts as a ligand for the receptor (Image adapted from Gether, 2000). 
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Both TM residues and residues within ECL2 make contacts with the ligands in the crystal 
structures (Palczewski et al., 2000; Okada et al., 2004; Cherezov et al., 2007; Rasmussen et 
al., 2007; Warne et al., 2008) although retinal binds deeper than the other ligands within the 
TM domains (Rosenbaum et al., 2009). Retinal is covalently linked to Lys
7.43
 via a protonated 
Schiff base (Kuhne, 1977; Palczewski et al., 2000) with the carboxyl group of Glu
3.28
, located 
at the extracellular interface of TMIII, being the counterion for this interaction (Sakmar et al., 
1989; Cohen et al., 1992). Retinal is unique amongst GPCR ligands in that it acts as an 
endogenous inverse agonist when in the 11-cis conformation. Absorption of a photon results 
in isomerisation of 11-cis retinal to all-trans retinal. This allows for structural rearrangements 
of the TM helices of Rho and therefore receptor activation (Wald, 1968; Okada et al., 2004). 
In the biogenic amine receptors a conserved aspartate at position 3.32 is required for agonist 
binding (Strader et al., 1988; Porter et al., 1996; Kristiansen et al., 2000). The carboxyl group 
of Asp
3.32
 participates in ionic bonding with the positive ion of the amino group of the 
agonists (Nagatomo et al., 2000). In peptide GPCRs, interactions with ligands vary depending 
on the ligand in question as there is great variation in peptide size. Studies have implicated the 
ECLs and TM domains in binding and it is proposed that similar interactions occur in the 
peptide receptors as in the biogenic amine GPCRs (Fong et al., 1995; Perlman et al., 1997a; 
Hawtin et al., 2006). 
 
1.5.1 Agonists 
Classical agonists are ligands which activate GPCRs and result in the activation of G-proteins 
and subsequent intracellular signalling cascades. Agonists act by altering the R↔R* 
equilibrium, due to their higher affinity for R*, and thus stabilise the R* state (Milligan et al., 
1995). Agonists can be classed as either full or partial agonists, depending on their intrinsic 
efficacy. Agonists may differ in their ability to stabilise different active conformations of 
GPCR, and each conformation may have varying abilities to activate, or different affinities 
for, G-proteins (Archer-Lahlou et al., 2005). The vast majority of endogenous GPCR ligands 
display agonistic properties, resulting in activation of the target receptor and of downstream 
signalling cascades, inducing a physiological response.  
 
1.5.2 Antagonists 
Antagonists do not stabilize either the R or the R* state, but instead block the activity of either 
agonists or inverse agonists at GPCRs. Consequently, antagonist binding to constitutively 
active members of the GPCR superfamily does not result in a reduction in basal signalling, 
but instead prevents the action of agonists, thus inhibiting further activation. GPCR 
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antagonists (and inverse agonists, see section 1.5.3) are one of the largest classes of 
pharmaceutical drugs currently in use, and present a broad spectrum of therapeutic uses 
(Baker, 2008). 
 
1.5.3 Inverse agonists 
Inverse agonism is a property of a number of GPCR ligands. Many ligands that were initially 
thought to be antagonists of GPCRs actually act as inverse agonists, but this is often apparent 
only in receptor systems that naturally have a high level of basal signalling (Milligan et al., 
1995; Kenakin, 2004). Identified in the δ-opioid receptor (δ-OR), constitutive activity could 
be reduced by some antagonists that were found to have negative intrinsic efficacy (Costa et 
al., 1989). Likewise, constitutive activity was identified in β2AR signalling pathway and it 
was revealed that some antagonists of this system actually acted to reduce the basal signalling 
of the receptor (Gotze et al., 1994). Inverse agonists display negative efficacy, being „active‟ 
in their ability to suppress the constitutive activity of a GPCR (Costa et al., 2005). There 
appear to be two mechanisms by which inverse agonists act; (i) by stabilising the inactive 
receptor, having higher affinity for the R-state, and so reduce the basal signalling of the 
receptor; (ii) by inactivating the receptor by forming an inactive inverse agonist-receptor 
complex (Strange, 2002). Inverse agonists may bind to GPCRs in a manner that prevents 
spontaneous receptor activation, binding to the receptor deep within the TM domain and thus 
restricting the movement of the top of TMVI and TMVII towards TMIII (Bond et al., 1995; 
Holst et al., 2006b). 11-cis retinal acts as an endogenous inverse agonist of Rho when bound, 
but not activated by a photon, by preventing the rotation of Trp
6.48
 and in doing so, maintains 
the Rho ground-state (Matsuyama et al., 2010). The melanocortin 4 receptor (MC4R) is a 
GPCR that is regulated in vivo by the endogenous inverse agonist, agouti-related peptide 
(AgRP) (Haskell-Luevano et al., 2001; Adan et al., 2003). The endogenous agonist in this 
system is melanocyte-stimulating hormone (MSH) and together with agouti (an antagonist) 
and AgRP, they act to control the activity of the MC4R (Adan, 2006).   
 
It has been proposed that some ligands may act as agonists or inverse agonists for different 
signalling pathways activated by the same GPCR (Westphal et al., 1996). Some β2AR inverse 
agonists have been found to recruit β-arrestin and activate ERK signalling cascades, 
suggesting that a ligand can be an inverse agonist through one signalling pathway and behave 
as an agonist in another (Azzi et al., 2003). There is the also the potential for protean agonist 
activity, where a ligand acts as either a classical agonist or an inverse agonist depending on 
the level of constitutive activity of the target receptor (Kenakin, 2001).   
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Inverse agonists are potentially invaluable therapeutic agents for the treatment of diseases that 
are caused by constitutively active mutations in GPCRs such as some forms of retinitis 
pigmentosa and hyperthyroidism (Smit et al., 2007). Some viral infections and autoimmune 
disorders can lead to constitutive GPCR pathology, which may then be a target for inverse 
agonists as treatment (de Ligt et al., 2000; Rosenkilde et al., 2000; Kenakin, 2001). Inverse 
agonists may also hold some potential as adjuvant treatments for certain types of cancer 
where GPCR constitutive activity has been detected and which often result in increased cell 
proliferation (Mitsuhashi et al., 1987; Kenakin, 2001).  
 
1.6 Allosteric modulation 
Allosteric ligand binding sites are distinct from the orthosteric binding sites of the 
endogenous ligands, enabling binding of allosteric modulators at the same time as the 
orthosteric agents (Monod et al., 1963; Conn et al., 2009). The main feature of allosteric 
modulators is that they increase or decrease the affinity of the endogenous or exogenous 
orthosteric ligands for the orthosteric binding site (Wess, 2005). An allosteric ligand can 
therefore have a positive or negative effect with respect to the ligand that binds the orthosteric 
site (Christopoulos et al., 2002).  
 
One well documented, non-selective, allosteric modulator of GPCR function is the 
monovalent cation, Na
+
. Sodium acts to neutralise the charge on the highly conserved 
aspartate (Asp
2.50
) in TMII. The change in charge can result in alterations to both the 
orthosteric ligand binding site and to the domains involved in G-protein coupling, thus 
affecting ligand binding affinity and receptor activation (Limbird, 1984; Horstman et al., 
1990; Neve et al., 1991; Ceresa et al., 1994). Na
+
 therefore acts as an allosteric inverse 
agonist at a number of GPCRs, reducing agonist affinity, potentially increasing antagonist 
affinity and stabilising the R state (Fraser et al., 1989; Horstman et al., 1990; Seifert et al., 
2002).  
 
Other metal ions may also function as allosteric modulators of GPCRs. Zn
2+
 has been shown 
to negatively affect the binding of antagonists of the dopamine D4 receptor (D4R), decreasing 
antagonist affinity (Schetz et al., 1997; Schetz et al., 1999). 
 
The potential therapeutic advantages of allosteric modulators of GPCR activity are aided by 
the observation that their effects are normally related to the enhancement or detriment of 
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endogenous ligand activity and are therefore saturable and less likely to induce adverse 
reactions in the event of overdose (Birdsall et al., 1996; Christopoulos et al., 2002). In 
relation to this, the effect of most allosteric modulators would only be observed in the 
presence of the orthosteric ligand, allowing physiological regulation of the drug‟s effects. In 
addition, the greater sequence variation in the non-orthosteric binding sites promises greater 
subtype selectivity of drugs that act as allosteric modulators (Birdsall et al., 1996; 
Christopoulos et al., 2002). 
 
1.7 GPCR oligomerisation 
Although previously considered to function as monomers, it is now accepted that some, if not 
all, GPCRs act as dimers or higher order oligomers in vivo. Studies carried out by Maggio et 
al. in the early 1990s used chimeric receptors of TMI-V and TMVI-VII of the α2-adrenergic 
receptor (α2AR) and the m3 mAChR and demonstrated that these chimeric receptors were 
dysfunctional when expressed alone. Co-transfection of the chimeras resulted in binding of 
both adrenergic and muscarinic ligands, and a certain degree of signalling (Emax 40-50 % of 
WT) after stimulation with a muscarinic agonist (Maggio et al., 1993). The results of this 
early study demonstrated the possibility that GPCRs may be capable of forming interactions 
with each other and that these interactions can produce functional receptors from otherwise 
inactive monomers (Maggio et al., 1993). The first clear evidence of dimer formation in 
native systems was for the Family C GABAb receptors, GABAbR1 and GABAbR2. These 
receptors function as a heterodimer to produce a functional GABAb receptor. It was found that 
expression of the GABAbR1 alone did not produce functional activity in vitro. After the 
identification of a homologous receptor, the GABAbR2, which was also dysfunctional when 
transfected alone, heterologous expression in cell lines demonstrated that the pharmacology 
exhibited by the combination of GABAbR1 and GABAbR2 was similar to that reported for 
GABAb receptors in the brain. It was further demonstrated that the two receptors are 
coexpressed in neurons and concluded that both subtypes are required to produce a functional 
GABAb receptor (Jones et al., 1998), with the GABAbR1 binding to ligands, and the 
GABAbR2 coupling to, and activating, G-proteins (Galvez et al., 2001). 
 
Biochemical techniques involving immunoprecipitation of differentially tagged receptors 
have been used to demonstrate that a number of GPCRs are capable of forming oligomeric 
complexes in vitro (Devi, 2001; Angers et al., 2002). Coimmunoprecipitation of GPCRs to 
demonstrate dimer formation does however present problems due to unspecific aggregation of 
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GPCRs after cell lysis (Angers et al., 2002). The biophysical techniques of fluorescence 
resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) 
eliminated some of the problems associated with coimmunoprecipitation studies. FRET and 
BRET can be carried out in living cells, avoiding unspecific aggregation, and dimerisation of 
GPCRs can be studied in a natural environment (Angers et al., 2002). Both FRET and BRET 
are used to measure the non-radiative transfer of energy between molecules that are less than 
100 Ǻ apart by the use of energy donors and acceptors. In FRET a fluorescent molecule, 
usually cyan-fluorescent protein, and in BRET the enzyme luciferase, act as energy donors. 
The energy acceptor is usually green-fluorescent protein (GFP) (Devi, 2001; Rios et al., 
2001). The first GPCR that was shown to form homodimers in vitro using BRET techniques 
was the β2AR (Angers et al., 2002). Since the identification of β2AR dimers, a number of 
GPCRs have now been shown to form homodimers including the m3 mAChR (Zeng et al., 
1999b), the dopamine D2 receptor (D2R) (Ng et al., 1996) and the gonadotropin-releasing 
hormone receptor (GnRHR) (Cornea et al., 2001). GPCR heterodimers have been shown 
between the A2AR and the metabotropic glutamate receptor 5 (Ferre et al., 2002) the β1AR 
and β2AR (Mercier et al., 2002) and the δ-OR and κ-OR (Ramsay et al., 2002) amongst 
others. 
 
GPCR dimers may be synthesised in the endoplasmic reticulum or at the cell surface, either 
independent of agonists, or upon agonist stimulation. The β2AR (Hebert et al., 1996) and the 
somatostatin (SST) receptors (Rocheville et al., 2000a; Rocheville et al., 2000b) have been 
found to dimerise after agonist stimulation, with the agonist acting to stabilise, and sometimes 
increase, dimer formation within the cell membrane. Studies on other receptors, such as the 
yeast α-mating factor receptor, Ste2p (Overton et al., 2000) the δ-OR (Cvejic et al., 1997) and 
the D1 dopamine receptor (D1R) (George et al., 1998) have demonstrated that agonist 
stimulation has no effect on the level of dimer formation at the cell surface, suggesting that 
the dimers are already formed before transport to the cell surface. In some cases, receptor 
dimerisation may be necessary for correct receptor folding and transportation. The GABAbR1 
has been shown have low cell-surface expression when transfected alone in COS-7 cells. The 
GABAbR2 heterodimer with GABAbR1 aids cell-surface delivery (Sullivan et al., 2000).  
 
Another factor influencing the formation of GPCR dimers is the presence of G-proteins. G-
protein coupling has been found to be a factor influencing the formation and maintenance of 
dimers of the δ- and μ-ORs (Fan et al., 2005; Law et al., 2005) the SST receptors; SST2R and 
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SST5R (Grant et al., 2010) and the neuropeptide Y1 and Y2 receptors (Parker et al., 2007; 
Parker et al., 2008).  
 
GPCR dimer formation has been found to alter receptor pharmacology in vitro. GPCRs 
exhibit a number of functions that cannot be explained by any theory other than that of 
dimerisation; ligand binding characteristics after the expression of two GPCRs in vitro are 
sometimes unexpected and not simply a combination of the individual receptor 
characteristics, such as the GABAb receptor pharmacology (Gouldson et al., 2000). 
Heterodimerisation in vitro can lead to the production of novel ligand binding characteristics. 
The GABAb receptor is an example of a receptor whose pharmacology is defined by 
dimerisation (Jones et al., 1998). Co-expression of μ- and δ-ORs affected a number of 
pharmacological properties. A novel binding site was created which had distinct 
pharmacological characteristics to the two receptors when expressed individually (George et 
al., 2000) and treatment with ligands selective for one subtype increased binding and 
signalling through the other receptor subtype (Gomes et al., 2000). Altered sensitivity to the 
pertussis toxin, a Gαi inhibitor, indicated that the µ/δ-OR heterodimer had altered G-protein 
coupling (George et al., 2000). A heterodimer of the growth hormone secretagogue 1a 
receptor (GHS-R1a, also known as the ghrelin-R) and a splice variant of the receptor, the 
GHS-R1b, which is truncated and only consists of only five TM domains, has been found to 
regulate ghrelin-R function. Coimmunoprecipitation and BRET studies indicated that ghrelin-
R/GHS-R1b heterodimers are produced and that overexpression of GHS-R1b leads to a 
decrease in the cell surface expression of the ghrelin-R, and a resultant decrease in signalling 
without an apparent change in the affinity of ghrelin for the ghrelin-R (Leung et al., 2007).  
 
There is also substantial data supporting the formation of dimers between GPCRs and other 
proteins. Accessory proteins, known as the receptor activity-modifying proteins (RAMPs) are 
known to form heterodimers with a number of Family B GPCRs. The RAMPs dictate the 
pharmacology of the receptors and therefore specify the ligand-binding characteristics by 
combining different RAMPs with the same GPCR (Juaneda et al., 2000). For example, the 
RAMP that is present within a cell will determine whether adrenomedullin or calcitonin gene-
related peptide receptors are produced on forming a dimer with the calcitonin receptor-like 
receptor (Hay et al., 2004b). There is evidence that the RAMPs associate with other GPCRs 
such as the calcitonin receptor (Hay et al., 2004a), the glucagon receptor, the parathyroid 
hormone receptor (PTHR) and the vasoactive intestinal polypeptide/pituitary adenylyl cyclase 
activating peptide receptor (Christopoulos et al., 2003).  
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Despite the increasing evidence of dimer and oligomer formation in vivo and in vitro, it has 
been demonstrated that a single GPCR is sufficient to activate G-proteins. Lipid nanodiscs 
containing Rho monomers were found to be able to fully activate transducin (Gαt) (Bayburt et 
al., 2007) and the same result was found for the β2AR in Gαs activation (Whorton et al., 
2007). 
   
1.8 Post-translational modifications 
Post-translational modifications have been shown to be important, if not essential, for receptor 
structure and function, influencing cell-surface expression, ligand binding, intracellular 
signalling and receptor regulation. There are four main types of post-translational 
modification of GPCRs; phosphorylation, glycosylation, palmitoylation and ubiquitination.  
 
1.8.1 Phosphorylation 
Phosphorylation occurs on specific serine, threonine and tyrosine residues of the intracellular 
domains of GPCRs. Phosphorylation modulates receptor signalling by allowing the 
association of the arrestin family of proteins and subsequent downregulation of the receptors 
(section 1.9).  
 
1.8.2 Glycosylation 
Glycosylation is the most common post-translational modification of GPCRs where 
carbohydrate moieties are added to asparagine residues (N-linked) or serine/threonine residues 
(O-linked) within the extracellular domain. Most GPCRs have putative N-linked 
glycosylation sites, which occur at the consensus sequence NxS/T, where „x‟ is any amino 
acid except proline (Kornfeld et al., 1985). The presence and utility of consensus sequences 
implies that glycosylation is functionally significant (Hawtin et al., 2001a). Studies have 
shown that glycosylation can play a role in trafficking and cell-surface expression in the 
vasopressin 1a receptor (V1aR) (Hawtin et al., 2001a), the β2AR (Rands et al., 1990), the 
AT1AR (Deslauriers et al., 1999), the β1AR (He et al., 2002) and the follicle-stimulating 
hormone receptor (FSHR) (Davis et al., 1995). Glycosylation has been shown to be important 
for agonist binding in the SST receptor (Christopoulos et al., 2003) and the luteinizing 
hormone receptor (LHR) (Zhang et al., 1991) and in signal transduction in Rho (Kaushal et 
al., 1994).  
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O-linked glycosylation is more rare in GPCRs than N-linked glycosylation, but is not 
unreported; the vasopressin V2 receptor (V2R) has O-linked glycosylation modifications at 
most serine and threonine residues within the N-terminus (Sadeghi et al., 1999) and the β1AR 
has recently been shown to be O-glycosylated at the N-teminus during transportation 
(Hakalahti et al., 2010). Other GPCRs that have been reported to be modified by O-linked 
carbohydrate moieties are the κ-OR (Li et al., 2007) the chemokine receptor, CCR5 (Bannert 
et al., 2001) and the bradykinin B2 receptor (Michineau et al., 2006). 
 
1.8.3 Palmitoylation 
Palmitoylation is a modification involving the formation of a thioester bond between cysteine 
residues and a fatty acyl chain. Palmitoylation can occur on cysteine residues within the C-
terminal tail of GPCRs (O'Brien et al., 1984). The 16-carbon fatty acid, palmitic acid, can be 
reversibly, covalently attached to cysteine residues of the protein whilst it is retained in the 
Golgi (Hawtin et al., 2001b). Palmitoylation and de-palmitoylation has also been observed to 
occur in an agonist-dependent manner (Hawtin et al., 2001b; Qanbar et al., 2003). These 
palmitic acid chains, being hydrophobic, are able to embed in the plasma membrane upon 
receptor expression at the cell surface. This creates a fourth intracellular loop structure, 
incorporating HelixVIII, that has structural and functional significance in some GPCRs 
(Hawtin et al., 2001b). In the β2AR crystal structure, the palmitic acid on Cys341 at the C-
terminal end of HelixVIII was clearly resolved (Cherezov et al., 2007). Studies have shown 
that palmitoylation regulates many functions of GPCRs including G-protein coupling 
(O'Dowd et al., 1989; Horstmeyer et al., 1996; Okamoto et al., 1997), cell-surface expression 
(van Koppen et al., 1991; Sadeghi et al., 1997; Petaja-Repo et al., 2006) and desensitisation 
and downregulation (Hawtin et al., 2001b). 
 
1.8.4 Ubiquitination 
Ubiquitination of GPCRs has been found to be important for lysosomal sorting of internalised 
receptors (Marchese et al., 2001; Shenoy et al., 2001). However, ubiquitination is rarely a 
prerequisite for internalisation itself (Marchese et al., 2001; Shenoy et al., 2001). Ubiquitin is 
a 76 amino acid protein which binds to lysine residues on the intracellular domains of GPCRs 
and is recognised by the ubiquitin binding domains (UBDs) of proteins of the endocytic 
pathways (Hicke et al., 2003). The proteins containing UBDs direct the ubiquitinylated 
GPCRs through different endosomal pathways, thus dictating the outcome of receptor 
internalisation (Hicke et al., 2005).     
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1.9 GPCR regulation 
GPCRs are extensively regulated by a number of cellular processes. This may be (i) to 
attenuate signalling in the presence of a specific ligand, (ii) to desensitise the cell to external 
signals or (iii) to up-regulate signalling through specific receptors by an increase in 
transcription. The attenuation of GPCR response to agonists involves three processes, namely 
desensitisation, sequestration and downregulation (Fig 1.8).  
 
Desensitisation of GPCRs involves the uncoupling of receptors from their G-proteins. In 
order to attenuate signalling from activated GPCRs, a group of protein kinases called the G-
protein-coupled receptor kinases (GRKs) phosphorylate active GPCRs on their cytoplasmic 
serine and threonine residues (Freedman et al., 1996). After phosphorylation, β-arrestins are 
recruited to the GRK-phosphorylated receptors, resulting in inhibition of G-protein coupling 
(Lohse et al., 1990; Shenoy et al., 2003). The GRK phosphorylation acts to increase the 
affinity of the receptor for the arrestins. This form of desensitisation is known as homologous 
desensitisation as it only occurs at activated GPCRs and results in attenuation of agonist-
mediated signalling. Homologous desensitisation does not always involve receptor 
endocytosis, as the steric hindrance of β-arrestin binding to the GPCR prevents G-protein 
coupling (Reiter et al., 2006). Other protein kinases are able to phosphorylate serine and 
threonine residues in order to promote desensitisation. These include casein kinase, PKA and 
PKC. PKA and PKC can phosphorylate GPCRs independent of agonist stimulation, 
producing heterologous desensitisation of GPCRs (Benovic et al., 1985).  
 
Reducing the cell-surface expression of GPCRs by means of phosphorylation and endocytosis 
can reduce receptor activity quickly. This process of sequestration is characterised by a 
decrease in cell-surface binding sites and is a form of desensitisation, easily reversible upon 
dephosphorylation of the receptors and re-sensitisation by recycling back to the cell surface 
(Pierce et al., 2001; von Zastrow, 2001). After the binding of β-arrestins during homologous 
desensitisation, β-arrestin binds simultaneously to the receptor and to a clathrin adaptor 
protein, AP-2. Clathrin is recruited to AP-2, facilitating the sequestration of the GPCRs into 
clathrin-coated pits (Krupnick et al., 1997; Laporte et al., 2002). The clathrin triskelions 
assemble spontaneously, creating an invagination of the membrane. Dynamin and other 
proteins assemble at the neck of the vesicle bud and promote the pinching off of the vesicle 
and its release into the cytoplasm. After internalisation, receptors are either rapidly
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Figure 1.8 Schematic of GPCR desensitisation, internalisation and recycling: 
Desensitisation of a receptor occurs when an agonist-bound GPCR is phosphorylated by the 
GRKs. β-arrestin is then recruited to the phosphorylated receptor and receptor signalling is 
terminated. β-arrestin acts as an adaptor protein for the clathrin proteins which cause the 
membrane to bud. Dynamin allows membrane fission, creating an endocytic vesicle and 
allowing sequestration of the receptors. Depending on the receptor, different pathways are 
followed after internalisation (Luttrell et al., 1999). 
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recycled, degraded, or retained in endosomes, resulting in attenuation of signalling without 
the complete termination of activity. Some GPCRs are capable of activating non-G-protein-
dependent signalling pathways, such as MAP kinase from cytosolic endosomes (Daaka et al., 
1998). 
 
The route taken by internalised GPCRs is dependent on sorting sequences contained within 
the cytoplasmic domain of the receptor and, for some GPCRs, the presence of ubiquitin, 
however these mechanisms are not well understood (Jean-Alphonse et al., 2010). Cells can be 
resensitised after dephosphorylation of the GPCR in acidic endosomal vesicles and 
subsequent recycling back to the plasma membrane. Downregulation of receptors involves 
the process of permanently removing receptors from the cell surface and the trafficking of 
them to lysosomes for proteolytic degradation. This process is characterised by a change in 
receptor number in cell lysates, demonstrating that all cellular membranes have reduced 
receptor number (von Zastrow, 2001).  
 
GPCRs may also be regulated at the G-protein level. RGS proteins are a class of 20 proteins 
that can accelerate the GTPase activity of the Gα-subunit by acting as GAPs, and in doing so, 
modulate G-protein activity. G-proteins can also be modulated by an increase in proteolysis, 
decreasing the ratio of G-proteins to GPCRs, potentially making the G-proteins a rate-limiting 
factor (Hepler, 1999; Schulte et al., 2007). 
 
GPCRs may also be regulated at the level of transcription. The oxytocin receptor (OTR) is 
one example of a receptor that demonstrates increases in cell-surface expression in vivo in 
response to external stimuli. The level of OTR expression in the uterus is low in early 
pregnancy, yet increases ~300-fold to peak during early labour (Fuchs et al., 1984; Kimura et 
al., 1996). Receptor regulation at the transcriptional level may act to regulate specific 
physiological functions, as with the OTR (Kimura et al., 1996), or may be to maintain 
homeostasis after a pronounced reduction in receptor cell-surface expression after 
downregulation.     
 
1.10 Ghrelin: an acylated peptide hormone 
Ghrelin is a 28 amino acid peptide hormone that is released, predominantly, from secretory 
granules contained within the X/A-like endocrine cells of the submucosal layer of the stomach 
(Kojima et al., 2001; Holst et al., 2004b). In addition to the stomach, ghrelin mRNA has been 
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found in the brain (Korbonits et al., 2001), small intestine, pancreas, heart, lungs and 
elsewhere (Gnanapavan et al., 2002). Ghrelin is a unique peptide hormone in that it has an n-
octanoic acid modification on Ser3, which is essential for its activity (Fig 1.9 (b)).  
 
1.10.1 The discovery of ghrelin 
Ghrelin is the first known biologically active peptide to be acylated (Kojima et al., 2001). 
Ghrelin is an example of an endogenous ligand discovered by reverse pharmacology after the 
discovery of its GPCR (Kojima et al., 2005). mRNA for the receptor for ghrelin, the ghrelin-
R (also known as the GHS-R1a) (section 1.11), was found to be expressed in the pituitary and 
hypothalamus of the brain where it is activated by the synthetic peptide or non-peptide 
ligands, the growth hormone secretagogues (GHSs) (Howard et al., 1996). These synthetic 
ligands were capable of stimulating growth hormone (GH) secretion in vivo (Bowers et al., 
1984) and were believed to mimic the activity of a natural hormone (Howard et al., 1996). 
CHO cells were stably transfected to express the rat ghrelin-R and were treated with extracts 
from a variety of tissues to establish which of these could effectively stimulate the receptor. 
The results were unexpected, showing that treatment with stomach extracts resulted in high 
activity of the receptors. Purification of the extracts lead to the isolation of a peptide named 
ghrelin, based on the Proto-Indo-European word root, “ghre”, which means “grow” (Kojima 
et al., 1999). Sequence analysis determined the 28 amino acids of ghrelin and identified Ser3 
as having a hydrophobic modification. Mass spectrometry identified an octanoyl moiety 
replacing the hydrogen of the hydroxyl group of Ser3. The n-octanoic acid was determined to 
be essential for ghrelin activity as des-acyl-ghrelin did not increase intracellular Ca
2+
 
concentration through the ghrelin-R (Kojima et al., 2001). 
 
1.10.2 Ghrelin processing  
Ghrelin is produced from a 117 amino acid precursor, preproghrelin. A full-length precursor 
of 94 amino acids, proghrelin, is produced after removal of a 23 amino acid signal peptide. 
The proghrelin precursor also contains the related hormone, obestatin (Zhang et al., 2005) 
(Fig 1.9 (a)). Prohormone convertase 1/3, found within ghrelin-positive cells of the stomach, 
is responsible for the post-translational proteolytic cleavage of proghrelin, at arginine 
residues, to produce ghrelin and obestatin (Kojima et al., 1999; Zhu et al., 2006). 
 
The octanoylation of Ser3 is essential for ghrelin biological activity. Although des-acyl 
ghrelin is found at 10-50 times the concentration of the n-octanoyl ghrelin in the circulation 
(Kojima et al., 2005) des-acyl ghrelin does not have the same physiological roles as ghrelin 
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Figure 1.9 Preproghrelin and the Human ghrelin sequence: (a) the 117 amino acid preproghrelin contains ghrelin and obestatin. The signal 
peptide is removed to give the 94 amino acid proghrelin. Proghrelin is cleaved at arginine residues by prohormone convertase 1/3 to produce 
mature ghrelin and obestatin, (b) sequence of human ghrelin showing the n-octanoyl modification of Ser3. 
(a) 
 
 
 
 
(b) 
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(Kojima et al., 1999; Gauna et al., 2007). The acyl modification is made to Ser3 of ghrelin, 
before its cleavage from proghrelin in the Golgi, by the enzyme ghrelin O-acyltransferase 
(GOAT) (Gutierrez et al., 2008; Yang et al., 2008). The ghrelin-GOAT system is an 
important mechanism in the control of energy homeostasis as des-acyl ghrelin has been found 
to antagonise the effects of ghrelin in vivo, and may therefore negatively regulate ghrelin 
function, probably via alternative receptors (Gauna et al., 2007; Romero et al., 2010). 
 
1.10.3 Ghrelin physiology and pathology 
Ghrelin is highly conserved in vertebrates, highlighting a crucial role in vertebrate physiology 
(Fig 1.10). Ghrelin has many functional roles, demonstrating both endocrine and paracrine 
effects (Pedretti et al., 2007). Initially identified for its GH secreting effects in the pituitary 
(Kojima et al., 1999; Arvat et al., 2000), it has since been implicated in the stimulation of 
appetite (Wren et al., 2000; Nakazato et al., 2001), gastric acid secretion (Masuda et al., 
2000; Date et al., 2001; Sibilia et al., 2002), adrenocorticotropin hormone and arginine 
vasopressin (AVP) release (Mozid et al., 2003), carbohydrate metabolism (Cruz et al., 2010), 
fat utilization (Tschop et al., 2000; Choi et al., 2003) and cell proliferation (Rak-Mardyla et 
al., 2010). Ghrelin is also involved in behavioural (Asakawa et al., 2001) cardiovascular 
(Nagaya et al., 2001b; Okumura et al., 2002), gastrointestinal (Masuda et al., 2000) and 
reproductive (Fernandez-Fernandez et al., 2004) functions. 
 
Ghrelin has a significant effect on energy homeostasis due to its orexigenic (appetite-
stimulating) and adipogenic (fat-storing) activity. Although ghrelin is the only currently 
identified orexigenic hormone released from the gut (Suzuki et al., 2010) ghrelin exerts its 
main activity on the hypothalamic arcuate (ARC) nuclei, stimulating the release of the 
orexigenic peptides, neuropeptide Y (NPY) and AgRP (Lu et al., 2002; Cowley et al., 2003). 
The ablation of NPY/AgRP neurons results in a loss of ghrelin orexigenic activity (Chen et 
al., 2004). Ghrelin also stimulates GABA which exerts an inhibitory effect on 
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART)-
expressing neurons resulting in a decrease in α-melanocyte-stimulating hormone (α-MSH) 
release and subsequent reduction in stimulation of the melanocortin pathway. α-MSH usually 
displays an anorexigenic effect and increases energy expenditure (Nogueiras et al., 2008). 
 
NPY and AgRP appetite-stimulating effects are inhibited by leptin, an anorexigenic hormone 
which also acts on the ARC, stimulating the POMC/CART neurons, and subsequently the 
melanocortin pathway, inhibiting the NPY/AgRP neurons, exerting the opposite 
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Figure 1.10 Comparison of the human ghrelin peptide and ghrelin from other mammalian species: Cattle* and sheep* ghrelin have only 27 
amino acids. 
#
Ser3 has an n-octanoyl modification. Green represents a conserved side chain characteristic between human ghrelin and the other 
species, but not an identical amino acid. Pink is a non-conservative amino acid substitution when compared to human ghrelin. Yellow is a 
missing amino acid compared to human ghrelin (Image adapted from van der Lely et al., 2004). 
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effects to those of ghrelin (Morton et al., 2001; Zigman et al., 2003; Nogueiras et al., 2008). 
 
Ghrelin is released from the X/A-like cells in response to fasting situations. The concentration 
of ghrelin in the blood is determined by the nutritional state of the individual, with plasma 
levels of the hormone being significantly elevated shortly before meals (Cummings et al., 
2001) and decreasing after eating (Tschop et al., 2001). The role of ghrelin in various eating 
disorders has been questioned; ghrelin concentration and the role that it plays in catabolism 
has been studied in anorexia nervosa (Otto et al., 2001), obesity (le Roux et al., 2005), cardiac 
cachexia (Nagaya et al., 2004) and cancer cachexia (Garcia et al., 2005). Ghrelin has been 
found to exist at high concentrations in patients suffering from anorexia nervosa (Otto et al., 
2001) and at low concentrations in obese subjects (le Roux et al., 2005). These observations 
suggest that ghrelin plays a substantial role in long-term energy homeostasis (Janssen et al., 
2004; Davenport et al., 2005). Despite this, ghrelin
-/-
 mice have been shown display growth 
rate, appetite, feeding behaviour and body composition comparable to ghrelin
+/+
 mice, 
implying that ghrelin is not an essential orexigenic factor or that ghrelin can be compensated 
for by other mechanisms (Sun et al., 2003). A high ghrelin concentration has been observed in 
patients with Prader-Willi syndrome (PWS) suggesting that the hyperphagia associated with 
PWS may be related to the increase in ghrelin (Cummings et al., 2002; DelParigi et al., 2002).  
 
The applications of ghrelin as a therapeutic agent are potentially many as ghrelin is involved 
in a diverse range of physiological functions (Espelund et al., 2003), although its uses in some 
areas may be limited, especially as its diverse distribution and extensive roles could lead to 
lack of specificity. In obesity, blocking ghrelin‟s actions may provide some therapeutic 
advantage, although compensatory mechanisms may prevent the full antagonistic activity 
from being observed, as demonstrated in the ghrelin
-/-
 mice (Sun et al., 2003; Bays, 2004; 
Kojima et al., 2005). Similarly, in anorexia nervosa, ghrelin levels are elevated suggesting 
that ghrelin sensitivity is affected and that ghrelin treatment, although having the potential to 
induce an orexigenic effect, is unlikely to be a successful therapeutic agent (Otto et al., 2001; 
Muccioli et al., 2002; Kojima et al., 2005). As a treatment for chronic heart failure, ghrelin 
holds more potential (Kojima et al., 2005). Ghrelin positively affects cardiac structure and 
function and decreases the development of cardiac cachexia (Nagaya et al., 2003). Similarly, 
ghrelin may hold therapeutic use as a treatment for other forms of disease-associated cachexia 
and lipodystophy (Koutkia et al., 2004; Garcia et al., 2005).     
 
 36 
1.11 The ghrelin receptor 
The ghrelin-R belongs to a subfamily of GPCRs that are all activated by gastrointestinal 
peptides or neuropeptides. Other receptors in the subfamily are the motilin receptor, 
neuromedin U receptors, the neurotensin receptors (NT-Rs) and the orphan receptor, GPR39 
(Kojima et al., 2005). 
 
The ghrelin-R is expressed primarily in the somatotroph cells of the pituitary and the ARC 
nucleus of the hypothalamus (Howard et al., 1996), but detectable levels of ghrelin-R mRNA 
have also been found in the hippocampus and a number of peripheral organs such as the 
pancreas (Guan et al., 1997), the heart (Nagaya et al., 2001a), the adrenal cortex (Carraro et 
al., 2004), the ovaries (Gaytan et al., 2005) and the stomach (Date et al., 2000). The ghrelin-
R, as with ghrelin, is well conserved in vertebrates, highlighting an important physiological 
function (Kojima et al., 2005). The relatively high conservation of ghrelin and the ghrelin-R 
in vertebrates supports both a common mechanism of action and an important physiological 
role as both are so well conserved throughout evolution.    
 
The discovery of the ghrelin-R by Howard et al. (1996) occurred after a synthetic peptide, 
growth hormone releasing peptide-6 (a GHS), was found to release GH independently of the 
growth hormone releasing hormone receptor (GHRH-R). It was apparent that another receptor 
was involved in this GH-releasing pathway. The GHS-induced rise in intracellular Ca
2+
 and 
InsP3 indicated that the target of the GHSs was likely to be a GPCR. Two receptors were 
identified in the pituitary that bound the GHSs; the GHS-R1a (ghrelin-R) and the GHS-R1b 
(Howard et al., 1996).  
 
The human ghrelin-R consists of 366 amino acids and forms the typical 7TM helical domains 
of a GPCR (Feighner et al., 1998). The ghrelin-R has been identified as a Family A GPCR 
that couples to Gαq/11 G-proteins. The GHS-R1b cDNA encodes only 289 amino acids; a 
splice-variant truncated protein, containing 5TM domains identical to the ghrelin-R, with 24 
additional amino acids at the C-terminus (Feighner et al., 1998) (Fig 1.11). The GHS-R1b 
failed to produce a response to the GHSs (Carraro et al., 2004) and the precise functional role 
of GHS-R1b has not yet been determined. Evidence suggests that the GHS-R1b acts as a 
dominant negative modulator of the ghrelin-R (Leung et al., 2007). Previous studies on the 
α1a adrenergic receptor (α1aAR) (Coge et al., 1999) and the V2R (Zhu et al., 1998) amongst 
others, have indicated that truncated variants of GPCRs may act as dominant negative
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Figure 1.11 Schematic representation of the ghrelin-R and GHS-R1b: 366 amino acids constitute the full length ghrelin-R (white and green). 
The truncated GHS-R1b consists of only 289 amino acids, 265 of which are identical to the ghrelin-R (white), with 24 additional amino acids at 
the C-terminal end (blue). 
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modulators of the full length GPCR. The ghrelin-R has been predicted to function as a 
homodimer (Holst et al., 2005) and coimmunoprecipitation and BRET studies indicated that 
homodimers, or oligomers, can form in vitro (Leung et al., 2007). When ghrelin-R and GHS-
R1b cDNAs were expressed in the same cells, ghrelin-R/GHS-R1b heterodimers were 
produced (Leung et al., 2007). The GHS-R1b appeared to act as a dominant negative when 
overexpressed, resulting in changes in the intracellular localisation of the ghrelin-R. Ghrelin-
R/GHS-R1b heterodimers co-localised inside the cell, resulting in a reduction in constitutive 
activity and [
125
I]ghrelin binding, without affecting ghrelin-R mRNA expression (Leung et 
al., 2007).   
 
1.11.1 The ghrelin-R displays high constitutive activity  
The ghrelin-R is a highly constitutively active GPCR, signalling at approximately 50 % of the 
ghrelin-induced maximum in the absence of agonist (Holst et al., 2004b). This was first 
identified using InsP-InsP3 accumulation assays in COS-7 cells transiently transfected with 
ghrelin-R cDNA (Holst et al., 2003a) and has since been confirmed in all cell lines tested to 
date. Also, in vivo, naturally occurring mutations of the ghrelin-R were identified that caused 
decreased constitutive activity (Holst et al., 2006b; Pantel et al., 2006). The Substance-P 
analogue [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P (SP-analogue) has been reported to 
reduce the basal activity of the ghrelin-R in COS-7 cells down to levels similar to that seen for 
cells transfected with empty expression vector in InsP-InsP3 accumulation assays. The SP-
analogue was therefore identified as being a full inverse agonist at the ghrelin-R (Holst et al., 
2003a). However, in cAMP-responsive element (CRE) reporter assays, which measure 
phosphorylation of the CRE binding protein (CREB) by the downstream kinases in the Gαq 
pathway, SP-analogue was identified as a partial inverse agonist (Holst et al., 2003a). The 
ghrelin-R has also been shown to signal through the MAP kinase pathway, stimulating 
ERK1/2 phosphorylation, although this only occurs in an agonist-dependent manner; the 
pathway is not activated constitutively (Holst et al., 2004a).   
 
Holst et al. (2004) studied the constitutively active ghrelin receptor and the related receptors, 
NT-R2 and GPR39, and identified an aromatic cluster within TMs VI and VII that was 
thought to be structurally important for the constitutive activity. This aromatic cluster allows 
TMVI and TMVII to approach TMIII in the absence of an agonist, shifting the receptor to its 
active conformation (Holst et al., 2004b; Pedretti et al., 2007). Mutational analysis of these 
residues showed that the size, aromaticity and hydrophobicity of residue 6.51 could alter the 
constitutive activity of, not only the ghrelin-R, but also the related GPR39. The high 
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constitutive activity also required a tyrosine or phenylalanine at position 7.42 (Holst et al., 
2004a), which is more commonly a small residue in Family A GPCRs (Mirzadegan et al., 
2003; Holst et al., 2004a). 
 
It has been suggested that the high level of ghrelin-R constitutive activity may be a “signalling 
set point,” designed to counterbalance the inhibitory effects of other hormones such as leptin 
and insulin (Holst et al., 2004b). As constitutive activity is related to the expression level of 
the receptor, the ghrelin-R expression is extensively regulated in vivo (Holst et al., 2004b). 
 
The mechanisms of action of ghrelin and the ghrelin-R are complex: a single nucleotide 
polymorphism that results in a point mutation (A204E in ECL2) in the ghrelin-R affects 
constitutive activity, but retains ghrelin sensitivity. This same mutation has been found to be 
responsible for both short stature (Pantel et al., 2006) and obesity (Wang et al., 2004) in 
different individuals. Ghrelin is an orexigenic hormone and therefore stimulation of the 
ghrelin-R results in an increase in appetite; loss of ghrelin-R constitutive activity would be 
expected to decrease hunger (Liu et al., 2007b). The reduction in constitutive activity might 
be expected to cause a decrease in GH release, and subsequent short stature, however the 
development of obesity from the same point mutation highlights the complexity of this 
system. Ghrelin-R
-/-
 mice have been found to have normal feeding behaviour and growth, 
again proving that other mechanisms compensate for the loss of the receptor (Sun et al., 2003; 
Sun et al., 2004). 
  
1.11.2 Alternative receptors for ghrelin  
There are still some uncertainties with respect to ghrelin-R subtypes. Alternative ghrelin-R 
have been identified in vivo which mediate the effects of both ghrelin and des-acyl ghrelin 
(Cassoni et al., 2001; Baldanzi et al., 2002; Cassoni et al., 2004). Uncharacterised receptors 
for ghrelin and des-acyl ghrelin have been identified in cardiomyocytes (Baldanzi et al., 2002) 
and breast cancer cells (Cassoni et al., 2001) and it appears that a distinct population of 
receptors are responsible for some non-endocrine actions of ghrelin (Camina et al., 2004).  
Separate des-acyl ghrelin receptors are also thought to exist, again indicating that the 
mechanisms involved in ghrelin physiology are many and complex (Camina, 2006).  
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1.12 Aims of this study 
The overall aim of this study is to investigate the structural and functional aspects of ghrelin-
R activity, specifically focusing on agonist-independent constitutive activity through the InsP3 
pathway. The high constitutive activity observed for the ghrelin-R is of great physiological 
importance and holds much therapeutic potential. 
 
Site-directed mutagenesis and subsequent characterisation of mutant ghrelin-R constructs 
enables investigation into the role of specific amino acids within the receptor. The TM 
domains have been found to be essential for ligand binding and intracellular signalling in 
Family A GPCRs with TMs III and VI being extensively involved in maintaining both the 
inactive and active receptor conformations. Chapters 4 and 5 within this thesis will focus on 
residues within TMIII and TMVI with the aim of elucidating the role of individual amino 
acids in maintaining ghrelin-R high basal signalling. Chapter 6 will address the role of ECL2 
of the ghrelin-R in both ghrelin binding and intracellular signalling, specifically aiming to 
identify residues which support the high basal signalling of the ghrelin-R.  
 
The effect of alanine substitution mutagenesis of the individual ghrelin-R residues examined 
in this study are summarised in Appendix Fig 9.4-9.8.   
 
 
 
 
 
 
 
 
 
 
 
 41 
CHAPTER 2. 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Antibodies 
Monoclonal anti-haemagglutinin (HA) (mouse clone HA-7) primary antibody was from 
Sigma (Dorset, UK). Anti-mouse IgG whole molecule, Horse radish peroxidase (HRP) -
linked, produced in horse was from New England Biolabs (NEB, Hitchin, UK). 
 
2.1.2 Cell culture reagents 
Dulbecco‟s modified Eagles medium (DMEM) and Dulbecco‟s phosphate-buffered saline 
(PBS) were from Lonza (Slough, UK). The inositol-free DMEM was custom synthesised by 
Lonza (Slough, UK) and Gibco (Paisley, UK). Foetal bovine serum (FBS) was from PAA 
(Pasching, Austria). Polyethyleneimine (PEI) and poly-D-lysine (PDL) were purchased from 
Sigma. Cell-culture plastic-ware was purchased from Triple Red (Long Crendon, UK) and 
Fisher Scientific (Loughborough, UK). 
  
2.1.3 Molecular biology reagents 
The DNA polymerase, Pfu, was from Promega (Southampton, UK). Restriction 
endonucleases, EcoRI and DpnI and NotI were from NEB. dNTPs were from Bioline 
(London, UK) and were stored at a stock concentration of 40 mM. Calf intestinal alkaline 
phosphatase and T4 DNA ligase were from NEB. The kits used for the isolation and 
purification of plasmid DNA were Promega Wizard  Plus SV Miniprep Kit (Southampton, 
UK) and High Purity Maxiprep System, Marligen Biosciences (High Wycombe, UK). The 
QIAquick® Gel Extraction Kit from Qiagen (Crawley, UK) was used for the purification of 
DNA from agarose gel. 
 
2.1.4 Oligonucleotides 
Oligonucleotides for QuikChange
TM
 and PCR were custom synthesised on the 200 or 500 nM 
scale and Sephadex G25 purified by Invitrogen (Paisley, UK). Oligonucleotides to introduce 
mutations were designed with minimal base changes to achieve the correct amino acid 
substitution. The specific sequences of oligonucleotide designed for each mutation are 
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described in the relevant chapters. Lyophilised oligonucleotides were dissolved in sterile 
distilled water, to a concentration of 100 pmol/μl and stored at -20 C. The oligonucleotide 
primer sequences for the expression vector pcDNA3.1(+) (S) and pcDNA3.1(+) (AS) were 5‟-
TAATACGACTCACTAT-3‟ and 5‟-TAGAAGGCACAGTCGAGGCTG-3‟ respectively. 
These oligonucleotides were used to confirm mutant receptor sequences. 
 
2.1.5 Peptide ligands 
Human ghrelin, [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P and [Arginine
8
]vasopressin 
(AVP) were purchased from Bachem (Weil am Rhine, Germany). 
 
2.1.6 Plasmid expression vectors 
The mammalian expression vector used to express the ghrelin-R and ghrelin-R mutants was 
pcDNA3.1(+) (Invitrogen). pcDNA3.1(+) (Fig 2.1) is a 5.4 kb vector. The vector contains 
ampicillin and neomycin resistance genes for selection in E.coli and production of stable cell 
lines respectively. It also contains the human cytomegalovirus (CMV) intermediate-early 
promoter, required for high level expression in a wide range of mammalian cell lines and the 
SV40 enhancer promoter region for high level expression and episomal replication in cell 
lines that express the large T antigen.  
 
2.1.7 Radiochemicals 
The radiochemicals [His [
125
I]-ghrelin (human) (specific activity of 2200 Ci/mmol) and myo-
[2-
3
H]inositol (specific activity of 22 Ci/mmol) were purchased from Perkin Elmer 
(Stevenage, UK). 
 
2.1.8 Substrates 
Sigma-fast O-phenylenediamine dihydrochloride (OPD) substrate for the enzyme-linked 
immunosorbent assay (ELISA) protocol was from Sigma. 
 
2.2 Methods 
2.2.1 Polymerase chain reaction (PCR) 
PCR was used to introduce the HA-epitope tag at the N-terminus of the ghrelin-R. Two 
separate reactions were carried out using the HA-tagged human vasopressin 1a receptor (HA-
hV1aR) and the ghrelin-R as templates (discussed further in Chapter 3). PCR reactions were 
set up using 2 μl of 10 pmol/μl sense and antisense primers, 1 μl of 40 mM dNTPs, 1 µl Pfu 
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Figure 2.1 Mammalian expression vector, pcDNA3.1: The main restriction sites found 
within the multiple cloning site are shown for pcDNA3.1(+) and pcDNA3.1(-). The ampicillin 
and neomycin resistance genes and SV40 enhancer promoter regions are indicated (Image 
adapted from Invitrogen.com). 
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polymerase or 0.5 μl High Fidelity DNA polymerase (Roche, Burgess Hill, UK) and 5 μl 
DMSO (Sigma) in a final volume of 50 μl with sterile distilled water and 1x polymerase 
buffer. The program used was as follows; initial hot start 95 °C for 1 min, followed by 
denaturing (temperature 95 °C for 30 sec), annealing (temperature 60 °C for 1 min) and 
extension (temperature 68 °C for 14 min) for 12 cycles. The reactions were stored at 4 °C 
once the cycle was complete. The PCR products were then analysed using agarose gel 
electrophoresis. 
 
2.2.2 Site-directed mutagenesis 
The nine amino acid haemagglutinin (HA) epitope tag (YPYDVPDYA) was engineered at the 
N-terminus of the human ghrelin-R and the tagged receptor was subcloned into pcDNA3.1(+) 
(discussed further in Chapter 3). Mutagenesis was conducted using the QuikChange™ site-
directed mutagenesis kit by Strategene (Cambridge, UK) according to the manufacturers‟ 
protocol. 100 ng plasmid cDNA in pcDNA3.1(+) was used as a template. The WT ghrelin-R 
or a mutant ghrelin-R construct previously constructed, was used as the template. The reaction 
also contained; 2 μl sense and antisense oligonucleotides, to introduce the desired mutation, at 
a stock concentration of 10 pmol/µl, 1 μl of 40 mM dNTPs, Pfu polymerase (0.5-2.0 units), 
Pfu buffer and sterile distilled water to make a final volume of 50 μl. Using a Biometra T3000 
Thermocycler, the amplification cycling conditions were; denaturing, 94 C, 1 min; 
annealing, 55 C, 1 min; extension, 72 C, 14 mins, for 12 cycles. Methylated template DNA 
was digested with DpnI for 90 min at 37 C.    
 
2.2.3 Restriction enzyme digests   
Restriction digests were carried out as recommended in the manufacturer‟s protocols.  Using 
approximately 5 μg of cDNA and 2-10 units of restriction enzyme with 1 x (or 2 x) restriction 
enzyme buffer in a final volume of 10 μl the samples were incubated for 3-6 h at 37 C. The 
restriction digests were analysed using agarose gel electrophoresis.   
 
2.2.4 Agarose gel electrophoresis 
QuikChange™ reactions, PCR products and restriction digests were analysed using horizontal 
gel electrophoresis on a 1 % agarose gel containing ethidium bromide (0.5 μg/ml). The 
samples were mixed (10:1) with a loading dye buffer (0.25 % (w/v) bromophenol blue, 10 
mM Tris, 1 mM EDTA and 30 % (v/v) glycerol). Molecular markers were used to determine 
the size of DNA fragments (NEB). The system was run at 80 mV for approximately 60 min.  
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The gels were visualised using an ultraviolet transilluminator. They were photographed using 
the Ultraviolet Products gel documentation system image store 5000 programme.  
 
2.2.5 Agarose gel cDNA purification 
cDNA bands were cut from the agarose gel and purified using the QIAquick® Gel Extraction 
Kit from Qiagen according to the manufacturer‟s protocol. 
 
2.2.6 Ligation of cDNA 
Ligation reactions contained approximately a 3:1 ratio of insert:vector (concentrations of 
DNA estimated using gel electrophoresis). 1-3 units of T4 DNA ligase, 1 x ligase buffer and 
sterile distilled water were combined to make a final volume of 20-50 μl. Ligations were 
incubated at 16 C for 16 h. 
 
2.2.7 Transformation 
XL-10 gold competent E.coli cells were made using a standard protocol (Sambrook et al., 
1989). The cells were aliquoted to reduce freeze-thaw cycles and stored at -80 C. 30 μl of 
ice-cold (thawed on ice prior to transformation) cells were incubated on ice with cDNA for 30 
min. After incubation, cells were heat shocked at 42 C for 30 sec. This was followed by a 
further 2 min incubation on ice, after which 0.8 ml of Luria broth (LB) (1 % (w/v) peptone, 
0.5 % (w/v) NaCl, 0.5 % yeast extract) was added and the cells were incubated at 37 C for 1 
h. After incubation, the cells were sedimented by centrifugation at 13,000 rpm for 10 min. 
The pellet was resuspended in approximately 50 μl of LB, and spread on LB agar plates, 
containing 100 μg/ml ampicillin, and incubated overnight at 37 C. Single colonies were 
selected from the plate and grown overnight in LB containing 100 μg/ml ampicillin at 37 C 
for cDNA extraction. 
 
2.2.8 Plasmid cDNA preparation 
The plasmid cDNA was extracted from the XL-10 gold cells and purified in a “mini-prep” 
using the Wizard
®
 Plus SV kit (1-10 μg yield), from Promega following the centrifugation 
method in the manufacturers‟ protocol. The cDNA was eluted into 100 μl of sterile distilled 
water. “Mini-prep” allowed small scale preparation of the cDNA for automated fluorescent 
sequencing. “Maxi-prep” cDNA preparation (0.5-3.0 mg) was carried out using the purified 
columns Powerprep™ HP Plasmid Purification Systems (Marligen) according to the 
manufacturers‟ protocol. The extracted cDNA was analysed by restriction digest and gel 
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electrophoresis. The “maxi-prep” cDNA concentration was determined by DNA absorbance 
spectroscopy, measuring the absorbance of a 1 in 100 dilution of the sample at 260 nm. The 
cDNA purity was determined by measuring the absorbance ratio at 260/280 nm. 
 
2.2.9 Automated fluorescent DNA sequencing 
The DNA sequence of all WT and mutant receptor constructs were obtained by fluorescent 
automated sequencing using the pcDNA3.1(+) sequencing primers at pM concentrations 
(Functional Genomics and Proteomics Laboratories, University of Birmingham). 
 
2.2.10 Cell culture 
Human embryonic kidney (HEK) 293T cells were cultured in DMEM supplemented with 10 
% (v/v) FBS, in a humidified 5 % (v/v) CO2 incubator at 37 C. Cells were subcultured twice 
weekly to maintain approximately 50 % confluence. For inositol phosphate accumulation 
assays, cells were seeded onto PDL-coated 12-well plates at a density of approximately 2.5 x 
10
5
 cells per well. For ligand binding assays cells were seeded at a density of approximately 5 
x 10
5
 cells/100 mm dish. For ELISA measurement of cell-surface expression, cells were 
seeded onto PDL-coated 24-well plates at an approximate density of 1.5 x10
5
 cells per well. 
 
2.2.11 PEI transfections 
For inositol phosphate accumulation assays and ELISA, transfections were carried out 24 h 
after seeding cells. HEK 293T cells were transfected using (per 1 μg cDNA), 8 μl 10 mM PEI 
and 60 μl 5 % glucose solution. Before transfection, this mixture was allowed to incubate at 
room temperature for 30 min. After incubation, DMEM was added to make an appropriate 
final volume, and the transfection mixture was added to cells. For ligand binding assays, cells 
were transfected 48 h after seeding with 5 μg cDNA per plate, 60 μl 10 mM PEI and 1.0 ml 5 
% glucose solution. Cells were incubated for 48 h at 37 C, 5 % CO2 (v/v) before 
characterisation. The dominant negative K44A dynamin mutant construct was a gift from Dr. 
Jeffrey Benovic (Thomas Jefferson University, Philadelphia, USA) and was transfected in a 
similar manner to the receptor cDNA.  
 
2.2.12 Inositol phosphate accumulation assays 
16-24 h post-transfection, the cell culture DMEM was replaced with inositol-free DMEM 
containing 1 μCi/ml myo-[2-3H]inositol and incubated for 24 h at 37 C, 5 % CO2 (v/v). Cells 
were then gently washed with 1 x PBS and incubated with inositol-free DMEM containing 10 
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mM LiCl for 30 min at 37 C. This was followed by a further incubation with ligand at 
concentrations ranging from 10
-11
 to 10
-5 
M for 45 min (see Chapter 3). The reaction was 
terminated by aspiration of media from each well, followed by the addition of 0.5 ml 5 % 
(v/v) perchloric acid, containing 1 mM EDTA and 1 mg/ml phytic acid, for 15 min at room 
temperature. Neutralisation with 1.2 M KOH, containing 10 mM EDTA and 50 mM HEPES, 
was followed by incubation on ice for at least 1 h, preferably overnight. Precipitate was 
sedimented by centrifugation at 13,000 rpm for 10 min, then the supernatant was loaded onto 
Bio-Rad AG1-X8 (formate form), (Hemel Hempstead, UK) filled columns. 10 ml of 60 mM 
ammonium formate (NH4COOH) with 0.1 M formic acid (HCOOH) was added to elute free 
inositol and glycerophosphoinositol. 10 ml 850 mM NH4COOH, 0.1 M HCOOH was used to 
elute inositol mono-, bis-, and trisphosphate (InsP-InsP3). The eluant was mixed with 10 ml 
UltimaFlo AF scintillation cocktail (Perkin Elmer) and radioactivity was quantified using 
liquid scintillation counting. Data was analysed by non-linear regression using GraphPad 
Prism 4.0 software (GraphPad, San Diego, USA). The ghrelin EC50 for each receptor 
construct was determined. pEC50 ± SEM are recorded in Appendix Table 9.2.          
 
2.2.13 Harvesting and preparation of cell membranes  
The harvesting of cell membrane extracts for the radioligand binding assays were carried out 
as described (Wheatley et al., 1997). Briefly, cells were washed twice in ice cold 1 x PBS. 
The cells were then scraped from the plates using a standard membrane harvesting buffer 
containing 20 mM HEPES, 1 mM EGTA, 10 mM Mg(CH3COO)2 at  pH 7.4, with the 
addition of 250 mM sucrose and 0.1 mg/ml of bacitracin. Cells were centrifuged at 4000 rpm 
at 4 C for 10 minutes and then resuspended in a harvesting buffer that contained 0.1 mg/ml 
bacitracin. The cells were then incubated for 20 min on ice. After incubation the cells were 
centrifuged as before and resuspended in a harvesting buffer containing 250 mM sucrose. The 
membranes were stored at –20 C in 500 μl aliquots. 
 
2.2.14 Protein Assays 
The approximate total protein concentration of membrane preparations was determined with 
the Pierce BCA (bicinchoninic acid) protein assay kit (Pierce, Northumberland, UK) 
following the manufacturers‟ protocol. A standard curve using bovine serum albumin (BSA) 
was produced to determine the unknown protein concentrations. 
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2.2.15 Radioligand binding assays 
The binding assays were performed using 10 pM His-[
125
I]ghrelin as a tracer. Membranes, 
harvested previously, containing 50-300 μg total protein (determined using protein assays) 
were diluted in 10.5 ml assay buffer (20 mM HEPES, 1 mM EGTA, 10 mM Mg(CH3COO)2, 
1 mg/ml BSA; pH 7.4). Competing ligand was added at a concentration range of 10
-6
 to 10
-11
 
M to make a final volume of 500 μl. Incubation was at 30 ˚C for 60 min to establish binding 
equilibrium. The bound and the free ligands were separated by centrifugation at 13,000 rpm 
for 10 min and the pelleted membranes were then washed and dried. 50 μl Soluene 350 
(Perkin Elmer) was added to each tube to solubilise the membranes. After solubilisation, 1 ml 
of ScintiSafe™ liquid scintillation cocktail (Fisher Scientific) was added and the radioactive 
content was counted using liquid scintillation counting. The experimental binding data was 
analysed using non-linear regression. A theoretical Langmuir binding isotherm was fitted to 
the experimental data using GraphPad Prism Version 4.0 software. pIC50 values were 
determined from the experimental data. 
 
2.2.16 Enzyme-linked immunosorbant assay (ELISA) 
48 h post-transfection, cell culture media was aspirated from the wells and cells were fixed for 
15 min with 0.5 ml 3.7 % formaldehyde. For internalisation experiments, cells were 
stimulated prior to fixing with 10
-7
 M ligand. After fixing, cells were washed three times with 
1 x PBS and treated for 45 min with 0.5 ml blocking solution (1 % BSA in 1 x PBS) to limit 
non-specific antibody binding. After treatment, 250 μl anti-HA primary antibody (made in 
mouse) (1:3000) was added to each well and incubated for 1 h at room temperature followed 
by three washes with 1 x PBS. Blocking treatment was reapplied for a further 15 min after 
which 250 μl anti-mouse secondary antibody (made in horse) conjugated to HRP (1:2000) 
was added for 1 h. Cells were washed again three times and OPD-substrate was added 
according to manufacturers‟ instructions. The reaction was terminated by the addition of 100 
μl, 1 M H2SO4 and the absorbance read at 492 nM.        
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CHAPTER 3. 
 THE GHRELIN-R: EPITOPE TAGGING, CONSTITUTIVE ACTIVITY 
AND FAMILY A CONSERVED RESIDUES 
 
3.1 The ghrelin-R haemagglutinin epitope tag 
3.1.1 Introduction 
Epitope tags can be incorporated into recombinant proteins to allow identification, 
characterisation and in vitro localisation of target proteins (Jarvik et al., 1998). By producing 
a protein that is immunoreactive to readily available commercial antibodies, proteins of 
interest can be isolated efficiently. Antibodies to the protein itself can be raised directly, but 
this is often costly and unreliable, particularly with GPCRs. Epitope tags can be introduced to 
make antibody detection easier, cheaper and more reliable. Epitope tags are generally small 
peptides consisting of between 6 and 30 amino acids and are engineered at a specific point 
within a protein to preserve biological activity, most commonly at the N- or C-terminus 
(Jarvik et al., 1998). Common epitope tags are the HA (YPYDVPDYA), derived from the 
human influenza virus (Wilson et al., 1984), the c-myc tag (EQKLISEEDL), and the 
FLAG™-tag (DYKDDDDK), a synthetic epitope designed by Strategene (Hopp et al., 1988). 
 
As yet, no useful antibody raised to the ghrelin-R has been reported, therefore it was 
necessary to introduce an epitope into the ghrelin-R sequence. The introduction of the tag 
enables ELISAs, Western blots and immunoprecipitation assays to be conducted using 
antibodies to the tag. To facilitate down-stream characterisation of both the WT receptor and 
the mutant ghrelin-R constructs, an HA-epitope tag was engineered at the N-terminus of the 
receptor. Studies on the ghrelin-R (Pantel et al., 2006), and other GPCRs (Schoneberg et al., 
1995; Hawtin et al., 1997; Gaylinn, 1999), have indicated that an N-terminal HA-tag is rarely 
obstructive and is unlikely to affect ligand binding or subsequent intracellular signalling 
cascades. The N-terminus is accessible in intact cells and therefore has greater utility than a 
C-terminal tag. Furthermore, an N-terminal tag is far removed from any receptor interactions 
with intracellular proteins.  
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3.1.2 Results 
The nine amino acid HA-tag (YPYDVPDYA) was engineered, using PCR-based techniques, 
into the N-terminus of the ghrelin-R, immediately after the initiation methionine. The HA-tag 
has been shown, with other GPCRs, to have no effect on hormone binding, receptor signalling 
or the translocation and cell-surface expression of the receptor and was thought therefore 
unlikely to have any detrimental effect on the WT ghrelin-R pharmacology. The Kozak 
consensus sequence was identified as a sequence necessary for the optimal initiation of 
translation (Kozak, 1991). The Kozak consensus sequence (GCCACC) and an EcoRI 
restriction endonuclease site (GAATTC) were engineered upstream of the ATG start codon to 
aid transcription and enable subcloning of the receptor constructs, respectively.  
 
The HA-tag was introduced using a PCR-based method that required the production of two 
fragments by two PCR reactions, in parallel. A third reaction was required to incorporate 
these fragments into a final product (Fig 3.1).  
 
For the first fragment (reaction 1) the template was the ghrelin-R clone in pcDNA5.1(+). A 
sense primer was required, that was complementary to the N-terminus of the receptor, minus 
the ATG, with a 5‟-end that was complementary to the C-terminal end of the HA-tag. The 
antisense primer annealed to the pcDNA5.1(+) vector downstream of the receptor (Table 3.1). 
The Bgh site at the 3‟-end of the multiple cloning site was used as the antisense primer region.  
 
The second reaction (reaction 2) required the HA-tagged V1aR in the pcDNA3.1(+) 
expression vector (tagged previously in our laboratory) as a template. The HA-tag, initiation 
methionine, Kozak consensus sequence, EcoRI restriction site and a section of pcDNA3.1 
were amplified using a sense primer, complementary to the T7 site found at the 5‟-end of the 
multiple cloning site of pcDNA3.1(+). The antisense primer was complementary to the C-
terminal end of the HA-tag.  
 
Two PCR-based reactions were carried out to amplify these regions producing two products, 
one encompassing the ghrelin-R, with the C-terminal end of the HA-tag located at the N-
terminus, and the other, smaller fragment, encompassing expression vector, the EcoRI 
restriction site, Kozak sequence, ATG start codon and the complete HA-tag. A third PCR 
reaction (reaction 3) was carried out using the two purified fragments from reactions 1 and 2 
as the template cDNA. Where the fragments were complementary, at the HA-tag sequence, 
the cDNA strands annealed, producing a template fragment that contained the HA-tag at the 
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HA-tag: YPYDVPDYA 
 
ATG-TAC-CCC-TAC-GAC-GTC-CCC-GAC-TAC-GCC 
Start   Tyr     Pro    Tyr    Asp    Val    Pro    Asp    Tyr    Ala 
 
 
 
 
  
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
Reaction 1 5‟-CGTCCCCGACTACGCCTGGAA 
CGCGACGCCCAGCGAAG-3‟ 
5‟-TAGAAGGCACAGTCGAGGCTG-3‟ 
Reaction 2 5‟-TAATACGACTCACTAT-3‟ 5‟-GGCGTAGTCGGGGACG-3‟ 
Reaction 3 5‟-TAATACGACTCACTAT-3‟ 5‟-TAGAAGGCACAGTCGAGGCTG-3‟ 
 
 
Table 3.1 Primers for introducing the HA-tag to the N-terminus of the ghrelin-R: 
Reaction 1, 2 and 3 primers for the introduction of the HA-tag to the ghrelin-R. The ghrelin-R 
was used as a template in reaction 1 and HA-V1aR as a template in reaction 2. Codons for the 
introduction of the HA-tag are shown in red. 
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Figure 3.1 PCR-based method for HA-tagging of the ghrelin-R: Reaction 1 template was 
the ghrelin-R in pcDNA5.1(+) and used a sense primer that was complementary to the N-
terminus of the ghrelin-R with a 5‟-overhanging end that was complementary to the HA-
epitope sequence (blue). The antisense primer was complementary to the multiple cloning site 
at the 3‟-end of the ghrelin-R (Bgh- red). Reaction 2 template was the HA-V1aR and used a 
sense primer complementary to the 5‟-end of the multiple cloning site (T7- yellow) and an 
antisense primer complementary to the C-terminal end of the HA-tag (green). Reaction 3 
required the products of reactions 1 and 2 and the T7 and Bgh primers to amplify a fragment 
containing the full HA-epitope tag sequence at the 5‟-end of the ghrelin-R. 
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N-terminus of the ghrelin-R. The T7 and Bgh primers were then used to amplify the complete 
fragment, which contained the restriction sites, Kozak consensus sequence, initiation 
methionine, HA-tag and ghrelin-R. Restriction digests using EcoRI, at the N-terminus, and 
NotI, located in the multiple cloning site at the C-terminal end of the ghrelin-R, were carried 
out and the insert ligated into purified pcDNA3.1(+). Automated DNA sequencing revealed 
the presence of the HA-tag at the N-terminus of the ghrelin-R, and that the receptor sequence 
was otherwise unchanged, compared to untagged ghrelin-R (Fig 3.2).  
 
3.1.2.1 Characterisation of the HA-ghrelin-R 
The HA-ghrelin-R was characterised pharmacologically with respect to ligand binding, 
intracellular signalling and cell-surface expression (Fig 3.3, Table 3.2). The HA-ghrelin-R 
was compared to the untagged ghrelin-R to determine i) whether the tag affected the 
pharmacology of the receptor and ii) that the HA-tag enabled detection of the receptor using 
antibodies. The radioligand binding assay using [
125
I]ghrelin vs. ghrelin demonstrated that the 
HA-ghrelin-R was able to bind ghrelin with an affinity comparable to the untagged receptor.  
The tag also had no effect on the intracellular signalling capabilities of the ghrelin-R, with the 
HA-ghrelin-R demonstrating basal signalling, ghrelin potency and efficacy comparable to 
untagged ghrelin-R and similar to the values reported by others (Matsumoto et al., 2001). The 
ELISA indicated that the HA-ghrelin-R could be detected at the cell surface using anti-HA 
antibodies. The untagged ghrelin-R did not appear to be detected at the cell-surface in 
transiently transfected HEK 293T cells using anti-HA antibody, as the expression was only 6 
± 2 % of the HA-ghrelin-R cell-surface expression. 
 
3.1.2.2 HA-ghrelin-R internalisation study 
The ghrelin-R has previously been shown to internalise in a time-dependant manner after 
ghrelin stimulation (Camina et al., 2004; Holliday et al., 2007). Holliday et al. (2007) 
demonstrated ghrelin-R internalisation using immunofluorescence microscopy after 
incubation of transiently transfected cells with 100 nM ghrelin. Furthermore, kinetic studies 
using confocal microscopy, GFP-tagged ghrelin-R and radioligand binding have demonstrated 
ghrelin-R internalisation that is maximal 20 min after stimulation with ghrelin (Camina et al., 
2004). Holst et al. (2004) conducted experiments on an N-terminally FLAG-tagged ghrelin-R 
which demonstrated a high degree of constitutive internalisation. It was found, however, in 
contrast to the results of a previous kinetic study (Camina et al., 2004) that stimulation of the 
FLAG-tagged ghrelin-R with ghrelin did not result in further receptor internalisation.
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Figure 3.2 Chromatogram displaying sequence of the HA-ghrelin-R: The EcoRI restriction site (underlined in orange), the Kozak consensus 
sequence (underlined in pink) and the HA-epitope tag (underlined in yellow) were engineered at the N-terminus of the ghrelin-R. The ATG start 
codon is located upstream of the HA-tag. 
 
 55 
 
 
 
 
 
-12 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
120
log {[ghrelin] (M)}
%
 S
p
e
c
if
ic
 B
in
d
in
g
HA-ghrelin-R untagged ghrelin-R
0
20
40
60
80
100
120
C
e
ll
-S
u
rf
a
c
e
 E
x
p
re
s
s
io
n
(%
 W
T
)
-11 -10 -9 -8 -7 -6
0
20
40
60
80
100
120
HA-ghrelin-R untagged ghrelin-R
log {[ghrelin] (M)}
In
s
P
-I
n
s
P
3
A
c
c
u
m
u
la
ti
o
n
(%
 W
T
)
 
Figure 3.3 Ligand binding, intracellular signalling and cell-surface expression profiles of the HA-ghrelin-R:  (a) Competition radioligand 
binding assays were performed on HEK 293T membranes from cells transiently transfected with untagged ghrelin-R or HA-ghrelin-R. Values 
expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with untagged ghrelin-R or HA-ghrelin-R. Values are expressed as a percentage of the HA-ghrelin-R (WT), ghrelin-induced 
maximum from experiments performed in parallel. (c) Cell-surface expression of HA-ghrelin-R and untagged ghrelin-R expressed as a 
percentage of the HA-ghrelin-R (WT). All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
 
(a)      (b)       (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% HA-ghrelin-R) 
  SEM 
 
EC50 (nM)  
 
Basal  
(% HA-ghrelin-R)  
 SEM 
Emax  
(% HA-ghrelin-R)  
 SEM 
untagged ghrelin-R 8.43  0.02 2.16  1.33 -7  4 88  10 6  2 
HA-ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
 
 
 
Table 3.2 Ligand binding, intracellular signalling and cell-surface expression for the HA-ghrelin-R and untagged ghrelin-R: Values were 
obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
Red indicates no detectable cell-surface expression.  
 57 
One suggestion for this lack of agonist-induced receptor internalisation was that there is a 
steric hindrance of the FLAG-tagged receptor with ghrelin (Camina, 2006).  
 
To investigate the effects of ghrelin stimulation on the HA-ghrelin-R in our system, the HA-
ghrelin-R was transiently transfected into HEK 293T cells and time-course ELISA 
experiments were conducted. Transfected cells were stimulated with 100 nM ghrelin and cell-
surface expression compared to that of unstimulated transfected cells. As a control 
experiment, the HA-V1aR was transfected in parallel and stimulated with the agonist, arginine 
vasopressin (AVP). The HA-V1aR is known to internalise upon receptor stimulation with 100 
nM AVP (Hawtin et al., 1997). The data from the time-course ELISA experiment indicated 
that the HA-ghrelin-R does not internalise significantly after ghrelin stimulation in HEK 293T 
cells (Fig 3.4 (a)). In contrast, the HA-V1aR showed a significant depletion in the number of 
receptors present at the cell surface after stimulation with AVP (Fig 3.4 (b)). A further time-
course ELISA was carried out, over a shorter period of time, to determine whether the HA-
ghrelin-R is internalised and recycled rapidly after ghrelin stimulation. In agreement with the 
longer time-course, rapid HA-ghrelin-R internalisation was not detectable (Fig 3.5). 
 
A dominant negative mutant of dynamin2, K44A-dynamin (van der Bliek et al., 1993), was 
transiently co-transfected with the HA-ghrelin-R and the HA-V1aR to investigate the effect of 
a disruption of the clathrin-mediated internalisation mechanisms on receptor cell-surface 
expression and internalisation. Co-transfection of K44A-dynamin with the HA-ghrelin-R 
resulted in significantly increased cell-surface expression of the HA-ghrelin-R (148 ± 9 % of 
HA-ghrelin-R), suggesting a disruption to the ligand-independent internalisation of the 
receptor. The HA-V1aR, which is known to display almost no constitutive activity, and is 
therefore unlikely to demonstrate significant ligand-independent internalisation, did not show 
a significant increase in the cell-surface expression of the receptor (114 ± 6 % of HA-V1aR) 
when co-transfected with K44A-dynamin (Fig 3.6, Table 3.3). 
 
Throughout the remainder of this study, WT ghrelin-R refers to the HA-ghrelin-R, which was 
used as a template for all subsequent site-directed mutagenesis, thereby enabling 
quantification of mutant receptor constructs at the cell-surface.     
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Figure 3.4 Time-course of cell-surface expression to determine agonist-induced 
internalisation: Time-course ELISA performed on HEK 293T cell transiently transfected 
with (a) HA-ghrelin-R or (b) HA-V1aR. The time-course was conducted over 60 minutes to 
investigate the effect of (a) 100 nM ghrelin on the HA-ghrelin-R cell-surface expression or (b) 
100 nM AVP on HA-V1aR cell-surface expression. Data are presented as a percentage of the 
unstimulated receptor  SEM of three separate experiments performed in triplicate. 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 3.5 Time-course of cell-surface HA-ghrelin-R expression following ghrelin (100 
nM) challenge: Time-course ELISA conducted on HEK 293T cell transiently transfected 
with HA-ghrelin-R and stimulated with 100 nM ghrelin. Data presented as a percentage of the 
unstimulated receptor  SEM of three separate experiments performed in triplicate. 
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Figure 3.6 Receptor cell-surface expression when co-transfected with K44A-dynamin: (a) HA-ghrelin-R 
cell-surface expression and co-transfected HA-ghrelin-R with K44A-dynamin and (b) HA-V1aR cell-surface 
expression and co-transfected HA-V1aR with K44A-dynamin. Data are a percentage of HA-ghrelin-R (WT) or 
HA-V1aR (WT) expression ± SEM of three separate experiments performed in triplicate. 
 
 
 
 
Receptor 
 
Cell-Surface Expression  
(% HA-tagged receptor) 
 
Cell-Surface Expression 
+ K44A-dynamin 
(% HA-tagged receptor) 
 SEM 
HA-ghrelin-R 100 148  9 ** 
HA-V1aR 100 114  6 
 
Table 3.3 Receptor cell-surface expression when co-transfected with K44-dynamin: HA-ghrelin-R and HA-
V1aR expression, alone, and when co-transfected with K44A-dynamin. Data shown are the mean  SEM of three 
separate experiments performed in triplicate. Pink indicates a significant increase in cell-surface expression 
compared to the receptor transfected alone (** P < 0.05).  
(a) 
 
 
 
 
 
 
 
(b) 
** 
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3.2 The ghrelin-R displays high constitutive activity 
3.2.1 Introduction 
It is well established that the ghrelin-R displays a high level of constitutive activity, signalling 
at approximately 50 % of the ghrelin-induced maximum in the absence of agonist (Holst et 
al., 2003a). The ghrelin-R has been found to signal to this extent in the absence of ligand, in 
vivo (Petersen et al., 2009), and in vitro (Holst et al., 2003a).  
 
3.2.2 Results 
To determine the level of constitutive activity of the ghrelin-R when expressed in HEK 293T 
cells, InsP-InsP3 accumulation assays were conducted on the ghrelin-R and the V1aR in 
parallel. The V1aR has been extensively studied and is known to demonstrate little constitutive 
activation of the InsP pathway in HEK 293T cells. InsP-InsP3 accumulation assays for mock-
transfected cells and for the ghrelin-R and V1aR, alone, and after stimulation with ghrelin or 
AVP respectively, were conducted and comparisons made between the ghrelin-R and V1aR. 
The data supported the high level of constitutive activity previously reported for the ghrelin-R 
(Fig 3.7, Table 3.4). 
 
Throughout this study, data have been presented normalised to the WT ghrelin-R basal 
activity and the ghrelin-induced maximum and are expressed as a percentage of the WT 
ghrelin-R maximum. The basal signalling for mutant receptor constructs that decrease 
constitutive activity are therefore expressed as negative values. Mutations that caused 
substantial decreases in constitutive activity were further analysed and normalised to mock-
transfected cells and to WT ghrelin-R basal, to gain a more comprehensive insight into the 
agonist-independent activity of the ghrelin-R and are expressed as a percentage of WT basal. 
 
3.2.2.1 Inositol phosphate accumulation assays 
A time-course of InsP-InsP3 accumulation was conducted to investigate the optimum period 
of ghrelin stimulation for InsP-InsP3 production. Figure 3.8 depicts a representative graph of 
the time-course assay, indicating the dpm for each time period. The basal InsP-InsP3 
accumulation corresponds to each period of stimulation. InsP-InsP3 production was near 
maximum after 15 min, increasing slightly up to 45 min post ghrelin stimulation, and little 
difference was observed between the accumulation after 45, 60 and 75 min.  
 
 62 
Mock Mock ghrelin-R ghrelin-R 
0
20
40
60
80
100
120
ghrelin (100 nM)    -     +   -    +
In
s
P
-I
n
s
P
3
A
c
c
u
m
u
la
ti
o
n
(%
 W
T
 M
a
x
im
u
m
)
Mock Mock V1aR V1aR 
0
20
40
60
80
100
120
AVP (100 nM)  -       +     -    +
In
s
P
-I
n
s
P
3
A
c
c
u
m
u
la
ti
o
n
(%
 W
T
 M
a
x
im
u
m
)
 
Figure 3.7 Ghrelin-R and V1aR constitutive activity: InsP-InsP3 accumulation assays demonstrating the 
agonist-independent activity of (a) the ghrelin-R and (b) the V1aR, expressed as a percentage of the maximal 
agonist-induced response (ghrelin and AVP respectively). 
 
  
InsP-InsP3 Accumulation  
(% WT max) 
± SEM 
 
Unstimulated 100 nM ghrelin 100 nM AVP 
Mock 0 3.6  0.9 0.5  1.4 
WT ghrelin-R 52.0  5.7 100 - 
WT V1aR 6.1  0.1 - 100 
 
 
Table 3.4 InsP-InsP3 accumulation assays demonstrating the agonist independent activity of the ghrelin-R 
and the V1aR: All data presented are the mean  SEM of three or more separate experiments performed in 
triplicate. Data normalised to mock unstimulated cells and WT receptor agonist-induced maximum. 
(a) 
 
 
 
 
 
 
 
(b) 
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Figure 3.8 Time-course InsP-InsP3 accumulation assay for the WT ghrelin-R: HEK 293T cell transiently transfected with ghrelin-R were 
stimulated with 100 nM ghrelin for 15, 30, 45, 60 or 75 min. Basal ghrelin-R InsP-InsP3 accumulation was determined in parallel and the 
difference between basal and ghrelin-induced maximum determined for each time period, in dpm. Data shown are representative of the results of 
three individual experiments. Graph shows the results of a single experiment, performed in triplicate.   
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3.2.2.2 Radioligand binding  
Radioligand binding curves were generated for the WT ghrelin-R and mock-transfections to 
determine the binding affinity of ghrelin for the WT ghrelin-R in transiently transfected HEK 
293T cells. Mock transfections were included to ensure that ghrelin did not bind appreciably 
in cells that were not transfected with the ghrelin-R. Specific binding of ghrelin was 
determined in crude HEK 293T membrane preparations and determined as total binding of 
[
125
I]ghrelin minus non-specific binding defined by the presence of 1 μM unlabelled ghrelin, 
in parallel. The mock-transfected cells displayed no detectable binding of 10 pM [
125
I]ghrelin. 
The WT ghrelin-R bound ghrelin with a pIC50 of 8.61 which was comparable to values 
reported by others (Bedendi et al., 2003) (Fig 3.9, Table 3.5). 
 
3.2.2.3 [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P is an inverse agonist at the 
ghrelin-R 
The SP-analogue has been reported to be an inverse agonist at the ghrelin-R (Holst et al., 
2003a). This was confirmed in our system. The affinity of SP-analogue was determined in 
competition radioligand binding assays using [
125
I]ghrelin. SP-analogue pIC50 = 7.92 in 
agreement with published values (Holst et al., 2003a) (Fig 3.10 (a), Table 3.6). 1 μM ghrelin 
was used to determine non-specific binding. InsP-InsP3 accumulation assays were conducted 
on the WT ghrelin-R in transiently transfected HEK 293T and the SP-analogue potency and 
efficacy were determined. SP-analogue inhibited basal signalling with a pIC50 = 7.72 (19 nM) 
in agreement with published values (Holst et al., 2006a). The maximum inhibition of ghrelin-
R constitutive signalling was 51 % of ghrelin-R basal (Fig 3.10 (c) and (d), Table 3.6). The 
SP-analogue was not able to reduce the constitutive activity of the ghrelin-R down to the 
levels observed for the mock-transfected controls. This is in contrast to data previously 
reported by Holst et al. (2003) which stated that SP-analogue is a full inverse agonist of the 
ghrelin-R and reduces ligand-independent signalling down to the levels observed for the 
empty expression vector controls.  
 
Some GPCR inverse agonists are known to cause an increase in cell-surface expression, 
potentially due to the reduction of constitutive internalisation (Shinyama et al., 2003; Pula et 
al., 2004). SP-analogue has been shown previously to increase the cell-surface expression of 
the WT ghrelin-R as indicated by ELISA (Liu et al., 2007a) and immunofluorescence 
microscopy (Holliday et al., 2007) in HEK 293 cells. In this study, the HEK 293T cells 
transiently transfected with the ghrelin-R were stimulated with 100 nM SP-analogue to
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Figure 3.9 Radioligand binding for WT ghrelin-R and mock-transfected membranes: 
Competition radioligand binding assays were performed on HEK 293T membranes from cells 
transiently transfected with WT ghrelin-R or on mock-transfected cells using [
125
I]ghrelin vs. 
ghrelin. Data are expressed as a percentage of WT ghrelin-R specific binding. Data are the 
mean  SEM of three or more separate experiments, performed in triplicate. To determine 
specific binding, ghrelin-R and mock-transfection binding assays were performed in parallel. 
 
 
  
Binding Affinity 
pIC50   
 SEM 
 
WT ghrelin-R 8.61 ± 0.02 
Mock NDB 
 
 
Table 3.5 Radioligand binding for WT ghrelin-R and mock-transfected membranes: 
Values were obtained using the methods described in Chapter 2. All data are the mean  SEM 
of three or more separate experiments, performed in triplicate and in parallel. Red indicates no 
detectable binding. 
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Figure 3.10 Ligand binding, cell-surface expression and intracellular signalling profiles for [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P:  (a) Competition 
radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R. [125I]ghrelin vs. ghrelin or [125I]ghrelin vs. SP-
analogue binding is expressed as a percentage of specific binding. (b) Cell-surface expression of the ghrelin-R alone or stimulated with SP-analogue (100 nM) expressed as a 
percentage of the WT ghrelin-R (* P < 0.05).  (c) SP-analogue-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT ghrelin-R. 
Values are expressed as a percentage of the WT ghrelin-R basal. (d) SP-analogue-induced reduction in constitutive activity as a percentage of WT ghrelin-R basal. All data 
are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d) 
* 
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Table 3.6 Pharmacological characterisation of the SP-analogue at the WT ghrelin-R: pIC50 for competition binding assays for [
125
I]ghrelin 
vs. SP-analogue, pIC50 and Imax values for InsP-InsP3 accumulation assays and cell-surface expression of the WT ghrelin-R after SP-analogue 
challenge. Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Pink indicates an increase in cell-surface expression compared to unstimulated WT ghrelin-R (* P < 0.05). 
  
Binding Affinity 
pIC50  
  SEM 
 
InsP-InsP3 Accumulation 
Cell-Surface 
Expression 
+ SP-analogue  
(100 nM)   
(% WT)  
 SEM 
  
pIC50 ± SEM 
 
Imax 
(% WT basal) 
 SEM 
WT-ghrelin-R 7.92  0.12 7.72  0.04 51  0.4 119  3 * 
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determine the effect on cell-surface expression in this system. Treatment with SP-analogue 
(30 min) resulted in a significant increase in the number of receptors located at the cell 
surface (119 ± 3 % of WT unstimulated receptor) (Fig 3.10 (b), Table 3.6).  
 
3.3 Functional importance of residues conserved in Family A GPCRs 
3.3.1 Introduction 
The TM helices of GPCRs display a relatively high degree of conservation. The most 
conserved residues in each helix in Family A GPCRs are Asn
1.50
, Asp
2.50
, Arg
3.50
, Trp
4.50
, 
Pro
5.50
, Pro
6.50
 and Pro
7.50
 (Fig 3.11). As these residues are so highly conserved amongst 
Family A GPCRs, they were chosen for mutation to alanine in the ghrelin-R. Point mutations 
were introduced into the ghrelin-R as described in Chapter 2. The effects of alanine 
substitution of the residues in this chapter are summarised in the Appendix (Fig 9.4-9.8). 
 
3.3.2 Results 
Alanine was introduced in order to delete the functional side chain from the β-carbon. Seven 
individual point mutations were introduced; the resulting mutant receptor constructs were 
N1.50A, D2.50A, R3.50A, W4.50A, P5.50A, P6.50A and P7.50A. The oligonucleotide 
primer sequences for each mutation are presented in Table 3.7.  
 
Each mutant receptor construct was characterised by radioligand binding using [
125
I]ghrelin. 
N1.50A, D2.50A, R3.50A and P5.50A all had similar binding affinities to the WT ghrelin-R, 
whereas W4.50A, P6.50A and P7.50A were unable to bind [
125
I]ghrelin at the concentrations 
used in the binding experiment (Fig 3.12, Table 3.8).  
 
Each of the mutant receptor constructs was then further characterised for their ability to signal 
through the InsP3 pathway. All of the mutant receptor constructs affected the basal signalling 
activity of the ghrelin-R to some degree, except for P7.50A, which retained constitutive 
activity similar to that seen for the WT receptor.  
 
N1.50A and D2.50A had similar characteristics, both presenting decreased constitutive 
activity (-67 % and -50 % respectively) and decreased Emax (61 % and 50 % respectively), but 
retaining sensitivity to ghrelin, supporting a functional link between these residues. N1.50A 
reduced cell-surface expression (41 %), whereas D2.50A retained „WT-like‟ expression 
characteristics (94 %) (Figs 3.13-3.14, Table 3.8). 
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R3.50A was unable to signal further through the InsP3 pathway when stimulated with ghrelin, 
but maintained constitutive activity (-22 %) that was only slightly reduced when compared to 
that seen for the WT ghrelin-R. The cell-surface expression (113 %) was comparable to the 
WT ghrelin-R (Figs 3.13-3.14, Table 3.8). 
 
W4.50A was the most detrimental mutation, resulting in loss of constitutive activity, down to 
levels observed for the mock-transfected cells and total loss of ghrelin-induced InsP-InsP3 
accumulation. The W4.50A mutation severely impaired cell-surface expression (19 % of WT) 
(Figs 3.13-3.14, Table 3.8). 
 
P6.50A caused an increase in EC50 (3.9-fold), a decrease in constitutive activity (-53 %) and a 
decrease in Emax (10 % of WT ghrelin-induced maximum). P6.50A also decreased cell-surface 
expression (37 %) compared to the WT ghrelin-R (Figs 3.13-3.14, Table 3.8). 
 
P5.50A and P7.50A produced increases in ghrelin-induced maximal responses (136 % and 
176 % respectively) whereas none of the other mutants in this Chapter were able to reach the 
WT ghrelin-R ghrelin-induced Emax. P5.50A increased the cell-surface expression to 157 % of 
the WT ghrelin-R and increased the EC50 (4.4-fold), whereas P7.50A did not affect ghrelin 
potency, basal activity or cell-surface expression (Figs 3.13-3.14, Table 3.8). 
 
 
 70 
 
 
 
 
Figure 3.11 Schematic representation of the ghrelin-R: the intramolecular disulphide bond is shown in yellow. Residues that represent the 
HA-epitope tag introduced at the N-terminus (blue) and the individual residues mutated in this chapter (green) are illustrated. 
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Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
N1.50A 5‟-GGC-ATC-GCT-GGC-GCC-CTG-
CTC-ACC-ATG-3‟ 
5‟-CAT-GGT-GAG-CAG-GGC-GCC-
AGC-GAT-GCC-3‟ 
D2.50A 5‟-CC-AGC-ATG-GCC-TTC-TCC-GCT-
CTG-CTC-ATC-TTC-C-3‟ 
5‟-G-GAA-GAT-GAG-CAG-AGC-GGA-
GAA-GGC-CAT-GCT-GG-3‟ 
R3.50A 5‟-CTG-AGC-GTC-GAG-GCC-TAC-
TTC-GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-GGC-CTC-
GAC-GCT-CAG-3‟ 
W4.50A 5‟-GTC-ATC-TTC-GTC-ATC-GCG-
GCC-GTG-GCC-TTC-TGC-3‟ 
5‟-GCA-GAA-GGC-CAC-GGC-CGC-
GAT-GAC-GAA-GAT-GAC-3‟ 
P5.50A 5‟-C-TTC-TTC-TTC-CTT-GCT-GTC-
TTC-TGT-CTC-ACG-3‟ 
5‟-CGT-GAG-ACA-GAA-GAC-AGC-
AAG-GAA-GAA-GAA-G-3‟ 
P6.50A 5‟-CTC-TGC-TGG-CTC-GCC-TTC-
CAC-GTA-GGG-3‟ 
5‟-CCC-TAC-GTG-GAA-GGC-GAG-
CCA-GCA-GAG-3‟ 
P7.50A 5‟-GCT-GCC-ATC-AAC-GCC-ATT-
CTG-TAC-AAC-3‟ 
5‟-GTT-GTA-CAG-AAT-GGC-GTT-
GAT-GGC-AGC-3‟ 
 
 
Table 3.7 Oligonucleotide primer sequences for QuikChange™ site-directed 
mutagenesis: Codon changes to introduce the mutations are shown in red.  
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Figure 3.12 Ligand binding profiles for conserved transmembrane residue mutant receptor constructs:  Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with (a) WT ghrelin-R, N1.50A, D2.50A, R3.50A or 
W4.50A and (b) WT ghrelin-R, P5.50A, P6.50A or P7.50A. Values are expressed as a percentage of specific binding. All data are the mean  
SEM of three or more separate experiments, performed in triplicate. 
 
    (a)          (b) 
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Figure 3.13 Inositol phosphate accumulation assay profiles for conserved transmembrane residue mutant receptor constructs: Assays 
were performed on HEK 293T cells transiently transfected with (a) WT ghrelin-R, N1.50A, D2.50A, R3.50A or W4.50A and (b) WT ghrelin-R, 
P5.50A, P6.50A or P7.50A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in 
parallel. (c) Basal InsP-InsP3 accumulation for W4.50A as a percentage of WT basal signalling. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. 
(a)             (b)       (c) 
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Figure 3.14 Cell-surface expression profiles for conserved transmembrane residue mutant receptor constructs: Assays were performed on 
HEK 293T cells transiently transfected with WT ghrelin-R, N1.50A, D2.50A, R3.50A, W4.50A, P5.50A, P6.50A and P7.50A. Values are 
expressed as a percentage of the WT ghrelin-R expression from experiments performed in parallel. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. 
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Table 3.8 Ligand binding, intracellular signalling and cell-surface expression for conserved transmembrane residue mutant receptor 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R. Red indicates no detectable binding, > 5-fold increase in EC50, > 60 % reduction in basal 
activity compared to WT, Emax < WT basal or a > 70 % reduction in cell-surface expression. Yellow indicates > 20 % reduction in basal activity 
or a > 30 % reduction in Emax. Orange indicates a > 4-fold increase in EC50, a reduction in basal activity > 40 % of WT, a reduction in Emax > 60 
% of WT, or a reduction in cell-surface expression > 50 %. Green indicates an increase in Emax > 130 % of WT. Blue indicates an increase in 
Emax > 160 % of WT or an increase in cell-surface expression > 150 % of WT. 
 
Construct 
 
Binding Affinity  
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal  
(% WT basal) 
 SEM 
Emax  
(% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
N1.50A 8.97  0.05 2.55  0.09 -67  11 - 61  5 41  1 
D2.50A  8.21  0.07 2.00  0.32 -50  8 - 50  6 94  12 
R3.50A 8.82  0.05 NDS -22  7 - NDS 113  16 
W4.50A NDB NDS -92  7 3  5 NDS 19  6 
P5.50A 8.31  0.03 9.40  4.70 -48  5 - 136  14 157  8 
P6.50A NDB 8.33  5.34 -53  2 - 10  2 37  9 
P7.50A NDB 5.27  0.92 1  14 - 176  21 92  11 
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3.4 Discussion 
3.4.1 The ghrelin-R haemagglutinin epitope tag 
The HA-epitope tag was introduced at the N-terminus of the ghrelin-R using a PCR-based 
method and the sequence was confirmed using fluorescence automated DNA sequencing. 
HA-epitope tags have been introduced previously at the N-terminus of GPCRs without any 
disruption to ligand binding, G-protein coupling or receptor cell-surface expression 
(Schoneberg et al., 1995; Hawtin et al., 1997; Gaylinn, 1999; Pantel et al., 2006). To 
determine whether the introduction of the HA-tag perturbed ghrelin-R function in HEK 293T 
cells, radioligand binding, InsP-InsP3 accumulation assays and ELISA were carried out on the 
HA-ghrelin-R. These results were compared to those obtained for the untagged ghrelin-R. 
Both the HA-tagged and the untagged ghrelin-R bound ghrelin with similar affinities and 
signalled through the InsP3 pathway with comparable ghrelin potency and efficacy. Basal 
InsP-InsP3 accumulation was similar for the HA-ghrelin-R and untagged ghrelin-R. Cell-
surface expression was detected for the HA-ghrelin-R, unlike the untagged receptor, for 
which cell-surface expression was not detectable (6 ± 2 % of HA-ghrelin-R). The introduction 
of the HA-epitope tag was concluded to have no adverse effects on ghrelin-R function. The 
HA-ghrelin-R was used as the WT receptor throughout the remainder of this investigation, 
and as template to introduce point mutations within the receptor, enabling analysis of mutant 
receptor cell-surface expression characteristics.   
 
3.4.1.1 HA-ghrelin-R internalisation study 
Internalisation of GPCRs after agonist stimulation is an important process in the regulation of 
receptor signalling. Rapid desensitisation of GPCRs by the uncoupling of receptors from G-
proteins occurs quickly after agonist stimulation and is followed by sequestration of receptors, 
involving their physical removal from the cell-surface and re-localisation to intracellular 
membranes (Krupnick et al., 1998). Sequestration of GPCRs attenuates signal transduction 
preventing excessive stimulation, which is important for the regulation of physiology. 
 
There is conflicting evidence about ghrelin-induced internalisation of the ghrelin-R in cell 
lines. In stably transfected HEK 293 and CHO cells, the ghrelin-R was found to internalise in 
a time-dependant manner after ghrelin stimulation, as determined by radioligand binding and 
confocal microscopy (Camina et al., 2004; Holliday et al., 2007). In contrast, an experiment 
using a FLAG-tagged ghrelin-R did not present any ghrelin-induced receptor internalisation, 
although constitutive internalisation was observed (Holst et al., 2004). A suggested reason for 
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this lack of observable agonist-induced internalisation is that the N-terminal FLAG-tag causes 
a steric hindrance between ghrelin and the receptor, potentially disrupting ligand binding and 
altering the ability of the receptor to internalise after agonist stimulation (Camina, 2006). This 
was not the case in a study by Holliday et al. (2007), who found that an N-terminally FLAG-
tagged receptor was able to internalise after stimulation with 100 nM ghrelin to a greater 
extent than the unstimulated receptor.  
 
To investigate the ghrelin-R ghrelin-induced internalisation in more detail, time-course 
ELISA were conducted on the HA-ghrelin-R transiently transfected in HEK 293T cells. The 
time-course assays indicated that the HA-ghrelin-R internalisation was not increased after 
agonist stimulation. In contrast, the time-course conducted in parallel on the HA-V1aR 
demonstrated ~35 % AVP-induced receptor internalisation after 10 min as demonstrated by 
the reduction in receptor number detected at the cell-surface. This indicates that the lack of 
ghrelin-R internalisation is related to the function of the ghrelin-R rather than an artefact of 
the assay in HEK 293T cells. The idea that the tag may be disrupting receptor-ghrelin 
interactions is not supported by the radioligand binding data on the HA-tagged ghrelin-R, 
which was found to bind ghrelin with a similar affinity to the untagged-ghrelin-R. It may be 
that a high level of constitutive internalisation is responsible for the lack of ghrelin-induced 
internalisation observed in the ELISA as agonist-dependent internalisation is masked by the 
constitutive internalisation.   
 
Dynamin is a large GTPase that is recruited to the neck of clathrin-coated pits to facilitate the 
pinching-off of vesicles from the membrane. Dynamin polymerises at the neck of the vesicle 
bud where it recruits other proteins that together bend and distort the membrane, allowing the 
membrane leaflets to fuse and produce a new vesicle. The intrinsic GTPase activity of 
dynamin is aided by the GTPase effector domain (GED) which acts as a GAP. GTP 
hydrolysis follows the dynamin recruitment and the energy released is thought to drive 
dynamin contraction, pinching-off the vesicle and allowing its release into the cytosol. The 
mutant dynamin2, K44A-dynamin, lacks the ability to bind GTP and act as a GTPase, thus 
preventing GTP hydrolysis. K44A-dynamin acts as a dominant negative of dynamin, 
preventing the pinching-off of vesicles in cells overexpressing the mutant form (van der Bliek 
et al., 1993; Damke et al., 1994) (Fig 3.15). GPCR agonist-induced endocytosis commonly 
involves clathrin and dynamin, although not all GPCRs are internalised using clathrin-coated 
pits (Zhang et al., 1996).  
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Figure 3.15 Dynamin action in the formation of membrane vesicles: Dynamin and the associated proteins bind to the forming vesicle neck 
and act to destabilise the membrane allowing the pinching off of the vesicle. Mutations of dynamin, such as the K44A mutation, block dynamin 
action, preventing the vesicle from pinching off (Image adapted from Alberts, 2002). 
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Co-transfection of the HA-ghrelin-R with the dominant negative K44A-dynamin resulted in a 
significant increase in receptor expression at the cell-surface (148 % of HA-ghrelin-R 
expression), suggesting that constitutive agonist-independent internalisation of the ghrelin-R 
occurs in a clathrin/dynamin-dependent manner. In contrast, the non-constitutively active 
V1aR did not present a significant increase in cell-surface expression when co-transfected with 
K44A-dynamin (114 % of HA-V1aR expression). This suggests that the V1aR does not 
undergo constitutive internalisation to any significant degree, or that constitutive 
internalisation does not involve clathrin/dynamin mechanisms. The high degree of 
constitutive internalisation of the ghrelin-R may go some way towards explaining the lack of 
ghrelin-induced receptor internalisation. It is possible that the constitutive internalisation of 
the ghrelin-R masks the agonist-induced internalisation. Rapid recycling of the constitutively 
internalised ghrelin-R may prevent detection of ghrelin-induced receptor internalisation. 
 
3.4.2 The ghrelin-R displays high constitutive activity 
3.4.2.1 Inositol phosphate accumulation assays 
The ghrelin-R is known to signal at approximately 50 % of the ghrelin-induced maximum in 
the absence of agonist (Holst et al., 2003a). To investigate ghrelin-R constitutive activity in 
HEK 293T cells, the ghrelin-R and the V1aR, which has not been reported to be constitutively 
active, were transiently transfected in parallel in HEK 293T cells for InsP-InsP3 accumulation 
assays. Mock-transfected cells were also included to determine basal InsP-InsP3 accumulation 
in the absence of transfected receptor. The mock-transfected cells, stimulated with ghrelin or 
with AVP, did not show any appreciable signalling through the InsP3 pathway compared to 
the mock unstimulated cells. The transfected ghrelin-R displayed constitutive InsP-InsP3 
accumulation of 52 ± 5.7 % of the ghrelin-induced maximum. The V1aR did not show any 
substantial increase in InsP-InsP3 accumulation (6.1 ± 0.1 % of AVP-induced maximum) 
when compared to the mock-transfected cells. After stimulation with 100 nM AVP however, 
there was an increase in InsP-InsP3 accumulation, confirming the InsP3 signalling of the 
receptor in response to AVP in HEK 293T cells.   
 
The time-course InsP-InsP3 accumulation assay was designed to investigate the optimal 
period of ghrelin stimulation in HEK 293T cells. InsP-InsP3 accumulation was greatest 45 
min after ghrelin stimulation. Stimulation for longer than 45 min was not beneficial to the 
InsP-InsP3 accumulation assay and therefore, in the remainder of this study, all InsP-InsP3 
accumulation assays were conducted with a period of 45 min for ghrelin stimulation.   
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3.4.2.2 Radioligand binding  
Radioligand binding curves were generated for the WT ghrelin-R and mock-transfected crude 
cell membrane preparations, as described in Chapter 2. The WT ghrelin-R bound ghrelin with 
a pIC50 of 8.61, similar to the published ghrelin affinity (Bedendi et al., 2003; Davenport et 
al., 2005). The mock transfections enabled detection of ghrelin binding in HEK 293T cells in 
the absence of the ghrelin-R. It was established that there was no appreciable binding of 
ghrelin in mock-transfected HEK 293T cells. 
 
3.4.2.3 [D-Arg
1
, D-Phe
5
, D-Trp
7, 9
, Leu
11
]-Substance P is an inverse agonist at the 
ghrelin-R 
The SP-analogue was found to be an inverse agonist at the ghrelin-R in the system used in this 
study. In contrast to previous reports, the SP-analogue was only a partial inverse agonist and 
so was unable to inhibit WT ghrelin-R constitutive signalling down to levels observed for the 
mock-transfected cells. Instead SP-analogue reduced basal signalling to an Imax of 51 % of 
WT ghrelin-R basal. The pIC50 of 7.72 (IC50 = 19 nM) was comparable to published data 
(Holst et al., 2003a).    
 
Stimulation of the ghrelin-R with 100 nM SP-analogue for 30 min resulted in an increase in 
cell-surface expression similar to the data from other studies (Holliday et al., 2007; Liu et al., 
2007a). This supports ghrelin-R constitutive internalisation, as determined using the mutant 
K44A-dynamin, as constitutive internalisation could be reduced with an inverse agonist of the 
system.  
 
3.4.3 Functional importance of residues conserved in Family A GPCRs 
The TM domains of Family A GPCRs are the most highly conserved regions, supporting a 
common mechanism of receptor activation that involves conserved TM residues and motifs. 
The Ballesteros-Weinstein reference residue is the most highly conserved in each helix. These 
residues are Asn
1.50 
(100 %), Asp
2.50 
(94 %), Arg
3.50
 (96 %), Trp
4.50
 (96 %), Pro
5.50
 (77 %), 
Pro
6.50 
(100 %) and Pro
7.50
 (96 %) (Mirzadegan et al., 2003). Due to the high level of 
conservation, it is probable that each of these residues plays an important role in Family A 
GPCR function. To investigate the role of the well-conserved residues in ghrelin-R function, 
each was mutated individually to alanine. Comparisons were drawn between the WT ghrelin-
R and mutant receptor constructs to determine the role of specific residues in receptor 
function.  
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Asn
1.50
, Asp
2.50
 and a conserved residue within the NPxxY motif of TMVII, Asn
7.49
 (Chapter 
4), have been shown to participate in a network of hydrogen bonds with water molecules in 
Family A GPCRs. In the Rho crystal structure the distance between Asp
2.50
 and Asn
7.49
 is too 
great to allow a direct hydrogen bond, so a water molecule mediates the interhelical 
interaction (Palczewski et al., 2000). These three integral residues along with Tyr
7.53
 of the 
NPxxY (Chapter 4) form a polar pocket within the TM bundle (Scheer et al., 1996). Alanine 
mutations of Asn
1.50
, Asp
2.50
 and Asn
7.49
 in the thyrotropin-releasing hormone receptor 
(TRHR) revealed that the conserved side chains are important in activation of the receptor, 
but not in ligand binding, suggesting conformational roles, rather than direct contacts with the 
ligand (Perlman et al., 1997b). In the 5HT2AR, Asp
2.50
 has been shown to be essential for 
receptor activation, with point mutations resulting in inactivation of the receptor. This 
inactivity could be overcome, in part, by a double reciprocal mutation of D2.50N/N7.49D 
supporting a direct interaction (Sealfon et al., 1995). Asn
1.50
 and Asp
2.50
 have been found to 
hydrogen bond in a number of Family A GPCRs, including the bRho crystal structure 
(Palczewski et al., 2000). Molecular modelling in the α1bAR suggested that mutation of 
Asn
1.50
 to alanine would result in constitutive activity, due to removal of a polar residue and 
disruption of the conserved hydrogen bonding network (Scheer et al., 1996). In the GnRH-R, 
asparagine is found at position 2.50 and aspartate at position 7.49 suggesting that similar 
interactions are occurring in this receptor as in most Family A GPCRs, where Asp
2.50 
and 
Asn
7.49
 are more highly conserved (Flanagan et al., 1999). Mutation of Asn
1.50
 and Asn
2.50
 to 
alanine resulted in a severe disruption to cell-surface expression making it difficult to 
determine the role of both of these residues in terms of activation (Flanagan et al., 1999).  
 
In the ghrelin-R mutation of Asn
1.50
 to alanine also caused substantially decreased cell-surface 
expression compared to WT although the mutant was expressed sufficiently for InsP-InsP3 
accumulation assays to be conducted. The N1.50A mutant retained “WT-like” binding affinity 
and signalling potency although there was a pronounced disruption to basal signalling and 
ghrelin efficacy. Agonist-independent signalling was reduced to -67 % of that seen for the 
WT ghrelin-R, suggesting a disruption to the mechanisms involved in ghrelin-R constitutive 
activity.  
 
Studies have demonstrated that mutation of Asp
2.50
 often results in a decrease in agonist 
affinity due to a disruption of the ability of the receptor to form the active state which has the 
highest affinity for agonist (Strader et al., 1988; Huang et al., 1995; Donnelly et al., 1999). In 
the ghrelin-R, the D2.50A mutation maintained „WT-like‟ affinity for ghrelin and WT 
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potency. As with the N1.50A mutation, basal activity and ghrelin efficacy were reduced, in 
parallel, suggesting that ghrelin maintains the same ability to activate the D2.50A mutant as 
the WT receptor, but that the decreased basal results in a decrease in Emax. Asp
2.50
 appears to 
participate in similar interactions in the ghrelin-R as seen in other Family A GPCRs as 
indicated by the decreased constitutive activity, which suggests that the mutant receptor is 
unable to form the WT basally active conformation, but is able to adopt an active 
conformation after stimulation with agonist.  
 
Arg
3.50
 is an integral residue in Family A GPCR activation, being involved in stabilising 
interactions with TMII, TMIII, TMV, TMVI and TMVII in various activation states (Chapter 
4). A number of studies have suggested that Arg
3.50
 of the D/ERY motif in TMIII interacts 
with Asp
2.50
 and participates in the hydrogen bonding network in the inactive receptor 
conformation (Cohen et al., 1993; Scheer et al., 1996). In contrast, a study on the histamine 
receptor 1 (H1R) suggested that the Asp
2.50
-Arg
3.50
 interaction occurs in the active receptor 
conformation (Bakker et al., 2008). A study on the GnRH-R demonstrated that Asp
7.49
 
(instead of the asparagine found at position 2.50) interacts with Arg
3.50
, but that in other 
Family A GPCRs, where the more highly conserved Asn
7.49
 and Asp
2.50
 are found, Asp
2.50
 and 
Arg
3.50
 are likely to stabilise the active state (Ballesteros et al., 1998). Arg
3.50
 has a key role in 
activation of GPCRs, changing contacts during the R→R* transition. The ghrelin-R R3.50A 
mutation resulted in a mutant construct that only decreased constitutive activity to -22 % of 
the WT ghrelin-induced maximum, but was unable to be further stimulated by ghrelin. This 
suggests that introduction of alanine resulted in a receptor that is unable to adopt the active 
conformation after ghrelin stimulation, suggesting a disruption to interactions that stabilise the 
active state. This is supported by the reduction in constitutive activity and Emax observed with 
the D2.50A mutation, which suggests that the fully active receptor conformation cannot be 
achieved in the absence of Asp
2.50
, but that D2.50A is not as detrimental to agonist-induced 
receptor activation as the R3.50A mutation, and conversely, Arg
3.50
 is not as important for 
basal ghrelin-R activity as Asp
2.50
. In the m3 mAChR Asp
2.50
, Arg
3.50
 and Tyr
5.58
 have been 
found to be interdependent with mutations of Arg
3.50
 and Tyr
5.58
 being able to functionally 
rescue the inactive D2.50N mutant receptor (Li et al., 2005). The opsin crystal structures both 
demonstrate that Arg
3.50
 interacts with Tyr
5.58
, indicating that Arg
3.50
 and Tyr
5.58
 stabilise the 
active receptor conformation. Arg
3.50
 is then able to interact with Gαt (Park et al., 2008; 
Scheerer et al., 2008). Arg
3.50
 and Tyr
5.58
 are mutated further and discussed in depth as part of 
the mutagenesis study in Chapter 4.   
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Trp
4.50
 is the most conserved residue in TMIV, found in 96 % of Family A GPCRs 
(Mirzadegan et al., 2003). In the ghrelin-R, mutation of Trp
4.50
 to alanine was severely 
detrimental to receptor function with the W4.50A mutant resulting in loss of [
125
I]ghrelin 
binding and of signalling, both in an agonist-independent and agonist-dependent manner. 
W4.50A also resulted in a loss of cell-surface expression. Tryptophan has been shown to be 
important at position 4.50 in a number of Family A GPCRs (Wess, 1993b; Roth et al., 1997; 
Rhee et al., 2000a). In the cannabinoid 2 (CB2) receptor only phenylalanine was found to be 
able to substitute for tryptophan at position 4.50 (Rhee et al., 2000a). Similarly, in the m3 
mAChR, a W4.50F mutation maintained WT signalling characteristics, although binding 
affinity was reduced for all ligand classes (Wess et al., 1993) and in the δ-OR a W4.50A 
mutation revealed that Trp
4.50
 was directly involved in ligand binding (Befort et al., 1996). In 
the m1 mAChR (Lu et al., 2001) and H1R, (Wieland et al., 1999), Trp
4.50
 was identified as 
being essential for correct receptor expression at the cell surface, as determined by alanine 
substitution mutagenesis. Interestingly, a non-conservative W4.50L mutation introduced into 
Rho retained WT characteristics (Nakayama et al., 1991). Trp
4.50
 therefore appears to 
demonstrate different roles in various Family A GPCRs, sometimes being essential for 
receptor function, but in other receptors, it appears to be less significant. In the ghrelin-R 
Trp
4.50
 is essential for all WT receptor characteristics.  
 
Pro
6.50
 is 100 % conserved in Family A GPCRs and is a critical residue in GPCR activation. 
A significant proline-induced kink was observed within TMVI in the bRho crystal structure 
(Palczewski et al., 2000). Rearrangement of interactions around Pro
6.50 
in TMVI, results in the 
movement of TMVI, via the straightening of the proline-induced kink. Conserved residues 
surrounding Pro
6.50
 modulate the bend angle of TMVI; residues 6.47, 6.48 and 6.52 within 
TMVI are believed to adopt different rotamer conformations and interact with different 
residues during receptor activation (Shi et al., 2002b). The crucial role of residue 6.50 is 
supported by its conservation in Family B GPCRs, where it has a similar function (Conner et 
al., 2005). In the ghrelin-R the P6.50A mutation was particularly detrimental to receptor 
function. The mutant was unable to bind [
125
I]ghrelin at the concentration used in the binding 
assay. Basal activity was reduced in the P6.50A mutant to -53 % of the WT ghrelin-R basal 
signalling. The mutant was able to respond to ghrelin and signal through the InsP3 pathway, 
although both the potency and efficacy were reduced. Various effects have been observed 
after mutation of Pro
6.50
 in Family A GPCRs. In the m3 mAChR, P6.50A retained functional 
activity, although a small reduction in agonist affinity was seen, as was substantially 
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decreased cell-surface expression (Wess, 1993a). As in the m3 mAChR, the ghrelin-R P6.50A 
mutation resulted in a substantial decrease in ghrelin-R expression (37 %). The P6.50A 
ghrelin-R mutant supports the high conservation of Pro
6.50
 in Family A GPCRs. Pro
6.50
 
appears to be vital for correct ghrelin-R function, enabling both agonist-independent, and 
agonist-dependent activation and ensuring high affinity ghrelin binding. Loss of signalling 
capabilities, may, in part, be due to the loss of receptor expression, which is particularly 
pronounced with the ghrelin-R P6.50A mutation.     
 
Pro
5.50
 and Pro
7.50
 mutation to alanine in the ghrelin-R both resulted in increases in ghrelin 
efficacy (136 % and 176 % respectively), although both had varying effects on binding, 
expression, basal signalling and ghrelin potency. P5.50A reduced the basal constitutive 
activity (-48 %) suggesting that the alanine substitution mutation adopts a more stable, 
inactive conformation in the absence of agonist. This is further supported by the increase in 
cell-surface expression found for this mutant, which implies that there may be reduced 
constitutive internalisation (section 3.1.2.2), and this therefore allows greater ghrelin-induced 
signalling and cell-surface expression. Alternatively, the P5.50A mutant might generate a 
receptor conformation that has a higher affinity for G-protein when occupied by an agonist, 
although ghrelin potency was decreased (4.4-fold increase in EC50), suggesting a disruption to 
ghrelin-induced activation. This disruption can be overcome at high ghrelin concentrations, 
resulting in increased efficacy. Different results were observed when a P5.50A mutation was 
carried out in the m3 mAChR. The proline was predicted to be essential for receptor folding 
or trafficking, as the P5.50A mutation disrupted expression and resulted in decreased agonist 
affinity, and efficacy. As seen with the ghrelin-R however, the alanine mutation did not 
critically affect receptor activation, suggesting that Pro
5.50
 is not directly involved in 
stabilising the active receptor state, or in G-protein coupling (Wess, 1993a).   
 
P7.50A was the only conserved residue mutation that retained „WT-like‟ constitutive activity.   
Pro
7.50
 forms part of the NPxxY motif (Chapter 4) in TMVII and has also been shown to 
induce a kink within the helix (Palczewski et al., 2000). Mutation of Pro
7.50
 to alanine did not 
impair ghrelin-R function, as the P7.50A mutant construct retained „WT-like‟ basal signalling 
and ghrelin potency. Cell-surface expression of the mutant was also comparable to WT and, 
although ghrelin binding was not detected at the radioligand concentration used, P7.50A 
retained „WT-like‟ ghrelin potency. Interestingly, there was also increased ghrelin efficacy 
with the P7.50A mutation, as seen with the P5.50A mutation, suggesting that the mutant 
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receptor construct is able to adopt a more active conformation than the WT ghrelin-R after 
ghrelin binding. In the LHR, P7.50F did not result in disruption of binding, signalling or cell-
surface expression (Hong et al., 1997) supporting the ghrelin-R data that suggests that Pro
7.50
 
is not essential for correct receptor folding and that removal of the proline, and thus possible 
straightening of the proline-induced kink, does not impair receptor function. In contrast, in the 
m3 mAChR, P7.50A reduced agonist efficacy and cell-surface expression (Wess, 1993a) 
implying that Pro
7.50
, as Trp
4.50
, might play different roles in various members of the 
superfamily. Pro
7.50
 is discussed in more detail in Chapter 4 as part of the investigation into 
the role of the NPxxY motif.  
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CHAPTER 4. 
MECHANISMS OF GHRELIN-R ACTIVATION 
 
4.1 Introduction 
GPCRs can be activated by a diverse range of natural ligands, however evidence suggests that 
there is a common method of activation within the superfamily. Supporting the evidence of a 
common mechanism, GPCRs that are activated by very different ligands can activate the same 
G-protein. Furthermore, sequence analysis has demonstrated that GPCRs are similar at the 
cytoplasmic ends of TMIII-TMVII, regions known, along with the ICLs, to interact with G-
proteins (Mirzadegan et al., 2003).  
 
The mechanisms of agonist-induced activation of Family A GPCRs have been studied in great 
depth. After agonist binding, conformational changes occur within the TM portion of the 
receptor, as well as in the extracellular and intracellular loop regions. This cascade of 
structural changes results in the binding and activation of associated G-proteins and 
subsequent intracellular signalling pathways. Activation of GPCRs involves the breaking of 
certain intramolecular ground-state interactions and the formation of new interactions that 
stabilise a more active receptor conformation. It has been clearly demonstrated that activation 
of GPCRs involves movement of the cytoplasmic end of TMVI away from TMIII, opening a 
G-protein binding site. Studies on Rho using electron paramagnetic resonance revealed that 
receptor activation requires a rotation and tilting of TMVI in relation to TMIII (Farrens et al., 
1996). Since this study, further studies have been conducted that support this helical 
movement during activation (Gether et al., 1997; Dunham et al., 1999; Jensen et al., 2000; 
Hubbell et al., 2003; Elling et al., 2006). The movement of TMVI relative to TMIII is thought 
to be centred at the highly conserved Pro
6.50 
(discussed in Chapter 3). TMVI is believed to 
rotate around Pro
6.50 
leading to a straightening of the proline-induced kink and subsequent 
“see-saw-like” movement of the helix referred to as the „global toggle switch‟ (Elling et al., 
2006; Schwartz et al., 2006).  
 
Trp
6.48
 in TMVI forms the rotamer toggle switch of activation. Trp
6.48 
undergoes a 
conformational rearrangement during receptor activation, releasing interactions with TMVII 
and forming new interactions with TMs V and III. The altered conformations of Trp
6.48 
and 
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the neighbouring Cys
6.47 
modulate the proline-induced kink, straightening TMVI and moving 
the cytoplasmic end of the helix away from TMIII (Shi et al., 2002a; Ruprecht et al., 2004; 
Schwartz et al., 2006). 
 
The highly conserved D/ERY motif is a key participant in both ground state interactions and 
in stabilising the R* state after receptor activation (Scheer et al., 1996; Ballesteros et al., 
1998; Ballesteros et al., 2001; Rovati et al., 2007; Park et al., 2008). The “ionic lock” found 
in some Family A GPCRs constitutes an interaction between Arg
3.50
 and a conserved charged 
residue in TMVI, Glu
6.30
. This interaction maintains the cytoplasmic ends of TMs III and VI 
in close proximity. The interaction can be disrupted on ligand binding to the receptor, 
releasing the ionic lock and facilitating the movement of the cytoplasmic end of TMVI away 
from TMIII, allowing receptor activation (Scheer et al., 1996; Ballesteros et al., 2001). 
 
The ghrelin-R is unusual amongst GPCRs in that it possesses high constitutive activity in the 
absence of agonist. To investigate the interactions occurring in the ghrelin-R and the role of 
individual residues in maintaining constitutive activity, key residues found within TMs III, VI 
and VII of the ghrelin-R were mutated and comparisons made to other GPCRs which do not 
exhibit high constitutive activity. The mutant receptor constructs were created using site-
directed mutagenesis following the QuikChange™ protocol and characterised by radioligand 
binding, intracellular signalling and cell-surface expression as described in Chapter 2. The 
effects of alanine substitution of the residues in this chapter are summarised in the Appendix 
(Fig 9.4-9.8).  
 
4.2 Results 
The residues selected for mutation in this chapter were substituted individually for alanine in 
order to delete the side chain from the β-carbon. Various other amino acids were incorporated 
at certain positions to investigate the effect of alteration of amino acid side chains. The amino 
acids selected for mutation were Thr
2.39
, Cys
3.35
, Thr
3.36
, Glu
3.49
, Arg
3.50
, Tyr
3.51
, Ala
3.60
, 
Tyr
5.58
, His
6.30
, Gln
6.32
, Thr
6.33
, Val
6.34
, Trp
6.48
, Ser
7.45
, Asn
7.49
, Pro
7.50
, Ile
7.51
, Leu
7.52
, Tyr
7.53
, 
Lys
7.58 
and Lys
7.59
 (Fig 4.1). The oligonucleotide sequences used to introduce each of the 
mutations are shown in Table 4.1. The resulting ghrelin-R mutant constructs were expressed 
in HEK 293T cells. Competition radioligand binding studies were conducted to demonstrate 
mutant receptor affinity for ghrelin compared to the WT ghrelin-R. InsP-InsP3 accumulation 
assays demonstrated the ability of each construct to signal through the InsP3 pathway after
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Figure 4.1 Schematic representation of the ghrelin-R: the intramolecular disulphide bond is shown in yellow. Residues that represent the HA-
epitope tag introduced at the N-terminus (blue) and the individual residues mutated in this chapter (green) are illustrated. 
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Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
T2.39A 5‟-CTG-CGC-ACC-ACC-GCC-AAC-CTC-
TAC-CTG-3‟ 
5‟-CAG-GTA-GAG-GTT-GGC-GTT-GGT-
GCG-CAG-3‟ 
C3.35A 5‟-GTC-AGT-GAG-AGC-GCC-ACC-TAC-
GCC-ACG-3‟ 
5‟-CGT-GGC-GTA-GGT-GGC-GCT-CTC-
ACT-GAC-3‟ 
T3.36A 5‟-C-AGT-GAG-AGC-TGC-GCC-TAC-
GCC-ACG-GTG-3‟ 
5‟-CAC-CGT-GGC-GTA-GGC-GCA-GCT-
CTC-ACT-G-3‟ 
T3.36C 5‟-GT-GAG-AGC-TGC-TGC-TAC-GCC-
ACG-GTG-3‟ 
5‟-CAC-CGT-GGC-GTA-GCA-GCA-GCT-
CTC-AC-3‟ 
T3.36F 5‟-GT-GAG-AGC-TGC-TTC-TAC-GCC-
ACG-GTG-3‟ 
5‟-CAC-CGT-GGC-GTA-GAA-GCA-GCT-
CTC-AC-3‟ 
T3.36M 5‟-GT-GAG-AGC-TGC-ATG-TAC-GCC-
ACG-GTG-3‟ 
5‟-CAC-CGT-GGC-GTA-CAT-GCA-GCT-
CTC-AC-3‟ 
T3.36S 5‟-GT-GAG-AGC-TGC-AGC-TAC-GCC-
ACG-GTG-3‟ 
5‟-CAC-CGT-GGC-GTA-GCT-GCA-GCT-
CTC-AC-3‟ 
E3.49A 5‟-GCG-CTG-AGC-GTC-GCG-CGC-TAC-
TTC-GCC-3‟ 
5‟-GGG-GAA-GTA-GCG-CGC-GAC-GCT-
CAG-CGC-3‟ 
E3.49D 5‟-GCG-CTG-AGC-GTC-GAC-CGC-TAC-
TTC-GCC-3‟ 
5‟-GGG-GAA-GTA-GCG-GTC-GAC-GCT-
CAG-CGC-3‟ 
E3.49R 5‟-GCG-CTG-AGC-GTC-CGG-CGC-TAC-
TTC-GCC-3‟ 
5‟-GGC-GAA-GTA-GCG-CCG-GAC-GCT-
CAG-CGC-3‟ 
E3.49Q 5‟-CA-GCG-CTG-AGC-GTC-CAG-CGC-
TAC-TTC-GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-GCG-CTG-GAC-
GCT-CAG-CGC-TG-3‟ 
R3.50A 5‟-CTG-AGC-GTC-GAG-GCC-TAC-TTC-
GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-GGC-CTC-GAC-
GCT-CAG-3‟ 
R3.50E 5‟-CTG-AGC-GTC-GAG-GAG-TAC-TTC-
GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-CTC-CTC-GAC-
GCT-CAG-3‟ 
R3.50H 5‟-CTG-AGC-GTC-GAG-CAC-TAC-TTC-
GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-GTG-CTC-GAC-
GCT-CAG-3‟ 
R3.50K 5‟-CTG-AGC-GTC-GAG-AAG-TAC-TTC-
GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-CTT-CTC-GAC-
GCT-CAG-3‟ 
R3.50L 5‟-CTG-AGC-GTC-GAG-CTC-TAC-TTC-
GCC-ATC-3‟ 
5‟-GAT-GGC-GAA-GTA-GAG-CTC-GAC-
GCT-CAG-3‟ 
R3.50Q 5‟-CTG-AGC-GTC-GAG-CAG-TAC-TTC-
GCC-ATC-3‟  
5‟-GAT-GGC-GAA-GTA-CTG-CTC-GAC-
GCT-CAG-3‟ 
Y3.51A 5‟-G-AGC-GTC-GAG-CGC-GCC-TTC-
GCC-ATC-TGC-3‟ 
5‟-GCA-GAT-GGC-GAA-GGC-GCG-CTC-
GAC-GCT-C-3‟ 
A3.60Y 5‟-C-CCA-CTC-CGG-TAC-AAG-GTG-
GTG-GTC-3‟ 
5‟-GAC-CAC-CAC-CTT-GTA-CCG-GAG-
TGG-G-3‟ 
Y5.58A 5‟-GT-CTC-ACG-GTC-CTC-GCC-AGT-
CTC-ATC-GGC-AGG-3‟ 
5‟-CCT-GCC-GAT-GAG-ACT-GGC-GAG-
GAC-CGT-GAG-AC-3‟ 
Y5.58Q 5‟-CTC-ACG-GTC-CTC-CAG-CGT-CTC-
ATC-GGC-3‟ 
5‟-GCC-GAT-GAG-ACT-CTG-GAG-GAC-
CGT-GAG-3‟ 
H6.30A 5‟-C-AGG-GAC-CAG-AAC-GCC-AAG-
CAA-ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-GGC-GTT-CTG-
GTC-CCT-G-3‟ 
H6.30D 5‟-C-AGG-GAC-CAG-AAC-GAC-AAG-
CAA-ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-GTC-GTT-CTG-
GTC-CCT-G-3‟ 
H6.30E 5‟-GG-GAC-CAG-AAC-GAA-AAG-CAA-
ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-TTC-GTT-CTG-
GTC-CC-3‟ 
H6.30K 5‟-C-AGG-GAC-CAG-AAC-AAG-AAG-
CAA-ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-CTT-GTT-CTG-
GTC-CCT-G-3‟ 
H6.30Q 5‟-C-AGG-GAC-CAG-AAC-CAG-AAG-
CAA-ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-CTG-GTT-CTG-
GTC-CCT-G-3‟ 
H6.30R 5‟-GG-GAC-CAG-AAC-CGC-AAG-CAA-
ACC-GTG-3‟ 
5‟-CAC-GGT-TTG-CTT-GCG-GTT-CTG-
GTC-CC-3‟ 
Q6.32A 5‟-C-CAG-AAC-CAC-AAG-GCA-ACC-
GTG-AAA-ATG-C-3‟ 
5‟-G-CAT-TTT-CAC-GGT-TGC-CTT-GTG-
GTT-CTG-G-3‟ 
Q6.32E 5‟-C-CAG-AAC-CAC-AAG-GAA-ACC-
GTG-AAA-ATG-C-3‟ 
5‟-G-CAT-TTT-CAC-GGT-TTC-CTT-GTG-
GTT-CTG-G-3‟ 
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Table 4.1 Oligonucleotide primer sequences for QuikChange™ site-directed 
mutagenesis: Codons changed to introduce mutations shown in red. 
 
 
 
 
 
 
 
Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
T6.33A 5‟-G-AAC-CAC-AAG-CAA-GCC-GTG-
AAA-ATG-CTG-G-3‟ 
5‟-C-CAG-CAT-TTT-CAC-GGC-TTG-CTT-
GTG-GTT-C-3‟ 
T6.33V 5‟-G-AAC-CAC-AAG-CAA-GTC-GTG-
AAA-ATG-CTG-G-3‟ 
5‟-C-CAG-CAT-TTT-CAC-GAC-TTG-CTT-
GTG-GTT-C-3‟ 
V6.34A 5‟-C-CAC-AAG-CAA-ACC-GCG-AAA-
ATG-CTG-GC-3‟ 
5‟-GC-CAG-CAT-TTT-CGC-GGT-TTG-
CTT-GTG-G-3‟ 
V6.34K 5‟-C-CAC-AAG-CAA-ACC-AAG-AAA-
ATG-CTG-GC-3‟ 
5‟-GC-CAG-CAT-TTT-CTT-GGT-TTG-
CTT-GTG-G-3‟ 
V6.34T 5‟-C-CAC-AAG-CAA-ACC-ACG-AAA-
ATG-CTG-GC-3‟ 
5‟-GC-CAG-CAT-TTT-CGT-GGT-TTG-
CTT-GTG-G-3‟ 
W6.48A 5‟-GCC-TTC-ATC-CTC-TGC-GCG-CTC-
CCC-TTC-CAC-G-3‟ 
5‟-C-GTG-GAA-GGG-GAG-CGC-GCA-
GAG-GAT-GAA-GGC-3‟ 
W6.48F 5‟-C-TTC-ATC-CTC-TGC-TTC-CTC-CCC-
TTC-CAC-3‟ 
5‟-GTG-GAA-GGG-GAG-GAA-GCA-GAG-
GAT-GAA-G-3‟ 
W6.48Y 5‟-C-TTC-ATC-CTC-TGC-TAC-CTC-CCC-
TTC-CAC-3‟ 
5‟-GTG-GAA-GGG-GAG-GTA-GCA-GAG-
GAT-GAA-G-3‟ 
S7.45A 5‟-CTC-TTC-TAC-CTC-GCT-GCT-GCC-
ATC-AAC-3‟ 
5‟-GTT-GAT-GGC-AGC-AGC-GAG-GTA-
GAA-GAG-3‟ 
S7.45N 5‟-CTC-TTC-TAC-CTC-AAT-GCT-GCC-
ATC-AAC-3‟ 
5‟-GTT-GAT-GGC-AGC-ATT-GAG-GTA-
GAA-GAG-3‟ 
N7.49A 5‟-CTC-AGT-GCT-GCC-ATC-GCC-CCC-
ATT-CTG-TAC-3‟ 
5‟-GTA-CAG-AAT-GGG-GGC-GAT-GGC-
AGC-ACT-GAG-3‟ 
P7.50A 5‟-GCT-GCC-ATC-AAC-GCC-ATT-CTG-
TAC-AAC-3‟ 
5‟-GTT-GTA-CAG-AAT-GGC-GTT-GAT-
GGC-AGC-3‟ 
I7.51A 5‟-GCC-ATC-AAC-CCC-GCT-CTG-TAC-
AAC-ATC-3‟ 
5‟-GAT-GTT-GTA-CAG-AGC-GGG-GTT-
GAT-GGC-3‟ 
L7.52A 5‟-C-ATC-AAC-CCC-ATT-GCG-TAC-
AAC-ATC-ATG-3‟ 
5‟-CAT-GAT-GTT-GTA-CGC-AAT-GGG-
GTT-GAT-G-3‟ 
Y7.53A 5‟-C-AAC-CCC-ATT-CTG-GCC-AAC-
ATC-ATG-TCC-3‟ 
5‟-GGA-CAT-GAT-GTT-GGC-CAG-AAT-
GGG-GTT-G-3‟ 
K7.58A 5‟-C-AAC-ATC-ATG-TCC-GCG-AAG-
TAC-CGG-GTG-G-3‟ 
5‟-C-CAC-CCG-GTA-CTT-CGC-GGA-
CAT-GAT-GTT-G-3‟ 
K7.59A 5‟-C-ATC-ATG-TCC-AAG-GCG-TAC-
CGG-GTG-GCA-G-3‟ 
5‟-C-TGC-CAC-CCG-GTA-CGC-CTT-
GGA-CAT-GAT-G-3 
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stimulation with ghrelin. Some of the constructs were further characterised by InsP-InsP3 
accumulation assays after stimulation with the ghrelin-R inverse agonist, SP-analogue. Cell-
surface expression of the mutant receptor constructs were determined by ELISA using the 
HA-tag engineered at the N-terminus of the receptor (Chapter 3). The cell-surface expression 
characteristics were indicative of the ability of the mutant receptors to be trafficked to the cell 
membrane and to be functionally folded prior to trafficking.   
 
4.2.1 The role of the highly conserved ERY motif 
Glu
3.49
, Arg
3.50 
and Tyr
3.51 
of the ERY motif were substituted individually for alanine to 
produce E3.49A, R3.50A and Y3.51A mutant ghrelin-R constructs. E3.49A demonstrated 
„WT-like‟ binding affinity for ghrelin (Fig 4.2 (a), Table 4.2), but was unable to signal 
through the InsP3 pathway when stimulated by ghrelin. The constitutive activity of the 
ghrelin-R was unchanged in the E3.49A mutant receptor construct, despite the inability to 
further signal after agonist stimulation (Fig 4.2 (c)). Cell-surface expression of E3.49A was 
greatly reduced (30 %) compared to the WT receptor (Fig 4.2 (b)). R3.50A displayed WT-like 
binding affinity (Fig 4.3 (a)), but prevented ghrelin-stimulated signalling and slightly reduced 
the constitutive activity (-22 %) compared to WT (Fig 4.4 (a), Table 4.3). The cell-surface 
expression of this mutant was similar to that seen for the WT ghrelin-R (Fig 4.5). Y3.51A was 
essentially WT in all respects (Fig 4.6, Table 4.4). 
 
4.2.2 Further analysis of the ERY motif 
In order to more extensively characterise the ghrelin-R and further investigate the role of the 
residues within the ERY motif in ghrelin-R function, Glu
3.49 
and Arg
3.50 
were mutated to other 
amino acids. The mutant receptor constructs E3.49D, E3.49Q, E3.49R, R3.50E, R3.50H, 
R3.50K, R3.50L and R3.50Q were produced to probe the functional effects of altering the 
side chain characteristics within the ERY motif. The mutant receptor constructs produced 
could then be characterised and analysed based on the new side-chain properties. Tyr
3.51
 is not 
as well conserved (67 %) as Asp/Glu
3.49
 or Arg
3.50
 and the initial Y3.51A mutation was 
essentially WT with respect to all characteristics, therefore Tyr
3.51 
was not mutated further. 
 
4.2.2.1 Extended Analysis of Glu
3.49
 
All of the Glu
3.49
 mutants retained „WT-like‟ binding affinities for ghrelin (Fig 4.2, Table 
4.2). Aspartate and glutamate are very similar, however, aspartate is often found at position 
3.49 (66 %) whereas glutamate, as found in the ghrelin-R, is only found in 20 % of Family A 
receptors (Mirzadegan et al., 2003). An aspartate was therefore introduced at position 3.49 of 
 92 
the ghrelin-R in the E3.49D mutant to study the effect of shortening the amino acid side 
chain, whilst still retaining the overall negative charge at this position. This resulted in a 
mutant receptor construct with „WT-like‟ signalling and expression, but almost total ablation 
of constitutive activity (-78 % of WT ghrelin-induced maximum) revealing that glutamate at 
this position is important for maintaining ghrelin-R constitutive activity (Fig 4.2 (c)). The 
charge neutralisation mutation of E3.49Q resulted in a receptor with „WT-like‟ expression, 
EC50 and basal constitutive activity, but one that was unable to be maximally stimulated by 
ghrelin, with an Emax of only 35 % of WT ghrelin-R. The E3.49R mutation reversed the 
charge found at this locus. E3.49R resulted in a receptor that lost its ability to signal through 
the InsP3 pathway and displayed reduced cell-surface expression at only 29 % of the WT, 
similar to that seen for the E3.49A mutant (Fig 4.2, Table 4.2). E3.49D and E3.49R were 
analysed to determine their constitutive activity compared to WT ghrelin-R and mock-
transfected cells and were found to reduce basal signalling substantially to 13 % and 21 % of 
WT basal, respectively (Fig 4.2 (d)).  
 
4.2.2.2 Extended Analysis of Arg
3.50
 
All of the Arg
3.50 
mutants displayed binding affinities for ghrelin similar to that seen for the 
WT ghrelin-R and all presented „WT-like‟ cell-surface expression, except for R3.50K and 
R3.50L which increased expression (134 and 150 % respectively) (Fig 4.3 & 4.5, Table 4.3). 
R3.50E was introduced to investigate the effects of a reversal of charge at such a highly 
conserved residue. Constitutive ghrelin-R activity was almost totally abolished however 
ghrelin sensitivity was maintained, with the mutant demonstrating an EC50 similar to WT. The 
Emax for this mutant was also dramatically reduced, reflecting the diminished constitutive 
activity. R3.50H displayed greatly reduced constitutive activity, an increase in EC50 (8-fold), 
but was still responsive to ghrelin, albeit with reduced Emax. R3.50K, conserving a positive 
charge, retained some of the ghrelin-R constitutive activity but had an increased EC50 (4.7-
fold). The decrease in Emax observed for this mutant corresponded to its decrease in basal 
signalling. R3.50L greatly diminished constitutive activity, and was effectively unable to 
signal through the InsP3 pathway after ghrelin stimulation. The charge neutralising mutation, 
R3.50Q displayed a 3-fold increase in EC50, only a slight decrease in basal level of signalling 
and a „WT-like‟ Emax (Fig 4.4, Table 4.3).  
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Figure 4.2 Ligand binding, intracellular signalling and cell-surface expression profiles for Glu
3.49 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, E3.49A, E3.49D, E3.49Q or E3.49R and are expressed as a 
percentage of specific binding. (b) Cell-surface expression of mutant receptor constructs expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R, E3.49A, E3.49D, E3.49Q or E3.49R. Values are expressed as a percentage of the WT 
ghrelin-R, ghrelin-induced maximum from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation for E3.49D and E3.49R as a percentage of WT basal. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
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Table 4.2 Ligand binding, intracellular signalling and cell-surface expression for Glu
3.49 
mutant receptor constructs: Values were obtained 
using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey 
indicates WT ghrelin-R. Red indicates no detectable signalling, > 60 % reduction in basal activity compared to WT or > 70 % reduction in cell-
surface expression. Orange indicates > 60 % reduction in Emax.  
 
 
Construct 
 
Binding Affinity  
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal 
(% WT basal) 
 SEM 
Emax  
(% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
E3.49A 8.68 ± 0.03 NDS -1 ± 1 - NDS 30 ± 7 
E3.49D 8.32 ± 0.04 7.31 ± 0.05 -78 ± 1 13  9 79 ± 1 89 ± 11 
E3.49Q 8.50 ± 0.10 1.03 ± 0.66 7 ± 1 - 35 ± 1 83 ± 7 
E3.49R 8.64 ± 0.04 NDS -97 ± 3 21  8 NDS 29 ± 11 
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Figure 4.3 Ligand binding profiles for Arg
3.50 
mutant receptor constructs:  Competition radioligand binding assays were performed on HEK 
293T membranes from cells transiently transfected with (a) WT ghrelin-R, R3.50A, R3.50E or R3.50H and (b) WT ghrelin-R, R3.50K, R3.50L 
or R3.50Q. Values are expressed as a percentage of specific binding. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)          (b)      
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Figure 4.4 Inositol phosphate accumulation assay profiles for Arg
3.50 
mutant receptor constructs: Assays were performed on HEK 293T 
cells transiently transfected with (a) WT ghrelin-R, R3.50A, R3.50E or R3.50H and (b) WT ghrelin-R, R3.50K, R3.50L or R3.50Q. Values are 
expressed as a percentage of the WT ghrelin-R, ghrelin-induced maximum from experiments performed in parallel. (c) Basal InsP-InsP3 
accumulation for R3.50E, R3.50H and R3.50L as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)            (b)       (c) 
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Figure 4.5 ELISA cell-surface expression profiles for Arg
3.50 
mutant receptor constructs: Assays were performed on HEK 293T cells 
transiently transfected with WT ghrelin-R, R3.50A, R3.50E, R3.50H, R3.50K, R3.50L or R3.50Q. Values are expressed as a percentage of WT 
ghrelin-R expression from experiments performed in parallel. All data are the mean  SEM of three or more separate experiments, performed in 
triplicate.
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Table 4.3 Ligand binding, intracellular signalling and cell-surface expression for Arg
3.50 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Yellow indicates > 3-fold increase in EC50, >20 % reduction in basal activity and >30 % reduction in Emax. Orange indicates > 4-
fold increase in EC50 reduction of basal activity > 40 % compared to WT. Red indicates no detectable signalling, > 5-fold shift in EC50, > 60 % 
reduction in basal activity compared to WT or an Emax < WT basal. Green indicates > 130 % cell-surface expression and blue indicates > 150 % 
cell-surface expression compared to WT. 
 
Construct 
 
Binding Affinity  
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal 
(% WT basal) 
 SEM 
Emax  
(% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
R3.50A 8.82  0.05 NDS -22  7 - NDS 115  14 
R3.50E 8.25  0.02 6.13  2.36 -88  1 11  6 -23  1 113  6 
R3.50H 8.55  0.09 16.2  6.51 -112  1 21  1 -33  2 90  13 
R3.50K 8.40  0.08 9.99  0.72 -45  1 - 68  1 134  1 
R3.50L 8.54  0.06 NDS -76  1 27  2 NDS 150  11 
R3.50Q 8.82  0.03 6.38  4.14 -29  4 - 113  4 125  14 
 99 
 
 
 
 
 
-12 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
120
Y3.51A
WT ghrelin-R
log {[ghrelin] (M)}
%
 S
p
e
c
if
ic
 B
in
d
in
g
W T ghrelin-R Y3.51A
0
20
40
60
80
100
120
140
C
e
ll
-S
u
rf
a
c
e
 E
x
p
re
s
s
io
n
(%
W
T
)
-10 -9 -8 -7 -6
-60
-40
-20
0
20
40
60
80
100
120
log {[ghrelin] (M)}
In
s
P
-I
n
s
P
3
 A
c
c
u
m
u
la
ti
o
n
(%
 W
T
)
 
Figure 4.6 Ligand binding, intracellular signalling and cell-surface expression profiles for Y3.51A:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or Y3.51A and are expressed as a 
percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT 
ghrelin-R, or Y3.51A. Values are expressed as a percentage of the WT ghrelin-R, ghrelin-induced maximum from experiments performed in 
parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of 
three or more separate experiments, performed in triplicate. 
(a)       (b)      (c) 
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Table 4.4 Ligand binding, intracellular signalling and cell-surface expression for Y3.51A: Values were obtained using the methods 
described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates WT ghrelin-
R. Yellow indicates > 20 % reduction in basal activity.  
 
 
Construct 
 
Binding Affinity  
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression 
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Emax  
(% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
Y3.51A 8.52  0.05 2.12  0.31 -24  10 93  13 107  13 
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4.2.2.3 Investigation of the ERY motif using an inverse agonist 
The ghrelin-R inverse agonist, SP-analogue, was used to determine the responsiveness of 
ERY mutant receptor constructs to inverse agonist challenge. E3.49A, E3.49Q and R3.50A 
were chosen for investigation due to their ability to retain „WT-like‟ constitutive activity, 
despite a severely detrimental effect on ghrelin-induced signalling. E3.49A, E3.49Q and 
R3.50A were all able to respond to SP-analogue in a similar manner to the WT ghrelin-R, 
retaining „WT-like‟ pIC50 and Imax (Fig 4.7, Table 4.5).  
 
4.2.3 The role of residue 6.30 in ghrelin-R function 
An acidic residue is found at position 6.30 in 32 %, and a robust basic residue (arginine or 
lysine) is found in 34 % of Family A GPCRs (Mirzadegan et al., 2003). In Rho and the 
biogenic amine receptors, a glutamate is highly conserved at this position and forms the ionic 
lock interaction with Arg
3.50
 (Ballesteros et al., 2001). A histidine is found at position 6.30 in 
the constitutively active ghrelin-R, indicating that an “ionic lock-like” interaction does not 
occur with Arg
3.50
 of the ERY motif. In order to investigate the role of the residue at position 
6.30, His
6.30 
was mutated to alanine (H6.30A). This mutation effectively removed the 
functional amino acid side-chain and perturbed potential any intramolecular interactions, in 
which histidine usually participates. H6.30A resulted in a receptor that was functionally 
similar to the WT receptor, displaying „WT-like‟ binding affinity, EC50, basal signalling and 
cell-surface expression (Fig 4.8-4.10, Table 4.6). The Emax for this mutant receptor construct 
was slightly increased (130 %) compared to WT, suggesting that this mutant receptor has a 
greater efficacy than WT (Fig 4.9 (a), Table 4.6).  
 
In order to investigate the role of residue 6.30 in more depth, further mutant receptor 
constructs were created, substituting His
6.30 
for amino acids that altered the side chain 
properties. The constructs H6.30D, H6.30E, H6.30K, H6.30Q and H6.30R were produced. All 
of the His
6.30 
mutants displayed high affinity for ghrelin as demonstrated by radioligand 
binding studies (Fig 4.8, Table 4.6). H6.30D and H6.30E were introduced to investigate the 
effects of the introduction of a negative charge, as found in Rho and the biogenic amine 
GPCRs. Both constructs had „WT-like‟ EC50 values. The basal constitutive activity was 
reduced to similar levels (approximately -40 % compared to WT ghrelin-induced maximum) 
in each case, suggesting that a negative charge at this position created a more stable ground 
state receptor conformation. Interestingly, H6.30E displayed increased cell-surface expression 
(161 %) compared to WT, suggesting a more stable receptor conformation at the cell surface 
and H6.30D demonstrated an increase in Emax of 169 % compared to the WT ghrelin-R (Fig 
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Figure 4.7 Intracellular signalling profile for ghrelin-R ERY motif mutant constructs 
using SP-analogue: InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with (a) WT ghrelin-R, E3.49A, E3.49Q or R3.50A. Values are expressed as a 
percentage of the WT ghrelin-R basal from experiments performed in parallel. All data are the 
mean  SEM of three or more separate experiments, performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
 
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
E3.49A 7.83  0.07 89  6 40  4 
E3.49Q 7.64  0.20 88  14 43  4 
R3.50A 7.83  0.10 76  22 36  7 
 
Table 4.5 Intracellular signalling of ERY mutant receptor constructs using SP-analogue: 
Values were obtained using the methods described in Chapter 2. Data are the mean  SEM of 
three or more separate experiments, performed in triplicate. Grey indicates WT ghrelin-R. 
Yellow indicates a > 20 % reduction in basal. 
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4.9 & 4.10, Table 4.6). H6.30K and H6.30R introduced a robust positive charge at position 
6.30 as found in many Family A peptide hormone GPCRs. Both constructs, H6.30K and 
H6.30R, reduced the basal constitutive activity (-87 and -48 % of WT ghrelin-induced 
maximum, respectively), but retained the ability to signal through the InsP3 pathway after 
ghrelin stimulation, with potencies similar to that seen for the WT receptor. H6.30K 
demonstrated a slight increase in Emax compared to WT, whereas the H6.30R Emax was 
decreased, in parallel with its decreased basal. Both constructs were expressed at levels 
similar to the WT ghrelin-R at the cell surface (Fig 4.9 & 4.10, Table 4.6). The H6.30Q 
mutant, neutralising the charge on the side-chain, resulted in a receptor that demonstrated 
„WT-like‟ basal activity and EC50, but had a significantly increased Emax (165 %) compared to 
WT, suggesting an increase in efficacy. The cell-surface expression for this construct was 
comparable to the WT ghrelin-R (Fig 4.9 & 4.10, Table 4.6). H6.30E and H6.30K were 
further analysed with respect to basal signalling. H6.30E and H6.30K reduced basal signalling 
to 60 % and 41 % of WT basal, respectively (Fig 4.9 (c), Table 4.6). 
 
4.2.3.1 Investigation of His
6.30
 using an inverse agonist 
H6.30E and H6.30K were chosen for further analysis using the SP-analogue to investigate the 
effect of the inverse agonist on mutant receptor constructs with reduced constitutive activity. 
The constitutive activity of the H6.30E and H6.30K mutants was not reduced further by the 
addition of the SP-analogue suggesting that neither mutant responded to inverse agonist and 
that the basal signalling could not be reduced further after inverse agonist challenge. The 
H6.30E basal signalling was comparable to the Imax value for the WT ghrelin-R after 
stimulation with SP-analogue. The data suggest that the basal signalling cannot be reduced 
further after SP-analogue addition in a mutant receptor construct that demonstrates 
substantially decreased basal signalling (Fig 4.11, Table 4.7). 
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Figure 4.8 Ligand binding profiles for His
6.30 
mutant receptor constructs:  Competition radioligand binding assays were performed on HEK 
293T membranes from cells transiently transfected with (a) WT ghrelin-R, H6.30A, H6.30D or H6.30E and (b) WT ghrelin-R, H6.30K, H6.30Q 
or H6.30R. Values are expressed as a percentage of specific binding. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
 
(a)          (b)      
 105 
 
 
 
 
 
-10 -9 -8 -7 -6
-120
-100
-80
-60
-40
-20
0
20
40
60
80
100
120
140
160
180
200
WT ghrelin-R
H6.30E
H6.30A
H6.30D
{log [ghrelin] (M)}
In
s
P
-I
n
s
P
3
 A
c
c
u
m
u
la
ti
o
n
(%
 W
T
)
-10 -9 -8 -7 -6
-120
-100
-80
-60
-40
-20
0
20
40
60
80
100
120
140
160
180
200
WT ghrelin-R
H6.30K
H6.30R
H6.30Q
{log [ghrelin] (M)}
In
s
P
-I
n
s
P
3
 A
c
c
u
m
u
la
ti
o
n
(%
 W
T
)
M
oc
k
W
T 
gh
re
lin
-R
H
6.
30
E
H
6.
30
K
0
20
40
60
80
100
120
B
a
s
a
l 
In
s
P
-I
n
s
P
3
A
c
c
u
m
u
la
ti
o
n
(%
 W
T
 b
a
s
a
l)
 
 
Figure 4.9 Inositol phosphate accumulation assay profiles for His
6.30 
mutant receptor constructs: Assays were performed on HEK 293T 
cells transiently transfected with (a) WT ghrelin-R, H6.30A, H6.30D or H6.30E and (b) WT ghrelin-R, H6.30K, H6.30Q or H6.30R. Values are 
expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (c) Basal InsP-InsP3 
accumulation for H6.30E and H6.30K as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments 
performed in triplicate. 
(a)            (b)       (c) 
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Figure 4.10 ELISA cell-surface expression profiles for His
6.30 
mutant receptor constructs: Assays were performed on HEK 293T cells 
transiently transfected with WT ghrelin-R, H6.30A, H6.30D, H6.30E, H6.30K, H6.30Q or H6.30R. Values are expressed as a percentage of the 
WT ghrelin-R from experiments performed in parallel. All data are the mean  SEM of three or more separate experiments performed in 
triplicate. 
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Table 4.6 Ligand binding, intracellular signalling and cell-surface expression for His
6.30 
mutant constructs: Values were obtained using the 
methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Yellow indicates > 0.5 log unit decrease in agonist affinity or > 30 % reduction in Emax. Green indicates and an increase in Emax > 130 
%. Orange indicates a reduction in basal activity > 40 % of WT. Blue indicates an increase in Emax > 160 % or > 160 % cell-surface expression 
compared to WT. Red indicates > 60 % reduction in basal activity compared to WT. 
 
Construct 
 
Binding Affinity 
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal  
(% WT basal) 
 SEM 
Emax  
(% WT max) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
H6.30A 8.35  0.05 3.06  0.58 -9  7  - 130  11 97  9 
H6.30D 8.71  0.10 1.26  30.3 -48  15 - 169  20 127  8 
H6.30E 8.07  0.04 2.43  0.86 -44  4 60  3 115  20 161  14 
H6.30K 8.52  0.09 4.41  0.57 -87  17 41  1 147  9 124  11 
H6.30Q 8.54  0.08 1.66  1.46 -10  9 - 165  22 137  13 
H6.30R 8.44  0.06 3.05  0.83 -48  12 - 61 15 74  7 
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Figure 4.11 Intracellular signalling profile for His
6.30 
mutant constructs using SP-
analogue: InsP-InsP3 accumulation assays were performed on cells transiently transfected 
with WT ghrelin-R, H6.30E or H6.30K. Values are expressed as a percentage of the WT 
ghrelin-R basal from experiments performed in parallel. All data are the mean  SEM of three 
or more separate experiments, performed in triplicate. 
 
 
Table 4.7 Intracellular signalling of His
6.30 
mutant receptor constructs using SP-
analogue: Values were obtained using the methods described in Chapter 2. Data are the mean 
 SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Red indicates no detectable signalling. Orange indicates > 40 % reduction in basal 
activity. 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
 
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  0.4 
H6.30E NDS 64  9 NDS 
H6.30K NDS 42  1 NDS 
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4.2.4 Investigation of further stabilising interactions  
4.2.4.1 Interactions with the D/ERY motif 
In the β1AR (Warne et al., 2008), β2AR (Rasmussen et al., 2007), and A2AR (Jaakola et al., 
2008) crystal structures, the D/ERY motif is involved in constraining interactions with 
residues found within ICL2 and with residue 2.39 in TMII. At present, the only crystal 
structure that demonstrates the presence of the ionic lock in the inactive conformation is that 
of bRho (Palczewski et al., 2000) and therefore other constraining interactions are likely to be 
occurring in Family A GPCRs that stabilise the ground state. One residue, identified in the 
A2AR crystal structure as forming important stabilising interactions with the D/ERY motif is 
Tyr
3.60
 (Jaakola et al., 2008). An alanine is found at position 3.60 in the ghrelin-R, whereas 
the A2AR and the βARs have a tyrosine at position 3.60 in ICL2. To investigate the potential 
of an interaction between the ERY motif and ICL2 in the ghrelin-R, Ala
3.60 
was mutated to 
tyrosine. A threonine is present at position 2.39 in the ghrelin-R, A2AR and βARs. Thr
2.39 
was 
mutated to alanine in the ghrelin-R in this study. The agonist affinity and the EC50 for the 
T2.39A and the A3.60Y mutants were similar to the WT ghrelin-R (Fig 4.12 & 4.13, Table 
4.8). T2.39A had reduced Emax (63 %) and slightly decreased cell-surface expression (69 %), 
but maintained „WT-like‟ basal signalling (Fig 4.12, Table 4.8). A3.60Y caused a substantial 
reduction in the constitutive activity. The Emax for A3.60Y was also decreased in parallel with 
the basal (44 % of WT). A3.60Y cell-surface expression was „WT-like‟ (Fig 4.13, Table 4.8).  
 
To further probe the potential of interactions within this region of the ghrelin-R, a double 
mutant of T2.39A/A3.60Y was produced. By removing the threonine in the T2.39A mutant, 
the introduction of tyrosine at position 3.60 can be investigated in isolation, rather than in 
combination with a threonine at position 2.39, with which it may form an interaction. 
T2.39A/A3.60Y maintained „WT-like‟ affinity and cell-surface expression. The constitutive 
activity was diminished to a similar level to that seen for the A3.60Y single mutant; however, 
ghrelin-induced InsP-InsP3 accumulation was no longer detectable revealing that the double 
mutant was more detrimental than either of the single point mutations (Fig 4.14, Table 4.8). 
 
4.2.4.2 The role of residues at the cytoplasmic ends of TMVI and TMVII 
In inactive Rho, Glu
6.32 
at the cytoplasmic end of TMVI appears to interact with the backbone 
of Lys
7.58 
at the C-terminal end of TMVII (Vogel et al., 2008). This interaction is predicted to 
be broken upon receptor activation as the TMVI-TMVII interface changes conformation 
(Abdulaev et al., 1998; Vogel et al., 2008). Neutralisation of Glu
6.32 
by mutation 
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Figure 4.12 Ligand binding, intracellular signalling and cell-surface expression profiles for T2.39A:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or T2.39A and are expressed as a 
percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT 
ghrelin-R or T2.39A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in 
parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of 
three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Figure 4.13 Ligand binding, intracellular signalling and cell-surface expression profiles for A3.60Y:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or A3.60Y and are expressed as a 
percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT 
ghrelin-R or A3.60Y. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in 
parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of 
three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Figure 4.14 Ligand binding, intracellular signalling and cell-surface expression profiles for T2.39A/A3.60Y:  (a) Competition radioligand 
binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or T2.39A/A3.60Y and are 
expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or T2.39A/A3.60Y. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Table 4.8 Ligand binding, intracellular signalling and cell-surface expression for T2.39A, A3.60Y and T2.39A/A3.60Y mutant 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R. Yellow indicates > 30 % reduction in Emax or > 30 % reduction in cell-surface expression. 
Red indicates no detectable signalling or a > 60 % reduction in basal activity compared to WT.  
 
Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal 
 (% WT max)  
 SEM 
Emax 
 (% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
T2.39A 8.40  0.05 4.45  8.04 2  6 63  11 69  3 
A3.60Y 8.49  0.05 2.03  0.25 -71  18 44  3 123  14 
T2.39A/A3.60Y 8.63  0.04 NDS  -66  2 NDS 80  3 
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to glutamine in Rho resulted in a shift towards Meta II, indicative of a more active receptor 
conformation (Vogel et al., 2008). Although a lysine is found at position 7.58 in the WT 
ghrelin-R, there is a glutamine at 6.32 in the WT receptor. This lack of charge may contribute 
to the ghrelin-R constitutive activity. Gln
6.32
 was mutated to alanine and glutamate in order to 
investigate whether the constitutive activity of the ghrelin-R is related to the neutral charge 
found at position 6.32 and the subsequent lack of a stabilising interaction with TMVII. Lys
7.58 
and the neighbouring Lys
7.59 
were both mutated to alanine as part of the extended 
investigation. All of the mutant receptor constructs retained high affinity binding to ghrelin 
and „WT-like‟ cell-surface expression (Fig 4.15 & 4.16, Table 4.9). Q6.32A was „WT-like‟ 
with respect to the basal activity, potency and efficacy. Introducing a negative charge in the 
Q6.32E mutant resulted in a receptor with basal activity and EC50 similar to the WT ghrelin-
R, suggesting that an inactive stabilising interaction is not formed. The Q6.32E construct did 
however have greatly increased ghrelin efficacy (Emax 199 %) compared to WT (Fig 4.15, 
Table 4.9), supporting the formation of a more active receptor conformation after agonist 
binding. K7.58A displayed characteristics similar to WT, but had a small decrease in 
constitutive activity (-24 %). K7.59A had the greatest affect on ghrelin-R function, having 
decreased constitutive activity (-53 %), and Emax (46 %) and, interestingly, decreased EC50 
(3.5-fold) compared to WT (Fig 4.16, Table 4.9). 
 
Thr
6.33
 is found at the cytoplasmic end of TMVI in the ghrelin-R and is ideally positioned to 
interact with TMIII in the inactive receptor conformation. Mutation of Thr
6.33 
to alanine in the 
T6.33A mutant resulted in a receptor that displayed increased agonist-independent signalling 
(18 % of WT ghrelin-induced maximum or 132 % of WT basal) compared to the WT ghrelin-
R although the ability of T6.33A to signal through the InsP-InsP3 pathway when stimulated 
with ghrelin was affected (Fig 4.17 (c) & (d)). Despite the increased basal activity, the Emax 
was reduced to only 60 % of WT. Cell-surface expression of this mutant was also decreased 
(54 %). The agonist affinity remained comparable to the WT receptor (Fig 4.17, Table 4.10). 
To further investigate Thr
6.33, valine was introduced at this position. T6.33V retained „WT-
like‟ binding affinity, constitutive activity and EC50 and only presented a very slight decrease 
in Emax (75 % of WT). The cell-surface expression for this mutant was decreased (57 %), 
similar to the expression of the T6.33A mutant (Fig 4.17, Table 4.10).  
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Figure 4.15 Ligand binding, intracellular signalling and cell-surface expression profiles for Gln
6.32 
mutant receptor constructs:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, Q6.32A 
or Q6.32E and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R, Q6.32A or Q6.32E. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced 
maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT 
ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Figure 4.16 Ligand binding, intracellular signalling and cell-surface expression profiles for K7.58A and K7.59A
 
mutant receptor 
constructs:  (a) Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT 
ghrelin-R, K7.58A or K7.59A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, K7.58A or K7.59A. Values are expressed as a percentage of the WT ghrelin-R 
ghrelin-induced maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a 
percentage of the WT ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate.
(a)            (b)       (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
Q6.32A 8.80  0.05 1.96  0.88 4  6 98  22 80  2 
Q6.32E 8.39  0.05 1.25  0.29 -15  14 199  18 114  6 
K7.58A 8.66  0.09 1.76  0.89 -24  16 107  15 124  4 
K7.59A 8.66  0.02 0.60  0.91 -53  11 46  3 89  10 
 
 
Table 4.9 Ligand binding, intracellular signalling and cell-surface expression for Q6.32A, Q6.32E, K7.58A and K7.59A mutant 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R. Green indicates a > 3-fold decrease in EC50. Yellow indicates a reduction in basal activity 
> 20 % or > 30 % reduction in Emax. Orange indicates reduction of basal activity > 40 % of WT. Pink indicates an increase in Emax > 190 % of 
WT. 
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Figure 4.17 Ligand binding, intracellular signalling and cell-surface expression profiles for Thr
6.33 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, T6.33A or T6.33V and are expressed as a percentage of specific 
binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, T6.33A or T6.33V. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum and 
ghrelin-R basal from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. 
(a)       (b) 
 
 
 
 
 
 
 
(c)       (d)  
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Table 4.10 Ligand binding, intracellular signalling and cell-surface expression for Thr
6.33 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Green indicates increased basal signalling > 10 % of WT. Yellow indicates a decrease in Emax > 30 % of WT or decreased cell 
surface expression > 30 % of WT.  
 
Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 0 100 100 
T6.33A 8.58  0.07 1.24  1.75 18  11 132  19 60  9 54  9 
T6.33V 8.59  0.05 2.38  2.79 4  14 108  10 75  11 57  8 
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The residue at position 6.34 has been shown to be highly important in a number of Family A 
GPCRs. Mutation of Ala
6.34
 to any other amino acid in the α1bAR resulted in a constitutively 
active receptor (Kjelsberg et al., 1992). Other receptors have also demonstrated changes in 
basal signalling activity after mutation of 6.34 (Ren et al., 1993; Samama et al., 1993; Lattion 
et al., 1999; Huang et al., 2001) and the bRho crystal structure demonstrated an interaction 
between Arg
3.50 
and Thr
6.34 
(Palczewski et al., 2000). Val
6.34 
in the ghrelin receptor was 
mutated to alanine, lysine and threonine to investigate the effects of amino acid size and 
polarity at this position. V6.34A and V6.34T were comparable to the WT ghrelin-R in all 
characteristics (Fig 4.18, Table 4.11). V6.34K produced a receptor that was unable to bind 
[
125
I]ghrelin at the concentrations used in assay. The EC50 and cell-surface expression were 
similar to the WT receptor, but the introduction of lysine resulted in a decrease in basal 
constitutive activity (- 56 %) and Emax (48 %) (Fig 4.18, Table 4.11). 
 
4.2.4.3 Analysis of T6.33A using an inverse agonist 
The ghrelin-R inverse agonist, SP-analogue, was used to characterise the InsP-InsP3 
accumulation profile of the T6.33A CAM. Despite the increased basal signalling of the 
T6.33A mutant, the pIC50 and Imax for SP-analogue were similar to that observed for the WT 
ghrelin-R (Fig 4.19, Table 4.12), indicating that the high basal signalling could be reduced 
after inverse agonist stimulation. 
 
4.2.5 The role of residue 5.58
 
in ghrelin-R activity 
In the active G-protein-interacting opsin crystal structure, Tyr
5.58 
interacts with Arg
3.50 
of the 
D/ERY motif and stabilises the Arg
3.50 
interaction with the G-protein (Scheerer et al., 2008). 
Residue 5.58 has also been implicated in G-protein specificity. A neutrally charged amino 
acid, glutamine, is found at position 5.58 in the V2R, which couples to Gαs G-proteins.  
 
To investigate the role of Tyr
5.58 
in the ghrelin-R, Y5.58A and Y5.58Q mutants were 
produced. Y5.58A had „WT-like‟ ghrelin affinity (Fig 4.20 (a)), but a profound effect on 
signalling through the InsP3 pathway. Basal constitutive activity was substantially reduced 
and the mutant displayed a 4-fold increase in EC50. Interestingly, the efficacy of the Y5.58A 
mutant was significantly increased with an Emax of 224 % of WT (Fig 4.20 (c), Table 4.13). 
Y5.58Q displayed „WT-like‟ potency, with decreased basal and related decreased Emax (Fig 
4.20 (Fig 4.20 (c) & (d), Table 4.13). Ghrelin affinity was reduced; the mutant was unable to 
bind at the radioligand concentration used (Fig 4.20 (a), Table 4.13). Both of the Tyr
5.58 
mutants expressed at levels similar to WT at the cell-surface (Fig 4.20 (b), Table 4.13).
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Figure 4.18 Ligand binding, intracellular signalling and cell-surface expression profiles for Val
6.34 
mutant receptor constructs:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, 
V6.34A, V6.34K or V6.34T and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, V6.34A, V6.34K or V6.34T. Values are expressed as a percentage of the WT 
ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed 
as a percentage of the WT ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
  SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
V6.34A 8.72  0.06 2.39  1.59 -19  8 72  13 107  3 
V6.34K NDB 2.77  0.79 -56  10 52  12 89  9 
V6.34T 8.74  0.06 1.80  1.39 9  16 108  5 125  11 
 
 
Table 4.11 Ligand binding, intracellular signalling and cell-surface expression for Val
6.34
 mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R.  Red indicates no detectable binding. Orange indicates reduction of basal activity > 40 % of WT. Yellow indicates > 30 % 
reduction in Emax. 
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Figure 4.19 Intracellular signalling profile for T6.33A ghrelin-R mutant construct using 
SP-analogue: SP-analogue-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or T6.33A. Values are expressed as a percentage of 
the WT ghrelin-R basal from experiments performed in parallel. All data are the mean  SEM 
of three or more separate experiments, performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
 
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  0.4 
T6.33A 7.78  0.09 115  4 47  9 
 
Table 4.12 Intracellular signalling of the T6.33A
 
mutant receptor construct using SP-
analogue: Values were obtained using the methods described in Chapter 2. Data are the mean 
 SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Green indicates increased constitutive activity > 10 % of WT. 
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(a)         (b) 
 
 
 
 
(c)         (d) 
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Figure 4.20 Ligand binding, intracellular signalling and cell-surface expression profiles for Tyr
5.58 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, Y5.58A or Y5.58Q and are expressed as a percentage of specific 
binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R.  (c) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, Y5.58A or Y5.58Q. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
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Table 4.13 Ligand binding, intracellular signalling and cell-surface expression for Tyr
5.58 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R.  Red indicates no detectable binding or a decrease in basal signalling > 60 %. Orange indicates an increase in EC50 > 4-fold or a 
reduction in basal activity > 40 %. Yellow indicates a decrease in Emax > 30 % of WT. Pink indicates an increase in Emax > 190 % of WT. 
 
Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
Y5.58A 8.24  0.08 8.47  1.98 -70  3 25  4 224  12 128  15 
Y5.58Q NDB 5.32  1.04 -54  8 41  4 67  19 81  5 
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4.2.6 Investigation of the rotamer toggle switch in the ghrelin-R 
The activation of Family A GPCRs involves the toggling of Trp
6.48
 and the formation of 
stabilising interactions with a number of amino acids within TMs III, VI and VII. Trp
6.48 
of 
the ghrelin-R was mutated to alanine, phenylalanine and tyrosine to investigate the effect of 
both side chain removal and the introduction of other aromatic residues at this position. The 
W6.48A mutant resulted in a receptor that had a „WT-like‟ affinity for ghrelin (Fig 4.21 (a)), 
but was detrimental to signalling via the InsP3 pathway. W6.48A resulted in a 13-fold 
increase in EC50, completely diminished basal signalling and had an Emax below the WT basal 
signalling (-22 %), however, the receptor was still responsive to ghrelin to some degree (Fig 
4.21, Table 4.14). Retaining an aromatic residue at position 6.48 in W6.48F and W6.48Y 
resulted in mutant receptors with similar phenotypes; both had 7-fold increases in EC50, 
reduced basal (-58 and -56 % respectively) and reduced ghrelin-induced maximum, to 
approximately the level observed for WT basal. Both mutants had a binding affinity similar 
the WT (Fig 4.21, Table 4.14). W6.48A and W6.48Y displayed increased cell-surface 
expression (170 and 137 % of WT, respectively) whereas W6.48F expression was comparable 
to WT (Fig 4.21 (b), Table 4.14). 
 
Thr
3.36 
was mutated to alanine to produce the T3.36A mutant. Interestingly, this mutant 
displayed a very pronounced increase in basal constitutive activity, signalling at 70 % of the 
WT ghrelin-R, ghrelin-induced maximum (172 % of WT basal) (Fig 4.22 (c) & (d)). There 
was however, a 6-fold increase in EC50 indicating a reduced ghrelin potency. The WT Emax 
was reached, but not exceeded, despite the dramatic increase in the basal signalling. The 
binding affinity and cell-surface expression were comparable to WT (Fig 4.22, Table 4.15). 
To further investigate the role of Thr
3.36 
in the ghrelin-R, T3.36C, T3.36F, T3.36M and 
T3.36S mutants were produced to examine various side chain lengths and characteristics. 
None of these additional Thr
3.36 
mutants displayed constitutive activity (Fig 4.22 (c), Table 
4.15). All of these mutants had „WT-like‟ affinity for ghrelin. T3.36C and T3.36M EC50, 
basal signalling and expression were comparable to WT however both had increased Emax 
(146 and 137 % respectively). T3.36F displayed increased potency (3-fold). Cell surface 
expression of this mutant was also increased (143 %). Basal signalling was slightly reduced in 
the T3.36F and T3.36S mutants (-25 and -21 %, respectively), but T3.36S signalling was very 
impaired with an Emax of only 36 % of the WT ghrelin-R (Fig 4.22, Table 4.15). 
 
An asparagine is highly conserved at position 7.45 in Family A GPCRs (67 %) (Mirzadegan 
et al., 2003) and forms part of the NSxx motif in TMVII of many Family A GPCRs. In the 
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ghrelin-R, a serine is found at this locus. Serine is the second most common residue at this 
position, found in 12 % of Family A receptors including Rho (Mirzadegan et al., 2003). 
Asn
7.45 
has been shown to be important for both ligand binding and intracellular signalling in 
some Family A GPCRs (Van Sande et al., 1995; Jongejan et al., 2005).  
 
To investigate the role of Ser
7.45
 in the ghrelin-R, mutant receptor constructs were produced. 
Alanine was introduced in the S7.45A mutant to investigate the effect of removing the side 
chain. S7.45N was produced to investigate introduction of the more conserved asparagine 
residue at this position. Both mutants retained „WT-like‟ affinity for ghrelin (Fig 4.23 (a), 
Table 4.16). S7.45A had increased basal constitutive activity (134 % of WT basal) and 
retained the ability to signal further after stimulation with ghrelin with a resultant increase in 
Emax (178 %) and „WT-like‟ potency. The S7.45N mutant reduced constitutive activity, but 
increased ghrelin potency (3.5-fold). The Emax was similar to the WT ghrelin-R. The cell-
surface expression for S7.45A and S7.45N were 115 and 145 % respectively (Fig 4.23, Table 
4.16).    
 
Residue 3.35 has been proposed to participate in the network of stabilising hydrogen bonds 
within Family A GPCRs. In the ghrelin-R Cys
3.35
 was mutated to alanine to examine the 
specific role of the cysteine side chain at this position. The C3.35A mutant retained „WT-like‟ 
ghrelin affinity, basal signalling and cell-surface expression, but affected the ghrelin-induced 
signalling with a reduced Emax of 48 % of the WT (Fig 4.24, Table 4.17).  
 
4.2.6.1 Investigation of T3.36A using an inverse agonist 
InsP-InsP3 accumulation assays were conducted on T3.36A using the inverse agonist, SP-
analogue. T3.36A retained a pIC50 comparable to the WT ghrelin-R. The constitutive activity 
of the T3.36A mutant was decreased on addition of the SP-analogue with an Imax similar to 
that seen for the WT ghrelin-R, suggesting that despite the increased basal activity, SP-
analogue was able to inhibit the T3.36A mutant receptor signalling to the same extent as seen 
for the WT ghrelin-R (Fig 4.25, Table 4.18). 
 
4.2.6.2 Investigation of S7.45A using an inverse agonist 
The constitutive activity of the S7.45A mutant was decreased on addition of the SP-analogue 
and was able to approach a value near to the WT Imax at μM concentrations (Fig 4.26, Table 
4.19). From the data gather for S7.45A, when stimulated with inverse agonist, it is unclear 
whether the mutant receptor construct retains a „WT-like‟ pIC50 and Imax as a greater
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(a)         (b) 
 
 
 
 
 
 
 
(c)         (d) 
 
 
 
 
 
 
 
 
 
Figure 4.21 Ligand binding, cell-surface expression and intracellular signalling profiles for Trp
6.48 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, W6.48A, W6.48F or W6.48Y and are expressed as a percentage of 
specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays 
were performed on cells transiently transfected with WT ghrelin-R, W6.48A, W6.48F or W6.48Y. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced 
maximum from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate 
experiments, performed in triplicate. 
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Construct 
 
Binding Affinity 
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal  
(% WT basal) 
 SEM 
Emax  
(% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
W6.48A 8.49  0.06 26.62  25.3  -96  9 8  6 -22  5 170  10 
W6.48F 8.24  0.06 15.88  8.29 -58  7 38  4 5  15 127  7 
W6.48Y 8.49  0.05 14.86  8.82 -56  15 43  3 -1  11 137  22 
 
 
 
Table 4.14 Ligand binding, intracellular signalling and cell-surface expression for Trp
6.48 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Red indicates > 5-fold increase in EC50, > 60 % decrease in constitutive activity or Emax < WT basal signalling. Orange indicates 
reduction of basal activity > 40 % of WT or decreased Emax > 60 % of WT. Pink indicates cell-surface expression > 170 % of WT. Green 
indicates increased cell-surface expression > 130 % of WT. 
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Figure 4.22 Ligand binding, intracellular signalling and cell-surface expression profiles for Thr
3.36 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, T3.36A, T3.36C, T3.36F, T3.36M or T3.36S and are expressed as a 
percentage of specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R, T3.36A, T3.36C, T3.36F, T3.36M or T3.36S. Values are expressed as a percentage 
of the WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal.  All data are the 
mean  SEM of three or more separate experiments, performed in triplicate. 
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Table 4.15 Ligand binding, intracellular signalling and cell-surface expression for Thr
3.36 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Red indicates > 5-fold increase in EC50. Pink indicates an increase in basal signalling of > 60 % of WT. Yellow indicates a 
reduction in basal activity > 20 % of WT. Orange indicates reduction in Emax > 60 % of WT. Green indicates a decrease in EC50 > 3-fold, an 
increase in Emax > 130 % or an increase in cell-surface expression > 130 % of WT.  
 
Construct 
 
Binding Affinity  
pIC50 
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
 SEM 
 
EC50 (nM) 
 
Basal  
(% WT max) 
 SEM 
Basal  
(% WT basal) 
 SEM 
Emax 
 (% WT) 
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
T3.36A 8.51  0.10 13.63  8.73 70  17 172  14 110  11 108  13 
T3.36C 8.63  0.04 2.24  0.75 -18  9 - 146  16 118  5 
T3.36F 8.18  0.06 0.66  0.50 -25  12 - 129  13 143  6 
T3.36M 8.39  0.05 1.34  0.93 -20  6 - 137  13 122  7 
T3.36S 8.55  0.09 0.85  0.60 -21  6 - 36  13 124  6 
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(c)        (d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Ligand binding, intracellular signalling and cell-surface expression profiles for Ser
7.45 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, S7.45A or S7.45N and are expressed as a percentage of specific 
binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, S7.45A or S7.45N. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
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Table 4.16 Ligand binding, intracellular signalling and cell-surface expression for Ser
7.45 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Green indicates an increase in EC50 > 3-fold, an increase in basal > 10 % of WT basal or an increase in cell-surface expression > 
130 % of WT. Blue indicates an increase in basal signalling > 40 % or an increase in Emax > 160 %. Orange indicates a reduction in basal activity 
> 40 %. Yellow indicates a reduction in basal signalling > 20 % of WT. 
 
Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
S7.45A 8.20  0.07 5.82  3.76 41  9 134  6 178  22 115  8 
S7.45N 8.52  0.07 0.61  0.24 -53  11 64  5 90  14 142  11 
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Figure 4.24 Ligand binding, intracellular signalling and cell-surface expression profiles for the C3.35A
 
mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
C3.35A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or C3.35A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)             (b)         (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
C3.35A 8.56 ± 0.01 0.86 ± 0.58 -3 ± 2 48 ± 2 101 ± 5 
 
 
 
 
 
Table 4.17 Ligand binding, intracellular signalling and cell-surface expression for C3.35A
 
mutant construct: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Yellow indicates > 30 % reduction in Emax. 
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Figure 4.25 Intracellular signalling profile for T3.36A
 
using SP-analogue: InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R or 
T3.36A. Values are expressed as a percentage of the WT ghrelin-R basal from experiments 
performed in parallel. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
 
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
T3.36A 7.55 ± 0.25 161 ± 11 57 ± 6 
 
 
Table 4.18 Intracellular signalling of the T3.36A
 
mutant receptor construct using SP-
analogue: Values were obtained using the methods described in Chapter 2. Data are the mean 
 SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Pink indicates increase in constitutive activity > 60 % of WT basal. 
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Figure 4.26 Intracellular signalling profile for S7.45A
 
using SP-analogue: InsP-InsP3 
accumulation assays were performed on HEK 293T cells transiently transfected with WT 
ghrelin-R or S7.45A. Values are expressed as a percentage of the WT ghrelin-R basal from 
experiments performed in parallel. All data are the mean  SEM of three or more separate 
experiments, performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
  
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
S7.45A - 168  24 - 
 
 
Table 4.19 Intracellular signalling of S7.45A
 
mutant receptor construct using SP-
analogue: Values were obtained using the methods described in Chapter 2. Data are the mean 
 SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Pink indicates an increase in constitutive activity > 60 % of WT basal. 
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concentration of SP-analogue is required, although it appears to retain „WT-like‟ SP-analogue 
potency and efficacy, despite the substantial increase in basal activity.   
 
4.2.7 The role of the highly conserved NPxxY motif in ghrelin-R activity 
The NPxxY motif located at the C-terminal end of TMVII is a highly conserved motif 
involved in activation in Family A GPCRs. To investigate the role of these amino acids in the 
ghrelin-R, each residue was individually mutated to alanine to produce N7.49A, P7.50A, 
I7.51A, L7.52A and Y7.53A mutant receptor constructs. Although Asp
7.49
, Pro
7.50
, and Tyr
7.53 
are the most highly conserved, an isoleucine is found at position 7.51 and a leucine at position 
7.52 in 32 % and 36 % of Family A GPCRs respectively (Mirzadegan et al., 2003). All 
mutants displayed „WT-like‟ ghrelin potency (Fig 4.27 (c), Table 4.20). N7.49A and Y7.53A 
retained „WT-like‟ affinity for ghrelin as determined by radioligand binding. P7.50A was 
unable to bind [
125
I]ghrelin at the concentrations used. Interestingly, both I7.51A and L7.52A 
demonstrated increased affinity for ghrelin, ~3-fold, relative to the WT ghrelin-R (Fig 4.27 
(a), Table 4.20). The mutants displayed moderately decreased constitutive activity except for 
P7.50A, which retained basal activity similar to WT, but produced a dramatic increase in 
ghrelin efficacy (Emax 176 % of WT ghrelin-R). I7.52A and Y7.53A had reduced Emax, 
possibly in relation to their decreased basal signalling activity (Fig 4.27 (b), Table 7.20). 
None of the mutations had a large effect on cell-surface expression; only L7.52A had any 
effect, reducing expression to 67 % of WT (Fig 4.27 (c), Table 4.20).   
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Figure 4.27 Ligand binding, intracellular signalling and cell-surface expression profiles for N7.49A, P7.50A, I7.51A, L7.52A and Y7.53A 
mutant receptor constructs:  (a) Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently 
transfected with WT ghrelin-R, N7.49A, P7.50A, I7.51A, L7.52A or Y7.53A and are expressed as a percentage of specific binding. (b) Ghrelin-
induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT ghrelin-R, N7.49A, P7.50A, I7.51A, L7.52A or 
Y7.53A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (c) Cell-
surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
N7.49A 8.72  0.05 4.12  2.52 -42  10 93  23 101  6 
P7.50A NDB                5.27  0.92 1  14 176  21 92  11 
I7.51A 9.34  0.07 1.66  0.11 -40  11 64  4 70  6 
L7.52A 9.20  0.07  3.14  0.77 -53  12 104  10 67  2 
Y7.53A 8.63  0.04 1.65  1.11 -24  2 48  6 82  5 
 
 
Table 4.20 Ligand binding, intracellular signalling and cell-surface expression for N7.49A, P7.50A, I7.51A, L7.52A and Y7.53A mutant 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R.  Red indicates no detectable binding. Orange indicates reduction basal activity > 40 % of 
WT. Blue indicates a > 160 % increase in Emax. Green indicates an increase in pIC50 > 0.5 log units. Yellow indicates a decrease in basal activity 
> 20 %, a decrease in Emax > 30 % of WT or a decrease in cell-surface expression > 30 % of WT.  
 141 
4.3 Discussion 
 
A number of conformational changes take place within the receptors after agonist binding that 
are similar in all Family A members, despite pronounced variations in ligand and in receptor 
sequence. Studies of receptor activation have revealed a universal molecular mechanism, 
termed the „global toggle switch‟, which incorporates the structural rearrangements of TMIII 
and TMVI, involving the “see-saw-like” movements of TMVI around Pro6.50 (Schwartz et al., 
2006). Arguably the most important feature of GPCR activation is the movement of TMVI 
away from TMIII at the cytoplasmic face of the receptor, resulting in the exposure of key 
amino acids to the G-protein, enabling coupling and activation. Despite a proposed general 
overall mechanism of GPCR activation, the precise interactions that occur within the 
receptors vary throughout the superfamily. 
 
Most GPCRs display very little agonist-independent activity although some, like the ghrelin-
R, are able to signal to a large extent in the absence of an agonist. It would therefore be 
expected that the mechanisms that are involved in ghrelin-R activation may differ from those 
of a GPCR that does not display substantial constitutive activity, as the ghrelin-R might be 
expected to exist in partial transition between the R and R* states. GPCR constitutive activity 
may be a result of inherent receptor flexibility and an ability to adopt multiple conformational 
states in the absence of ligands, or it might be a reflection of high affinity for a G-protein, 
despite a constrained state (Kobilka et al., 2007). Rho is restrained in the inactive 
conformation by the endogenous, covalently bound, inverse agonist, 11-cis retinal. In the 
absence of retinal, the opsin protein adopts a more active conformation. The crystal structures 
of opsin, both alone and in the G-protein-interacting conformation, are the only crystal 
structures that denote active receptors (Park et al., 2008; Scheerer et al., 2008). The β2AR has 
been shown to display a certain amount of constitutive activity although the crystal structure 
of the β2AR is of an inactive receptor bound to the inverse agonist, carazolol (Rasmussen et 
al., 2007).  
 
To gain an insight into the underlying mechanisms of ghrelin-R constitutive and agonist-
induced activation, key motifs and individual residues, implicated in Family A GPCR 
activation, were extensively investigated. 
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4.3.1 The role of the ERY motif in ghrelin-R activity 
Activation of Family A GPCRs involves the rearrangement of interactions with and within the 
highly conserved D/ERY motif in TMIII. In Rho, protonation of Glu
3.49 
is predicted to allow 
movement of this residue
 
to a non-polar environment resulting in the loss of the salt bridge 
interaction with the neighbouring Arg
3.50
 (Palczewski et al., 2000; Li et al., 2004). Mutation 
of Asp/Glu
3.49
 in a number of GPCRs has allowed the characterisation of Family A receptors 
into two distinct phenotypes: phenotype 1 is characterised by increased constitutive receptor 
activity as a result of the aspartate/glutamate mutation, whereas phenotype 2 receptors do not 
demonstrate increased agonist-independent activity (Chung et al., 2002). It has therefore been 
concluded that despite an acknowledged essential role in GPCR function, Asp/Glu
3.49 
may 
participate in different interactions in different GPCRs of the same family. Examples of 
phenotype 1 receptors, where mutation of Asp/Glu
3.49 
to alanine results in constitutive activity 
include the V2R (Morin et al., 1998), the β2AR (Rasmussen et al., 1999), the α1bAR (Scheer et 
al., 1996), the MC4R (Yamano et al., 2004) and the H2R (Alewijnse et al., 2000). However, 
mutation of Asp
3.49 
to alanine in the GnRHR (Ballesteros et al., 1998), and the CB2 receptor 
(Feng et al., 2003), eliminated detectable activation and agonist binding. The mutation of 
Asp/Glu
3.49
 of the D/ERY motif is thought to result in constitutive activity due to the 
induction of conformational changes which result in a shift of Arg
3.50 
out of its constraining 
polar pocket. The disruption of the Asp/Glu
3.49
 interaction with Arg
3.50 
is believed to be a 
significant factor influencing the ability of a number of Family A GPCRs to adopt the R* 
active conformation (Scheer et al., 1996). In this study, substitution of Glu
3.49 
with alanine did 
not result in constitutive activity in the ghrelin-R; the E3.49A mutant was able to retain WT 
ghrelin-R constitutive activity. Ghrelin-induced signalling however was abolished, 
implicating Glu
3.49 
in the formation of the active conformation and not in the stabilisation of 
the inactive state implicated in phenotype 1, above.  
 
Mutation of Asp/Glu
3.49
 to residues other than alanine has also resulted in increased agonist-
independent activity in Family A GPCRs (Cohen et al., 1993; Scheer et al., 1996; Scheer et 
al., 1997; Morin et al., 1998; Alewijnse et al., 2000; Ballesteros et al., 2001; Favre et al., 
2005). In the α1bAR mutation of Asp
3.49 
to glutamate, arginine or asparagine resulted in 
significant increases in basal activity (Scheer et al., 1996). Mutation of Glu
3.49 
to glutamine in 
opsin resulted in increased constitutive activity, whereas mutation to aspartate resulted in 
inhibition of opsin activation highlighting the importance of a negative charge at this locus in 
maintaining an inactive state (Cohen et al., 1993; Arnis et al., 1994). 
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The E3.49D mutation converted the ghrelin-R into a „typical GPCR‟ with very little basal 
signalling, but a robust response to ghrelin. E3.49R ablates signalling whether constitutive, or 
ghrelin-induced, revealing that the charge reversal is not tolerated, possibly due to a repulsion 
of the neighbouring Arg
3.50
. Interestingly, mutation of Glu
3.49 
to aspartate was equally as 
detrimental to constitutive activity as reversing the charge by the introduction of arginine, and 
reduced basal activity to levels similar to that seen for the mock-transfected cells. The 
introduction of a glutamine at position 3.49, neutralising the charge found at this locus, did 
not affect the ghrelin-R constitutive activity although the receptor was unable to respond to 
ghrelin stimulation with anything like the same efficacy as observed for the WT ghrelin-R. 
This result highlights the requirement of a negative charge at this position for ghrelin-induced 
activation. The H2R has previously been studied to determine the effects of mutations within 
the DRY motif on Gαs-coupled receptors which display constitutive activity. Mutation of 
Asp
3.49 
to both alanine and asparagine produced increases in basal cAMP production 
indicating that the constitutive activity is able to be increased, even in receptors that already 
exhibit endogenous constitutive activity (Alewijnse et al., 2000). This is not found to be the 
case for the ghrelin-R.  
 
The introduction of alanine or a reversal of charge at position 3.49 in the E3.49A and E3.49R 
mutants respectively, were severely detrimental to cell-surface expression and were unable to 
signal after stimulation with ghrelin. E3.49A, however, retained „WT-like‟ constitutive 
activity, indicating that the 70 % reduction in cell-surface expression was not the reason 
underlying the loss of signalling capabilities. Ligand binding was not affected by either 
mutation suggesting that the decrease in cell-surface expression might be a result of a 
disruption of receptor trafficking, rather than gross miss-folding. Both the E3.49D and 
E3.49Q mutant receptor constructs expressed at the cell-surface at levels similar to that seen 
for the WT ghrelin-R. Consequently, the reduction in constitutive activity observed for the 
E3.49D mutant was not a result of decrease receptor expression and was a genuine 
characteristic of the introduction of an aspartate. Cell-surface expression has been shown to 
be reduced in a number of Asp/Glu
3.49
 mutations, possibly due to disruption of stabilising 
interactions, resulting in increased internalisation (Lu et al., 1997; Morin et al., 1998; 
Alewijnse et al., 2000). 
 
One of the most highly conserved residues in Family A GPCRs is the arginine located at the 
cytoplasmic side of TMIII. Forming part of the highly conserved D/ERY motif, Arg
3.50 
is 
involved in stabilising the ground state of GPCRs and in stabilising interactions that occur in 
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the active state (Ballesteros et al., 1998; Alewijnse et al., 2000; Scheer et al., 2000; Scheerer 
et al., 2008). Arg
3.50 
has also been reported to be directly involved in binding to G-proteins in 
a number of Family A GPCRs (Zhu et al., 1994; Scheer et al., 1996; Feng et al., 2003; 
Scheerer et al., 2008;). Studies have also shown that mutation of Arg
3.50
 is often particularly 
detrimental to GPCR function, suggesting a crucial role of this residue in receptor activation 
(Ballesteros et al., 1998; Alewijnse et al., 2000; Scheer et al., 2000; Lagane et al., 2005). 
Mutation of Arg
3.50
 has resulted in impaired signalling and complete loss of G-protein 
coupling in different receptors and the effect produced is often dependant on the amino acid 
that is introduced. A study by Scheer et al. (2000) mutated Arg
3.50
 of the α1bAR to several 
amino acids. Most substitutions resulted in receptors with impaired signalling capabilities, 
however, the R3.50K, R3.50D and R3.50H mutants all produced increases in agonist-
independent signalling through the InsP3 pathway. Mutation of Arg
3.50
 to alanine or 
asparagine did not produce constitutive activity, but resulted in receptors that were unable to 
signal through the InsP3 pathway (Scheer et al., 1996). This is in agreement with studies on 
the m1 mAChR and m2 mAChR (Zhu et al., 1994) and the V2R (Rosenthal et al., 1993). In 
contrast, in the oxytocin receptor, mutation of Arg
3.50 
to alanine resulted in constitutive 
activity (Fanelli et al., 1999). 
 
The mutations carried out at position 3.50 of the ghrelin-R had varying effects on receptor 
activation, however, none of the mutations induced further constitutive activation as seen for 
some GPCRs. The R3.50A receptor construct was unable to signal after stimulation with 
ghrelin, but retained a substantial level of constitutive activity suggesting that the introduction 
of a small, hydrophobic amino acid did not substantially affect G-protein coupling itself, but 
instead altered the ability of the receptor to adopt a fully active conformation. R3.50L was 
unable to signal after ghrelin stimulation but also diminished the WT ghrelin-R constitutive 
activity to levels near that seen for the mock-transfected cells. R3.50L was far more 
detrimental to receptor function than the alanine mutation which implies that the larger side 
chain of leucine obstructs interactions that allow the ghrelin-R to be constitutively active, 
possibly direct interactions with the G-protein. Leucine might be stabilising ground state 
interactions and these cannot be overcome by stimulation with ghrelin, or might interfere with 
receptor-G-protein coupling. The polar mutation, R3.50Q, was the least detrimental, 
maintaining characteristics similar to WT except for a slight reduction in constitutive activity 
and 3-fold increase in EC50. This suggests that the positive charge at position 3.50 is not 
essential for receptor activation. Supporting this finding, mutation of Arg
3.50 
to glutamine in 
the GnRHR was more tolerated than mutation to a conserved positive residue, lysine 
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(Ballesteros et al., 1998). For the ghrelin-R, constitutive activity was affected in the 
conservative R3.50K mutation and completely abolished in the R3.50H mutation, indicating 
that substitution of arginine with another positive residue is not capable of restoring ghrelin-R 
agonist-independent activity. R3.50K and R3.50H were more detrimental to constitutive 
activity than the R3.50A mutant and this suggests that introduction of lysine or histidine 
disrupts an interaction that is essential for constitutive activity. Although both the R3.50K and 
R3.50H mutants were capable of signalling after stimulation with ghrelin, neither mutant was 
able to signal to the same extent as the WT ghrelin-R and both displayed increases in EC50 
indicating that the ability of the receptor to adopt a fully active state was compromised. 
Reversing the charge found at position 3.50 by the introduction of glutamate eliminated any 
ghrelin-R constitutive activity but maintained ghrelin sensitivity. Interestingly, this mutant 
had a „WT-like‟ EC50 despite a severe reduction in Emax. These results suggest that, as found 
in many Family A GPCRs, an arginine at position 3.50
 
is necessary for WT ghrelin-R activity 
and that other amino acids cannot successfully substitute.  
 
Studies have suggested that, despite detrimental effects on G-protein coupling, agonist 
affinity can be increased with Arg
3.50 
mutation (Seibold et al., 1998; Scheer et al., 2000). This 
implies that substitution of Arg
3.50 
removes a stabilising interaction that keeps the receptor in 
the ground state, thereby allowing an R* conformation to be adopted and resulting in 
increased agonist affinity, but that G-protein coupling and activation is affected due to 
removal of a G-protein interaction site. There was no observed increase in agonist affinity for 
any of the Arg
3.50
 mutant receptor constructs. All of the Arg
3.50 
substitutions in the ghrelin-R 
retained „WT-like‟ affinity for ghrelin and „WT-like‟ expression at the cell-surface, indicative 
of correct folding and trafficking of the receptor constructs to the cell-surface. Any 
detrimental effects of the mutations on intracellular signalling were not, therefore, a result of 
reduced receptor expression or of a disruption to ghrelin binding.       
 
Further analysis of E3.49A, E3.49Q and R3.50A using SP-analogue demonstrated that the 
detrimental effect of these mutations on receptor responsiveness is related only to the agonist-
induced InsP-InsP3 accumulation. The effect of the SP-analogue on the mutant receptor 
constructs was comparable to the data for the WT ghrelin-R, despite the lack of ghrelin 
responsiveness. This suggests that a more inactive conformation is able to be formed after 
inverse agonist stimulation, and supports and highlights the retention of some level of 
constitutive activity in each of these mutants.   
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The tyrosine residue found at position 3.51 in TMIII is the least well conserved  residue (67 
%) of the D/ERY motif in Family A GPCRs (Mirzadegan et al., 2003) and is generally 
accepted to have little significance in receptor function (Lu et al., 1997; Wess, 1998; Rhee et 
al., 2000b). Mutation of Tyr
3.51 
to alanine resulted in a mutant ghrelin-R which displayed 
„WT-like‟ binding affinity, cell-surface expression and intracellular signalling capabilities and 
presented only a small decrease in basal activity. It is clear that a tyrosine at position 3.51 is 
not essential for correct receptor functioning in the ghrelin-R and therefore this residue was 
not mutated further in this investigation. 
 
4.3.2 Investigation of ‘ionic lock’ interactions within the ghrelin-R 
A number of residues within TMVI have been identified as being important for maintaining 
the inactive state of Family A receptors. A conserved glutamate residue at position 6.30 has 
been shown to interact with the D/ERY motif, through a hydrogen bonding network, creating 
the ionic lock (Ballesteros et al., 2001). The crystal structure of bRho demonstrated that, in 
the inactive conformation, TMIII and TMVI are constrained at their cytoplasmic ends by a 
salt bridge interaction (Palczewski et al., 2000). Glu
6.30 
at the cytoplasmic face of TMVI can 
form an ionic bond with the highly conserved Arg
3.50 
in the D/ERY motif of TMIII. Arg
3.50 
is, 
in turn, interacting with the neighbouring Glu
3.49 
creating a stabilising network of ionic bonds 
which maintain the inactive state. A negative charge is found at position 6.30 in 32 % of 
Family A GPCRs (Mirzadegan et al., 2003) including all of the receptors that currently have 
determined crystal structures. Despite this, only the dark-state Rho crystal structures 
demonstrate the presence of the ionic lock interaction. The crystal structure of the β2AR, 
where ICL3 was replaced by the T4L and the receptor is bound to a partial inverse agonist, 
carazolol, demonstrated that Arg
3.50
 and Glu
6.30
 are 10 Å apart and are therefore not capable of 
interacting to produce the proposed ionic lock (Cherezov et al., 2007). However, the presence 
of the T4L has been suggested to influence the positioning of the helices in the crystal 
structure due to the interaction of Glu
6.30
 and Arg8 of the T4L and similar disruptions to the 
cytoplasmic conformation of the receptor have been observed in the β2AR-Fab crystal 
structure (Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007). Carazolol 
is only a partial inverse agonist of the β2AR, and so there may be some constitutive activity 
retained in the β2AR-T4L and this may also account for the absence of the ionic lock 
interaction (Rasmussen et al., 2007). Furthermore, it is thought that the T4L may, in itself, be 
inducing a partial constitutively active phenotype due to its presence in ICL3 and subsequent 
disruption of the close contacts between TMIII and TMVI (Cherezov et al., 2007; Rosenbaum 
et al., 2007).  
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In peptide GPCRs, a negative charge is found at position 6.30 in only 14 % of receptors 
indicating that the classical „ionic lock‟ does not occur in most members of this family. In a 
constitutively active GPCR such as the ghrelin-R, it could be predicted that a number of the 
constraining intramolecular interactions seen in Family A GPCRs do not occur and that this 
results in the more active phenotype. In the ghrelin-R, a histidine is found at position 6.30, 
indicative of the absence of an amine-GPCR-like “ionic lock” interaction (Fig 4.28). Despite 
this, molecular modelling of the ghrelin-R has indicated that activation of the receptor 
involves the classical movement of TMVI and TMVII toward each other and the movement 
of the cytoplasmic end of TMVI away from TMIII (Floquet et al., 2010). In order to 
investigate the activation mechanisms of the ghrelin-R in detail, His
6.30 
was mutated to 
various other amino acids. Each mutation was designed to probe potential interactions 
occurring at the cytoplasmic face of the receptor and to determine interactions that are integral 
to the ghrelin-R constitutive activity.  
 
The introduction of alanine in the H6.30A mutant resulted in a receptor that displayed „WT-
like‟ characteristics suggesting that removal of the histidine side chain at the β-carbon did not 
perturb the receptor. In the WT ghrelin-R, His
6.30
 does not appear to be structurally or 
functionally significant as substitution of His
6.30 
for alanine results in very little overall effect. 
Introduction of a negative charge in both the H6.30E and H6.30D mutants resulted in 
decreased constitutive activity of the ghrelin-R, suggesting that a more inactive receptor 
conformation was adopted (Fig 4.29). Both mutants were able to signal when stimulated with 
ghrelin, indicating that a fully active conformation could still be achieved. The introduction of 
glutamate at this position appeared to result in a more stable receptor conformation. Cell-
surface expression of this mutant construct was increased to 161 % of WT, suggesting a 
stabilised receptor at the cell surface, potentially with less constitutive internalisation than 
seen for the WT ghrelin-R (Chapter 3). Mutation of Arg
6.30 
to glutamate or aspartate in the 
CCR5 resulted in ablation of constitutive activity, suggesting that introduction of a potential 
ionic interaction with Arg
3.50 
stabilises the inactive receptor (Springael et al., 2007). In the 
constitutively active H4R, alanine is found at position 6.30, unusually for a biogenic amine 
receptor. Ala
6.30
 was mutated to glutamate to investigate the introduction of an “ionic lock-
like” residue on the constitutive receptor activity. No significant reduction in receptor 
constitutive activity was observed in the H4R A6.30E mutant suggesting that the introduction 
of an “ionic lock-type” interaction is not sufficient to significantly reduce constitutive activity 
(Schneider et al., 2010). Interestingly, histidine and alanine are found in only 4 % of Family 
A GPCRs (Mirzadegan et al., 2003) possibly being a factor in receptor constitutive activity. 
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Figure 4.28 ghrelin-R model: (a) Model of the ghrelin-R viewed from the cytoplasmic 
surface showing the position of His
6.30 
on TMVI and neighbouring residues that might engage 
in interactions in the receptor ground state. (b) Forced activation of the ghrelin-R model based 
on the adenosine A2AR crystal structure (Jaakola et al., 2008) and the GαCT-bound opsin 
(Scheerer et al., 2008). Model produced by N. Floquet, Montpellier, France. 
(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 4.29 ghrelin-R model: (a) Mutation of His
6.30 
to glutamate in the H6.30E mutant 
resulted in the formation of ionic lock-type interaction with Arg
3.50 
in TMIII (b) Molecular 
dynamic simulations were conducted based on the crystal structures of the A2AR (Jaakola et 
al., 2008) and the GαCT-bound opsin (Scheerer et al., 2008). The data show the disruption of 
the ionic lock as the model is forced into the active conformation. Model produced by N. 
Floquet, Montpellier, France.  
 
 
Inactive      Active 
(a) 
 
 
 
 
 
 
 
 
 
(b) 
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In other Family A GPCRs, mutation of residue 6.30 has varied effects on constitutive activity. 
The basal activity of the constitutively active mutant, T6.34K, in the μ-OR, could be reduced 
when a Leu
6.30
 to glutamate mutation was introduced (Huang et al., 2002) and the naturally 
occurring Asp
6.30 
has been shown to form stabilising interactions in the glycoprotein hormone 
receptors. Mutation of Asp
6.30 
increased constitutive activity in the thyrotropin-stimulating 
hormone receptor (TSHR) (Parma et al., 1993), FSHR (Montanelli et al., 2004a) and the LHR 
(Laue et al., 1995; Kosugi et al., 1996). In contrast, in the constitutively active CB1 and CB2 
receptors, which also have an aspartate located at position 6.30, the charge-neutralising 
mutation of Asp
6.30 
to asparagine did not increase the constitutive activity, indicating that 
Asp
6.30
 does not form an ionic bond interaction with Arg
3.50 
in these receptors, or if it does, 
that the ionic bond is not essential to the maintenance of ground-state interactions (Nebane et 
al., 2006).  
 
Charge-neutralising mutations of Asp
3.49 
and Glu
6.30
 in the β2AR demonstrated that removal of 
both the Asp
3.49
-Arg
3.50
 interaction and the Arg
3.50
-Glu
6.30
 interaction resulted in a receptor 
that was more readily able to adopt an active conformation (Ballesteros et al., 2001). 
Mutagenesis and modelling carried out on the α1bAR suggested that similar interactions are 
occurring between Glu
6.30
 and Arg
3.50
 as those found in Rho and the β2AR. The mutation of 
Glu
6.30 
to glutamine did not change the receptor constitutive activity however it did result in a 
mutant α1bAR that displayed a 50 % increase in maximal response after agonist stimulation. 
Computer simulations were inconclusive when attempting to provide explanation for this 
observation (Greasley et al., 2002). A similar result was observed when His
6.30 
was mutated to 
glutamine in the H6.30Q ghrelin-R mutant. No change was observed in the constitutive 
activity; however, the maximal ghrelin-induced signal was increased to 165 % of WT.    
 
The introduction of a positive charge in the H6.30K and H6.30R mutations both resulted in 
receptors with decreased constitutive activity relative to the WT ghrelin-R. H6.30K had a 
particularly profound effect, reducing the constitutive activity to -87 % of the WT (41 % of 
WT basal). It might have been predicted that the introduction of a robust positive charge 
would repel Arg
3.50
, resulting in a more active receptor conformation, as found with the 
5HT2AR (Shapiro et al., 2002), and the α1bAR (Greasley et al., 2002). However, 54 % of 
peptide receptors have a positive charge at this locus, and most present no appreciable 
constitutive activity, suggesting that other interactions must be occurring that stabilise the 
ground state. This is supported by the H6.30K and H6.30R ghrelin-R mutants, where agonist-
independent activity was reduced. Modelling can provide mechanistic insight into the loss of 
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constitutive activity observed with the H6.30K and H6.30R mutants. H6.30K loss of 
constitutive activity is likely caused by repulsion between H6.30K and neighbouring 
positively charged residues found in TMV (Lys
5.69
) and TMVI (Lys
6.31
) (Fig 4.30). A large 
cluster of positive residues are located at the cytoplasmic face of TMV. These positive 
residues inhibit the TM movement associated with activation in the H6.30K and H6.30R 
mutants, thereby decreasing constitutive activity. Interactions also occurred between Arg
3.50
 
and Thr
6.33
 in the H6.30K mutant ghrelin-R, stabilising the inactive receptor conformation by 
maintaining the cytoplasmic ends of TMIII and TMVI in close proximity.  
 
It is apparent from the molecular modelling and mutagenesis of the ghrelin-R that when 
His
6.30
 is substituted by either a negative or a positive residue, different interactions are 
formed which act to stabilise the inactive R state of the receptor, but that the mechanisms 
involved are distinct in the different mutant receptor constructs. H6.30D and H6.30E may act 
to produce an “ionic lock-type” interaction with Arg3.50 (Fig 4.29 (a) & (b)), whereas H6.30K 
and H6.30R appear to repel TMV and allow Thr
6.33
 to form a stabilising hydrogen bond 
interaction with Arg
3.50
 (Fig 4.30).     
 
4.3.3 Investigation of further stabilising interactions 
4.3.3.1 Interactions with the ERY motif 
In the β1AR (Warne et al., 2008), β2AR (Rasmussen et al., 2007) and A2AR (Jaakola et al., 
2008) crystal structures, the D/ERY motif is involved in constraining interactions with ICL2. 
In the A2AR and the β1AR, Asp
3.49
 forms hydrogen bond interactions with Tyr
3.60 
found in 
ICL2 and in the A2AR stabilising interactions also include Thr
2.39
 located at the cytoplasmic 
face of TMII (Fig 4.31 (insert)). These interactions are thought to be possible due to a short 
helical section within ICL2 that is present in the β1AR (Warne et al., 2008), and the A2AR 
(Jaakola et al., 2008), but not in the other crystal structures, and positions Tyr
3.60
 close to 
Asp
3.49. In the β1AR, mutation of Tyr
3.60 
results in a thermally unstable receptor supporting the 
proposed stabilising interaction that occurs between Asp
3.49
 and Tyr
3.60
 (Warne et al., 2008). 
Mutation of Tyr
3.60
 in the m5 mAChR resulted in increased constitutive activity and this 
receptor also displays an α-helical conformation of ICL2 (Burstein et al., 1998). The 
interaction between Tyr
3.60 
and Asp
3.49
 is lacking in the constitutively active β2AR. In this 
receptor other interactions have been proposed to form between the D/ERY motif and ICL2 at 
residue 3.62 (Jaakola et al., 2008).  
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Figure 4.30 ghrelin-R model: (a) Mutation of His
6.30 
to lysine in the H6.30K mutant resulted 
in repulsion of positively charged residues within TMV and allowed Thr
6.33 
to interact with 
Arg
3.50 
accounting for the reduction in constitutive activity observed, (b) Molecular dynamic 
simulations were conducted based on the crystal structures of the A2AR (Jaakola et al., 2008) 
and the GαCT-bound opsin (Scheerer et al., 2008). Lysine was energetically unfavourable at 
position 6.30 due to charge-charge repulsions with TMV residues. Model produced by N. 
Floquet, Montpellier, France. 
 
Inactive      Active 
(a) 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 4.31 ghrelin-R model: the ghrelin-R viewed from the cytoplasmic face showing the 
short helical region of ICL2. Model produced by N. Floquet (Montpellier, France). Insert: 
Crystal structure of ICL2 of the A2AR showing the hydrogen bond between Asp
3.49
 and Tyr
3.60 
(image adapted from Worth et al., 2009). 
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The ghrelin-R model produced by N. Floquet (Montpellier, France), demonstrated the 
presence of a short helical region in ICL2, as found in the β1AR, m5 mAChR and A2AR (Fig 
4.31). To investigate the potential of interactions between the ERY motif, Thr
2.39 
and Ala
3.60
 
were mutated in the ghrelin-R.
 
T2.39A, A3.60Y and a double mutant, T2.39A/A3.60Y, were 
introduced into the ghrelin-R. 
 
Removing the threonine side chain at position 2.39 in the T2.39A mutant had very little effect 
on ghrelin-R function. The introduction of alanine did not affect the constitutive activity of 
the ghrelin-R indicating that threonine is not essential at this locus for maintaining the WT 
basal signalling. In contrast, A3.60Y caused a substantial reduction in the constitutive activity 
of the receptor, suggesting that new ground-state stabilising interactions may have been 
formed, perhaps with Glu
3.49
, similar to those interactions observed in the A2AR crystal 
structure (Jaakola et al., 2008) and β1AR (Warne et al., 2008). The A3.60Y mutant was still 
able to respond to ghrelin stimulation, but with reduced efficacy, in parallel with the 
decreased constitutive activity, which implies that the receptor is unable to adopt the fully 
active conformation in the presence of ghrelin.  
 
To further probe the potential of interactions within this region of the ghrelin-R, a double 
mutant of T2.39A/A3.60Y was produced. By removing the threonine at position 2.39, but 
maintaining a tyrosine at 3.60, as in the A3.60Y mutant, the effect of the introduction of 
Tyr
3.60
, in the absence of the potentially stabilising interaction with Thr
2.39
, can be 
investigated. T2.39A/A3.60Y maintained the ability to bind ghrelin with „WT-like‟ affinity 
and to express at the cell-surface. The constitutive activity was diminished to a similar level to 
that seen for the A3.60Y single mutant; however, ghrelin-induced InsP-InsP3 accumulation 
was no longer detectable. This suggests that there may be an interaction occurring between 
Thr
2.39
, Glu
3.49
 and Tyr
3.60
 in the A3.60Y ghrelin-R mutant. Although both the single T2.39A 
and A3.60Y mutants reduced ghrelin efficacy, a response was still able to be elicited. 
Removal of the threonine after introduction of the tyrosine resulted in a receptor that was 
unable to adopt an active conformation after ghrelin stimulation. 
 
4.3.3.2 The role of residues at the cytoplasmic ends of TMVI and TMVII 
Crystal structures and molecular modelling have demonstrated that the cytoplasmic ends of 
TMVI and TMVII participate in significant conformational changes that are critical to 
receptor activation (Rosenbaum et al., 2009). In Rho, antibodies specific to the cytoplasmic 
end of TMVII were only able to bind the Meta II state, suggesting that a section of TMVII is 
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exposed in the Meta II state and is inaccessible in the dark state (Abdulaev et al., 1998) and 
this supports data for conformational rearrangements of TMVII as well as TMVI.  
 
In the dark state of Rho, Glu
6.32
 at the cytoplasmic end of TMVI
 
is proposed to interact with 
the backbone of a lysine residue, located at the TMVII-HelixVIII interface, Lys
7.58
. It was 
suggested, through mutagenesis studies, that this interaction is broken upon receptor 
activation and subsequent transition to Meta II (Vogel et al., 2008). Mutation of Glu
6.32 
to 
glutamine in Rho resulted in a small shift in the equilibrium between Meta I and Meta II 
towards Meta II, suggesting a weakening of the stabilising interhelical interactions, 
facilitating a transition towards a more active state (Vogel et al., 2008). In the ghrelin-R, a 
glutamine is present at position 6.32 and a lysine at position 7.58. Gln
6.32
 was mutated to 
glutamate to investigate the effect of the introduction of a potentially stabilising interaction 
between TMVI and TMVII. This residue was also substituted by alanine to investigate 
interactions occurring with and around position 6.32 in more detail.  
 
The Q6.32A mutation has no effect on radioligand binding, intracellular signalling or cell-
surface expression in the ghrelin-R, suggesting that glutamine is not important for normal 
receptor function. Mutation to glutamate did not affect ligand binding, constitutive activity or 
cell-surface expression. This suggests that stabilising interactions with TMVII are not formed. 
However, the Q6.32E mutation did have a profound effect on the ghrelin-induced InsP-InsP3 
accumulation profile. The efficacy of ghrelin was greatly increased, with the mutant receptor 
construct displaying an Emax of 199 % of WT. Consequently, in contrast to Rho, new 
interactions must be occurring when a glutamate is introduced at position 6.32, that stabilise 
the active receptor conformation after agonist stimulation, or that support a different form of 
active state. The introduction of glutamate may influence G-protein coupling itself, increasing 
the affinity of the receptor for G-protein, in the ghrelin-induced active conformation.  
 
Lys
7.58 
and Lys
7.59
, located at the TMVII-HelixVIII interface, were mutated to alanine to 
investigate the potential of an interaction with residues in TMVI similar to those found in 
Rho. K7.58A was „WT-like‟ with respect to binding affinity, cell-surface expression and 
intracellular signalling characteristics. Only a slight decrease in basal constitutive activity was 
observed. The K7.59A mutant had a more detrimental effect on receptor function. Ghrelin 
binding affinity was „WT-like‟, whilst the signalling was affected by the alanine substitution. 
Constitutive activity was diminished to -53 % of that seen for the WT ghrelin-R and the 
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K7.59A mutant was unable to signal to the same extent as the WT ghrelin-R (Emax = 46 %). A 
small decrease in EC50 (3.5-fold) was observed, indicative of increased potency of ghrelin. 
The data for the Gln
6.32
, Lys
7.58
 and Lys
7.59
 mutations suggest that an interaction does not 
occur between these residues in the WT ghrelin-R, nor in the Q6.32E mutant receptor 
construct. The Q6.32E mutation must form new stabilising interactions that allow a more 
active conformation to be adopted after ghrelin stimulation and must support interactions that 
maintain ghrelin-R constitutive activity, although, currently, it is unclear as to what these 
interactions may be. 
 
Another residue at the cytoplasmic end of TMVI, Thr
6.33
, might be involved in interactions 
that stabilise either the ground state, or the active receptor conformation. The positioning of 
Thr
6.33
 at the cytoplasmic end of TMVI in the ghrelin-R means that this residue may interact 
with TMIII in the inactive receptor conformation. Thr
6.33
 was mutated to alanine in the 
ghrelin-R to investigate its role in the WT receptor. Mutation of Thr
6.33 
to alanine resulted in 
increased constitutive activity of the ghrelin-R suggesting that threonine in the WT receptor 
engages in stabilising interactions that maintain the ghrelin-R basal activity at appropriate 
levels. The T6.33A mutant appears to release a constraint allowing the receptor to adopt a 
more active conformation in the absence of the agonist, ghrelin. After stimulation with 
ghrelin, the T6.33A mutant receptor construct was unable to reach the WT Emax suggesting 
that Thr
6.33
 contributes to interactions that stabilise the R and the R* state. Molecular 
modelling of the H6.30K mutant ghrelin-R implicated Thr
6.33
 in the stabilising of the inactive 
state through the formation of a hydrogen bond with Arg
3.50
. It is possible that Thr
6.33
 plays a 
similar role in stabilising the WT ghrelin-R, as the T6.33A mutant increased constitutive 
activity.  
 
Valine was introduced as it has a similar side chain size as threonine, but lacks the polar 
character, to further probe the role of Thr
6.33
. The T6.33V mutant did not affect ghrelin-R 
constitutive activity suggesting that the side chain size, and not the polarity of the residue, is 
responsible for maintaining the basal activity of the WT receptor. Neither mutation at position 
6.33 affected agonist affinity however both reduced the receptor cell-surface expression. 
Mutation of Thr
6.33
 in the V1aR to valine resulted in increased basal activity suggesting that in 
the V1aR, the ability of the residue at position 6.33 to hydrogen bond is essential for 
suppressing basal signalling. This was further supported by the conservative T6.33S mutation 
that retained „WT-like‟ characteristics (Wootten & Wheatley, manuscript in preparation).     
 157 
The intracellular signalling capabilities of the T6.33A mutant were investigated further using 
the ghrelin-R inverse agonist SP-analogue. The T6.33A mutant affected the efficacy of 
ghrelin; however, the potency and efficacy of SP-analogue were not affected by the mutation. 
The basal signalling of the T6.33A mutant was decreased using the SP-analogue with „WT-
like‟ Imax and pIC50. This suggests that T6.33A only affects the agonist response and the 
ability of the receptor to adopt the fully active conformation, and not the ability of the 
receptor to form a more stable inactive conformation after stimulation with an inverse agonist.    
 
Residue 6.34 has been studied extensively in Family A GPCRs due to its relationship with 
receptor activation and the maintenance of ground-state interactions. In the crystal structure of 
bRho, an interaction has been demonstrated between Arg
3.50
 and Thr
6.34
 in the ground state 
(Palczewski et al., 2000).  
 
Both V6.34A and V6.34T in the ghrelin-R were „WT-like‟ with respect to all receptor 
characteristics. The V6.34K mutant displayed a reduction in agonist affinity, demonstrated by 
the lack of radioligand binding at the concentrations used. V6.34K also had decreased 
constitutive activity and decreased efficacy, but was „WT-like‟ in relation to EC50. In the 
biogenic amine receptors, mutation of residue 6.34 often results in increased constitutive 
activity (Kjelsberg et al., 1992; Ren et al., 1993; Samama et al., 1993; Lattion et al., 1999; 
Parnot et al., 2002). In the α1bAR mutation of Ala
6.34 
to all other amino acids resulted in 
constitutive activity, highlighting the requirement of the WT alanine in maintaining the 
inactive receptor conformation. There appeared to be no correlation between the properties of 
the amino acid side chain and the increase in constitutive activity, nor between the 
constitutive activity and the effect on agonist affinity (Kjelsberg et al., 1992; Parnot et al., 
2002). Mutation of Leu
6.34
 to alanine in the β2AR resulted in increased constitutive activity 
suggesting that the intracellular end of TMVI is crucial for maintaining the inactive β2AR 
conformation (Samama et al., 1993). In the β2AR Leu
6.34
 has been shown to interact via van 
der Waals forces with Tyr
5.58
. Leu
6.34 
was identified as producing constitutive activity when 
mutated to alanine and that the stabilising van der Waals interactions minimise basal activity 
(Rasmussen et al., 2007). Similarly, mutation of Thr
6.34 
to phenylalanine, alanine, glutamate, 
cysteine or lysine resulted in increased constitutive activity in the α2AR (Ren et al., 1993). In 
the β1AR mutation of Leu
6.34 
also increased the constitutive activity, with the L6.34K mutant 
displaying the greatest increase in basal cAMP accumulation (Lattion et al., 1999). The 
T6.34K mutant in the μ-OR resulted in constitutive receptor activation presumably, by 
disrupting a stabilising interaction between 6.34 and Arg
3.50
,
 
after the introduction of the 
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repulsive positive charge. In contrast, the T6.34D mutant stabilised the inactive state of the 
receptor by the introduction of a negative charge (Huang et al., 2001). In the Gαi-coupled CB2 
receptor, mutation of Ala
6.34 
to glutamate reduced the WT constitutive inhibition of AC 
suggesting that this mutation alters the receptor conformation to a more inactive state, 
possibly due to the introduction of a negative charge. This may have resulted in stabilising 
interactions with Arg
3.50 
of the D/ERY motif and would therefore explain the lack of agonist-
independent activation observed with this mutation (Feng et al., 2003). In the TSHR 
molecular modelling predicted that a hydrogen bond is formed between Tyr
5.58
 and Ala
6.34
 that 
is essential for WT receptor signalling capabilities (Biebermann et al., 1998).  
 
Interactions may be occurring between TMVI, TMIII and TMV in the ghrelin-R, supporting 
the high basal signalling in the WT receptor that can be decreased after introduction of 
charged residues, although the introduction of a positive lysine did not increase constitutive 
activity as observed in other Family A GPCRs. This suggests that the V6.34K mutant does 
not disrupt an interaction with Arg
3.50
, and does not repel the cytoplasmic end of TMIII. It is 
unclear as to the role of Val
6.34
 in the WT ghrelin-R and further investigation is required at 
this locus to interpret the current findings with more accuracy.  
 
4.3.4 The role of residue Tyr
5.58
 in ghrelin-R activity 
Tyr
5.58
 is conserved in 77 % of Family A GPCRs (Mirzadegan et al., 2003) and has been 
implicated in receptor activation in a number of receptors. To investigate the functional role 
of residue 5.58 in the ghrelin-R, Tyr
5.58
 was substituted with alanine and with glutamine. 
Alanine substitution removed the side chain and therefore was likely to disrupt potential 
intramolecular interactions. Y5.58A was able to bind ghrelin with a similar affinity to the WT 
ghrelin-R but had a dramatic effect on intracellular signalling. There was a substantial 
decrease in constitutive activity, indicative of the stabilisation of a relatively inactive receptor 
conformation or decreased Gαq/11 activation. Interestingly, Y5.58A had a very large increase 
in ghrelin efficacy, resulting in a receptor that had an Emax of 224 % of the WT ghrelin-R. 
This suggests that the Y5.58A mutant produces a receptor that can adopt a more active state, 
when stimulated by ghrelin, than the WT ghrelin-R. Removal of the tyrosine side chain at 
position 5.58 therefore has an interesting effect on signalling and coupling to G-proteins. 
Agonist-independent signalling was severely perturbed, but the mutant receptor was still 
particularly responsive to ghrelin, and was capable of signalling to a much greater extent than 
the WT receptor. 
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Due to the high conservation of tyrosine at position 5.58 in Family A GPCRs, Tyr
5.58
 has been 
extensively studied. (Hunyady et al., 1995a; Biebermann et al., 1998; Erlenbach et al., 1998; 
Palczewski et al., 2000; Li et al., 2005). One role that has been proposed for Tyr
5.58 
is in the 
selectivity of receptor-G-protein interactions. The location of Tyr
5.58
 at the cytoplasmic 
interface of TMV and ICL3 suggests that this residue may be involved in G-protein selectivity 
and this has been confirmed in the V2R, where the side chain of Gln
5.58 
is predicted to play a 
role in G-protein recognition and specificity. Glutamine is required at position 5.58, in the 
V2R, for efficient activation of the Gαs G-proteins (Erlenbach et al., 1998). Other members of 
the neurohypophysial hormone receptor family have a tyrosine at position 5.58 and all couple 
to Gαq/11, further supporting the role of Tyr/Gln
5.58 
in G-protein coupling, selectivity and 
activation. In the TSHR Tyr
5.58
 was mutated to various amino acids to investigate the effects 
of side chain substitution. The TSHR has dual signalling capabilities, signalling through 
Gαq/11 and Gαs G-proteins. Some of the mutations resulted in a loss of activation through one 
pathway, again suggesting that Tyr
5.58
 is important for G-protein specificity, as found with the 
V2R. Constitutive activity, cell-surface expression and agonist-induced signalling were all 
affected in the TSHR mutants, highlighting an essential role of tyrosine at this position 
(Biebermann et al., 1998).  Mutational studies on the AT1aR found that a Tyr
5.58
 mutation to 
phenylalanine resulted in a loss of agonist-induced InsP-InsP3 accumulation, again suggesting 
that tyrosine is required for efficient G-protein coupling (Hunyady et al., 1995a).  
 
The Y5.58Q mutant was produced in the ghrelin-R to investigate whether this mutation 
affected coupling or altered G-protein specificity. The mutant receptor was still able to signal 
through the InsP3 pathway, demonstrating Gαq/11 selectivity, with „WT-like‟ ghrelin potency, 
but had a decreased efficacy and decreased basal activity. The Y5.58Q mutant was unable to 
bind ghrelin at the radioligand concentrations used. Combined, this data suggests that 
glutamine substitution of Tyr
5.58
 was more detrimental to ghrelin-R function than the alanine 
substitution.    
 
The crystal structure of Rho demonstrated that the phenolic ring of Tyr
5.58 
extends into the 
interhelical region between TMV and TMVI (Palczewski et al., 2000). Baldwin et al. (1997) 
conducted molecular modelling of typical Family A GPCRs and predicted that the side chains 
of residues 5.58 and 3.50 project into the cavity formed between TMIII and TMVI. The 
crystal structures of opsin revealed that the hydroxyl group of Tyr
5.58
 interacts with Arg
3.50
 of 
the ERY motif, replacing the carboxyl group of Glu
3.49
 in the active state. Release of Arg
3.50 
from Glu
3.49 
and Glu
6.30
 also allows Arg
3.50 
to interact with Gαt (Park et al., 2008; Scheerer et 
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al., 2008). This interaction forms the basis of the hydrogen bonding network between Rho 
and Gαt and potentially forms the basis for activation of all Family A GPCRs. The results of 
the Tyr
5.58
 mutations in the ghrelin-R, clearly implicate the tyrosine residue in receptor 
activation and imply that Tyr
5.58
 may have a number of functions including maintaining 
ghrelin-R constitutive activity and stabilising an active receptor conformation, perhaps 
preventing hyperstimulation, as indicated by the increased efficacy with the Y5.58A mutation.   
 
4.3.5 Investigation of the rotamer toggle switch in the ghrelin-R 
The highly conserved tryptophan at position 6.48 is an important residue in GPCR activation, 
making up part of the CWxP motif in TMVI. Changes in the rotameric conformation of 
Trp
6.48 
and other residues within an aromatic cluster in TMVI are thought to accompany 
Family A receptor activation and constitute the rotamer toggle switch (Schwartz et al., 1996; 
Shi et al., 2002b; Schwartz et al., 2006). The aromatic cluster is believed to aid receptor 
activation by stabilising the various conformations of the side chains of each residue within 
the cluster. The toggling of Trp
6.48 
modulates the proline kink in TMVI at Pro
6.50
, 
straightening the bend angle of the helix and resulting in the movement of the cytoplasmic 
end of TMVI away from TMIII, facilitating receptor activation (Shi et al., 2002b; 
Bhattacharya et al., 2008). The Trp
6.48
 side chain is proposed to adopt different 
conformations, being an important microswitch in GPCR activation (Nygaard et al., 2009).
 
 
Studies on Rho measuring the UV-absorbance of specific tryptophan residues identified the 
change in position of TMVI relative to TMIII based on the absorbance of Trp265
(6.48) 
(Lin et 
al., 1996). This movement was further supported by computer simulations of the β2AR (Shi et 
al., 2002b), and the crystal structure of the Meta I state of Rho (Ruprecht et al., 2004). In all 
of the crystal structures to date Trp
6.48
 is found in a similar position and rotameric 
conformation, although none of the structures are of agonist-bound receptors, and this may 
account for the stability of the Trp
6.48 
side chain in the crystal structures (Nygaard et al., 
2009). In Rho, Trp
6.48 
forms a direct contact with retinal in the binding pocket (Palczewski et 
al., 2000), whereas in the β2AR crystal structure, there is no direct ligand-Trp
6.48 
contact 
observed (Cherezov et al., 2007). In fact, there is great variation in the contact area between 
ligand and Trp
6.48 
in all of the resolved GPCR crystal structures, perhaps reflecting the 
observed level of constitutive activity for each receptor (Jaakola et al., 2008). In the inactive 
Rho, Trp
6.48
 points towards TMVII and is constrained by a network of hydrogen bonds. 
Trp
6.48 
forms a hydrogen bond with Asn
7.49 
which is disrupted upon isomerisation of retinal 
and subsequent receptor activation. Upon activation and isomerisation of 11-cis retinal to all-
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trans retinal, Trp
6.48 
is released from this constraint and moves to point towards TMV 
(Crocker et al., 2006). Trp
6.48
 flips around to face TMV and forms a new hydrogen bond with 
His
5.46 
(Bhattacharya et al., 2008). Molecular modelling of the inactive ghrelin-R has 
demonstrated that Trp
6.48
 establishes hydrophobic contacts with surrounding phenylalanine 
residues (Floquet et al., 2010), which have previously been implicated in ghrelin-R activation 
(Holst et al., 2004a). In the active state Trp
6.48
 assumes a different rotamer conformation, 
making contact with His
6.52
 (Floquet et al., 2010).    
 
In this study, Trp
6.48
 of the ghrelin-R was substituted by alanine, phenylalanine and tyrosine to 
look at the effects of a dramatic reduction in side chain size and of conservative substitution 
with other aromatic residues. All three Trp
6.48
 mutations were detrimental to ghrelin-R 
function with the W6.48A being the most pronounced. There was an increase in EC50 of 12.5-
fold indicating that the mutant receptor is still able to signal in response to ghrelin, despite 
ablation of agonist-independent signalling (basal signalling 8 % of WT basal). The efficacy 
was affected by the alanine substitution with the mutant receptor construct only able to signal 
at -22 % of the ghrelin-R ghrelin-induced maximum. The W6.48A mutant retained a ghrelin 
binding affinity that was comparable to WT and increased cell-surface expression to 170 % of 
the WT ghrelin-R implying that the mutant adopted a more stable inactive conformation at the 
cell-surface, perhaps reducing the constitutive internalisation observed for the ghrelin-R 
(Chapter 3). Any adverse effect on ghrelin-induced signalling was not therefore a result of 
decreased receptor expression or disruption to the ghrelin binding pocket. Holst et al. (2010) 
recently also mutated Trp
6.48 
in the ghrelin-R. Similar results were seen; the W6.48A mutant 
was severely detrimental to constitutive and ghrelin-induced signalling, without any adverse 
effect on ghrelin binding affinity or cell-surface expression. In fact, as observed in our study, 
the cell-surface expression was increased beyond the levels observed for the WT ghrelin-R 
(Holst et al., 2010). Alanine substitution of Trp
6.48 
results in disruption of the rotamer toggle 
switch that has been shown to be integral to receptor activation in a number of Family A 
GPCRs. Although the mutant receptor construct is still able to adopt an active receptor 
conformation after ghrelin stimulation, the ghrelin efficacy and potency are affected and the 
effect is not related to a disruption to ghrelin binding or to cell-surface expression. The 
location of Trp
6.48 
within TMVI suggests that disruption of a G-protein interaction, directly, is 
not responsible for the detrimental effect on receptor activation. Instead, an inability of the 
receptor to adopt a fully active conformation is likely to be involved. To further investigate 
the role of Trp
6.48
, this residue was replaced by phenylalanine and tyrosine, retaining the 
aromatic character. Both the W6.48F and W6.48Y mutants retained „WT-like‟ binding 
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affinity and cell-surface expression. Both affected basal and agonist-induced InsP3 signalling 
to the same extent, with an increase in EC50 of 7.5-fold and 7-fold respectively and both 
displayed similar reductions in basal signalling (38 and 43 % of WT basal, respectively). 
Neither construct was able to signal to the same extent as the WT receptor after stimulation 
with ghrelin, only presenting Emax similar to the WT constitutive activity. Maintaining an 
aromatic at position 6.48 was unable to retain WT signalling properties, revealing that only 
tryptophan can reside at position 6.48 and supporting the important functional role of Trp
6.48
 
in GPCR activation.  
 
Gly
3.36 
forms packing interactions with Trp
6.48
 in the Rho inactive state and this interaction is 
removed upon receptor activation due to the relative movement of TMVI away from TMIII 
(Crocker et al., 2006). In the ghrelin-R, Thr
3.36
 mutation to alanine resulted in a dramatic 
increase in constitutive activity revealing that removal of the threonine side chain releases 
constraining intramolecular interactions. Introduction of conservative cysteine or serine 
residues did not induce further ghrelin-R agonist-independent activity, but instead retained 
basal signalling at levels similar to that seen for the WT ghrelin-R. This result, along with the 
„WT-like‟ binding affinity and EC50 suggested that cysteine or serine can successfully 
substitute for threonine at this position. Interestingly however, the ghrelin efficacy was 
affected in both cases, with the T3.36C mutant having an increased Emax (146 % of WT) and 
the T3.36S mutant displaying a decrease (36% of WT). This indicates that, despite having 
binding affinity, constitutive activity and ghrelin potency similar to the WT ghrelin-R, both 
the T3.36C and T3.36S mutants affected ghrelin-R function in a different manner. None of the 
Thr
3.36
 mutations affected ghrelin binding or cell-surface expression suggesting that all of the 
mutant constructs are correctly folded and expressed in HEK 293T cells.    
 
In the H1R (Jongejan et al., 2005), the 5HT4R (Pellissier et al., 2009) and the CB1 receptor 
(McAllister et al., 2004), as in Rho (Crocker et al., 2006), residue 3.36 has been shown to 
participate in the rotamer toggle switch, although in these cases, residues 3.36 appears to have 
different roles, stabilising the inactive and active receptor conformations. In the H1R, 
mutation of Ser
3.36 
to alanine resulted in a reduction in the WT basal signalling and agonist 
affinity, suggesting that serine in the WT receptor acts to stabilise the active conformation. 
Mutation of Ser
3.36
 to cysteine or threonine increased the constitutive activity and resulted in 
mutant receptor constructs that could not be activated further by histamine, but that could be 
inhibited by an inverse agonist. Ser
3.36
 was shown to interact with Asn
7.45
 as part of a toggle 
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switch of activation, representing an early stage in receptor activation before important and 
pronounced structural changes occur within the TM helices (Jongejan et al., 2005). Similarly, 
in the constitutively active 5HT4R, the T3.36A mutation resulted in ablation of constitutive 
activity, suggesting an important role of the WT threonine in stabilising active receptor 
conformations (Pellissier et al., 2009). In contrast, substitution of Phe
3.36 
with alanine in the 
CB1 receptor resulted in increased constitutive activity. This may be due to the removal of a 
steric block of the conformational change of Trp
6.48
, allowing greater ligand-independent 
activation (McAllister et al., 2004) and suggests that similar interactions may be occurring in 
the CB1 receptor as the ghrelin-R.  
 
The conserved TMVI aromatic cluster is not found in the CB1 receptor, although a 
phenylalanine is found at position 3.36. Phe
3.36
 may act to stabilise the ground state of the 
receptor via aromatic-aromatic interactions with Trp
6.48
 and other aromatics found within TMs 
III-V (McAllister et al., 2004). Phenylalanine was introduced at position 3.36 in the ghrelin-R 
to investigate introduction of an aromatic at this locus. T3.36F had no effect on ghrelin 
binding, but had an interesting effect on intracellular signalling. The T3.36F mutant resulted 
in a 3.2-fold increase in ghrelin potency and a small reduction in basal signalling without 
affecting the efficacy. There was also a small increase in cell-surface expression (143 %). 
This suggested that the T3.36F mutant is more readily able to be activated by ghrelin and 
adopt the active conformation, without a direct effect on ghrelin binding. 
 
Serine is found at position 7.45 in Rho and has been suggested to form an interaction with 
Trp
6.48
 via a water molecule as Trp
6.48
 toggles during the activation of Rho (Bhattacharya et 
al., 2008). The more highly conserved Asn
7.45 
has been proposed to restrain the side chain of 
Trp
6.48
 in the inactive conformation in the H1R. Mutation of Asn
7.45
 in the H1R had various 
effects on constitutive activity depending on the amino acid introduced (Jongejan et al., 
2005). In the ghrelin-R, mutation of Ser
7.45
 to alanine resulted in increased constitutive 
activity indicating that removal of the polar side chain released a stabilising interaction, 
possibly with Trp
6.48
, and allowed the ghrelin-R to adopt a more active conformation in the 
absence of ghrelin. Introduction of the more polar asparagine at position 7.45 restrained an 
inactive receptor conformation, with the S7.45N ghrelin-R construct displaying decreased 
basal activity compared to WT, and suggesting that similar interactions can be introduced into 
the ghrelin-R as those observed in many WT Family A GPCRs. The WT ghrelin-R may 
display similar interactions as those observed in Rho, involving hydrogen bonding networks 
 164 
with water molecules. The presence of serine and alanine instead of the more highly 
conserved asparagine and serine at positions 7.45 and 7.46 in the ghrelin-R and Rho further 
supports the idea that interactions may be conserved in the two receptors. These interactions 
may dictate the constitutive activity of the receptor, as supported by opsin constitutive activity 
when 11-cis retinal is absent (Cohen et al., 1993). 
 
Trp
6.48
, Thr
3.36
 and Ser
7.45
 appear to be involved in a stabilising network of interactions which 
can be disrupted by alanine mutations. The T3.36A mutation removes a stabilising packing 
interaction allowing Trp
6.48
 to adopt the active rotamer conformation in the absence of 
agonist. In turn, S7.45A may allow the release of Trp
6.48
 from the inactive rotamer 
conformation, pointing toward TMVII, again allowing the receptor to adopt a more active 
conformation without ghrelin binding.   
 
The extended network of hydrogen bonds stabilising GPCRs also includes residue 3.35. 
Asparagine is located at position 3.35 in 29 % of Family A GPCRs (Mirzadegan et al., 2003) 
and has been found to make important hydrogen bond interactions. Cysteine is found at this 
locus in the ghrelin-R. Cys
3.35
 was mutated to alanine and the resultant C3.35A mutant had no 
effect on ghrelin binding, basal activity or cell-surface expression. The introduction of an 
alanine at this position was however detrimental to ghrelin-induced signalling efficacy (Emax 
48 % of WT). 
 
Mutation of Asn
3.35
 in the CXC chemokine receptor type 4 (CXCR4) to alanine or serine 
resulted in constitutive activity, whereas introduction of a positive charge (N3.35K) stabilised 
the inactive receptor conformation. Positive charges are never found at position 3.35 in 
Family A GPCRs (Mirzadegan et al., 2003), supporting the inactivity found in the N3.35K 
CXCR4 mutant (Zhang et al., 2002). Mutation of Asn
3.35
 in the AT1R (Groblewski et al., 
1997) and Cys
3.35
 in the α1bAR (Perez et al., 1996) also resulted in constitutive receptor 
activity. In Rho, interactions were proposed between Gly
3.35
 and Met
2.53
 in the inactive state 
and in Meta II, suggesting that TMIII is stationary during receptor activation and that toggling 
and movement of TMVI, not TMIII, is responsible for receptor activation (Crocker et al., 
2006). Any detrimental effect on receptor activation caused by mutation of Cys
3.35
 in the 
ghrelin-R is therefore unlikely to be related to a disruption of the formation of the active 
receptor conformation itself, and is more likely to be due to a disruption of the formation of 
the fully active conformation via alteration of TMIII-TMVI-TMVII interactions.   
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4.3.6 The role of the highly conserved NPxxY motif in ghrelin-R function 
The NPxxY motif is a highly conserved sequence in Family A GPCRs that is found at the 
cytoplasmic end of TMVII. The NPxxY motif has been extensively studied in Family A 
GPCRs, however, studies have indicated that the residues have various roles despite their 
conserved nature. In Rho, the D/ERY motif and the NPxxY motif have been proposed to 
provide a dual control in the structural changes leading to receptor activation (Fritze et al., 
2003). The NPxxY participates in a network of interactions with water molecules, stabilising 
the inactive receptor conformation, but allowing ease of breaking for rapid formation of the 
active state (Rosenbaum et al., 2009).   
 
Alanine substitution of the residues within the NPxxY of the ghrelin-R had no effect on 
ghrelin potency, but each mutant affected ghrelin binding affinity or constitutive activity. 
N7.49A retained „WT-like‟ binding affinity and efficacy although constitutive activity was 
reduced, with basal signalling being -42 % of the WT ghrelin-induced maximum. In the 
prostaglandin EP3 receptor (Audoly et al., 1997) and the cholecystokinin type B receptor 
(Gales et al., 2000), mutation of residue 7.49 disrupted signalling but did not affect ligand 
binding. In the ghrelin-R, only constitutive receptor activation was affected by the Asn
7.49 
mutation to alanine indicating that, despite its high conservation, Asn
7.49 
is not essential for 
ghrelin-induced receptor activation. The alanine substitution may have affected interactions 
with other residues that normally act to stabilise the more active ghrelin-R conformation 
required for WT constitutive activity. In contrast, in the TSHR, Asn
7.49 
was found to be 
required for agonist-induced receptor activation (Claeysen et al., 2002).  
 
Asn
7.49 
has been proposed to form an interaction, via water molecules, with the highly 
conserved aspartic acid at position 2.50 (Asp
2.50
). The crystal structure of Rho revealed that 
the distance between Asp
2.50
 and Asn
7.49
 is too great for a direct interaction, but that water can 
mediate the contact, and that this interaction stabilises the active receptor conformation 
(Palczewski et al., 2000; Okada et al., 2002). Molecular modelling of the TSHR based on the 
2.2 Å Rho crystal structure (Okada et al., 2004) implicated a water molecule as a hydrogen 
bond acceptor in the Asp
2.50
-Asn
7.49
 interaction and suggested that this water-mediated 
interaction restrains the side chain of Asn
7.49
, maintaining an active receptor conformation 
(Urizar et al., 2005). Mutation of Asp
2.50
 to alanine in the ghrelin-R affected ghrelin-R basal 
signalling and efficacy suggesting that removal of the putative Asp
2.50
-Asn
7.49 
interaction by 
alanine substitution, acted to produce a more inactive receptor conformation (Chapter 3). The 
interaction between Asp
2.50 
and Asn
7.49 
has been shown in a number of Family A GPCRs 
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including the 5HT2AR (Sealfon et al., 1995), the m1 mAChR (Bee et al., 2007), the CB1 
receptor (Shim, 2009), the GnRHR (Flanagan et al., 1999), the TRHR (Perlman et al., 1997b) 
and the tachykinin NK2 receptor (Donnelly et al., 1999). Alanine substitution of the residues 
at either position 2.50 or 7.49 resulted in a similar reduction in ghrelin-R constitutive activity 
supporting the potential interaction between the residues. Neither mutation resulted in a 
change in binding affinity or ghrelin potency, indicating that these residues do not form part 
of the ghrelin binding pocket. Similarly, high affinity agonist and antagonist binding were 
retained after mutation of Asn
7.49
 in the 5HT2AR (Sealfon et al., 1995).  
 
The network of interactions that involve Asn
7.49
 are both extensive and complex. CAMs of the 
H1R, induced by mutation at position 6.40, highlighted a network of interactions known as the 
asparagine cage that appear to restrain Asn
7.49
 in the inactive conformation and pointing 
towards TMVI. Mutation of Ile
6.40
, which is a highly conserved hydrophobic residue, to a 
charged residue, removed hydrophobic constraints and allowed for constitutive receptor 
activation (Bakker et al., 2008) (discussed further in Chapter 5).     
 
Prolines within TM domains have been shown to induce kinks within the helical structure due 
to steric conflicts with the previous residue and the lack of ability of the proline backbone to 
hydrogen bond (von Heijne, 1991). Helical distortions in membrane proteins are well 
tolerated due to the stability provided by the membrane environment and can provide weak 
points that add flexibility to allow movement of the helix (Yohannan et al., 2004). Studies on 
Rho and bacteriorhodopsin have shown that alanine substitution of prolines found within TM 
helices does not necessarily result in straightening of proline-induced kinks. Stabilising 
interactions are often present which support the structure of the helix even after removal of 
the proline residue (Faham et al., 2004; Yohannan et al., 2004). In the ghrelin-R, mutation of 
Pro
7.50
 of the NPxxY to alanine, caused a decrease in ghrelin binding affinity so that binding 
was not detectable at the [
125
I]ghrelin concentrations used in assay. Despite this, both agonist-
independent signalling and ghrelin potency were unaffected by the P7.50A mutation. 
Interestingly, ghrelin efficacy was increased, with the P7.50A mutant having an Emax of 176 
% of the WT receptor. This suggests that the P7.50A mutant receptor construct is able to 
adopt a more active conformation than the WT ghrelin-R without having an effect on 
constitutive activity. In contrast, in the m3 mAChR mutation of Pro
7.50 
to alanine affected 
cell-surface expression and intracellular signalling but not agonist binding affinity suggesting 
that Pro
7.50
 might be involved directly in G-protein coupling and agonist-induced 
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conformational changes (Wess et al., 1993). Although the P7.50A mutation in the ghrelin-R 
was not detrimental to ghrelin-R signalling, there was a detrimental effect on ghrelin binding 
suggesting that Pro
7.50 
may form part of the ghrelin binding pocket or might act to stabilise the 
binding pocket through its interaction with other residues. The P7.50A mutant affected 
ghrelin affinity, as indicated by the radioligand binding, although ghrelin binding cannot have 
been eliminated as ghrelin-induced signalling was not impaired.   
 
Ile
7.51 
and Leu
7.52 are found at the „xx‟ positions of the NPxxY motif. These residues are the 
least conserved within the NPxxY motif although hydrophobic amino acids in general are 
highly conserved (Mirzadegan et al., 2003). Compared to the asparagine, proline and tyrosine 
residues of the NPxxY motif, the „xx‟ are also the least well studied. Interestingly, alanine 
mutation of both Ile
7.51 
and Leu
7.52
 resulted in an increase in ghrelin binding affinity. 
Mutations within the NPxxY motif in other GPCRs have been found to increase receptor 
function; mutation of Tyr
7.53 
has been found to increase agonist binding affinity in the 
5HT2CR (Rosendorff et al., 2000). The NPxxY may be involved in interactions with ligands 
as supported by the increased affinity found with the I7.51A and L7.52A ghrelin-R mutants 
and the disruption to binding caused by the P7.50A mutation. Mutation of Phe
7.52
 in the 
AT1aR to alanine resulted in severe impairment of agonist binding without affecting G-protein 
coupling (Hunyady et al., 1995b).  
 
The constitutive activity of the two alanine mutants, I7.51A and L7.52A, was decreased 
compared to the WT ghrelin-R suggesting that the increase in affinity is not a result of a 
constitutively active conformation and that the residues may instead be involved directly in 
ghrelin binding or in moulding the binding pocket. The decreased constitutive activity 
observed for the I7.51A and L7.52A mutants was not unexpected, despite the increased 
agonist affinity. Mutations within such a highly conserved motif would be unlikely to have no 
effect on signalling, especially when the mutations are at the cytoplasmic end of a TM helix 
known to be closely involved in the coupling and activation of G-proteins. Both the I7.51A 
and L7.52A mutants were able to signal in response to ghrelin with „WT-like‟ EC50. I7.51A 
altered the ghrelin efficacy with an Emax of 64 % of WT suggesting that this mutation was 
moderately detrimental to agonist-induced signalling.  
 
Tyr
7.53 
of the NPxxY motif is 92 % conserved in Family A GPCRs (Mirzadegan et al., 2003). 
Tyr
7.53
 has been implicated in the network of hydrogen bonds that stabilise the inactive GPCR 
conformation, forming a hydrogen bond with Asn
1.50
 in TMI, which interacts with Asp
2.50 
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(Chapter 3). This hydrogen bond network is proposed to occur in the inactive receptor, 
maintaining the ground state (Konvicka et al., 1998; Okada et al., 2002). Mutation of Tyr
7.53 
to alanine in the ghrelin-R affected both constitutive and ghrelin-induced receptor activation. 
The basal signalling was reduced to -24 % of the ghrelin-induced maximum and the efficacy 
was reduced, with the Emax being only 48 % of WT. Mutation of Tyr
7.53 
has been found to 
have various effects in different Family A GPCRs. Mutation of Tyr
7.53 
to all other naturally 
occurring amino acids gave rise to mutant 5HT2CR with varying levels of constitutive activity, 
implicating Tyr
7.53 
in the transition of receptors between inactive and active states (Prioleau et 
al., 2002). In the formyl peptide receptor (FPR) a Y7.53F mutation resulted in constitutive 
activity suggesting that a tyrosine is essential at this position (He et al., 2001). In the V2R, 
phenylalanine could substitute successfully for tyrosine and retain high affinity AVP binding 
and signal transduction (Bouley et al., 2003). As seen in the ghrelin-R, the Y7.53A mutant in 
the B2 bradykinin receptor had no effect on ligand binding affinity or EC50. This mutant was 
however poorly expressed at the cell membrane and underwent substantial constitutive 
internalisation (Kalatskaya et al., 2004). In contrast, the ghrelin-R Y7.53A mutant was 
expressed at near-WT levels at the cell surface, suggesting no enhanced constitutive 
internalisation. A Tyr
7.53 
to phenylalanine mutation was found in the MCR4 in a patient 
suffering from severe childhood obesity. The mutation resulted in decreased cell-surface 
expression and signal transduction (Roth et al., 2009). This data provides evidence in a 
clinical study, that a Tyr
7.53 
mutation is detrimental to GPCR function. In the ghrelin-R 
Y7.53A was the most detrimental mutation within the NPxxY in terms of ghrelin-induced 
activation, reducing the Emax to only 48 % of that seen for the WT receptor.    
 
Mutation of Tyr
7.53 
to alanine, cysteine or phenylalanine in the 5HT2C receptor increased the 
binding affinity of 5-hydroxytryptamine despite differing effects of each mutant on 
constitutive activity. This suggests that activating and inactivating mutations at position 7.53 
stabilise a high affinity state of the 5HT2CR (Rosendorff et al., 2000). Although no increase in 
agonist affinity was observed with the ghrelin-R Y7.53A mutation, „WT-like‟ ghrelin affinity 
was maintained, despite a detrimental effect on intracellular signalling, suggesting that 
inactivating mutations at this locus also retain high agonist affinity.  
 
Tyr
7.53
 and a highly conserved phenylalanine located seven residues away, within HelixVIII 
have been shown to be essential for activation of Rho. Mutation of the residues within the 
NPxxY5,6F motif to alanine identified Tyr306
(7.53)
 and Phe313
(7.60)
 as being essential for Gαt 
activation. Mutation of these conserved aromatics released stabilising constraints, facilitating 
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Meta II formation, but did not aid Gαt-coupling (Fritze et al., 2003). An extensive 
investigation of Tyr
7.53 
in the serotonin 5HT2CR highlighted this residue along with Tyr
7.60
 as 
a functional microdomain that influences receptor activation (Prioleau et al., 2002). Similar 
aromatic stacking interactions may be occurring in the ghrelin-R between Tyr
7.53
 and Tyr
7.60
, 
located at the TMVII-HelixVIII interface, supporting the role of Tyr
7.53
 in efficient activation 
of the WT receptor.  
 
Figure 4.32 presents schematic representations of the ghrelin-R showing each of the alanine 
substitution mutations in this Chapter and their effects on ghrelin-R signalling. The location 
of each residue within the TM domain is indicated and the effect of the mutation on ghrelin 
potency, basal signalling and ghrelin efficacy are indicated by colour. 
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Figure 4.32 Schematic representations of the ghrelin-R demonstrating signalling 
characteristics for ghrelin-R alanine substitutions in Chapter 4: each residue mutated to 
alanine (Ala
3.60 
to tyrosine) was characterised using InsP-InsP3 accumulation assays to 
determine (a) ghrelin potency (b) basal constitutive activity and (c) ghrelin efficacy (see 
Appendix Table 9.1 for colour code). HA-epitope tag at the N-terminus is shown in purple.  
(a) 
 
 
 
 
 
(b) 
 
               
 
 
 
 
 
(c) 
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CHAPTER 5.  
GHRELIN RECEPTOR CONSTITUTIVE ACTIVITY:  
THE ROLE OF HYDROPHOBIC AND POLAR RESIDUES WITHIN THE 
TRANSMEMBRANE DOMAINS 
 
5.1 Introduction 
The TM domains of GPCRs are the most conserved regions within the receptor superfamily. 
Hydrophobic interactions occur frequently within α-helices and contribute in a significant 
manner to the stabilisation of protein tertiary structure. Mutation of conserved hydrophobic 
residues in Family A GPCRs can result in a disruption to receptor activation, either in an 
agonist-independent (Latronico et al., 1998; Tao et al., 2000; Shapiro et al., 2002; Urizar et 
al., 2005; Proneth et al., 2006; Ringkananont et al., 2006), or an agonist-dependent manner 
(Blin et al., 1995; Latronico et al., 1998).     
 
Polar residues are not commonly found within α-helices of membrane proteins, but can be 
shielded from the non-polar membrane environment by being clustered within the helical 
bundle (Dube et al., 1998). Although small and polar residues are not highly conserved 
individually in GPCR TM domains, when considered as a group, they are often relatively well 
conserved (Eilers et al., 2005). Small and polar amino acids are important in protein tertiary 
structure as they mediate tight helical packing via van der Waals interactions between, and 
within, helices. Within tightly packed helices, the ability of residues to form stabilising 
hydrogen bonds is increased and therefore both strong and weakly polar amino acids can 
facilitate further stabilising and structural interactions (Liu et al., 2004).  
 
A number of conserved hydrophobic and polar residues in TMIII and TMVI have been 
implicated in preventing or supporting constitutive activity in Family A GPCRs. To 
investigate the role of some of these residues in the ghrelin-R, mutations were introduced 
within the TM helices. The mutant receptor constructs were characterised to determine the 
role of these amino acids in both constitutive activity and agonist-induced signalling. The 
effects of alanine substitution of the residues in this chapter are summarised in the Appendix 
(Fig 9.4-9.8). 
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5.2 Results 
Mutations were introduced within the ghrelin-R to investigate the effect of substitution of 
conserved hydrophobic and polar amino acids within the TM domains. The constructs were 
expressed in HEK 293T cells and pharmacologically characterised by competition radioligand 
binding studies and InsP-InsP3 accumulation assays. Specific residues were selected for 
mutagenesis based on their reported role in constitutive activation in other Family A GPCRs 
or their relative positions within the TM domains. In TMIII, Ser
3.32
, Thr
3.42
, Ile
3.43
, Thr
3.44
, 
Leu
3.46
 and Ser
3.47
 were mutated and in TMVI, Met
6.36
, Leu
6.37
 and Val
6.40
. Met
2.46
 was 
included due to its role in stabilising interactions in other Family A GPCRs (Fig 5.1) (Bakker 
et al., 2008; Okada et al., 2001b; Urizar et al., 2005). The oligonucleotide sequences used to 
introduce each of the mutations are shown in Table 5.1.   
 
5.2.1 The role of the conserved hydrophobic residues
 
in ghrelin-R function 
A leucine is highly conserved at position 2.46 in Family A GPCRs (91 %) (Mirzadegan et al., 
2003). Methionine (4 % abundance) replaces the more conserved leucine in the ghrelin-R. To 
investigate the role of Met
2.46 
in the ghrelin-R an M2.46A mutant construct was produced. 
The M2.46A mutant had a detrimental effect on ghrelin-R function. M2.46A retained „WT-
like‟ agonist affinity and potency, however the basal signalling was slightly reduced to -26 % 
of the WT ghrelin-induced maximum and the Emax was only 55 % of WT. Cell-surface 
expression was also found to be reduced (55 % of WT) (Fig 5.2, Table 5.2). 
 
A hydrophobic residue is almost absolutely conserved at position 3.43 in Family A GPCRs 
and has been implicated in maintaining the inactive receptor conformation (Lu et al., 2000). 
Mutation of residue 3.43 to alanine and arginine has been found to increase constitutive 
activity in some Family A GPCRs (Latronico et al., 1998; Lu et al., 2000; Tao et al., 2000). 
To investigate the role of Ile
3.43 
in the ghrelin-R, two mutant receptor constructs were 
produced; I3.43A and I3.43R. The I3.43A mutant displayed a dramatic increase in agonist-
independent activity (140 % of WT basal), comparable to stimulation of the WT ghrelin-R 
with ~3 nM ghrelin. The mutant was still slightly responsive to further stimulation with 
ghrelin, reaching an Emax similar to that seen for the WT receptor. Agonist affinity and cell-
surface expression were both comparable to WT (Fig 5.3, Table 5.3). In contrast, the I3.43R 
was detrimental to ghrelin-R function. The mutant did not display constitutive activity, with 
basal InsP3 signalling reduced to levels similar to those seen for the mock-transfection (12 % 
of WT basal). The I3.43R mutant retained some agonist responsiveness, increasing the EC50
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Figure 5.1 Schematic representation of the ghrelin-R: the intramolecular disulphide bond is shown in yellow. Residues that represent the HA-
epitope tag introduced at the N-terminus (blue) and the individual residues mutated in this chapter (green) are illustrated. 
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Table 5.1 Oligonucleotide primer sequences for QuikChange™ site-directed 
mutagenesis: Codons to introduce mutations are shown in red. 
 
 
 
 
Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
M2.46A 5‟-C-TAC-CTG-TCC-AGC-GCG-GCC-
TTC-TCC-GAT-C-3‟ 
5‟-G-ATC-GGA-GAA-GGC-CGC-GCT-
GGA-CAG-GTA-G-3‟ 
S3.32A 5‟-C-TTC-CAA-TTC-GTC-GCT-GAG-
AGC-TGC-ACC-3‟ 
5‟-GGT-GCA-GCT-CTC-AGC-GAC-
GAA-TTG-GAA-G-3‟ 
T3.42A 5‟-C-GCC-ACG-GTG-CTC-GCC-ATC-
ACA-GCG-CTG-3‟ 
5‟-CAG-CGC-TGT-GAT-GGC-GAG-
CAC-CGT-GGC-G-3‟ 
I3.43A 5‟-GCC-ACG-GTG-CTC-ACC-GCC-
ACA-GCG-CTG-AGC-GTC-3‟ 
5‟-GAC-GCT-CAG-CGC-TGT-GGC-
GGT-GAG-CAC-CGT-GGC-3‟ 
I3.43R 5‟-GCC-ACG-GTG-CTC-ACC-CGC-
ACA-GCG-CTG-AGC-GTC-3‟  
5‟-GAC-GCT-CAG-CGC-TGT-GCG-
GGT-GAG-CAC-CGT-GGC-3‟  
T3.44A 5‟-CG-GTG-CTC-ACC-ATC-GCA-GCG-
CTG-AGC-GTC-G-3‟ 
5‟-C-GAC-GCT-CAG-CGC-TGC-GAT-
GGT-GAG-CAC-CG-3‟ 
L3.46A 5‟-C-ACC-ATC-ACA-GCG-GCG-AGC-
GTC-GAG-CGC-3‟ 
5‟-GCG-CTC-GAC-GCT-CGC-CGC-TGT-
GAT-GGT-G-3‟ 
L3.46I 5‟-C-ACC-ATC-ACA-GCG-ATC-AGC-
GTG-CAG-CGC-3‟ 
5‟-GCG-CTC-GAC-GCT-GAT-CGC-TGT-
GAT-GGT-G-3‟ 
L3.46M 5‟-C-ACC-ATC-ACA-GCG-ATG-AGC-
GTC-GAG-CGC-3‟ 
5‟-GCG-CTC-GAC-GCT-CAT-CGC-TGT-
GAT-GGT-G-3‟ 
S3.47A 5‟-C-CAT-CAC-AGC-GCT-GCC-GTC-
GAG-CGC-TAC-3‟ 
5‟-GTA-GCG-CTC-GAC-GGC-CAG-
CGC-TGT-GAT-GG-3‟ 
M6.36A 5‟-G-CAA-ACC-GTG-AAA-GCG-CTG-
GCT-GTA-GTG-G-3‟ 
5‟-C-CAC-TAC-AGC-CAG-CGC-TTT-
CAC-GGT-TTG-C-3‟ 
L6.37A 5‟-C-CGT-GAA-ATG-GCG-GCT-GTA-
GTG-GTG-3‟ 
5‟-CAC-CAC-TAC-AGC-CGC-CAT-TTT-
CAC-GG-3‟ 
L6.37M 5‟-CC-GTG-AAA-ATG-ATG-GCT-GTA-
GTG-GTG-3‟ 
5‟-CAC-CAC-TAC-AGC-CAT-CAT-TTT-
CAC-GG-3‟ 
L6.37I 5‟-CC-GTG-AAA-ATG-ATC-GCT-GTA-
GTG-GTG-3‟ 
5‟-CAC-CAC-TAC-AGC-GAT-CAT-TTT-
CAC-GG-3‟ 
L6.37T 5‟-CC-GTG-AAA-ATG-ACG-GCT-GTA-
GTG-GTG-3‟ 
5‟-CAC-CAC-TAC-AGC-CGT-CAT-TTT-
CAC-GG-3‟ 
V6.40A 5‟-CTG-GCT-GTA-GCG-GTG-TTT-GCC-
TTC-3‟ 
5‟-GAA-GGC-AAA-CAC-CGC-TAC-
AGC-CAG-3‟ 
V6.40F 5‟-CTG-GCT-GTA-TTC-GTG-TTT-GCC-
TTC-3‟ 
5‟-GAA-GGC-AAA-CAC-GAA-TAC-
AGC-CAG-3‟ 
V6.40M 5‟-CTG-GCT-GTA-ATG-GTG-TTT-GCC-
TTC-3‟ 
5‟-GAA-GGC-AAA-CAC-CAT-TAC-
AGC-CAG-3‟ 
V6.40Y 5‟-G-AAA-ATG-CTG-GCT-GTA-TAC-
GTG-TTT-GCC-TTC-ATC-3‟ 
5‟-GAT-GAA-GGC-AAA-CAC-GTA-
TAC-AGC-CAG-CAT-TTT-C-3‟ 
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Figure 5.2 Ligand binding, intracellular signalling and cell-surface expression profiles for M2.46A
 
mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
M2.46A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or M2.46A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
 (a)              (b)              (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
M2.46A 8.45  0.07 1.44  0.62 -27  6 55  6 55  7 
 
 
 
Table 5.2 Ligand binding, intracellular signalling and cell-surface expression for M2.46A
 
mutant construct: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Yellow indicates a decrease basal signalling > 20 % of WT, a decrease in Emax > 30 % of WT and a decrease in cell-surface 
expression > 30 % of WT. 
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4.7-fold and reaching an Emax comparable to WT basal, reflecting the greatly reduced basal 
activity. [
125
I]ghrelin binding was not detectable at the radioligand concentrations used in the 
binding assay and cell-surface expression was drastically reduced to only 43 % of WT (Fig 
5.3, Table 5.3). 
 
In the TSHR a constitutively activating mutation was found with a methionine to isoleucine 
substitution in TMVI (M6.37I). The constitutive activity was believed to be a result of steric 
hindrance with the side chain of Ile
3.46
 as a reciprocal mutation, I3.46M in the M6.37I 
background, resulted in constitutive activity comparable to the WT TSHR. Furthermore, 
M6.37A, M6.37L and M6.37V mutants all displayed „WT-like‟ constitutive activity 
(Ringkananont et al., 2006). In the ghrelin-R Leu
6.37 
and Leu
3.46 
were mutated, initially to 
alanine, and then to other amino acids to investigate the role of these residues in receptor 
activity. All of the Leu
3.46 
and Leu
6.37 mutants retained „WT-like‟ affinity for ghrelin (Fig 5.4 
& 5.5, Table 5.4 & 5.5). L6.37A and L6.37I displayed „WT-like‟ characteristics. L3.46A and 
L3.46M caused almost complete ablation of ghrelin-R constitutive activity and L6.37T 
reduced basal signalling to -37 % of WT ghrelin-induced maximum, whereas L3.46I, L6.37A, 
L6.37I and L6.37M retained „WT-like‟ basal activity. L3.46I and L6.37M were detrimental to 
agonist-induced receptor activation, with Emax values of 38 % and 67 % respectively, although 
potency was increased 3.3-fold compared to WT for the L3.46I mutant. Despite the reduction 
in constitutive activity in the L3.46A and L3.46M mutants, both were able to signal through 
the InsP3 pathway maintaining ghrelin efficacy. L3.46A increased the EC50 7.6-fold compared 
to WT. All of the mutants expressed at the cell-surface at levels comparable to WT, except 
L6.37M, which was reduced to 66 %, and L3.46A, which expressed at a greater extent than 
the WT ghrelin-R (142 %) (Fig 5.4 & 5.5, Table 5.4 & 5.5).  
 
Met
6.36 
was mutated to alanine as part of the investigation into the conserved hydrophobic 
residues in TMVI.  Residue 6.36 is of hydrophobic character in 61 % of Family A GPCRs 
(Mirzadegan et al., 2003). The M6.36A mutation in the ghrelin-R displayed „WT-like‟ 
characteristics in relation to agonist binding, cell-surface expression and agonist-induced 
signalling, but displayed a reduction in agonist-independent basal signalling (-40 % of WT 
ghrelin-induced maximum) (Fig 5.6, Table 5.6).   
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Figure 5.3 Ligand binding, intracellular signalling and cell-surface expression profiles for Ile
3.43 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, I3.43A or I3.43R and are expressed as a percentage of specific 
binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, I3.43A or I3.43R. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal 
(% WT max)  
 SEM 
Basal 
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
I3.43A 8.70  0.07 1.18  0.56 46  14 140  13 84  9 73  2 
I3.43R NDB 10.00  16.37 -82  6 12  5 -2  5 43  5 
 
 
 
Table 5.3 Ligand binding, intracellular signalling and cell-surface expression for Ile
3.43 
mutant constructs: Values were obtained using the 
methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Blue indicates an increase in constitutive activity > 40 % of WT. Red indicates no detectable binding, a decrease in constitutive 
activity > 60 % or a decrease in Emax to less than the value observed for WT basal. Orange indicates an increase in EC50 > 4-fold or a reduction in 
cell-surface expression > 50 % of WT. 
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Figure 5.4 Ligand binding, intracellular signalling and cell-surface expression profiles for Leu
3.46 
mutant receptor constructs:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, 
L3.46A, L3.46I or L3.46M and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, L3.46A, L3.46I or L3.46M. Values are expressed as a percentage of the WT 
ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed 
as a percentage of the WT ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)               (b)               (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
L3.46A 8.58  0.10 16.1  5.82 -86  9 110  20 142  12 
L3.46I 8.64  0.04 0.65  1.26 4  15 38  11 99  18 
L3.46M 8.77  0.05 2.91  0.24 -59  8 109  19 95  7 
 
 
 
 
Table 5.4 Ligand binding, intracellular signalling and cell-surface expression for Leu
3.46 
mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Red indicates an > 5-fold increase in EC50 or a decrease in basal activity > 60 %. Green indicates a decrease in EC50 > 3-fold or an 
increase in cell-surface expression > 130 %. Orange indicates reduction of basal activity > 40 % of WT or a reduction in Emax > 60 %.  
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Figure 5.5 Ligand binding, intracellular signalling and cell-surface expression profiles for Leu
6.37 
mutant receptor constructs:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, 
L6.37A, L6.37I, L6.37M or L6.37T and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays 
were performed on cells transiently transfected with WT ghrelin-R, L6.37A, L6.37I, L6.37M or L6.37T. Values are expressed as a percentage of 
the WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct 
expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)              (b)      (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression 
 (% WT) 
  SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
L6.37A 8.61  0.07 1.56  1.64 -10  10 105  15 83  4 
L6.37I 8.55  0.07 1.95  0.68 -11  5 91  11 75  6 
L6.37M 8.58  0.05 5.08  1.02 -18  9 67  1 66  4 
L6.37T 8.45  0.03 1.09  0.49 -37  16 110  13 80  8 
 
 
 
Table 5.5 Ligand binding, intracellular signalling and cell-surface expression for Leu
6.37
 mutant constructs: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Yellow indicates a reduction in basal activity > 20 %, a reduction in Emax > 30 % or a reduction in cell surface expression > 30 %.  
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Figure 5.6 Ligand binding, intracellular signalling and cell-surface expression profiles for M6.36A
 
mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
M6.36A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or M6.36A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)            (b)       (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
M6.36A 8.38  0.10 1.94  0.25 -40  9 98  15 102  6 
 
 
Table 5.6 Ligand binding, intracellular signalling and cell-surface expression for M6.36A mutant construct: Values were obtained using 
the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Orange indicates reduction of basal activity > 40 % of WT.  
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Residue 6.40 has been extensively studied in Family A GPCRs. Met
6.40 
in opsin was 
substituted by the remaining 19 amino acids. All of the mutant receptors except for M6.40L 
and M6.40R resulted in the constitutive activation of opsin to varying degrees. M6.40L 
displayed basal activity comparable to WT and M6.40R failed to express at the cell surface 
meaning characterisation was not possible (Han et al., 1998). Valine is found at position 6.40 
in the ghrelin-R. Valine was found to produce significant constitutive activity (~110 % of 
WT) when substituting for methionine in opsin (Han et al., 1998). Val
6.40 
was mutated to 
various amino acids in the ghrelin-R to investigate whether this residue has a similar role in 
regulating constitutive activity in the ghrelin-R as found in Rho. V6.40A, V6.40M, V6.40F 
and V6.40Y receptor constructs were produced. All Val
6.40 mutants demonstrated „WT-like‟ 
ghrelin binding affinity (Fig 5.7 (a), Table 5.7). V6.40A resulted in an increase in basal 
activity (124 % of WT basal) but was unable to be further stimulated by ghrelin. V6.40F and 
V6.40Y both increased basal constitutive activity in the ghrelin-R, to 111 % and 142 % of 
WT basal, respectively. V6.40F was still responsive to further stimulation with ghrelin 
although there was a 3.9-fold increase in EC50. V6.40Y basal was approaching WT maximum 
signalling and this mutant did not respond further to ghrelin stimulation. V6.40M was 
detrimental to ghrelin-R constitutive activity (56 % of WT basal), however this mutant had a 
„WT-like‟ EC50 and Emax (Fig 5.7 (c) & (d), Table 5.7). V6.40F, V6.40M and V6.40Y all 
displayed „WT-like‟ cell-surface expression characteristics whereas V6.40A was detrimental 
to expression (65 % of WT) (Fig 5.7 (b), Table 5.7).      
 
5.2.2 Investigation of the conserved hydrophobic residues using an inverse agonist 
Based on the results of the ghrelin-induced InsP-InsP3 accumulation assays, I3.43A, V6.40A, 
V6.40M and V6.40Y were chosen for characterisation with the ghrelin-R inverse agonist, SP-
analogue. I3.43A was investigated using the inverse agonist as the mutant displays an 
increase in basal activity. The pIC50 for the I3.43A mutant was „WT-like‟ although the mutant 
receptor construct was unable to reach the same maximal inhibition of basal activity as seen 
for the WT (Imax 83 % compared to the WT Imax 51 %). This may reflect the increased basal 
signalling observed with this mutant receptor construct (Fig 5.8, Table 5.8). V6.40A and 
V6.40Y were also more constitutively active than the WT ghrelin-R and were therefore 
characterised with SP-analogue. V6.40A had a WT pIC50 and Imax despite the increased basal, 
suggesting that the introduction of alanine at position 6.40 does not affect the inverse agonist 
response despite having a lower Emax for ghrelin-induced signalling (Fig 5.9, Table 5.9). The 
constitutive activity of the V6.40Y mutant was not reduced by stimulation with the
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Figure 5.7 Ligand binding, intracellular signalling and cell-surface expression profiles for Val
6.40 
mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, V6.40A, V6.40F, V6.40M or V6.40Y and are expressed as a 
percentage of specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R, V6.40A, V6.40F, V6.40M or V6.40Y. Values are expressed as a percentage of the 
WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  
SEM of three or more separate experiments, performed in triplicate. 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
V6.40A 8.57  0.05 NDS 16  5 124  8 NDS 65  8 
V6.40F 8.34  0.07 8.20  2.77 12  9 111  8 104  8 83  11 
V6.40M 8.65  0.04 4.62  2.49 -41  13 56  5 107  16 111  9 
V6.40Y 8.36  0.09 NDS 55  12 142  6 NDS 106  12 
 
 
Table 5.7 Ligand binding, intracellular signalling and cell-surface expression for Val
6.40
 mutant constructs: Values were obtained using the 
methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R.  Red indicates no detectable signalling. Orange indicates an increase in EC50 > 4-fold or a reduction in basal activity > 40 % of WT. 
Green indicates an increase in basal activity > 10 % of WT. Blue indicates an increase in basal activity > 40 % of WT. Yellow indicates a 
reduction in cell surface expression > 30 % of WT.  
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Figure 5.8 Intracellular signalling profile for I3.43A
 
using SP-analogue: InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R or 
I3.43A. Values are expressed as a percentage of the WT ghrelin-R basal from experiments 
performed in parallel. All data are mean  SEM of three or more separate experiments, 
performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
  
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
I3.43A 7.62  0.09 132  8 83  7 
 
Table 5.8 Intracellular signalling of I3.43A
 
mutant receptor construct using SP-
analogue: Values were obtained using the methods described in Chapter 2. Data are the mean 
 SEM of three or more separate experiments, performed in triplicate. Grey indicates WT 
ghrelin-R. Green indicates increase constitutive activity > 10 % of WT. Yellow indicates a 
reduction in Imax > 30 %. 
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Figure 5.9 Intracellular signalling profile for Val
6.40 
mutant constructs using SP-
analogue: InsP-InsP3 accumulation assays were performed on cells transiently transfected 
with WT ghrelin-R, V6.40A, V6.40M or V6.40Y. Values are expressed as a percentage of the 
WT ghrelin-R basal from experiments performed in parallel. All data are the mean  SEM of 
three or more separate experiments, performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
  
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
V6.40A 7.51  0.07 112  7 54  5 
V6.40F Not characterised 
V6.40M NDS 62  3 NDS 
V6.40Y NDS 131  14 NDS 
 
Table 5.9 Intracellular signalling of Val
6.40 
mutant constructs using SP-analogue: Values 
were obtained using the methods described in Chapter 2. Data are the mean  SEM of three or 
more separate experiments, performed in triplicate. Grey indicates WT ghrelin-R. Green 
indicates an increase in basal > 10 % of WT. Red indicates no detectable signalling. Yellow 
indicates reduced basal > 20 % of WT.   
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inverse agonist, implying that substitution of valine with tyrosine affected agonist and inverse 
agonist sensitivity. V6.40M decreased ghrelin-R constitutive activity to a level comparable to 
the Imax observed with SP-analogue on the WT ghrelin-R and this was not decreased further 
by SP-analogue (Fig 5.9, Table 5.9).  
 
5.2.3 The role of polar residues in TMIII of the ghrelin-R 
Three polar residues in TMIII were mutated to alanine in the ghrelin-R. Although not 
absolutely conserved, serine and threonine residues are often found at these positions in 
Family A GPCRs. Residue 3.32 is polar in 15 %, 3.42 is polar in 38 %, residue 3.44 is polar 
in 37 % and residue 3.47 is polar in 54 % of Family A GPCRs (Mirzadegan et al., 2003).    
 
Ser
3.32 
is found at the extracellular side of TMIII in the ghrelin-R. In the V1aR, molecular 
modelling revealed that Gln
3.32
 interacts, via a hydrogen bond, with Asp204 in ECL2 (Hawtin 
et al., 2006) (Chapter 6). Thr
3.32 
has been shown to be involved in restraining the ground state 
of the FSHR. Mutation of this residue in the FSHR to a number of different amino acids, 
including alanine, resulted in increased constitutive activity and resulted in abnormal 
responses to agonist (Montanelli et al., 2004b). This residue is also known to play a role in 
binding of biogenic amine ligands (Strader et al., 1988; Porter et al., 1996; Kristiansen et al., 
2000). To investigate whether Ser
3.32 
in important in maintaining the natural constitutive 
activity in the ghrelin-R the mutant, S3.32A, was constructed. S3.32A demonstrated „WT-
like‟ agonist affinity, cell-surface expression, and intracellular signalling characteristics, 
although the basal constitutive activity was found to be slightly reduced (-26 % of WT) (Fig 
5.10, Table 5.10). 
 
T3.42A was „WT-like‟ with respect to ghrelin binding, potency, efficacy and cell-surface 
expression. There was an increase in basal constitutive activity to 124 % (27 % of WT 
ghrelin-induced maximum) suggesting that the introduction of alanine results in a more active 
receptor conformation in the absence of agonist (Fig 5.11, Table 5.10).  
 
Mutation of Thr
3.44 
to alanine in the T3.44A mutant resulted in a receptor that displayed 
decreased agonist-independent signalling (-29 %) compared to the WT ghrelin-R. The ability 
of T3.44A to signal when stimulated with ghrelin was also affected; the Emax was greatly 
reduced (55 %) and potency decreased 3.8-fold compared to WT. Cell-surface expression of 
this mutant was also slightly decreased (69 %). The agonist affinity remained similar to that 
seen for the WT receptor (Fig 5.12, Table 5.10).  
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Figure 5.10 Ligand binding, intracellular signalling and cell-surface expression profiles for S3.32A:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or S3.32A and are expressed as a 
percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT 
ghrelin-R or S3.32A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in 
parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the mean  SEM of 
three or more separate experiments, performed in triplicate. 
(a)             (b)       (c)   
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Figure 5.11 Ligand binding, intracellular signalling and cell-surface expression profiles for T3.42A
 
mutant receptor construct:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or T3.42A and are expressed as a percentage of specific binding. (b) 
Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were performed on 
cells transiently transfected with WT ghrelin-R or T3.42A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed 
in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
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Figure 5.12 Ligand binding, intracellular signalling and cell-surface expression profiles for T3.44A
 
mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
T3.44A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or T3.44A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum and 
ghrelin-R basal from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the 
WT ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)               (b)      (c) 
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Figure 5.13 Ligand binding, intracellular signalling and cell-surface expression profiles for S3.47A
 
mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
S3.47A and are expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or S3.47A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum and 
ghrelin-R basal from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the 
WT ghrelin-R maximum. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)               (b)      (c) 
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
S3.32A 8.54  0.09 1.74  0.19 -26  12 108  21 124  12 
T3.42A 8.51  0.08 0.83  0.43 27  8 124  9 96  15 
T3.44A 8.80  0.07 8.12  3.36 -29  8 55  9 69  10 
S3.47A 8.64  0.08 NDS 7  11 NDS 73  9 
 
 
 
 
Table 5.10 Ligand binding, intracellular signalling and cell-surface expression for S3.32A, T3.42A, T3.44A and S3.47A mutant 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R. Yellow indicates > 20% reduction in basal activity, a decrease in Emax > 30 % of WT or a 
decrease in cell-surface expression > 30 %. Green indicates an increase basal signalling > 10 % of WT. Orange indicates an increase in EC50 > 4-
fold. Red indicates no detectable signalling.  
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The S3.47A mutant was unable to signal in response to ghrelin despite retaining „WT-like‟ 
constitutive activity, ghrelin binding affinity and cell-surface expression, suggesting that the 
S3.47A mutation disrupts the ability of the ghrelin-R to adopt the fully active conformation in 
response to agonist (Fig 5.13, Table 5.10).    
 
5.2.4 Investigation of polar residues using an inverse agonist 
T3.42A and S3.47A were analysed further using the inverse agonist, SP-analogue. InsP-InsP3 
accumulation assays indicated that T3.42A was „WT-like‟ in its response to SP-analogue, 
despite the increased basal signalling compared to the WT ghrelin-R. The constitutive activity 
was decreased on addition of the SP-analogue and the resultant Imax (55 %) was comparable to 
the Imax observed for the WT ghrelin-R (51 %) (Fig 5.14, Table 5.11). The S3.47A mutation, 
which was unresponsive to ghrelin despite retaining WT constitutive activity, displayed „WT-
like‟ signalling characteristics in response to SP-analogue (Fig 5.15, Table 5.12). This 
suggests that the effect of the S3.47A mutation is specific to agonists and that there appears to 
be a disruption to the ability of the ghrelin-R to adopt a more active conformation in response 
to ghrelin, but that the mutation does not cause a disruption to the conformational re-
arrangements induced by binding to the inverse agonist. 
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Figure 5.14 Intracellular signalling profile for T3.42A ghrelin-R mutant construct using 
SP-analogue: InsP-InsP3 accumulation assays were performed on cells transiently transfected 
with WT ghrelin-R or T3.42A. Values are expressed as a percentage of the WT ghrelin-R 
basal from experiments performed in parallel. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced Ins-InsP3 Accumulation 
  
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
T3.42A 7.29  0.05 112  4 55  6 
 
 
 
Table 5.11 Intracellular signalling of the T3.42A mutant using SP-analogue: Values were 
obtained using the methods described in Chapter 2. Data are the mean  SEM of three or 
more separate experiments, performed in triplicate. Grey indicates WT ghrelin-R. Green 
indicates an increase in basal > 10 % of WT. 
 
 199 
 
-11 -10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120
140
S3.47AWT ghrelin-R
log {[SP-analogue] (M)}
In
s
P
-I
n
s
P
3
 A
c
c
u
m
u
la
ti
o
n
(%
 W
T
 b
a
s
a
l)
 
Figure 5.15 Intracellular signalling profile for S3.47A
 
using SP-analogue: InsP-InsP3 
accumulation assays were performed on cells transiently transfected with WT ghrelin-R or 
S3.47A. Values are expressed as a percentage of the WT ghrelin-R basal from experiments 
performed in parallel. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
 
 
 
Construct 
 
SP-analogue-induced InsP-InsP3 Accumulation 
  
pIC50 ± SEM 
 
Basal  
(% WT basal)  
 SEM 
Imax 
(% WT basal)  
 SEM 
WT ghrelin-R 7.72  0.04 97  2 51  1 
S3.47A 7.39  0.12 109  11 69  5 
 
 
Table 5.12 Intracellular signalling of the S3.47A
 
mutant receptor using SP-analogue: 
Values were obtained using the methods described in Chapter 2. Data are the mean  SEM of 
three or more separate experiments, performed in triplicate. Grey indicates WT ghrelin-R.  
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5.3 Discussion 
 
Hydrophobic and polar residues within TMs III and VI of Family A GPCRs have been found 
to be involved in a number of stabilising and constraining interactions, indicated by the 
production of constitutive activity after mutation of some of these key residues. A 
„hydrophobic latch‟ has been proposed to occur in the TM domain of Family A GPCRs with 
mutation of residues within this cluster resulting in a favouring of the active receptor 
conformation (Meng et al., 2001; Hulme et al., 2003). Hydrophobic interactions occur 
between residues in TMs II, III, VI and VII in Rho and these interactions include Leu
3.43
 and 
Met
6.40
 investigated in this study (Okada et al., 2001a).  
    
Individual hydrophobic and polar residues within TMIII and TMVI were mutated to alanine 
and characterised in the ghrelin-R, probing the molecular basis of the high constitutive 
activity of the ghrelin-R. To gain further insight into the role of individual residues in the TM 
domains, highly conserved residues and some less well conserved residues, were targeted for 
mutagenesis. Each mutant was characterised in terms of their ability to bind ghrelin, express 
at the cell-surface and signal through the InsP3 pathway, in both an agonist-independent and 
agonist-dependent manner. 
 
5.3.1 The role of the conserved hydrophobic residues in ghrelin-R function 
A leucine is highly conserved at position 2.46 in Family A GPCRs (91 %) (Mirzadegan et al., 
2003). Leu
2.46
 has been proposed to form part of the asparagine cage, along with residue 6.40, 
restraining Asn
7.49
 of the NPxxY motif (Chapter 4) in an inactive conformation and pointing 
towards TMVI (Okada et al., 2001a; Bakker et al., 2008). Leu
2.46
 mutation to alanine in Rho 
resulted in constitutive activity (Okada et al., 2001a), as did mutation of Met
6.40
 (Han et al., 
1998) (discussed later in this section) highlighting the role of these residues in stabilising an 
inactive receptor (Madabushi et al., 2004). Similarly, in the TSHR, an L2.46A mutation 
increased receptor constitutive activity (Urizar et al., 2005). Met
2.46
 in the ghrelin-R was 
mutated to alanine to investigate whether methionine plays a similar role in stabilising the 
basal state of the ghrelin-R. The M2.46A mutation moderately decreased ghrelin-R basal 
signalling to -27 % of the WT ghrelin-R ghrelin-induced maximal response. Ghrelin affinity 
and potency were maintained, but efficacy was reduced with the mutant receptor presenting 
an Emax of only 55 % of the WT. Cell-surface expression was also substantially reduced (55 % 
of WT), possibly providing an explanation of the decreased constitutive activity and Emax, if 
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the receptor was not present at the cell-surface in sufficient quantities to signal in a „WT-like‟ 
manner. However, other ghrelin-R mutants that demonstrate low expression have been found 
to retain „WT-like‟ constitutive activity (see Chapter 4, section 4.4.4.2, T6.33V), suggesting 
that the reduced expression is unlikely to be the cause of the decreased basal or Emax. It could 
be suggested that the presence of methionine at position 2.46, instead of the much more 
highly conserved leucine, may in part be responsible for the high level of constitutive activity 
observed for the ghrelin-R. Further mutations are required at this locus to investigate the 
effect of introducing a leucine, thus stabilising a potential asparagine cage, on ghrelin-R 
constitutive activity, as it is unclear from the single alanine mutation, whether Met
2.46
 plays a 
crucial role in the structure and function of the constitutively active ghrelin-R.       
 
A leucine is highly conserved (74 %) in Family A GPCRs at position 3.43 in TMIII. An 
isoleucine is found in the ghrelin-R, which occurs in 10 % of the superfamily (Mirzadegan et 
al., 2003). Residue 3.43 has been proposed to form part of a cluster of hydrophobic residues 
connecting TMs III, VI and VII, referred to as the hydrophobic latch (Lu et al., 2000; 
Palczewski et al., 2000; Okada et al., 2001a). Residue 3.43 has been extensively investigated 
in the glycoprotein hormone receptors. In the LHR mutation of Leu
3.43 
to arginine was found 
to result in constitutive activity (Latronico et al., 1998) and in the FSHR an L3.43R mutant 
also resulted in constitutive activity, whereas mutation of Leu
3.43 
to alanine, aspartate or lysine 
did not affect basal signalling (Tao et al., 2000). Similarly in the C5a anaphylatoxin 
chemotactic receptor (C5aR), an L3.43Q mutation resulted in weak constitutive activity 
(Baranski et al., 1999) and in the β2AR, three Leu
3.43 
substitutions resulted in increased 
constitutive activity: L3.43A, L3.43K and L3.43R (Tao et al., 2000). 
 
In the ghrelin-R, mutation of Ile
3.43
 to alanine resulted in increased constitutive activity (140 
% of WT basal) without affecting ghrelin binding affinity, potency, efficacy or receptor cell-
surface expression. Disruption of potential stabilising interactions by the I3.43A mutation in 
the ghrelin-R caused increased constitutive activity, suggesting that Ile
3.43
 must form 
stabilising interactions that maintain the receptor in the basal conformation in the absence of 
ghrelin. 
 
To further investigate the role of Ile
3.43
 in the ghrelin-R, an I3.43R mutant was produced. 
Arginine introduction at this locus in the LHR, FSHR and β2AR resulted in constitutive 
activity (Latronico et al., 1998; Tao et al., 2000). The introduction of arginine in the ghrelin-R 
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was particularly detrimental to receptor function, affecting ghrelin binding affinity (no 
detectable binding at the [
125
I]ghrelin concentration used), potency (decreased 4.7-fold), 
efficacy (-2 % of WT ghrelin-induced maximum), constitutive activity (12 % of WT basal) 
and cell-surface expression (43 % of WT). This is in contrast to the data from the β2AR, in 
which the introduction of a positive charge (L3.43K and L3.43R), resulted in increased 
constitutive activity as found with the L3.43A mutation (Tao et al., 2000) and the LHR, 
where positive charges introduced at position 3.43 caused constitutive activity, possibly via 
the formation of a salt bridge with Asp
6.44
 (Zhang et al., 2005).  
 
Liu et al. (2007), found that an I3.43T mutant in the ghrelin-R, which has been identified as a 
mutation resulting from a single nucleotide polymorphism in human subjects, did not affect 
ghrelin-R constitutive activity, but resulted in a receptor that was unresponsive to ghrelin and 
only partially responsive to the inverse agonist, SP-analogue (Liu et al., 2007b). I3.43A was 
investigated using SP-analogue in this study. The I3.43A mutant was „WT-like‟ in terms of 
inverse agonist potency, although the mutant receptor construct was not able to reach the 
same maximal inhibition of basal activity as seen for the WT. Similar to that seen for the 
I3.43T mutation in the study by Liu et al. the I3.43A mutant was only partially responsive to 
inverse agonist. The data from Liu et al. (2007), combined with that of our current study, 
suggests that Ile
3.43
 has a significant role in all aspects of ghrelin-R activity, as mutations at 
this locus can cause both increases and decreases in constitutive activity and can affect the 
ability of the receptor to be further activated by ghrelin, or inactivated by the SP-analogue, to 
varying degrees. 
 
Residues 3.46 and 6.37 are highly conserved as hydrophobic amino acids in Family A GPCRs 
(98 % and 90 % respectively). In the TSHR, Ile
3.46
 and Met
6.37
 have been identified as 
interaction partners through site-directed mutagenesis after identification of a CAM TSHR 
(M6.37I) in humans suffering from hyperthyroidism. A reciprocal mutation producing 
I3.46M/M6.37I was able to restore WT constitutive activity, suggesting the recovery of 
stabilising interactions that were released through the M6.37I mutation alone, possibly due to 
a repulsive force between TMs III and VI (Ringkananont et al., 2006). 
 
Leu
3.46
 and Leu
6.37
 were both mutated in the ghrelin-R to other hydrophobic amino acids to 
investigate the potential of a stabilising interaction between these residues that maintains the 
ghrelin-R basal activity. All of the Leu
3.46
 and Leu
6.37
 mutants retained „WT-like‟ ghrelin 
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binding affinity. Both the L3.46A and L3.46M mutations reduced the constitutive signalling 
(-86 % and -59 % respectively), with the L3.46A mutant constitutive activity being 
comparable to that seen for mock transfected cells. Despite this reduction in basal signalling, 
both mutants were able to signal to the same extent as the WT ghrelin-R in response to 
ghrelin. The L3.46A mutant did however show decreased ghrelin potency (7.6-fold). The 
L3.46I mutation had a particular effect on ghrelin-R function, affecting potency (3.3-fold 
increase in EC50), and efficacy (Emax 38 % of WT maximum) although it maintained basal 
signalling capabilities. Similarly, in the GnRHR, mutation of Ile
3.46
 to alanine or valine, were 
not well tolerated in terms of retaining „WT-like‟ binding and signalling properties although a 
conservative I3.46L mutation retained „WT-like‟ GnRH binding and signal transduction 
(Ballesteros et al., 1998).  
 
Mutation of Leu
6.37
 to alanine, isoleucine and methionine, thus conserving the hydrophobicity 
at this locus, had no effect on ghrelin-R basal activity. L6.37A and L6.37I were „WT-like‟ 
with regards to all characteristics. Only L6.37M demonstrated any difference in 
characteristics, having decreased efficacy (Emax 67 % of WT) and decreased cell-surface 
expression (66 % of WT). The constitutive activity was slightly decreased (-18 % of WT 
ghrelin-induced maximum) and the EC50 was increased compared to WT, (2.4-fold), although 
neither to any notable degree. The decreased efficacy was unlikely to be a result of the 
decreased number of receptors present at the cell surface as other mutations within the 
ghrelin-R have expression of approximately 66 % and still display „WT-like‟ efficacy (see 
Chapter 4, section 4.2.7, L7.52A). Hydrophobic residues have been shown to be important at 
position 6.37 in the m3 mAChR for coupling to G-proteins, suggesting an essential role of the 
conserved hydrophobic character in activation (Blin et al., 1995). To investigate whether the 
maintenance of a hydrophobic residue is responsible for the „WT-like‟ characteristics in the 
ghrelin-R mutants, a L6.37T mutant was produced. This introduced a polar threonine residue, 
which is only found at this position in 4 % of Family A GPCRs (serine found in 2 %) 
(Mirzadegan et al., 2003). The L6.37T mutation had reduced basal signalling (-37 % of the 
WT ghrelin-induced maximum), without affecting other aspects of receptor function.  
 
From the data in this study it is clear that many different residues are tolerated at position 6.37 
and that, unlike the TSHR, an interaction between 6.37 and 3.46 was not contributing to the 
ghrelin-R constitutive activity. Alone, Leu
3.46
 appears to be particularly important to ghrelin-R 
activity; the data demonstrate that maintaining a hydrophobic residue does not necessarily 
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retain WT activity. Introduction of isoleucine in the L3.46I mutant retained WT constitutive 
activity, suggesting that maintaining a similar side chain size and character to leucine is 
essential for ghrelin-R constitutive activity. This was further supported by the loss of ghrelin-
R constitutive activity in the L3.46A mutant, and the substantial reduction with the L3.46M 
mutant.      
 
Residue 6.36 in not as highly conserved as residue 6.37 or some of the other residues within 
TMs III and VI, although a hydrophobic amino acid is found in 64 % of Family A GPCRs 
(Mirzadegan et al., 2003). An M6.36A mutant was included in the ghrelin-R mutagenesis 
study due to its location at the cytoplasmic end of TMVI to gain a greater insight into the role 
of individual residues in ghrelin-R function. The M6.36A mutant retained „WT-like‟ ghrelin 
affinity, potency, efficacy and cell-surface expression, but reduced ghrelin-R constitutive 
activity to -40 % of the WT ghrelin-R ghrelin-induced maximum. Mutation of Arg
6.36
 in the 
TSHR to alanine caused a similar effect to that seen in the ghrelin-R, with the mutant causing 
a small reduction in constitutive activity, but not affecting agonist responsiveness, or affinity 
(Urizar et al., 2005). Many of the mutations introduced in to the ghrelin-R caused small 
decreases in constitutive activity, potentially due to small disruptions to the microenvironment 
surrounding each residue. This combined data suggests that residue 6.36 is not as significant 
in Family A receptor function as some of the other hydrophobic residues found within TMVI, 
and does not appear to form major stabilising interactions, although it is required for 
maintaining full WT constitutive activity. 
 
Residue 6.40 is a highly conserved hydrophobic residue in Family A GPCRs (93 %) 
(Mirzadegan et al., 2003). Met
6.40 
was substituted by all 19 amino acids in opsin and all 
mutants, except the conservative M6.40L and M6.40R, which failed to express at the cell 
surface, resulted in increased constitutive activity compared to WT (Han et al., 1998). 
Similarly, in the H1R, mutation of Ile
6.40
 to glutamate, glycine, alanine, arginine, lysine and 
serine resulted in increased constitutive activity (Bakker et al., 2008).  
 
The four ghrelin-R Val
6.40 
mutants demonstrated different pharmacological characteristics. 
Mutation of Val
6.40 
in the ghrelin-R resulted in varying levels of constitutive activity 
depending on the amino acid introduced. V6.40A, V6.40F and V6.40Y all increased 
constitutive activity, whereas V6.40M reduced agonist-independent signalling. The V6.40A 
mutant displayed CAM activity (124 % of WT ghrelin-R basal), but as seen with all the 
Val
6.40
 substitutions, retained „WT-like‟ agonist affinity, unlike many classical CAMs which 
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increase agonist affinity. The V6.40A mutant was unable to signal further when stimulated 
with ghrelin suggesting that, despite the increase in agonist-independent activity, ghrelin 
potency and efficacy were greatly affected. Other alanine mutations at position 6.40 also 
resulted in increased constitutive activity in Family A GPCRs including opsin (Han et al., 
1998), the H1R (Bakker et al., 2008), and the 5HT2AR (Shapiro et al., 2002).  
 
The M6.40Y mutation in opsin resulted in the biggest increase in constitutive activity (Han et 
al., 1998). To investigate the effects of a tyrosine at 6.40 in the ghrelin-R, a V6.40Y mutation 
was produced. V6.40Y was highly constitutively active (143 % of WT basal), suggesting that 
the introduction of tyrosine potentially stabilises an active receptor conformation. As seen 
with the V6.40A mutation, V6.40Y was unable to be further stimulated by ghrelin. This could 
be for a number of reasons; the V6.40Y conformation may resemble the active state of the 
receptor when stimulated with ghrelin, with TMIII and TMVI being separated by a repulsive 
action of tyrosine at position 6.40, or the V6.40Y mutation may represent a different receptor 
conformation that is partially active, but cannot be further activated by ghrelin.    
 
V6.40F only increased constitutive activity to 111 % of WT basal, the lowest effect of all the 
CAMs at position 6.40 in the ghrelin-R. Similarly, in opsin, the introduction of phenylalanine 
did not produce a dramatic increase in constitutive activity, although some measurable 
increase was observed (Han et al., 1998). This suggests that phenylalanine forms different 
interactions, in both Rho and the ghrelin-R, to the alanine and tyrosine substitutions, which 
both presented substantially increased constitutive activity when introduced into the receptors. 
This also suggests that it is unlikely that activation in the V6.40Y mutation is caused by the 
increased side chain bulk of tyrosine forcing TMIII and TMVI apart and thus mimicking 
activation, as the substitution with phenylalanine would be expected to result in a similar 
phenotype.  
 
The V6.40M mutation decreased the agonist-independent activity of the ghrelin-R (56 % of 
WT basal) suggesting that this mutant receptor adopts a more inactive conformation. Ghrelin-
induced activation was unaffected by the mutation, with V6.40M displaying „WT-like‟ EC50 
and Emax, therefore only the basal state of the receptor was altered and not the ability of the 
receptor to adopt an active conformation after stimulation with ghrelin. Methionine is found at 
position 6.40 in Rho, and it is assumed that Met
6.40
 must retain the lowest level of constitutive 
activity in opsin, as mutation to any other amino acid (except leucine) resulted in constitutive 
activity (Han et al., 1998). This result is consistent with our findings in the ghrelin-R. 
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Molecular modelling and mutagenesis in the V1aR suggested that mutations of Ile
6.40
 either 
disrupted or strengthened TMIII and/or TMVII interactions with TMVI, depending on the 
effect of the introduced amino acid on receptor constitutive activity (Wootten &Wheatley, 
manuscript in preparation). In the current study, the data for the ghrelin-R appears to represent 
that found in Rho (Han et al., 1998) and the V1aR, in that there was no apparent correlation 
between the side chain properties of the amino acids introduced and the level of constitutive 
activity. In Rho and the H1R, Met/Ile
6.40
 is predicted to have a role in stabilising the side chain 
conformation of Asn
7.49
 of the NPxxY motif in the inactive receptor, as part of the asparagine 
cage, and therefore mutation of 6.40 releases this constraint and allows the receptor to adopt a 
more active conformation causing constitutive activity (Okada et al., 2001a; Bakker et al., 
2008). A mutagenesis study of the MC4R found that Leu
6.40
 substitution with arginine, lysine, 
glutamate, glutamine and asparagine resulted in increased receptor constitutive activity that 
appeared to relate to the side chain properties of the amino acid introduced. It was suggested 
in the MC4R that the constitutively active mutations at 6.40 acted to stabilise the active state 
of the receptor rather than destabilise the inactive conformation, possibly through interactions 
with Arg
3.50
 and Tyr
5.58
, and this is supported by the high level of constitutive activity 
observed for L6.40E, L6.40N and L6.40Q mutants (Proneth et al., 2006). Interestingly, the 
alanine and phenylalanine mutants did not cause increased basal signalling, and this was 
suggested to be due to the destabilisation of the inactive and the active state with the alanine 
mutant, and due to reinforcement of interactions with TMVII in the L6.40F mutant, thus 
affecting movement of the helices in activation (Proneth et al., 2006). It can be assumed that 
different interactions are occurring in the ghrelin-R, as both the alanine and phenylalanine 
introductions at position 6.40 increased the constitutive activity of the receptor. 
 
Characterisation of the Val
6.40
 mutants using SP-analogue showed that V6.40A displayed 
„WT-like‟ characteristics in response to the inverse agonist, despite an increase in constitutive 
activity. In contrast, the constitutive activity of the V6.40Y mutant was not able to be reduced 
by SP-analogue. This correlates with the data for ghrelin-induced activation of V6.40Y, and 
indicates that V6.40Y results in a reduction in both agonist and inverse agonist sensitivity, 
and supports the important disruptive action of tyrosine at this locus. The data suggests that 
tyrosine may be stabilising an active receptor conformation that is unable to be activated 
further by ghrelin, or disrupted by inverse agonist challenge. To investigate Val
6.40
 in more 
detail, V6.40M was also characterised for SP-analogue sensitivity. V6.40M was unresponsive 
to SP-analogue stimulation, highlighting the decreased constitutive activity found for this 
mutation and suggesting that, despite retaining ghrelin sensitivity, the inverse agonist is 
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unable to reduce constitutive activity further. It can be assumed that the V6.40M mutation 
reduces constitutive activity down to a level similar to the observed Imax for the SP-analogue, 
meaning that basal signalling cannot be reduced further using the inverse agonist (see Chapter 
4, section 4.2.3.1, H6.30E & H6.30K). 
 
5.3.2 The role of polar residues in TMIII of the ghrelin-R 
Serine, threonine and cysteine are readily able to form interhelical hydrogen bonds, and thus 
form stabilising interactions within TM domains (Liu et al., 2004). Four of these polar 
residues, within TMIII of the ghrelin-R, were chosen for alanine substitution mutagenesis to 
investigate their role in ghrelin-R function.  
 
Residue 3.32 has been found to be involved in ligand binding and activation in a number of 
Family A GPCRs, in particular, the biogenic amine receptors (Strader et al., 1988; Porter et 
al., 1996). In the 5HT2AR, Asn
3.32
 was identified as being an important anchor site for 
agonists (Kristiansen et al., 2000) and the same residue is essential for agonist and antagonist 
binding in the β2AR (Strader et al., 1988), and the α2aAR (Wang et al., 1991). Mutation of 
Asp
3.32
 in the δ-OR resulted in constitutive activity (Befort et al., 2001) as did mutation at this 
position in the α1bAR (Porter et al., 1996). In the 5HT4R, mutation of Asp
3.32
 only affected 
receptor signalling, and was not particularly detrimental to ligand binding (Claeysen et al., 
2003). This combined data supports a multifunctional role of residue 3.32 both in individual 
receptors, and within Family A as a whole. Ser
3.32
 mutation to alanine in the ghrelin-R did not 
have a profound effect on any receptor characteristic. There was a small decrease in 
constitutive activity (-26 % of WT ghrelin-induced maximum), but no effect on ghrelin 
binding or agonist-induced receptor signalling, suggesting that a serine at position 3.32 is not 
vital for ghrelin-R activity. 
 
Two threonine residues within TMIII were mutated to alanine to investigate the role of these 
polar residues in ghrelin-R function. Residue 3.42 is not highly conserved in Family A 
GPCRs, but is often a hydrophobic or polar residue. The Thr
3.42
 mutation to alanine in the 
ghrelin-R caused increased constitutive activity (124 % of WT basal), suggesting that alanine 
substitution either disrupts interactions that stabilise the basal state of the receptor, or that 
alanine allows the formation of new interactions that stabilise the R* conformation. In 
contrast, the T3.44A mutation was detrimental to ghrelin-R function and activity, reducing 
cell-surface expression, constitutive activity, ghrelin potency and efficacy. The combined data 
suggests that the two threonine residues within TMIII play different roles in the ghrelin-R; 
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either stabilising the basally active conformation, but preventing excessive constitutive 
activation (Thr
3.42
), or affecting all aspects of receptor signalling (Thr
3.44
). T3.42A was further 
analysed using the inverse agonist, SP-analogue, to determine whether the increased 
constitutive activity had any effect on the inverse agonist response. The T3.42A was „WT-
like‟ in its response to the SP-analogue, despite the increased basal signalling compared to the 
WT ghrelin-R, with the SP-analogue reducing the constitutive activity so that the Imax (55 %) 
was comparable to the Imax observed for the WT receptor (51 %). This revealed that the 
T3.42A mutation only affects basal signalling and has no effect on ligand-induced receptor 
conformational changes.  
 
In the m1 mAChR three residues, including Ser
3.47
, were identified as potentials for forming 
intramolecular interactions that stabilise the R state of the receptor. Alanine substitution of 
Ser
3.47
 resulted in increased agonist affinity, efficacy and constitutive activity (Lu et al., 1999; 
Lu et al., 2000). In contrast, mutation of Ala
3.47
 in the β2AR to serine, valine or leucine, did 
not result in increased agonist-independent activity (Chelikani et al., 2007).  
 
Mutation of Ser
3.47
 to alanine in the ghrelin-R was particularly detrimental to agonist-induced 
receptor activation, although constitutive activity was retained at levels similar to WT. 
Ghrelin binding and cell-surface expression were not affected by the S3.47A mutation, 
suggesting that the detrimental effect on agonist-induced receptor activation is a direct effect 
on receptor activation and is not related to a reduction in expression, or loss of high affinity 
agonist binding. The S3.47A mutation also displayed „WT-like‟ characteristics in response to 
the SP-analogue. This suggests that the effect of the S3.47A mutation is specific to the action 
of agonists. It is apparent that there is a disruption to the ability of the mutant ghrelin-R to 
adopt a more active R* state in response to ghrelin stimulation, but that the S3.47A mutation 
does not disrupt inverse agonist mechanisms of action. As Ser
3.47
 is located in close proximity 
to the highly conserved ERY motif in TMIII (Chapter 4), it is possible that the disruption to 
agonist-induced activation is due to changes to the highly conserved region of the ERY motif 
and perturbation of Glu
3.49
/Arg
3.50
 interactions.   
 
Figure 5.16 presents schematic representations of the ghrelin-R showing each of the alanine 
substitution mutations in this chapter and their effects on ghrelin-R signalling. The location of 
each residue within the TM domain is indicated and the effect of the mutation on basal 
signalling and ghrelin potency and efficacy are indicated by colour. 
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Figure 5.16 Schematic representations of the ghrelin-R demonstrating signalling 
characteristics for ghrelin-R alanine substitutions in Chapter 5: each residue mutated to 
alanine was characterised using InsP-InsP3 accumulation assays to determine (a) ghrelin 
potency (b) basal constitutive activity and (c) ghrelin efficacy (see Appendix Table 9.1 for 
colour code). HA-epitope tag engineered at the N-terminus (purple). 
(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
(c) 
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CHAPTER 6.  
THE ROLE OF ECL2 AND EXTRACELLULAR RESIDUES IN  
GHRELIN-R FUNCTION 
 
6.1 Introduction  
The extracellular domains of GPCRs are the most diverse regions and this is linked to the 
wide variety of ligands that are able to activate the members of the receptor superfamily. The 
roles of the extracellular surfaces in GPCR activation are not as well defined as the TM 
domains, although ECL2 has been shown to be important for ligand binding and activation in 
a number of GPCRs (abu Alla et al., 1996; Ott et al., 2002; Karnik et al., 2003; Klco et al., 
2005; Massotte et al., 2005). 
 
The crystal structure of Rho revealed that ECL2 forms a β-hairpin which extends into the 
ligand binding pocket, making extensive contacts with retinal and with the extracellular 
domains (Palczewski et al., 2000). In contrast, the crystal structure of the β2AR demonstrated 
that ECL2 comprises an α-helix and a β-strand, stabilised by two disulphide bonds. This 
conformation allows the diffusion of ligands into, and out of, the binding pocket (Cherezov et 
al., 2007) (Fig 6.1). It is unclear which of these structures best represents ECL2 of peptide 
GPCRs. It might be presumed that, in a peptide GPCR, the ECL2 structure is similar to the 
β2AR ECL2 structure, as both are activated by diffusible ligands rather than by a covalently-
bound ligand as in Rho. However, many peptide hormone receptors, including the ghrelin-R, 
lack the second disulphide bond within ECL2, which constrains the helical structure and adds 
rigidity to the exposed loop.    
 
ECL regions vary in length between different members of the GPCR superfamily. As such, it 
is often difficult to determine the boundaries of the ECLs. Four secondary structure prediction 
programs (Phobius, JPred3, TMHMM and MEMSAT) were used to determine the residues 
comprising ECL2 in the ghrelin-R. The SwissProt entry Q92847-1 (2010) for the ghrelin-R 
states that ECL2 is residues 184-211. To investigate the role of ECL2 in ghrelin-R function, 
each residue within ECL2 was substituted by alanine. The effects of alanine substitution of 
residues in this chapter are summarised in the Appendix (Fig 9.4-9.8).   
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Figure 6.1 Extracellular domains of the β2AR and rhodopsin: Crystal structure of bRho (yellow) and the β2AR (red) extracellular domains 
showing the β-hairpin and α-helical region of ECL2 respectively (a) as viewed from the extracellular side, (b) as viewed through the membrane.  
(a)        (b) 
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To ensure that all ECL2 residues were mutated in the alanine scan, residues 180-212 were 
mutated as part of this study (Fig 6.2). Most of these mutants were only characterised with 
respect to ligand binding and cell-surface expression. Further mutagenesis and analysis of 
intracellular signalling capabilities were conducted on those residues that have been found to 
have a particular functional relevance in other Family A GPCRs and therefore might play a 
significant role in ghrelin-R function. 
 
Due to the large degree of variation in ECL2 length and sequence, a direct comparison 
between ECL2 regions in different Family A GPCRs is difficult. Conner et al. (2007) 
proposed a numbering system for residues within ECL2 based on the highly conserved 
cysteine that forms the intramolecular disulphide bond with Cys
3.25 
at the top of TMIII in most 
Family A GPCRs. Residues to the C-terminal side of the conserved ECL2 cysteine (Cys198 
in the ghrelin-R) are numbered C+ and residues to the N-terminal side are numbered C-, e.g. 
Ala204 in ECL2 of the ghrelin-R is C+6. For ease of comparison with other Family A 
GPCRs, this numbering system has been used throughout this investigation.   
 
6.2 Results 
6.2.1 ECL2 alanine scanning mutagenesis study 
All of the residues within ECL2 were mutated to alanine (Ala204
(C+6)
 to glycine) to 
investigate the effect of removal of the side chains. The mutant ghrelin-R constructs produced 
were V180A, L181A, V182A, G183A, V184A, E185A, H186A, E187A, N188A, G189A, 
T190A, D191A, P192A, W193A, D194A, T195A, N196A, E197A, C198A, R199A, P200A, 
T201A, E202A, F203A, A204G, V205A, R206A, S207A, G208A, L209A, L210A, T211A 
and V212A (Fig 6.2). The sequences of the oligonucleotide primers for site-directed 
mutagenesis are detailed in Table 6.1. 
 
The mutant receptor constructs were expressed in HEK 293T cells and pharmacologically 
characterised for ghrelin binding and cell-surface expression. V180A, L181A, G183A, 
V184A, E185A, H186A, E187A, P192A, W193A, D194A, T195A, V205A, R206A, S207A, 
G208A, L209A, T211A and V212A constructs all demonstrated „WT-like‟ binding affinity 
for ghrelin (Figs 6.3-6.5, Table 6.2). 
 213 
 
 
 
 
 
 
Figure 6.2 Schematic representation of the ghrelin-R: the intramolecular disulphide bond is shown in yellow. Residues that represent the HA-
epitope tag introduced at the N-terminus (blue) and the individual residues mutated in this chapter (green) are illustrated.
 214 
Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
V180A 5‟-GGG-CCC-ATC-TTC-GCG-CTA-GTC-
GGG-GTG-3‟ 
5‟-CAC-CCC-GAC-TAG-CGC-GAA-GAT-
GGG-CCC-3‟ 
L181A 5‟-CCC-ATC-TTC-GTG-GCA-GTC-GGG-
GTG-GAG-3‟ 
5‟-CTC-CAC-CCC-GAC-TGC-CAC-GAA-
GAT-GGG-3‟ 
V182A 5‟-ATC-TTC-GTG-CTA-GCC-GGG-GTG-
GAGCAC-3‟ 
5‟-GTG-CTC-CAC-CCC-GGC-TAG-CAC-
GAA-GAT-3‟ 
G183A 5‟-TTC-GTG-CTA-GTC-GCG-GTG-GAG-
CAC-GAG-3‟ 
5‟-CTC-GTG-CTC-CAC-CGC-GAC-TAG-
CAC-GAA-3‟ 
V184A 5‟-GTG-CTA-GTC-GGG-GCG-GAG-CAC-
GAG-AAC-3‟ 
5‟-GTT-CTC-GTG-CTC-CGC-CCC-GAC-
TAG-CAC-3‟ 
E185A 5‟-CTA-GTC-GGG-GTG-GCG-CAC-GAG-
AAC-GGC-3‟ 
5‟-GCC-GTT-CTC-GTG-CGC-CAC-CCC-
GAC-TAG-3‟ 
H186A 5‟-GTC-GGG-GTG-GAG-GCC-GAG-AAC-
GGC-ACC-3‟ 
5‟-GGT-GCC-GTT-CTC-GGC-CTC-CAC-
CCC-GAC-3‟ 
E187A 5‟-GGG-GTG-GAG-CAC-GCG-AAC-GGC-
ACC-GAC-3‟ 
5‟-GTC-GGT-GCC-GTT-CGC-GTG-CTC-
CAC-CCC-3‟ 
N188A 5‟-GTG-GAG-CAC-GAG-GCC-GGC-ACC-
GAC-CC-3‟ 
5‟-GG-GTC-GGT-GCC-GGC-CTC-GTG-
CTC-CAC-3‟ 
G189A 5‟-GAG-CAC-GAG-AAC-GCC-ACC-GAC-
CCT-TGG-3‟ 
5‟-CCA-AGG-GTC-GGT-GGC-GTT-CTC-
GTG-CTC-3‟ 
T190A 5‟-CAC-GAG-AAC-GGC-GCC-GAC-CCT-
TGG-GAC-3‟ 
5‟-GTC-CCA-AGG-GTC-GGC-GCC-GTT-
CTC-GTG-3‟ 
D191A 5‟-GAG-AAC-GGC-ACC-GCC-CCT-TGG-
GAC-ACC-3‟ 
5‟-GGT-GTC-CCA-AGG-GGC-GGT-GCC-
GTT-CTC-3‟ 
P192A 5‟-G-AAC-GGC-ACC-GAC-GCT-TGG-
GAC-ACC-AAC-3‟ 
5‟-GTT-GGT-GTC-CCA-AGC-GTC-GGT-
GCC-GTT-3‟ 
W193A 5‟-GGC-ACC-GAC-CCT-GCG-GAC-ACC-
AAC-GAG-3‟ 
5‟-CTC-GTT-GGT-GTC-CGC-AGG-GTC-
GGT-GCC-3‟ 
D194A 5‟-C-ACC-GAC-CCT-TGG-GCC-ACC-
AAC-GAG-TGC-3‟ 
5‟-GCA-CTC-GTT-GGT-GGC-CCA-AGG-
GTC-GGT-G-3‟ 
T195A 5‟-GAC-CCT-TGG-GAC-GCC-AAC-GAG-
TGC-CGC-3‟ 
5‟-GCG-GCA-CTC-GTT-GGC-GTC-CCA-
AGG-GTC-3‟ 
N196A 5‟-CT-TGG-GAC-ACC-GCC-GAG-TGC-
CGC-CCC-3‟ 
5‟-GGG-GCG-GCA-CTC-GGC-GGT-GTC-
CCA-AG-3‟ 
E197A 5‟-GG-GAC-ACC-AAC-GCG-TGC-CGC-
CCC-ACC-3‟ 
5‟-GGT-GGG-GCG-GCA-CGC-GTT-GGT-
GTC-CC-3‟ 
C198A 5‟-GAC-ACC-AAC-GAG-GCC-CGC-CCC-
ACC-GAG-3‟ 
5‟-CTC-GGT-GGG-GCG-GGC-CTC-GTT-
GGT-GTC-3‟ 
R199A 5‟-C-ACC-AAC-GAG-TGC-GCC-CCC-
ACC-GAG-TTT-G-3‟ 
5‟-C-AAA-CTC-GGT-GGG-GGC-GCA-
CTC-GTT-GGT-G-3‟ 
P200A 5‟-C-AAC-GAG-TGC-CGC-GCC-ACC-
GAG-TTT-GCG-3‟ 
5‟-CGC-AAA-CTC-GGT-GGC-GCG-GCA-
CTC-GTT-G-3‟ 
T201A 5‟-G-TGC-CGC-CCC-GCC-GAG-TTT-
GCG-GTG-3‟ 
5‟-CAC-CGC-AAA-CTC-GGC-GGG-GCG-
GCA-C-3‟ 
E202A 5‟-C-CGC-CCC-ACC-GCG-TTT-GCG-
GTG-CGC-3‟ 
5‟-GCG-CAC-CGC-AAA-CGC-GGT-GGG-
GCG-G-3‟ 
F203A 5‟-CGC-CCC-ACC-GAG-GCT-GCG-GTG-
CGC-TCT-G-3‟ 
5‟-C-AGA-GCG-CAC-CGC-AGC-CTC-
GGT-GGG-GCG-3‟ 
A204G 5‟-CCC-ACC-GAG-TTT-GGG-GTG-CGC-
TCT-GG-3‟ 
5‟-CC-AGA-GCG-CAC-CCC-AAA-CTC-
GGT-GGG-3‟ 
V205A 5‟-CC-GAG-TTT-GCG-GCG-CGC-TCT-
GGA-CTG-3‟ 
5‟-CAG-TCC-AGA-GCG-CGC-CGC-AAA-
CTC-GG-3‟ 
R206A 5‟-CC-GAG-TTT-GCG-GTG-GCC-TCT-
GGA-CTG-CTC-3‟ 
5‟-GAG-CAG-TCC-AGA-GGC-CAC-CGC-
AAA-CTC-GG-3‟ 
S207A 5‟-G-TTT-GCG-GTG-CGC-GCT-GGA-
CTG-CTC-ACG-3‟ 
5‟-CGT-GAG-CAG-TCC-AGC-GCG-CAC-
CGC-AAA-C-3‟ 
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Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
G208A 5‟-CG-GTG-CGC-TCT-GCA-CTG-CTC-
ACG-GTC-3‟ 
5‟-GAC-CGT-GAG-CAG-TGC-AGA-GCG-
CAC-CG-3‟ 
L209A 5‟-G-GTG-CGC-TCT-GGA-GCG-CTC-
ACG-GTC-ATG-3‟ 
5‟-CAT-GAC-CGT-GAG-CGC-TCC-AGA-
GCG-CAC-C-3‟ 
L210A 5‟-G-CGC-TCT-GGA-CTG-GCC-ACG-
GTC-ATG-GTG-3‟ 
5‟-CAC-CAT-GAC-CGT-GGC-CAG-TCC-
AGA-GCG-C-3‟ 
T211A 5‟-CT-GGA-CTG-CTC-GCG-GTC-ATG-
GTG-TGG-3‟ 
5‟-CCA-CAC-CAT-GAC-CGC-GAG-CAG-
TCC-AG-3‟ 
V212A 5‟-GGA-CTG-CTC-ACG-GCC-ATG-GTG-
TGG-GTG-3‟ 
5‟-CAC-CCA-CAC-CAT-GGC-CGT-GAG-
CAG-TCC-3‟ 
 
 
Table 6.1 Oligonucleotide primer sequences for QuikChange™ site-directed 
mutagenesis: Codons changed to introduce mutations are shown in red. 
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Figure 6.3 Ligand binding profiles for ECL2
 
mutant receptor constructs:  Competition radioligand binding assays were performed on HEK 
293T membranes from cells transiently transfected with (a) WT ghrelin-R, V180A, L181A, V182A or G183A and (b) WT ghrelin-R, V184A, 
E185A, H186A or E187A. Values are expressed as a percentage of specific binding. All data are the mean  SEM of three or more separate 
experiments, performed in triplicate. 
(a)          (b)  
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Figure 6.4 Ligand binding profiles for ECL2
 
mutant receptor constructs:  Competition radioligand binding assays were performed on HEK 
293T membranes from cells transiently transfected with (a) WT ghrelin-R, G189A, D191A, P192A or W193A and (b) WT ghrelin-R, D194A, 
T195A, V205A or R206A. Values are expressed as a percentage of specific binding. All data are the mean  SEM of three or more separate 
experiments, performed in triplicate. 
(a)          (b)  
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Figure 6.5 Ligand binding profiles for ECL2
 
mutant receptor constructs:  Competition radioligand binding assays were performed on HEK 
293T membranes from cells transiently transfected with (a) WT ghrelin-R, S207A, G208A, L209A or L210A and (b) WT ghrelin-R, T211A or 
V212A. Values are expressed as a percentage of specific binding. All data are the mean  SEM of three or more separate experiments, performed 
in triplicate. 
(a)          (b)  
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Figure 6.6 ELISA cell-surface expression profiles for ECL2
 
mutant receptor constructs: Assays were performed on HEK 293T cells 
transiently transfected with WT ghrelin-R, V180A, L181A, V182A, G183A, V184A, E185A, H186A, E187A, G189A, D191A, P192A, W193A, 
D194A, T195A, V205A, R206A, S207A, G208A, L209A, L210A, T211A or V212A. Values are expressed as a percentage of the WT ghrelin-R 
expression from experiments performed in parallel. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
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Table 6.2 Ligand binding and cell-surface expression for ECL2
 
mutant receptor 
constructs: Values were obtained using the methods described in Chapter 2. All data are the 
mean  SEM of three or more separate experiments, performed in triplicate. Grey indicates 
WT ghrelin-R. Yellow indicates an increase in pIC50 > 0.5 log units or a reduction in cell-
surface expression >30 % of the WT ghrelin-R expression. Orange indicates an increase in 
pIC50 > 0.75 log units or a reduction in cell-surface expression > 50 % of the WT ghrelin-R 
expression. Red indicates no detectable binding. 
 
Construct 
 
Binding Affinity  
pIC50  
 SEM 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 100 
V180A 8.23 ± 0.10 57 ± 12 
L181A 8.31 ± 0.12 105 ± 15 
V182A NDB 36 ± 9 
G183A 8.46 ± 0.06 43 ± 4 
V184A 8.31 ± 0.06 52 ± 8 
E185A 8.68 ± 0.07 81 ± 11 
H186A 8.23 ± 0.07 66 ± 4 
E187A 8.23 ± 0.07 106 ± 3 
G189A 7.86 ± 0.07 85 ± 8 
D191A 8.09 ± 0.09 119  12 
P192A 8.19 ± 0.07 112  10 
W193A 8.39 ± 0.18 108 ± 1 
D194A 8.22 ± 0.08 95  9 
T195A 9.05 ± 0.10 100  12 
V205A 8.49  0.06  83  3 
R206A 8.22  0.08 123 ± 16 
S207A 8.73  0.08 76 ± 19 
G208A 8.27  0.06 59 ± 9 
L209A 8.25  0.12 83  3 
L210A NDB 114  8 
T211A 8.08  0.07 116  10 
V212A 8.47  0.09 112  15 
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The G189A, D191A and T211A mutants decreased the binding affinity of ghrelin; G189A by 
~5-fold, and D191A and T211A by ~3-fold (Fig 6.4-6.5, Table 6.2). V182A and L210A 
exhibited no detectable binding of [
125
I]ghrelin at the concentration used in the assay (Fig 6.3 
& 6.5, Table 6.2). V182A was also particularly detrimental to cell-surface expression (36 % 
of WT). In contrast, L210A did not decrease cell-surface expression. V180A, G183A, 
V184A, H186A and G208A also exhibited decreased cell-surface expression (40-70 % of 
WT), although none of these mutants affected binding. All of the other alanine substitution 
mutants of ECL2 residues expressed at the cell surface at levels similar (70-100 %) to that 
seen for the WT ghrelin-R (Fig 6.6, Table 6.2).  
 
6.2.2 Extended ECL2 mutagenesis study  
The residues flanking the conserved ECL2 cysteine (Cys198
(C)
) and the residues of the 
putative N-linked glycosylation site in ECL2 were chosen for extended analysis. The mutants 
included in the extended study were N188A, T190A, N196A, E197A, C198A, R199A, 
P200A, T201A, E202A, F203A, F203G, A204G, A204E and A204V. Additional residues 
within the TM helices, which have been implicated in potential interactions with ECL2, were 
also included in this extended study. These residues were Cys116
(3.25)
, the highly conserved 
cysteine that forms a disulphide bond with Cys198
(C)
, Arg
6.55
, Phe
6.58 
and Lys
6.60
. The 
sequences of the oligonucleotide primers for site-directed mutagenesis are detailed in Table 
6.1 and Table 6.3. 
 
6.2.2.1 The role of Cys116
(3.25)
 and Cys198
(C)
  
Two cysteine residues are highly conserved in GPCRs; one in ECL2 (Cys
(C)
) and the other at 
the extracellular boundary of TMIII (Cys
3.25
). These cysteines form a disulphide bond in most 
Family A GPCRs; Cys
3.25 
is found in 90 % of Family A receptors (Mirzadegan et al., 2003). 
Cys116
(3.25)
 and Cys198
(C)
 in the ghrelin-R were mutated individually to alanine and mutated 
in tandem as a double mutant, C116A/C198A. The C116A, C198A and C116A/C198A 
mutants were all unable to bind ghrelin at the radioligand concentration available, or to signal 
in response to ghrelin (Fig 6.7-6.8, Table 6.4). Each mutation also resulted in a loss of 
constitutive activity to levels similar to that seen for the mock-transfected cells and all 
resulted in substantially decreased cell-surface expression; C116A (23 %), C198A (33 %) and 
C116A/C198A (27 %) (Fig 6.7-6.8, Table 6.4).     
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Table 6.3 Oligonucleotide primer sequences for QuikChange™ site-directed 
mutagenesis: Codons changed to introduce mutations are shown in red. 
Mutant 
Receptor 
Construct 
 
Sense Oligonucleotide 
 
Antisense Oligonucleotide 
C116A 5‟-C-GGC-GAC-CTC-CTC-GCC-AAA-
CTC-TTC-CAA-TTC-G-3‟ 
5‟-C-GAA-TTG-GAA-GAG-TTT-GGC-
GAG-GAG-GTC-GCC-G-3‟ 
F203G 5‟-CGC-CCC-ACC-GAG-GGT-GCG-GTG-
CGC-TCT-G-3‟ 
5‟-C-AGA-GCG-CAC-CGC-ACC-CTC-
GGT-GGG-GCG-3‟ 
A204E 5‟-CGC-CCC-ACC-GAG-TTT-GAG-GTG-
CGC-TCT-GGA-CTG-C-3‟ 
5‟-G-CAG-TCC-AGA-GCG-CAC-CTC-
AAA-CTC-GGT-GGG-GCG-3‟ 
A204V 5‟-CCC-ACC-GAG-TTT-GTG-GTG-CGC-
TCT-GG-3‟ 
5‟-CC-AGA-GCG-CAC-CAC-AAA-CTC-
GGT-GGG-3‟ 
R6.55A 5‟-CCC-TTC-CAC-GTA-GGG-GCA-TAT-
TTA-TTT-TCC-3‟ 
5‟-GGA-AAA-TAA-ATA-TGC-CCC-TAC-
GTG-GAA-GGG-3‟ 
F6.58A 5‟-GTA-GGG-CGA-TAT-TTA-GCT-TCC-
AAA-TCC-TTT-GAG-C-3‟ 
5‟-G-CTC-AAA-GGA-TTT-GGA-AGC-
TAA-ATA-TCG-CCC-TAC-3‟ 
K6.60A 5‟-GA-TAT-TTA-TTT-TCC-GCA-TCC-
TTT-GAG-CC-3‟ 
5‟-GG-CTC-AAA-GGA-TGC-GGA-AAA-
TAA-ATA-TC-3‟ 
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Figure 6.7 Ligand binding, cell-surface expression and intracellular signalling profiles for C116A and C198A mutant receptor constructs:  (a) Competition 
radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, C116A or C198A expressed as a percentage of 
specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays 
were performed on cells transiently transfected with WT ghrelin-R, C116A or C198A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum 
from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d)  
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Figure 6.8 Ligand binding, cell-surface expression and intracellular signalling profiles for the C116A/C198A double mutant receptor construct:  (a) Competition 
radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or C116A/C198A expressed as a percentage of 
specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays 
were performed on cells transiently transfected with WT ghrelin-R or C116A/C198A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum 
from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d)  
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Construct 
 
Binding  
Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
C116A NDB NDS -84  7 8  12 NDS 23  7 
C198A NDB NDS -86  7 7  11 NDS 33 3 
C116A/C198A NDB NDS -65  5 14  9 NDS 27  8 
 
 
 
 
Table 6.4 Ligand binding, intracellular signalling and cell-surface expression for C116A, C198A and C116A/C198A mutant constructs: 
Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed 
in triplicate. Grey indicates WT ghrelin-R. Red indicates no detectable binding, no detectable signalling, > 60 % reduction in basal activity and > 
70 % reduction in cell-surface expression compared to WT. Orange indicates > 50 % reduction in cell-surface expression compared to WT.  
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6.2.2.2 Asn188 and Thr190: A potential glycosylation motif 
Residues Asn188
(C-10)
 and Thr190
(C-8)
 form part of an N-linked glycosylation consensus motif 
(NxS/T) within ECL2, where „x‟ is any amino acid except for proline. Not all GPCR 
glycosylation consensus sequences are utilised, however, regions within the N-terminus and 
ECL2 are often glycosylated suggesting the potential for glycosylation of the ghrelin-R at this 
locus. For many GPCRs, glycosylation is essential for normal receptor function (Wheatley et 
al., 1999). In order to investigate the potential role of glycosylation of the ghrelin-R within 
ECL2, Asn188
(C-10)
 and Thr190
(C-8) 
were mutated individually to alanine as part of the alanine 
scan and were subsequently characterised. N188A displayed „WT-like‟ binding affinity for 
ghrelin and „WT-like‟ signalling except for a small reduction in constitutive activity (-28 %) 
(Fig 6.9, Table 6.5). T190A was unable to bind [
125
I]ghrelin at the concentrations used and 
signalling through the InsP3 pathway was affected to a small degree with a 2-fold increase in 
EC50 and a reduction in basal constitutive activity (-35 %) (Fig 6.9, Table 6.5). The T190A 
mutation also resulted in a small decrease in cell-surface expression (68 % of WT) whereas 
N188A was expressed at levels similar to the WT receptor (Fig 6.9, Table 6.5). 
 
6.2.2.3 The role of key ECL2 residues in ghrelin-R function 
N196A, E197A, R199A, P200A, T201A and E202A were characterised for radioligand 
binding, cell-surface expression and intracellular signalling capabilities. R199A, P200A and 
E202A displayed „WT-like‟ binding affinity for ghrelin (Fig 6.12, 6.13 & 6.15, Table 6.6). 
N196A, E197A and T201A displayed no detectable binding at the [
125
I]ghrelin concentration 
used (Fig 6.10, 6.11 & 6.14, Table 6.6). All of the mutants retained the ability to signal 
through the InsP pathway, although N196A, E197A and T201A displayed increases in EC50 
(9.6-fold, 4.5-fold and 4.2-fold respectively). (Fig 6.10, 6.11 & 6.14, Table 6.6). Basal 
constitutive activity was affected in all mutants to varying degrees, except R199A, which 
retained „WT-like‟ constitutive activity (Fig 6.10-6.15, Table 6.6). N196A was the mutant 
that was most detrimental to basal signalling, reducing the constitutive signalling to 26 % of 
the WT basal (Fig 6.10 (d), Table 6.6) (-120 % when normalised to WT ghrelin-induced 
maximum, Fig 6.10 (c)). E197A, P200A, T201A and E202A displayed constitutive activity of 
-35 %, -42 %, -45 % and -32 % of WT ghrelin-induced maximum, respectively. Emax was 
reduced in N196A and E197A mutants (57 % and 67 % of WT, respectively) and increased to 
161 % for the T201A construct. Cell-surface expression was „WT-like‟ for all mutants except 
N196A which reduced expression to 51 % of the WT (Fig 6.10-6.15, Table 6.6). 
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Figure 6.9 Ligand binding, intracellular signalling and cell-surface expression profiles for N188A and T190A mutant receptor 
constructs:  (a) Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT 
ghrelin-R, N188A or T190A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed 
on cells transiently transfected with WT ghrelin-R, N188A or T190A. Values are expressed as a percentage of the WT ghrelin-R, ghrelin-induced 
maximum from experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT 
ghrelin-R. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Table 6.5 Ligand binding, intracellular signalling and cell-surface expression for N188A and T190A mutant receptor constructs: Values 
were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in 
triplicate. Grey indicates WT ghrelin-R. Red indicates no detectable binding. Yellow indicates a > 20 % decrease in basal activity compared to 
WT or a decrease in cell-surface expression > 30 % of WT.  
 
Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT) 
  SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
N188A 8.37  0.06 1.72  0.30 -28  17 105  23 84  4 
T190A NDB 4.46  0.90 -35  5 118  10 68  9 
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Figure 6.10 Ligand binding, intracellular signalling and cell-surface expression profiles for N196A mutant receptor construct:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or N196A expressed as a percentage of specific binding. (b) Cell-
surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells 
transiently transfected with WT ghrelin-R or N196A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in 
parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d)  
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Figure 6.11 Ligand binding, intracellular signalling and cell-surface expression profiles for E197A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
E197A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or E197A.Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments 
performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All data are the 
mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Figure 6.12 Ligand binding, intracellular signalling and cell-surface expression profiles for R199A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
R199A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or R199A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Figure 6.13 Ligand binding, intracellular signalling and cell-surface expression profiles for P200A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
P200A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or P200A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Figure 6.14 Ligand binding, intracellular signalling and cell-surface expression profiles for T201A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
T201A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or T201A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Figure 6.15 Ligand binding, intracellular signalling and cell-surface expression profiles for E202A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
E202A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or E202A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Table 6.6 Ligand binding, intracellular signalling and cell-surface expression for N196A, E197A, R199A, P200A, T201A and E202A 
mutant receptor constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more 
separate experiments, performed in triplicate. Grey indicates WT ghrelin-R. Red indicates no detectable binding, > 5-fold increase in EC50 
compared to WT or a reduction in basal activity > 60 % of WT. Orange indicates an increase in EC50 > 4-fold or a reduction in basal activity > 40 
% of WT. Yellow indicates a > 20 % decrease in basal activity compared to WT, a decrease in Emax > 30 % or a decrease in cell-surface 
expression > 30 % of WT. Blue indicates and increase in Emax > 160 % of WT.  
 
Mutant 
 
Binding  
Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
N196A NDB 20.37  12.38 -120  17 26  13 57  18 51  5 
E197A NDB 9.54  5.25 -35  4 - 67  10 87  1 
R199A 8.70  0.14 1.32  0.22 -9  12 - 125  14 93  10 
P200A 8.51  0.14 3.00  2.97 -42  9 - 101  19 77  7 
T201A NDB 8.89  1.62 -45  12 - 161  18 70  9 
E202A 8.28  0.05 3.60  2.23 -32  11 - 103  6 106  3 
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6.2.2.4 The role of Phe203
(C+5)
 and Ala204
(C+6)
 in ghrelin-R function 
Phe203
(C+5)
 was mutated to alanine and Ala204
(C+6) to glycine as part of the “alanine scan” of 
ECL2. Both F203A and A204G displayed „WT-like‟ affinity for ghrelin, „WT-like‟ EC50 and 
„WT-like‟ expression, although F203A resulted in a small decrease in basal activity (Fig 6.16 
& 6.17, Table 6.7 & 6.8). Interestingly, A204G resulted in a dramatic increase in efficacy 
with an Emax of 217 % of the WT (Fig 6.17, Table 6.8). To investigate the role of these two 
residues in more detail, Phe203
(C+5)
 was mutated to glycine examining the effects of replacing 
phenylalanine with a residue that would allow greater flexibility within the loop. F203G had a 
similar phenotype to F203A, displaying „WT-like‟ characteristics except a small decrease in 
agonist-independent activity (Fig 6.16, Table 6.7).  
 
Ala204
(C+6)
 has previously been identified as a key residue in the ghrelin-R; the naturally 
occurring mutation A204E in humans, results in short stature presumably due to a loss of 
ghrelin-R constitutive activity (Pantel et al., 2006). The A204E mutant was introduced to 
complete the investigation of Ala204 and to facilitate the probing of potential interactions 
occurring in the A204E receptor that result in the observed decrease in constitutive activity. It 
was confirmed that A204E results in a marked loss of ghrelin-R basal activity. Unlike 
previous studies (Pantel et al., 2006; Liu et al., 2007a) the A204E mutant was found to 
express well at the cell-surface (80 % of WT), but was unable to bind [
125
I]ghrelin at the 
concentrations used (Fig 6.17, Table 6.8). Valine was also introduced at position 204 to 
examine the effects of maintaining a small hydrophobic residue at this locus. A204V 
displayed characteristics similar to the WT ghrelin-R (Fig 6.17, Table 6.8), suggesting a 
hydrophobic residue is required at this position but that there is not a specific requirement for 
alanine. The data suggested that the effects that occur in the A204E mutation are not due to 
the loss of a functionally important alanine, but rather to the introduction of a glutamate.      
 
6.2.3 Investigation of the role of residues at the extracellular face of TMVI 
Three residues located at the TMVI-ECL3 interface were mutated to investigate their roles in 
ligand binding and ghrelin-R activation. Studies on the free fatty acid receptor 1 (FFAR1) 
have demonstrated that ionic interactions occur between glutamate residues in ECL2 and 
arginine residues in TMs V and VII, and that these interactions act to stabilise the inactive 
receptor conformation, as mutation of the glutamate residues to alanine resulted in 
constitutive activity (Sum et al., 2009). Similarly, in the β2AR, an ionic interaction occurs 
between Asp192
(C+1)
 in ECL2 and Lys
7.32 
and this is broken upon receptor activation (Bokoch 
et al., 2010). It was hypothesised that interactions in the ghrelin-R between A204E and
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Figure 6.16 Ligand binding, intracellular signalling and cell-surface expression profiles for Phe203 mutant receptor constructs:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, F203A 
or F203G expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R, F203A or F203G. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
F203A 8.33  0.07 1.11  0.43 -39  8 127  13 103  11 
F203G 8.63  0.07 1.18  0.12 -30  8 99  4 101  2 
 
 
 
Table 6.7 Ligand binding, intracellular signalling and cell-surface expression for Phe203 mutant receptor constructs: Values were 
obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
Grey indicates WT ghrelin-R. Yellow indicates a > 20 % decrease in basal activity compared to WT.  
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Figure 6.17 Ligand binding, intracellular signalling and cell-surface expression profiles for Ala204 mutant receptor constructs:  (a) Competition radioligand binding 
assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, A204G, A204E or A204V expressed as a percentage of specific 
binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays were 
performed on cells transiently transfected with WT ghrelin-R, A204G, A204E or A204. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum 
from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d)  
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Construct 
 
Binding  
Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
A204G 8.82  0.09 1.87  0.14 -5  11 - 217  11 107  3 
A204E NDB 1.62  1.14 -84  9 18  6 124  20 80  9 
A204V NDB 1.70  0.59 -8  12 - 97  17 95  3 
 
 
Table 6.8 Ligand binding, intracellular signalling and cell-surface expression for Ala204 mutant receptor constructs: Values were 
obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
Grey indicates WT ghrelin-R. Red indicates no detectable binding or a > 60 % reduction in basal activity compared to WT. Pink indicates an 
increase in Emax > 190 %. 
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positively charged residues at the extracellular TM boundaries might be responsible for the 
decreased constitutive activity found with the A204E mutant. Removal of the positive charge 
by mutation to alanine might therefore remove an interaction partner and allow the restoration 
of WT constitutive activity. Arg
6.55 
and Lys
6.60
 at the top of TMVI were mutated to alanine to 
investigate potential interactions. Arg
6.55 
has previously been identified as important in both 
constitutive and agonist-induced InsP-InsP3 accumulation in the ghrelin-R (Holst et al., 
2004a). The same results were found for R6.55A in this study. There was no detectable 
binding or signalling and cell-surface expression was diminished to 50 % of WT (Fig 6.18, 
Table 6.9). K6.60A retained a „WT-like‟ EC50, but reduced basal activity to -32 % of the WT 
ghrelin-induced maximal response. The Emax was also slightly increased (142 % of WT). 
Interestingly, the pIC50 was decreased by ~3-fold, suggesting the formation of a receptor 
conformation that had a higher affinity for ghrelin. Cell-surface expression for the K6.60A 
mutant was similar to that seen for the WT ghrelin-R (117 %) (Fig 6.18, Table 6.9).      
 
In order to investigate the potential interactions between ECL2 and the positive charges at the 
top of TMVI, double mutants were produced. A204E/R6.55A was unable to bind [
125
I]ghrelin 
or to signal through the InsP pathway either in response to ghrelin, or in an agonist-
independent manner. Cell-surface expression of this double mutant was also dramatically 
decreased to only 29 % of the WT ghrelin-R (Fig 6.19, Table 6.9). These results suggest that 
removal of the positive charge at position 6.55 does not prevent the loss of constitutive 
activity observed for the A204E mutant, but this may be explained by the Arg
6.55 
mutation 
alone being particularly detrimental to constitutive activity and ghrelin-induced signalling. 
The A204E/K6.60A mutant also failed to recover the loss of constitutive activity observed for 
the A204E mutant. This double mutant retained the ability to signal in response to ghrelin, but 
displayed a 6.8-fold increase in EC50 and was unable to bind ghrelin at the radioligand 
concentration used (Fig 6.19, Table 6.9).   
 
To further investigate the extracellular domain of the ghrelin-R, Phe
6.58 
was included in the 
study. Phe
6.58
 was mutated to alanine to investigate the role of this aromatic residue in ghrelin 
binding and activation. Residue 6.58 has been shown to be important for ligand binding in a 
number of Family A GPCRs (Bhogal et al., 1994; Leong et al., 1994; Yamano et al., 1995; 
Coetsee et al., 2008). F6.58A expressed well at the cell surface but resulted in a loss of 
ghrelin binding and affected the ability of the receptor to signal. The ghrelin potency was 
decreased (EC50 = 18.32 nM), basal activity reduced to -26 % of the WT ghrelin-induced 
maximum and the Emax was decreased to only 49 % of WT (Fig 6.20, Table 6.10). 
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Figure 6.18 Ligand binding, intracellular signalling and cell-surface expression profiles for Arg
6.55 
and Lys
6.60 
mutant receptor constructs:  (a) Competition 
radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, R6.55A or K6.60A expressed as a percentage of 
specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) Ghrelin-induced InsP-InsP3 accumulation assays 
were performed on cells transiently transfected with WT ghrelin-R, R6.55A or K6.60A. Values are expressed as a percentage of the WT ghrelin-R ghrelin-induced maximum 
from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. 
(a)       (b) 
 
 
 
(c)       (d)  
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Figure 6.19 Ligand binding, intracellular signalling and cell-surface expression profiles for A204E/R6.55A and A204E/K6.60A double mutant receptor constructs:  
(a) Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R, A204E/R6.55A or 
A204E/K6.60A expressed as a percentage of specific binding. (b) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. (c) 
Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently transfected with WT ghrelin-R, A204E/R6.55A or A204E/K6.60A. Values are expressed 
as a percentage of the WT ghrelin-R ghrelin-induced maximum from experiments performed in parallel. (d) Basal InsP-InsP3 accumulation as a percentage of WT basal. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)        (b) 
 
 
 
(c)        (d)  
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Construct 
 
Binding  
Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression  
(% WT)  
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT max)  
 SEM 
Basal  
(% WT basal)  
 SEM 
Emax 
 (% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 100 
R6.55A NDB NDS -93  10 21  8 NDS 50  8 
K6.60A 9.09  0.07 1.47  0.16 -32  7 69  3 142  18 117  12 
A204E/R6.55A NDB NDS -98  4 8  4 NDS 29  6 
A204E/K6.60A NDB 14.35  8.79 -70  18 35  19 133  7 81  9 
 
 
Table 6.9 Ligand binding, intracellular signalling and cell-surface expression for R6.55A, K6.60A and Ala204 double mutant receptor 
constructs: Values were obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, 
performed in triplicate. Grey indicates WT ghrelin-R. Red indicates no detectable binding, no detectable signalling, > 5-fold increase in EC50, > 
60 % reduction in basal activity compared to WT or a decrease in cell-surface expression > 70 %. Orange indicates a decrease in cell-surface 
expression > 50 % of WT. Green indicates an increase in ghrelin affinity > 0.5 log units or an increase in Emax > 130 %. Yellow indicates a > 20 
% decrease in basal activity compared to WT.  
 245 
 
 
 
 
 
-12 -11 -10 -9 -8 -7 -6
0
20
40
60
80
100
120
F6.58A
WT ghrelin-R
log {[ghrelin] (M)}
%
 S
p
e
c
if
ic
 B
in
d
in
g
-10 -9 -8 -7 -6
-60
-40
-20
0
20
40
60
80
100
120
log {[ghrelin] (M)}
In
s
P
-I
n
s
P
3
A
c
c
u
m
u
la
ti
o
n
(%
 W
T
)
WT ghrelin-R F6.58A
0
20
40
60
80
100
120
C
e
ll
-S
u
rf
a
c
e
 E
x
p
re
s
s
io
n
 (
%
 W
T
)
 
 
Figure 6.20 Ligand binding, intracellular signalling and cell-surface expression profiles for F6.58A mutant receptor construct:  (a) 
Competition radioligand binding assays were performed on HEK 293T membranes from cells transiently transfected with WT ghrelin-R or 
F6.58A expressed as a percentage of specific binding. (b) Ghrelin-induced InsP-InsP3 accumulation assays were performed on cells transiently 
transfected with WT ghrelin-R or F6.58A. Values are expressed as a percentage of the WT ghrelin-R, ghrelin-induced maximum from 
experiments performed in parallel. (c) Cell-surface expression of mutant receptor construct expressed as a percentage of the WT ghrelin-R. All 
data are the mean  SEM of three or more separate experiments, performed in triplicate. 
(a)       (b)      (c)   
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Construct 
 
Binding Affinity 
pIC50  
 SEM 
 
InsP-InsP3 Accumulation 
 
Cell-Surface 
Expression 
(% WT) 
 SEM 
 
EC50 (nM)  
 
Basal  
(% WT)  
 SEM 
Emax  
(% WT)  
 SEM 
WT ghrelin-R 8.61 ± 0.02 2.12 ± 0.23 0 100 100 
F6.58A NDB  18.32  2.80  -26  13 49  18 98  16 
 
 
Table 6.10 Ligand binding, intracellular signalling and cell-surface expression for F6.58A mutant receptor construct: Values were 
obtained using the methods described in Chapter 2. All data are the mean  SEM of three or more separate experiments, performed in triplicate. 
Grey indicates WT ghrelin-R. Red indicates no detectable binding or a > 5-fold increase in EC50. Yellow indicates a > 20 % decrease in basal 
activity compared to WT or a decrease in Emax > 30 % of WT.  
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6.3 Discussion 
 
The differences in the ECL2 regions of Family A GPCRs are pronounced and this is 
highlighted by the structural differences in the Rho, β2AR and A2AR crystal structures. The 
β1AR (Warne et al., 2008), and β2AR (Cherezov et al., 2007) crystal structures display similar 
ECL2 conformations reflecting their relatedness and high sequence homology. The β2AR and 
β1AR crystal structures demonstrate a rigid conformation of ECL2, with an intra-loop 
disulphide bond which appears to act to stabilise ECL2 (Cherezov et al., 2007; Warne et al., 
2008). Rho ECL2 consists of a β-hairpin that dips into the retinal binding pocket and creates 
extensive contacts with the extracellular domains and with retinal (Palczewski et al., 2000). In 
contrast to these structures, in the A2AR crystal structure appears to demonstrate a random coil 
within ECL2, with several disulphide bonds constraining a more unstructured loop (Jaakola et 
al., 2008).  
 
The structure of ECL2 in peptide receptors is currently unknown due to the lack of a crystal 
structure for this GPCR subfamily. It might be predicted that the peptide GPCR ECL2 
structure would most likely resemble that of the β1AR/β2AR, as peptide ligands rapidly bind 
and dissociate from their appropriate receptor. This rapid binding requires unhindered access 
to the binding cavity which is prevented in Rho, not only by ECL2, but also by the N-terminal 
domain (Okada et al., 2004).   
 
The extracellular regions of Family A GPCRs have been shown to be involved in ligand 
binding in a number of receptors. Despite this, aside from the highly conserved cysteine in 
ECL2, the role of individual residues has not been studied in great depth. A number of 
different functions of ECL2 have been highlighted in studies of Family A GPCRs, including 
binding of peptide (Ding et al., 2002) and amine (Shi et al., 2002a) ligands, modulating 
internalisation (Li et al., 2001) and participating in conformational changes that accompany 
receptor activation (Baneres et al., 2005). The specific functioning of ECL2 is presumed to 
vary greatly between members of the GPCR superfamily and this is supported by the great 
variation in sequence and length found within the loop region. 
 
6.3.1 Alanine scanning mutagenesis of ECL2 of the ghrelin-R 
Each residue within ECL2 of the ghrelin-R was mutated individually to alanine to determine 
the role of single amino acids in receptor function. In order to ensure that every residue within 
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the loop was mutated, residues 180-212 were incorporated in the study. Mutant ECL2 
receptor constructs were pharmacologically characterised after being expressed in HEK 293T 
cells. Radioligand binding assays and ELISA were conducted on each mutant receptor 
construct to investigate the effects of alanine substitution on ghrelin-R function.  
 
All of the ghrelin-R alanine substitution mutants bound ghrelin with an affinity similar to the 
WT receptor except for V182A, G189A, T190A, D191A, C198A, N196A, E197A, T201A, 
L210A and T211A. The mutants T190A, C198A, N196A, E197A and T201A are included in 
the extended ECL2 study and are therefore discussed in detail in sections 6.3.2-6.3.4. V182A 
and L210A displayed no detectable binding at the [
125
I]ghrelin concentrations used. D191A 
and T211A displayed ~3-fold increases in pIC50 and G189A displayed ~5-fold increase in 
pIC50. This suggests that these mutations are detrimental to binding, possibly through a direct 
disruption of interactions with ghrelin, or due to changes in receptor conformation that result 
in modifications to the ghrelin binding pocket. In the m3 mAChR (Scarselli et al., 2007) and 
the V1aR (Conner et al., 2007) a number of residues have been identified within ECL2 that 
affect the receptor function. Interestingly, in the m3 mAChR, mutation of ECL2 residues had 
little effect on ligand binding characteristics, but instead affected the intracellular signalling 
capabilities of the receptors. The residues identified were proposed to be involved in 
stabilising active receptor conformations, rather than participating in agonist binding or 
forming part of the binding pocket (Scarselli et al., 2007). Recently, Glu187 has been found 
to affect ghrelin binding affinity and intracellular signalling of the ghrelin-R, with E187A and 
E187D mutants increasing ghrelin Ki and EC50 (Ueda et al., 2010). This is in contrast to the 
results of the current study, in which E187A has no effect on ghrelin binding.   
 
The residue corresponding to the ghrelin-R Thr211
(C+13)
, in the V1aR [Tyr218
(C+13)
], has been 
shown to be important for high affinity agonist binding (Conner et al., 2007). Both T211A 
and the adjacent L210A mutant had a detrimental effect on ghrelin binding, suggesting that 
this residue may have a similar function in the ghrelin-R as observed in the V1aR. The 
V1aR[Tyr218
(C+13)
] has been proposed to form stabilising interactions with V1aR[Phe189
(C-14)
], 
influencing the stability and orientation of the loop region (Conner et al., 2007). In the V1aR 
mutation of Phe189
(C-14)
 was found to severely disrupt ligand binding and InsP-InsP3 
accumulation, supporting its high conservation in the neurohypophysial hormone receptor 
sub-family (Conner et al., 2007). Val182
(C-16)
, located at the TMIV-ECL2 interface in the 
ghrelin-R, disrupted ghrelin binding substantially when mutated to alanine in the V182A 
construct, being unable to bind 10 pM [
125
I]ghrelin. Because of their localisation within 
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ECL2, the residues Val182
(C-16)
, Leu210
(C+12)
 and Thr211
(C+13)
 may play a similar role in 
ghrelin-R function as proposed for Phe189
(C-14) 
and Tyr218
(C+13)
 in the V1aR. Stabilising 
interactions of the same nature might be occurring in the ghrelin-R accounting for the 
disruption to ghrelin binding observed for these mutations. Interestingly, V182A was 
particularly detrimental to cell-surface expression, being only 36 % of that seen for the WT 
ghrelin-R. The substantial reduction in cell-surface expression supports the theory that 
Val182
(C-16)
 may be participating in interactions that stabilise the ghrelin-R conformation, 
allowing delivery and maintenance at the cell surface. Despite conserving a small 
hydrophobic residue at position 182, alanine substitution is particularly disruptive to ghrelin-
R function. This suggests that a valine can form interactions, either with the ligand, or with 
other residues, that alanine is unable to form. 
 
The residues Gly189
(C-9)
, Thr190
(C-8) 
and Asp191
(C-7)
 affected ghrelin binding affinity when 
mutated to alanine as part of the ECL2 alanine scan. These residues are gathered in a cluster 
within ECL2 and Gly189 and Thr190 form part of the putative glycosylation site along with 
Asn188
(C-10)
. The effect of these mutations on ghrelin binding does not appear to be related to 
potential removal of a glycosylation motif (section 6.3.3). These three residues may make 
specific contacts with ghrelin, thus affecting ligand binding directly, or may influence the 
conformation of ECL2 and hence the ghrelin binding pocket.  
 
A number of the alanine substitution mutants also affected cell-surface expression of the 
receptors. V180A, V182A, G183A, V184A, H186A, T190A, N196A, C198A, and G208A all 
affected ghrelin-R cell-surface expression, reducing the number of receptors detectable at the 
cell surface. C198A, T190A and N196A are discussed in detail in the extended analysis of 
ECL2 (sections 6.3.2-6.3.4). Disruption of cell-surface expression has been observed in other 
GPCRs with mutations within ECL2. As seen in the ghrelin-R, these disruptions were of little 
consequence to ligand binding (Conner et al., 2007).   
 
6.3.2 The role of Cys116
(3.25)
 and Cys198
(C)
  
The most common feature of ECL2 is the conserved disulphide bond that occurs between two 
highly conserved cysteines at the extracellular end of TMIII and in ECL2. These cysteines 
have been subjected to a number of mutagenesis studies in Family A GPCRs. In the ghrelin-
R, Cys116
(3.25) 
and Cys198
(C)
 were mutated to alanine individually and together to produce 
C116A, C198A and C116A/C198A mutant constructs. All three mutants were particularly 
detrimental to ghrelin-R function resulting in loss of ghrelin binding, loss of intracellular 
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signalling (both in an agonist-dependent and agonist-independent manner), and a substantial 
reduction in cell-surface expression. The loss of ghrelin-R constitutive activity indicates that 
the cysteines are essential for agonist-independent receptor activation as well as agonist-
induced activation. The reduction in cell surface expression may be, in part, responsible for 
the loss of ghrelin-induced signalling observed for the cysteine mutants. Mutation of the 
disulphide cysteines has been found to have various effects in different members of the 
family. In Rho, mutation of Cys110
(3.25) 
and Cys187
(C)
 to alanine resulted in a receptor that 
displayed a ground-state structure that was comparable to WT suggesting that the mutant 
opsin still binds retinal and that the presence of the disulphide bond is not essential for 
receptor folding. This receptor was however compromised in activation, with the Meta II 
conformation being destabilised (Davidson et al., 1994). In the μ-OR (Zhang et al., 1999), the 
GnRHR (Cook et al., 1997), the NK1 receptor (Elling et al., 2000), and the C5aR (Klco et al., 
2005), mutation of the disulphide cysteines did not affect receptor expression, but instead 
altered the ability of the receptor to bind ligands and to activate G-proteins. This was not seen 
in the m3 mAChR where mutation of the conserved cysteines only resulted in inefficient 
receptor localisation at the plasma membrane (Zeng et al., 1999a). Interestingly, the 
disulphide bond in the C5aR appears not to be essential for achieving an active receptor 
conformation, only for agonist-induced receptor activation. Activating mutations within 
TMIII retained their constitutive activity when the disulphide bond was removed by mutation 
of Cys188
(C)
 in ECL2 to alanine (Klco et al., 2005). This suggests that removal of the 
disulphide bond affects ligand binding, rather than receptor activation directly. Mutation of 
the cysteines that form the disulphide bond in GPR39 eliminated agonist-induced InsP-InsP3 
accumulation and resulted in decreased receptor cell-surface expression, but interestingly the 
disruption of the disulphide bond caused an increase in agonist-independent signalling. The 
presence of the conserved disulphide bond and another disulphide between ECL2 and the N-
terminus appears to have a dampening effect, reducing the constitutive activity of GPR39 
(Storjohann et al., 2008).  
 
The inability of the cysteine mutant constructs to bind ghrelin suggests that the receptors may 
be incorrectly folded. Similar results were seen in the V1aR, where mutation of Cys205
(C)
 to 
alanine had a particularly detrimental effect on receptor structure and function resulting in 
ablation of ligand binding and intracellular signalling and decreasing the receptor cell-surface 
expression (Conner et al., 2007). Receptor-mediated G-protein activation was unaffected by 
the conserved cysteine mutations in the m3 mAChR. The mutation of either residue only 
affected localization of the receptor at the cell-surface, not the receptor structure, as G-protein 
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coupling was still detectable (Zeng et al., 1999a). This was not the case in the ghrelin-R, 
where the mutation of the disulphide cysteines appeared to be far more detrimental; both 
Cys116
(3.25)
 and Cys198
(C)
 are essential for ghrelin-R function. In a recent study, Cys116 and 
Cys198 were deleted from the ghrelin-R and the resultant Δ116C and Δ198C mutants 
severely affected ghrelin binding affinity and intracellular signalling (Ueda et al., 2010) 
supporting the data from our study and the importance of these cysteine residues in ghrelin-R 
function. When the cysteines are mutated to alanine individually, or in parallel, the effect on 
ghrelin-R function is profound. Both cysteines are required for ghrelin binding and correct 
receptor delivery to the cell-surface, as indicated by ELISA, suggesting that the disulphide 
bond may be essential for ghrelin-R folding as well as cell-surface localisation.            
 
6.3.3 Asn188 and Thr190: A potential glycosylation motif 
There are four potential glycosylation sites within the extracellular domains of the ghrelin-R. 
Three are located within the N-terminal domain at residues Asn3, Asn13 and Asn27. The 
other is located within ECL2 at Asn188
(C-10)
. To date, it is unknown which of the putative 
glycosylation sites are utilised in the ghrelin-R. In order to investigate ECL2 of the ghrelin-R, 
Asn188 and Thr190 were included in the alanine scan. By mutating these residues to alanine, 
a potential carbohydrate modification was removed. The inclusion of the Thr190 mutation 
was important as any effects of Asn188 mutation might be due to a disruption of 
glycosylation, or conversely, may be due to the loss of the asparagine, independent of 
glycosylation. Substitution of the threonine provided a second approach for examining the 
potential glycosylation site, whilst preserving the asparagine side chain. Removal of the 
putative glycosylation site by mutation of Asn188
(C-10)
 to alanine in the ghrelin-R had little 
effect on receptor function. The N188A mutant displayed „WT-like‟ characteristics except for 
a small decrease in constitutive activity (-28 %). This suggests that, if Asn188 is glycosylated, 
the glycosylation is not essential for receptor function. There are however three further 
putative sites for carbohydrate modification within the N-terminus of the ghrelin-R, therefore 
glycosylation of ECL2 may not be necessary for correct ghrelin-R function. In some Family 
A GPCRs carbohydrate modifications appear to have no direct consequences. Glycosylation 
of the m2 mAChR is not essential for receptor function or cell-surface localisation as 
determined by mutagenesis studies (Habecker et al., 1993). 
 
However, glycosylation has been shown to be essential for correct cell-surface delivery and 
expression of a number of Family A GPCRs. The PAF receptor has a single glycosylation site 
located in ECL2 which was removed by mutation of the asparagine to alanine. This mutant 
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PAF receptor retained „WT-like‟ signalling characteristics, but cell-surface expression of the 
mutant receptor construct was diminished. Introduction of glycosylation sites into the N-
terminus of the mutant receptor regained WT expression characteristics suggesting that 
although glycosylation is essential for receptor expression, the position of the carbohydrate 
moiety is not relevant (Garcia Rodriguez et al., 1995). Similar results were found in the β-
ARs, where glycosylation of the receptor was needed for cell-surface expression, but not for 
G-protein coupling (Rands et al., 1990). Glycosylation of ECL2 of the PAR1 receptor is 
important for endocytosis and activation of the receptor whereas glycosylation of the N-
terminus mediates trafficking to the cell-surface indicating that glycosylation at different 
positions within the extracellular domains of the PAR1 receptor may regulate different 
aspects of receptor function (Soto et al., 2010). In the V1aR glycosylation was found to be 
essential for receptor expression, but of the three glycosylation sites utilised, none was found 
to be important alone. Only removal of all three sites resulted in a detrimental effect on 
expression (Hawtin et al., 2001a). Glycosylation of GPCRs has also been shown to be 
important for receptor activation and ligand binding. Glycosylation at one of the consensus 
sites in the N-terminus of Rho (Asn15) was shown to be essential for correct signal 
transduction (Kaushal et al., 1994) and in the SST receptor, removal of glycosylation resulted 
in reduced binding affinity of agonists (Rens-Domiano et al., 1991).  
 
Threonine and serine residues, located two residues after the asparagine of the glycosylation 
consensus motif, are required for their ability to hydrogen bond during precursor 
oligosaccharide transfer to the asparagine residue (Hortin et al., 1980). Alanine mutation of 
Thr190
(C-9)
 would result in a loss of the glycosylation consensus sequence in ECL2, and 
therefore mutation of Thr190 to alanine might be expected to result in similar receptor 
characteristics to the N188A mutant. The T190A mutant however was much more detrimental 
to ghrelin-R function, affecting ghrelin binding, constitutive activity and cell-surface 
expression. Ghrelin binding was not detectable at the radioligand concentrations used in 
binding assays suggesting a disruption to the binding pocket or removal of an interaction with 
the ligand directly. Molecular modelling of the ghrelin-R docked to a tetrapeptide based on 
the ghrelin active core, suggested that hydrogen bonds are formed between the ligand and the 
backbone atoms of both Asn188 and Thr190 (Pedretti et al., 2007). Constitutive activity, but 
not ghrelin-induced InsP-InsP3 accumulation, was impaired to a similar extent (-35 %) as that 
observed for the N188A mutant. Cell-surface expression of the T190A mutant was also 
slightly decreased (68 % of WT). Thr190 appears to have a functional role, independent of 
glycosylation, as indicated by the decreased binding affinity and cell-surface expression. 
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6.3.4 The role of key ECL2 residues in ghrelin-R function 
Previous studies on Family A GPCRs have demonstrated that individual residues or regions 
of ECL2 are critical for ligand binding, activation and receptor trafficking. An alanine 
scanning study conducted on ECL2 of the CB1 receptor identified two regions that are 
required for correct receptor function. This data supported a dual role of ECL2 of the CB1 
receptor in ligand binding and in stabilising GPCRs, allowing localisation at the cell surface 
(Ahn et al., 2009). In the α1bAR three residues were identified as being critical for antagonist 
specificity, implicating them in ligand binding. Mutation of these residues; Gly196
(C+1)
, 
Val197
(C+2)
 and Thr198
(C+3)
 (producing mutants G196Q, V197I, T198N) altered antagonist 
specificity from α1bAR-specific to α1aAR-specific (Zhao et al., 1996). Similarly, in the Rho 
crystal structure Glu181
(C-6)
, Ser186
(C-1)
, Cys187
(C)
, Gly188
(C+1)
, Ile189
(C+2)
 and Tyr191
(C+4)
 
have been shown to contact retinal (Palczewski et al., 2000). In the V1aR residues within 
ECL2 were found to be important for high affinity agonist binding and intracellular 
signalling. These residues were Phe189
(C-14)
, Asp204
(C-1)
, Cys205
(C)
, Trp206
(C+1)
, Phe209
(C+4)
 
and Tyr218
(C+13)
 (Conner et al., 2007). In order to investigate the role of residues in ECL2 of 
the ghrelin-R, the residues corresponding to those identified as crucial in other Family A 
GPCRs, were extensively investigated.   
 
Asn196
(C-2)
, Glu197
(C-1)
, Arg199
(C+1)
, Pro200
(C+2)
, Thr201
(C+3)
 and Glu202
(C+4)
 were all 
mutated to alanine as part of the initial alanine scan of ECL2. This incorporated N196A, 
E197A, R199A, P200A, T201A and E202A mutations independently into the ghrelin-R. 
N196A, E197A and T201A were all detrimental mutations within the ghrelin-R in terms of 
ghrelin binding. These mutations resulted in receptors that were unable to bind ghrelin at the 
radioligand concentration used in the binding assay. This suggests that substitution of any of 
these amino acids with alanine resulted in receptor constructs that demonstrated a substantial 
decrease in affinity for ghrelin. The negatively charged C-1 residue was found to affect V1aR 
binding to AVP when mutated to alanine (Hawtin et al., 2006). This supports the importance 
of Glu197
(C-1)
 in ghrelin binding in the ghrelin-R. Asp204
(C-1)
 in the V1aR was mutated to 
glutamate, conserving the negative charge at this position and the resultant D204E mutant 
retained „WT-like‟ characteristics, suggesting that glutamate can successfully substitute for 
aspartate at this position, whereas mutation to alanine or arginine resulted in disruption of 
vasopressin binding (Hawtin et al., 2006). As found in the D204A mutation in the V1aR, 
E197A in the ghrelin-R resulted in an increase in EC50 (4.2-fold) compared to WT. A 
previous study on the ghrelin-R revealed that mutation of Glu197 to glutamine resulted in 
decreased ghrelin potency (Holst et al., 2009). Molecular modelling in the V1aR revealed that 
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Asp204
(C-1)
 is in close contact with residues located at the extracellular side of TMIII and 
forms a salt bridge with Lys
3.29 
and a hydrogen bond with Gln
3.32
. This is demonstrated in Fig 
6.21. Removing the negative charge in the D204A mutant disrupted these interactions and 
resulted in partial unfolding of the β-hairpin that forms ECL2 (Hawtin et al., 2006). From the 
mutagenesis data, similar interactions can be proposed to occur in the ghrelin-R. Gln
3.29
 or 
Ser
3.32 
may form a hydrogen bond with Glu197
(C-1)
 and this may restrain one conformation of 
ECL2. Mutational analysis of Gln
3.29 
in the ghrelin-R has revealed that a Q3.29A mutation 
resulted in a 6.5-fold increase in EC50 and implicated Gln
3.29 
in ghrelin binding (Holst et al., 
2006a). A Q3.29L mutant resulted in total loss of signalling through the InsP3 pathway, both 
constitutively, and in response to ghrelin (Holst et al., 2004a). Mutation of Ser
3.32 
to alanine 
(Chapter 5) resulted in a receptor construct that was essentially WT in its characteristics 
except for a slight decrease in constitutive activity and the same result was observed by Holst 
et al. (2004) in a study which included the S3.32A mutant. In the m3 mAChR a negative 
charge is also found at position C-1 of ECL2; however, the residue Glu219
(C-1)
 was not found 
to be required for efficient function of the m3 mAChR as mutation to alanine produced a 
mutant receptor with similar binding and signalling characteristics to the WT receptor 
(Scarselli et al., 2007). 
 
Mutation of Asn196
(C-2)
 is particularly detrimental to ghrelin-R function, with this residue 
being required for high affinity ghrelin binding, efficacy, potency, basal signalling and cell-
surface expression. N196A substantially decreased ghrelin-R constitutive activity, but was 
still able to respond to ghrelin stimulation. It appeared that Asn196 contributes to interactions 
that stabilise the ghrelin-R constitutive activity, but does not prevent activation in the 
presence of agonist. Asn196 may be providing stabilising contacts with other residues in the 
ghrelin-R. Interestingly, a recent study found that the deletion of 11 residues in ECL2 (Δ188-
197) which included Asn196, had no effect on ghrelin binding affinity (Ueda et al., 2010). 
This is in contrast to the data presented in this study, perhaps suggesting that it is the 
interaction of Asn196 with surround residues that is disrupted in the N196A mutant, and that 
removal of neighbouring residues as well as Asn196 is less detrimental that an N196A mutant 
alone. 
 
One residue that may form an interaction with Asn196 is Glu
3.33
 at the extracellular end of 
TMIII. Glu
3.33
 has been identified as a potential counterion in the binding of ghrelin and the 
GHSs to the ghrelin-R. An E3.33D mutation retained „WT-like‟ characteristics, whereas an 
E3.33Q mutation severely disrupted binding, suggesting that the charge on this residue is 
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Figure 6.21 Model of the V1aR: Model showing the hydrogen bonding and salt bridge 
interactions between Asp204
(C-1)
 in ECL2 and Lys128
(3.29)
 and Gln131
(3.32) 
in TMIII of the 
V1aR. Similar interactions may be occurring in the ghrelin-R between Glu197
(C-1)
 and Gln
3.29
 
(Image taken from Hawtin et al., 2006).  
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essential for agonist binding (Feighner et al., 1998; Holst et al., 2009). Removal of this 
putative interaction in the N196A mutation appears to cause a disruption to the ability of the 
ghrelin-R to signal in the absence of agonist. The loss of constitutive activity observed with 
the N196A mutation, but not the E3.33Q mutation, might be explained by the loss of an ionic 
interaction between Asn196 and Glu
3.33
, in the E3.33Q receptor, whilst still retaining a 
hydrogen bond. Ionic interactions have previously been identified between residues within 
ECL2 and the TM domains in Family A GPCRs (Jiang et al., 1997; Hoffmann et al., 1999; 
Costanzi et al., 2005; Hawtin et al., 2006; Sum et al., 2009; Wang et al., 2009; Bokoch et al., 
2010).    
 
In this study, the R199A mutant was „WT-like‟ in all characteristics. An R199L mutant was 
produced by Holst et al. (2004) in the ghrelin-R as part of an investigation into the 
constitutive activity of the receptor. The R199L mutant displayed a reduction in agonist-
independent activity (Holst et al., 2004a). These data, combined with the results of the current 
study, suggest that Arg199
(C+1)
 itself is not important in maintaining WT ghrelin-R 
functioning, as alanine substitution does not appear to affect receptor function, rather that the 
introduction of leucine is detrimental to receptor pharmacology.    
 
Mutation of Thr201
(C+3)
 in the T201A mutant construct had a severely detrimental effect on 
ghrelin binding, and also resulted in a decrease in ghrelin potency (EC50 4-fold increase), and 
constitutive activity (-45 % of WT ghrelin-induced maximum), however, this mutant 
displayed an increase in efficacy (Emax 161 % of WT) despite „WT-like‟ cell-surface 
expression. This suggests that, although T201A is detrimental to ghrelin binding and to 
agonist-induced and basal InsP-InsP3 accumulation, once the agonist is bound the response is 
greater than that seen for the WT receptor. Mutation-induced increases in efficacy have been 
identified in a number of GPCRs, including the ghrelin-R (Holst et al., 2004a), and reflect the 
complexity of GPCR activation, and the multiple signalling conformations adopted during 
ligand-induced activation. Investigations into mutation-induced changes in efficacy in the 
gastrin receptor identified mutations within the transmembrane domains that enhanced ligand 
efficacy without affecting binding or potency (Blaker et al., 2000).  
 
An aromatic residue at position C+4 is conserved in 59 % of peptide and amine Family A 
GPCRs. Aromatics at this position have been found to be important in a number of GPCRs 
for ligand binding (Palczewski et al., 2000; Zhou et al., 2001; Conner et al., 2007). In the 
ghrelin-R a glutamate is found at position C+4 and this residue was not identified as being 
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important for ghrelin-R function as mutation to alanine had no effect on ligand binding, 
agonist-induced InsP-InsP3 accumulation or receptor cell-surface expression, and only 
minimally affected basal signalling, reducing the constitutive activity to -32 % of WT 
maximal ghrelin-induced response. None of the members of the ghrelin-R subfamily have an 
aromatic at C+4 despite the reasonable conservation of an aromatic at this locus in peptide 
GPCRs therefore the ghrelin-R subfamily is somewhat unusual with respect to residue C+4. 
      
In the C5aR, a random saturation mutagenesis study of ECL2 revealed 23 mutant receptors 
that demonstrated constitutive activity. This suggests that ECL2 may be acting as a negative 
regulator of GPCR function. However, for GPCRs in general, activating mutations are rarely 
reported in ECL2, perhaps highlighting the need for multiple mutations within the domain as 
observed for the C5aR (Klco et al., 2005). However, the C5aR data demonstrate that ECL2 
may play a significant role in stabilising inactive receptor conformations, and in allowing 
agonist binding and subsequent receptor activation. Several studies have revealed that 
autoantibodies to ECL2 can activate GPCRs, perhaps by mimicking ligand binding (Lebesgue 
et al., 1998; Mobini et al., 1999; Wang et al., 2000). This further supports the role of ECL2 in 
maintaining receptor conformations and in restraining inactive states. A study on Rho 
demonstrated that ECL2 acts as a plug that requires rearrangement for activation of the 
receptor. The rearrangement of a hydrogen bonding network with ECL2 and TMV is 
supported by ECL2 movement after receptor activation (Ahuja et al., 2009).  
 
The highly constitutively active melanocortin receptors exhibit an almost total lack of ECL2. 
This unique feature is believed to be responsible, in part, for the agonist-independent activity 
observed for this sub-family of GPCRs, potentially due to the removal of restraining 
interactions between the helical bundle and ECL2 (Holst et al., 2003b). 
 
6.3.5 The role of Phe203
(C+5)
 and Ala204
(C+6)
 in ghrelin-R function 
A single nucleotide substitution within the ghrelin-R coding exons has been reported to result 
in obesity (Wang et al., 2004) and short stature (Pantel et al., 2006) in humans. This cytosine 
to adenine substitution results in a missense mutation of Ala204 in ECL2 to glutamate. 
Ala204 is conserved in ECL2 of the ghrelin-R in all species, conveying its importance in 
ghrelin-R function (Pantel et al., 2006). The A204E mutation has been previously shown to 
result in decreased surface expression of the mutant ghrelin-R, without ultimately affecting 
ghrelin binding affinity or agonist-responsiveness (Pantel et al., 2006; Liu et al., 2007a). This 
mutation did, however, result in a substantial decrease in ghrelin-R constitutive activity, both 
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as a result of decreased cell-surface expression and a loss of the intrinsic ability to signal in 
the absence of ghrelin (Pantel et al., 2006; Liu et al., 2007a). In order to investigate the role of 
Ala204 in ghrelin-R function in more depth, Ala204 was mutated to glycine, glutamate and 
valine in this study. The A204G mutant resulted in a receptor construct that presented similar 
binding, signalling and cell-surface expression characteristics to the WT ghrelin-R, except for 
a dramatic increase in the Emax after ghrelin stimulation. The A204G Emax was 217 % of that 
seen for the WT ghrelin-R, suggesting that the introduction of glycine resulted in a receptor 
that bound ghrelin in a „WT-like‟ manner and had „WT-like‟ potency, but displayed increased 
efficacy, being able to signal to a much greater extent than the WT when stimulated with 
ghrelin. The increased efficacy seen with the A204G mutant indicated that the introduction of 
glycine at this position within ECL2 resulted in the release of a stabilising constraint probably 
due to the inherent conformational flexibility of glycine, without drastic changes to amino 
acid side chain size. To investigate the increase in efficacy further, the neighbouring residue, 
Phe203, was also mutated to glycine. Mutation of Phe203 to alanine, as part of the alanine 
scan of ECL2, produced a receptor that displayed „WT-like‟ characteristics except for a small 
decrease in basal InsP3 signalling (-39 % of WT). This implies that a phenylalanine at this 
position is not essential to receptor function. Knowing that a small residue is well tolerated at 
position 203, the F203G mutant was characterised. The F203G mutant displayed „WT-like‟ 
characteristics, similar to that seen with the F203A mutant, with the observed small decrease 
in constitutive activity (-30 % of WT). This suggests that the glycine introduced at position 
204 in the A204G mutant produces its effects via a direct disruption at position 204 rather 
than by introducing flexibility within the loop, as mutation of the adjacent Phe203 to glycine 
did not yield the same result. To aid further understanding, Ala204 was mutated to valine, 
retaining a small hydrophobic residue at this position. A204V was essentially WT with 
regards to InsP-InsP3 accumulation and cell-surface expression. This mutant was, however, 
unable to bind [
125
I]ghrelin at the concentrations used, suggesting a decrease in ghrelin 
affinity. As the signalling characteristics were unchanged, it is clear that ghrelin does bind to 
the A204V mutant receptor, but that this was not detectable in the assay.  
 
In the A204E mutation, similar results were seen to those previously reported (Pantel et al., 
2006; Liu et al., 2007a). Ghrelin binding affinity was affected, with the A204E mutant being 
unable to bind [
125
I]ghrelin at the concentrations used. Previous studies have concluded that 
loss of binding is related to a substantial decrease in cell-surface expression, and that 
expressing the A204E mutant at levels similar to WT resulted in „WT-like‟ binding 
characteristics (Pantel et al., 2006). However, in the A204E mutant in this study, expression 
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at the cell-surface was similar to the WT ghrelin-R (80 %) and therefore this appears not to be 
responsible for the reduction in ghrelin affinity observed. The ghrelin-R has however been 
shown to undergo substantial constitutive internalisation (Chapter 3), related to its constitutive 
activity, and therefore the high cell-surface expression of the A204E mutant observed in the 
ELISA assay may be a reflection of the reduction in constitutive internalisation as a result of 
the loss of basal activity. Feighner et al. (1998) predicted that Ala204 is distant from the 
ghrelin binding pocket, and therefore not directly involved in ghrelin binding. Consequently, 
any effect of mutation of Ala204 on binding could be assumed to be due to disruption of 
intramolecular interactions, resulting in conformational modifications. A ghrelin-R model 
produced by Pedretti et al. (2007) suggested that ECL2 forms the upper part of a polar 
binding site and that several residues, including Ala204, are directly involved in interacting 
with the octanoyl chain of a ghrelin active core-based tetrapeptide. The results of the current 
study suggest that Ala204 may be involved in high affinity ghrelin binding as binding was 
only observed when Ala204 was mutated to glycine and was not detectable with the A204E or 
A204V mutants despite both mutant constructs retaining the ability to signal in response to 
ghrelin stimulation.   
 
It is still unclear as to the mechanisms involved the substantial reduction in constitutive 
activity observed for the A204E mutant. The results from this study allow for the proposal of 
a potential interaction between residues within ECL2. Asn196 mutation to alanine results in a 
dramatic decrease in ghrelin-R constitutive activity as seen with the A204E mutation. Asn196 
may be forming an ionic interaction with Glu
3.33 
in TMIII, stabilising basal signalling, and this 
interaction might be broken after alanine substitution of Asn196 (section 6.3.4). In the A204E 
mutant receptor construct, it is possible that the glutamate introduced at position 204 interacts 
with Asn196, thus disrupting the Glu
3.33
-Asn196 interaction and resulting in the decreased 
constitutive activity, whilst still retaining agonist sensitivity. 
 
Figure 6.22 is a summary schematic of the alanine scan of residues within ECL2 of the 
ghrelin-R. The schematics depict the effect of each mutation, colour coding the effect on; (a) 
radioligand binding, (b) cell-surface expression, (c) ghrelin potency and (d) constitutive 
activity, compared to the WT ghrelin-R.   
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Figure 6.22 Summary schematics of the residues within ECL2 of the ghrelin-R: 
Individual residues coloured according to their effects, after alanine substitution, on (a) 
ghrelin binding, (b) cell-surface expression, (c) EC50 and (d) constitutive activity. See 
Appendix Table 9.1 for colour code. Purple = not characterised. Grey = „WT-like‟ 
characteristics.  
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6.3.6 Investigation of the role of residues at the extracellular face of TMVI 
In the FFAR1 two glutamate residues in ECL2 have been proposed to interact with positively 
charged arginine residues at the extracellular ends of TMV and TMVII (Sum et al., 2009). 
The FFAR1 lacks the ionic lock (discussed in Chapter 4) that stabilises the inactive state of 
some Family A GPCRs and it has therefore been suggested that other interactions must be 
occurring that maintain the receptor in the inactive conformation in the absence of agonist. 
Activation of the FFAR1 is believed to involve the breaking of the ionic interactions that 
occur at the extracellular surface of the receptor. Mutation of the glutamate residues within 
ECL2 to alanine resulted in constitutive receptor activation suggesting that stabilising 
interactions are broken (Sum et al., 2009). Similarly, in the purinoceptor P2Y6 (P2Y6 
receptor), molecular modelling has shown that Asp179
(C+2)
 in ECL2 forms a stabilising 
interaction with Arg
3.29 
located at the extracellular side of TMIII. This interaction appears to 
be disrupted upon agonist binding, allowing extensive ECL2 conformational changes 
promoting activation (Costanzi et al., 2005). In the related purinoceptor P2Y1 (P2Y1 
receptor), similar interactions between the top of TMIII and ECL2 were observed (Jiang et al., 
1997; Hoffmann et al., 1999) and in the inactive β2AR, a salt bridge has been proposed to 
form between Asp192
(C+1)
 in ECL2 and Lys
7.32 
at the top of TMVII (Wang et al., 2009). This 
interaction appears to be weaker in the β2AR active state, as demonstrated by nuclear 
magnetic resonance (NMR) data (Bokoch et al., 2010). Molecular modelling of the V1aR 
suggested that Lys
3.29 
forms a salt bridge with Asp204
(C-1)
 in ECL2 which is disrupted by 
mutation of either residue to alanine and results in receptors that have impaired agonist 
binding and signalling capabilities (section 6.3.4) (Hawtin et al., 2006). As the ghrelin-R is 
highly constitutively active, it could be assumed that no such stabilising interactions occur 
within ECL2, restraining the ground state. Mutation of the residues within ECL2 did not 
result in increased constitutive activity suggesting that none of the residues are involved in 
stabilising the ligand-free receptor conformation. Interestingly, introduction of a glutamate at 
position 204 in ECL2 results in a loss of ghrelin-R constitutive activity, whereas mutation to 
valine or glycine did not result in a disruption to the basal signalling. This suggests that an 
interaction may be occurring in the A204E mutant ghrelin-R that does not occur in the WT 
receptor and requires the presence of a negatively charged residue. In order to investigate 
potential stabilising interactions, positive charges, located in the extracellular domains of the 
ghrelin-R, were mutated to alanine. Arg
6.55 
had previously been found to be essential for 
ghrelin-R function and mutation to alanine (Holst et al., 2004a) or glutamine (Feighner et al., 
1998) resulted in reduction of ghrelin-R constitutive activity. It was proposed that Arg
6.55 
may 
interact with a glutamate residue in TMIII (Glu
3.33
) as mutation of this glutamate also resulted 
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in perturbed receptor function (Feighner et al., 1998; Holst et al., 2003a). The data from the 
FFAR1 and the β2AR suggested that the ghrelin-R ECL2 may potentially form stabilising 
interactions with the arginine when the A204E mutation is introduced into the loop. As found 
previously, mutation of Arg
6.55 
to alanine was particularly detrimental to receptor function, 
resulting in a loss of [
125
I]ghrelin binding, agonist-induced intracellular signalling, agonist-
independent signalling and a reduction in cell-surface expression to 50 % of the WT receptor. 
To investigate the potential of an ionic interaction, the R6.55A mutant was introduced into the 
A204E ghrelin-R background. The A204E/R6.55A double mutant was unable to recover 
ghrelin-R function. The constitutive activity was diminished, as seen in the two single 
mutations, and the double mutant construct was also unable to signal in response to ghrelin. 
Although the data implies that an interaction does not occur between the glutamate at position 
204 and Arg
6.55
, as removal of the positive residue was unable to restore ghrelin-R function, 
the R6.55A mutation was severely detrimental to the receptor. Therefore, it may be that 
Arg
6.55 
plays such a significant role in receptor function that the true effect of the double 
mutant is unable to be seen. The corresponding residue, Asn
6.55
, was found to directly contact 
5-HT in the 5HT2bR, and therefore directly influence binding (Manivet et al., 2002) 
highlighting the crucial role of residues at this position.    
 
Another positively charged residue is located at position 6.60 in TMVI/ECL3. Lys
6.60 
was 
mutated to alanine. The K6.60A mutant construct was not detrimental to agonist binding; the 
mutation produced an increase in ghrelin affinity of ~3-fold. There was also little effect on the 
intracellular signalling capabilities of the ghrelin-R as a result of the K6.60A mutation. 
Constitutive activity was slightly reduced to -32 % of the WT maximum activity and there 
was a small increase in the ghrelin-induced Emax. Overall, this mutation retained 
characteristics similar to that seen for the WT ghrelin-R, suggesting that Lys
6.60
 is not as vital 
for ghrelin-R function as Arg
6.55
. The double mutation A204E/K6.60A was introduced to 
further investigate the potential of an ionic interaction between A204E and positive residues 
in the extracellular domain. A204E/K6.60A retained some of the agonist responsiveness seen 
for the A204E and K6.60A single point mutations, but was unable to restore WT constitutive 
activity. The binding affinity for ghrelin was reduced as seen for the A204E mutant. This 
suggests that an ionic interaction does not occur between the glutamate in the A204E mutant 
and Lys
6.60
, as removal of the positive charge in the A204E/K6.60A double mutant construct, 
did not counteract the loss of constitutive activity observed for the A204E single mutation.  
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The residue at position 6.58 has been shown to be important for ligand binding in a number of 
Family A GPCRs to date. In the GnRHR, Tyr
6.58 
has been shown to be essential for ligand 
binding and only substitution with phenylalanine retained GnRH potency (Coetsee et al., 
2008). A Gly
6.58 
to threonine mutation in the neurokinin A receptor (NK2R) also resulted in a 
loss of agonist binding, although non-peptide antagonist binding was maintained (Bhogal et 
al., 1994). An Asp
6.58 
to alanine mutant greatly reduced the binding affinity of angiotensin II 
for the AT1R (Yamano et al., 1995) and a D6.58A mutant in the CXCR1 resulted in reduced 
binding affinity and loss of agonist-induced signal transduction (Leong et al., 1994).  
 
There is relatively little conservation of this residue within the GPCR superfamily, possibly 
supporting a role in binding various GPCR ligands. Phe
6.58
 was mutated to alanine in the 
ghrelin-R to investigate the role of this aromatic residue in ghrelin binding and activation. The 
F6.58A mutation resulted in a loss of ghrelin binding and affected the ability of the receptor 
to signal through the InsP3 pathway, both in response to ghrelin and in an agonist-independent 
manner. The F6.58A mutant had no effect on cell-surface expression. This is similar to the 
results observed for the GnRHR where mutation of Tyr
6.58 to alanine retained „WT-like‟ cell-
surface expression despite other mutations at this locus altering receptor localisation (Coetsee 
et al., 2008). The „WT-like‟ cell-surface expression observed for the ghrelin-R F6.58A mutant 
indicates that the detrimental effect observed on ligand binding and intracellular signalling is 
a direct consequence of disruption of the receptor-ghrelin interaction, rather than an artefact 
of decreased receptor number.    
 
Aromatic residues found within TMVI and TMVII have previously been identified as being 
vital for ghrelin-R constitutive activity. Mutation of Phe
6.51 
to various other amino acids 
enabled the constitutive activity to be systematically turned up and down depending on the 
size and aromaticity of the residue (Holst et al., 2004a). Phe
6.58
 is located two turns above this 
aromatic cluster and is not predicted to be involved in the same interactions. Whereas the 
F6.51A mutation resulted in total ablation of ghrelin-R constitutive activity (Holst et al., 
2004a) the F6.58A mutant in this study only resulted in a partial loss of basal agonist-
independent activity (-26 %) suggesting that the role of Phe
6.58 
is not related to the conserved 
aromatic cluster in the ghrelin-R family.   
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CHAPTER 7. 
SUMMARY, CONCLUSIONS AND FUTURE WORK 
 
7.1 Summary and Conclusions 
The structural and functional requirements of ghrelin-R constitutive activity are of potential 
therapeutic importance and are likely to be relevant to other Family A GPCRs. The work 
presented in this thesis addresses the importance of individual residues in both constitutive 
and ghrelin-induced receptor activation. Amino acid substitutions were performed in the 
ghrelin-R to investigate the role of individual residues in receptor function. Each mutation 
was assayed for its effects on ghrelin binding affinity and intracellular signalling, both in an 
agonist-dependent and agonist-independent manner, and for receptor cell-surface expression. 
Specifically, the residues were assessed for their ability to influence the constitutive activity 
of the ghrelin-R, and to extend this study some of the point mutations were further 
characterised using the ghrelin-R inverse agonist, SP-analogue.  
 
Chapter 3 detailed the introduction of the HA-epitope tag at the N-terminus of the ghrelin-R. 
The HA-tag enabled analysis of WT and mutant receptor expression at the cell-surface when 
transiently transfected into HEK 293T cells. ELISA analysis of ghrelin-stimulated receptors 
revealed that the ghrelin-R does not internalise in response to ghrelin stimulation in HEK 
293T cells. It is known that the ghrelin-R undergoes a high level of constitutive internalisation 
and it is predicted that this tonic internalisation is responsible for the apparent lack of ghrelin-
induced internalisation in this system. In order to further assess the constitutive 
internalisation, the ghrelin-R was cotransfected with a dominant negative mutant of dynamin, 
K44A dynamin. It was subsequently found that receptor cell-surface expression could be 
significantly increased, supporting the high level of constitutive internalisation observed for 
the ghrelin-R, which occurs in a dynamin-dependent manner.    
 
The WT ghrelin-R was extensively characterised and each assay optimised to the WT so that 
comparisons could be drawn between the WT and mutant ghrelin-R constructs. The third part 
of Chapter 3 examined the effect of alanine substitution mutations of the most conserved 
residue within each helix. Each residue investigated in this section appears to be important, in 
some respect, to ghrelin-R function, highlighting the highly conserved nature of these residues 
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within the family and indicating that their conservation is crucial in terms of maintaining WT 
receptor characteristics. The similarities in characteristics for the N1.50A and D2.50A 
mutants appeared to confirm their role as part of an interhelical hydrogen bonding network, 
identified in a number of Family A GPCRs.  
 
Chapter 4 examined the role of specific residues within the TM domains in receptor 
activation. TMIII and VI have been extensively investigated in Family A GPCRs and have 
been proved to be critical to the formation of both the inactive and active receptor 
conformations. The highly conserved ERY motif was revealed to be of functional importance 
in activation of the ghrelin-R in both an agonist-independent and agonist-dependent manner. 
The residues within the motif were found to influence constitutive activity of the ghrelin-R, 
although no substitutions within the ERY increased the constitutive activity, in contrast to a 
number of other Family A GPCRs.  
 
The “ionic lock” is found between TMs III and VI some Family A GPCRs, but is not present 
in the ghrelin-R. Mutations of His
6.30
 provided an insight into potential intramolecular 
interactions between TMs III and VI. Substitution of His
6.30
 with acidic residues decreased 
constitutive activity in a manner consistent with the introduction of an “ionic lock”-type 
interaction between Arg
3.50
 and residue 6.30. Substitution of His
6.30
 with basic amino acids 
also decreased the basal signalling of the ghrelin-R, but by different intramolecular 
mechanisms. It is thought that the introduction of a positive charge repels the cytoplasmic end 
of TMV and allows other residues at the bottom of TMVI to form stabilising contacts. This 
indicates that the cytoplasmic end of TMVI is extensively involved in maintaining ground 
state and active state interactions.      
 
Despite the high level of constitutive activity observed for the WT ghrelin-R, it was apparent 
from this study that the ghrelin-R basal signalling could be increased with a number of 
individual point mutations. In Chapters 4 and 5, residues within TMs III, VI and VII were 
identified for their role in maintaining ghrelin-R constitutive activity, with substitutions either 
impairing (Thr
3.44
, Leu
3.46
, Glu
3.49
, Arg
3.50
, Ala
3.60
,  His
6.30
, Val
6.34
, Met
6.36
, Val
6.40
, Trp
6.48
, 
Pro
6.50
, Ser
7.45
, Asn
7.49
, Ile
7.51
, Leu
7.52
, Tyr
7.53
, Lys
7.59
) or enhancing (Thr
3.36
, Thr
3.42
, Ile
3.43
, 
Thr
6.33
, Val
6.40
, Ser
7.45
) basal InsP3 signalling. Interactions between TMs III, V, VI and VII 
have been found to be responsible for stabilising both the inactive and active receptor 
conformations. As discussed in Chapter 4, the Trp
6.48
 „rotamer toggle switch‟ involves 
residues 3.36 and 7.45. Mutation of these later residues to alanine resulted in increased 
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constitutive activity revealing their importance in maintaining the inactive Trp
6.48
 
conformation. Mutating Ser
7.45
 to alanine may release Trp
6.48
 from its inactive conformation, 
pointing towards TMVII, whereas mutating Thr
3.36
 to alanine appears to allow Trp
6.48
 to adopt 
the active rotamer conformation, pointing towards TMV, due to the removal of the restraining 
threonine side chain.  
 
In Chapter 5, Val
6.40 
was found to be important for ghrelin-R basal activation, with mutations 
at this position being able to turn constitutive activity up and down, and therefore implicating 
position 6.40 in the transition from the R to the R* state. The mechanisms by which residue 
6.40 alters ghrelin-R basal signalling activity are unknown, but it might be assumed that 
removal of stabilising interactions with TMVII are responsible for the increased constitutive 
activity in the V6.40Y mutant. Similar interactions would however be expected in the V6.40F 
mutant, but this mutation did not increase basal signalling to the same extent as V6.40Y, 
implicating the tyrosine alone in the formation of specific interactions that stabilise a more 
active receptor conformation and a possible role for the hydroxyl which is absent in 
phenylalanine.  
 
Apart from Thr
3.36
, two other residues within TMIII were found to increase constitutive 
activity when mutated to alanine. These were Thr
3.42 
and Ile
3.43
, located adjacent to each other 
at the cytoplasmic end of the helix. Both the T3.42A and I3.43A mutants retained the ability 
to signal further when stimulated with ghrelin and the constitutive signalling of both mutants 
could be inhibited by the inverse agonist, SP-analogue. This suggests that the introduction of 
alanine at these loci disrupted interactions which usually stabilise the basal receptor 
conformation, or introduced interactions which stabilise new, increased basal levels of 
signalling, without affecting the ability of the receptors to be activated further by agonist, or 
inactivated by inverse agonist.  
 
Unlike many CAMs of Family A GPCRs, the CAMs of the ghrelin-R did not affect ghrelin 
binding affinity. „Classical‟ CAMs usually increase agonist affinity as they stabilise the R* 
state for which agonists have a greater affinity. The lack of increased ghrelin affinity in any of 
the CAM ghrelin-R might reflect a different receptor conformation that does not resemble the 
classical R* state. Theoretically, any number of receptor conformations are possible; the 
ghrelin-R CAMs may reflect receptor states that are not typically active and therefore do not 
display increased agonist affinity, and can usually be activated further after ghrelin 
stimulation. Conversely, the mutations that decrease constitutive activity do not appear to 
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decrease ghrelin affinity suggesting that agonist affinity is not a sensitive gauge of 
constitutive activity in this system.         
 
Chapter 6 was an investigation into the role of ECL2 in the ghrelin-R. A systematic alanine 
scan was conducted, mutating all residues within ECL2 to alanine to investigate the effect of 
removing the amino acid side chains on ghrelin binding and cell-surface expression. Most 
amino acids substitutions within ECL2 had little effect on ghrelin-R function. A few residues 
were more extensively characterised using InsP-InsP3 accumulation assays. This identified 
Asn196 as a residue that is essential for ghrelin-R receptor function, with the N196A mutation 
affecting all aspects pharmacology studied. It was proposed that Asn196 may be forming 
stabilising interactions with Glu
3.33
 in TMIII, a residue identified previously as essential for 
agonist binding (Feighner et al., 1998; Holst et al., 2009). Stabilising ionic interactions have 
been found between ECL2 and the extracellular ends of the TM domains in other Family A 
GPCRs. These interactions were further investigated in relation to the effects of the naturally 
occurring A204E mutation, previously identified as causing a substantial decrease in ghrelin-
R constitutive activity (Pantel et al., 2006). The glutamate in the A204E mutant did not 
appear to interact with basic residues at the top of TMVI, although it is unclear whether 
interactions are occurring with Arg
6.55
, as the R6.55A mutation is particularly detrimental to 
receptor function. We propose a potential interaction may be occurring between the glutamate 
and Asn196, pulling Asn196 away from Glu
3.33 
and resulting in the basally inactive phenotype 
observed for the A204E mutant construct.  
 
7.2 Future Work 
The study on the ghrelin-R can be extended to enhance the knowledge surrounding ghrelin-R 
constitutive activity. In Chapter 3 the internalisation study revealed that the HA-ghrelin-R 
does not display agonist-dependent internalisation in HEK 293T cells. It was however 
concluded that the ghrelin-R undergoes a high degree of constitutive internalisation in a 
dynamin-dependent manner, as indicated by the increase in cell-surface expression after co-
transfection with a dominant negative mutant of dynamin. It would be interesting to examine 
the consequences of a reduction or increase in constitutive signalling through the InsP3 
pathway on receptor agonist-independent internalisation. Although some of the mutant 
receptor constructs that displayed reduced constitutive InsP3 signalling also had increased 
cell-surface expression (e.g. L3.46A, H6.30E, W6.48A, S7.45N), this was not the case for all 
mutants studied as the remainder displayed „WT-like‟ (or decreased) cell-surface expression. 
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Conversely, the T6.33A and V6.40A mutations displayed increased basal signalling and 
deceased cell-surface expression, possibly suggesting increased constitutive internalisation, 
although this was not found with any of the other CAM ghrelin-R constructs. Further analysis 
of both the WT and the mutant ghrelin-R constructs, in terms of cell-surface expression using 
K44A dynamin, may indicate whether constitutive signalling through the InsP3 pathway is 
necessary for constitutive internalisation, or whether the two are functionally distinct. From 
the data in this study, no correlation can be made between cell-surface expression and the 
level of constitutive activity observed for each mutant receptor.  
 
In relation to cell-surface expression, it would be of interest to characterise the constitutive 
activity of the E3.49A mutant after increasing its level of expression at the cell-surface. The 
E3.49A construct retains „WT-like‟ constitutive activity, despite its cell-surface expression 
being reduced to only 30 % of the WT expression. Greater insight into the mechanism of 
action of Glu
3.49
 could be gained by expressing E3.49A at levels comparable to the WT 
expression in HEK 293T cells. It may be that E3.49A does adopt a more constitutively active 
conformation than the WT ghrelin-R, but that the CAM effect is masked by the substantial 
decrease in cell-surface expression. It would also be interesting to investigate whether the 
decreased cell-surface expression of the E3.49A mutant is due to increased constitutive 
internalisation caused by a disruption of stabilising interactions as found in some Family A 
GPCRs, or is a result of decreased trafficking of the receptor to the cell surface initially.  
 
The T2.39A, A3.60Y and T2.39/A3.60Y mutations indicated that there was a potential 
interaction between TMII, TMIII and ICL2 in the ghrelin-R, as found in the A2AR (Jaakola et 
al., 2008). To investigate these potential interactions further, reciprocal mutations within the 
ERY motif and at Thr
2.39
 and Ala
3.60
,
 
could be introduced into the ghrelin-R. Difficulties may 
arise in the reciprocal mutations, as introduction of mutations within the ERY motif have 
been found to be particularly detrimental to receptor function. However, they may provide a 
means for investigating the stabilising interactions in the ghrelin-R further and may give more 
detailed insight into the mechanisms involved in ghrelin-R constitutive activity. Residue 3.62 
has been found to be involved in stabilising interactions in the constitutively active β2AR 
(Rasmussen et al., 2007) and it may therefore be advantageous to extend this investigation to 
incorporate Val
3.62
 of the ghrelin-R.  
 
In Chapter 4, Tyr
5.58
 was found to be important in maintaining ghrelin-R constitutive activity 
and in restraining ghrelin-induced activation, preventing hyperstimulation of the receptor. The 
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alanine substitution resulted in a dramatic increase in ghrelin efficacy, increasing signalling to 
224 % of the WT receptor after stimulation with 1 µM ghrelin. In contrast, the Y5.58Q 
mutation reduced signalling Emax. Residue 5.58 has been implicated in G-protein coupling and 
in G-protein selectivity in other Family A GPCRs and it would therefore be of interest to 
determine whether mutation of Tyr
5.58
 in the ghrelin-R alters G-protein selectivity and to 
further investigate the mechanisms by which alanine substitution causes such a dramatic 
increase in ghrelin efficacy.              
 
The results from the mutagenesis study and the molecular modelling carried out by N. Floquet 
(Montpellier, France) implicated residues 6.33 and 6.34 in ghrelin-R constitutive and agonist-
induced activation. Further mutagenesis studies could be conducted at these two positions to 
determine the roles that Thr
6.33
 and Val
6.34
 play in the WT ghrelin-R. Mutating Thr
6.33
 to a 
negatively charged residue may stabilise an inactive receptor conformation through an 
interaction with Arg
3.50
, especially in the context of an H6.30K background. Similarly, 
mutation of Val
6.34
 to a negative charge as conducted in the CB2 receptor (Feng et al., 2003) 
and µ-OR (Huang et al., 2001), might reveal more about the molecular mechanisms involved 
in ghrelin-R activity. The positive charge introduction in the ghrelin-R V6.34K mutant did not 
increase the constitutive activity, and so had the opposite effect to that observed in many other 
Family A GPCRs. It would therefore be of interest to see the effect of a negative charge at this 
position on basal signalling.  
 
In ECL2, interactions have been proposed between residues within the loop and charged 
residues at the extracellular ends of the TM domains in other members of the GPCR 
superfamily. The results of this study have lead to the proposal of an interaction between 
Asn196 and Glu
3.33
 at the top of TMIII in the ghrelin-R. Further site-directed mutagenesis 
including reciprocal mutations would aid the investigation into potential interactions within 
the extracellular domain of the ghrelin-R. Furthermore, the effect of the A204E mutation can 
be more extensively investigated with extended mutagenesis of ECL2. The proposed 
interaction between Asn196 and the glutamate in the A204E construct needs to be 
investigated further to probe the exact molecular mechanisms involved in the loss of 
constitutive activity observed in the A204E and N196A mutations.     
 
The future work suggested here may help to build on our findings and extend the molecular 
insight into ghrelin-R structure and the underlying mechanisms of ghrelin-R function, aiding 
Family A GPCR research. 
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CHAPTER 9. 
APPENDIX 
Table 9.1: Colour code for changes in mutant receptor characteristics compared to the WT 
ghrelin-R. 
 
 
 
 
 
 
   Increase in pIC50 > 1 log unit 
Increase in EC50 > 5-fold 
Decrease in basal signalling > 60 %  
Decrease in Emax ≥ WT basal signalling ( 0 % or less) 
Decrease in expression > 70 %  
 
   
   
   
   
   Increase in  pIC50 > 0.75 log unit 
Increase in  EC50 > 4-fold 
Decrease in basal signalling > 40 % 
Decrease in  Emax  > 60 %  
Decrease in expression > 50 % 
 
   
   
   
   
   Increase in  pIC50 > 0.50 log unit 
Increase in  EC50 > 3-fold 
Decrease in basal signalling > 20 %  
Decrease in  Emax > 30 %  
Decrease in expression > 70 % 
 
   
   
   
   
   Decrease in  pIC50 > 0.50 log unit 
Decrease in  EC50 > 3-fold 
Increase in basal signalling > 10 % 
Increase in  Emax  > 130 % 
Increase in expression > 130 % 
 
   
   
   
   
   Decrease in  pIC50 > 0.75 log unit 
Decrease in  EC50 > 4-fold 
Increase in basal signalling > 40 % 
Increase in  Emax  > 160 % 
Increase in expression > 150 % 
 
   
   
   
   
   Decrease in  pIC50 > 1 log unit 
Decrease in  EC50 > 5-fold 
Increase in basal signalling > 60 % 
Increase in  Emax  > 190 % 
Increase in expression > 170 % 
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Table 9.2: Data in main text for InsP-InsP3 accumulation is presented as EC50 (nM) ± spread 
of the 95 % confidence interval. For clarity and ease of comparison, EC50 are quoted in nM. 
To complete the data and enable correct analysis of the SEM of the EC50, this table is 
included of pEC50 ± SEM for the WT ghrelin-R and all mutant ghrelin-R constructs studied. 
 
Construct 
 
 
pEC50 ± SEM 
 
WT ghrelin-R 8.67 ± 0.01 
N1.50A 8.59 ± 0.03 
T2.39A 8.35 ± 0.15 
M2.46A 8.84 ± 0.04 
D2.50A 8.70 ± 0.10 
C3.25A No detectable signal 
S3.32A 8.76 ± 0.01 
C3.35A 9.07 ± 0.07 
T3.36A 7.87 ± 0.07 
T3.36C 8.65 ± 0.03 
T3.36F 9.18 ± 0.08 
T3.36M 8.87 ± 0.07 
T3.36S 9.07 ± 0.07 
T3.42A 9.08 ± 0.05 
I3.43A 8.93 ± 8.13 
I3.43R 8.00 ± 0.02 
T3.44A 8.09 ± 0.04 
L3.46A 7.79 ± 0.04 
L3.46I 9.18 ± 0.18 
L3.46M 8.54 ± 0.01 
S3.47A No detectable signal 
E3.49A No detectable signal 
E3.49D 8.14 ± 0.01 
E3.49Q 8.97 ± 29.3 
E3.49R No detectable signal 
R3.50A No detectable signal 
R3.50E 8.21 ± 0.04 
R3.50H 7.79 ± 0.04 
R3.50L 7.12 ± 0.07 
R3.50K 8.00 ± 0.07 
R3.50Q 8.20 ± 0.01 
Y3.51A 8.67 ± 0.02 
A3.60Y 8.69 ± 0.10 
T2.39A/A3.60Y No detectable signal 
W4.50A No detectable signal 
N188A 8.76 ± 0.02 
T190A 8.35 ± 0.02 
N196A 7.65 ± 0.02 
E197A 8.02 ± 0.06 
C198A No detectable signal 
C116A/C198A No detectable signal 
R199A 8.88 ± 0.02 
P200A 8.52 ± 0.03 
T201A 8.05 ± 0.02 
E202A 8.44 ± 0.06 
F203A 8.96 ± 0.04 
  
 
Construct 
 
 
pEC50 ± SEM 
 
F203G 8.93 ± 0.01 
A204G 8.73 ± 0.01 
A204E 8.79 ± 0.07 
A204V 8.77 ± 0.04 
P5.50A 8.03 ± 0.05 
Y5.58A 8.07 ± 0.02 
Y5.58Q 8.27 ± 0.02 
H6.30A 8.52 ± 0.02 
H6.30D 8.90 ± 0.68 
H6.30E 8.62 ± 0.04 
H6.30K 8.36 ± 0.01 
H6.30Q 8.78 ± 0.09 
H6.30R 8.52 ± 0.02 
Q6.32A 8.70 ± 0.05 
Q6.32E 8.90 ± 0.02 
T6.33A 8.91 ± 60.8 
T6.33V 8.62 ± 0.12 
V6.34A 8.62 ± 0.07 
V6.34K 8.56 ± 0.02 
V6.34T 8.75 ± 0.08 
M6.36A 8.71 ± 0.01 
L6.37A 8.81 ± 0.10 
L6.37I 8.71 ± 0.04 
L6.37M 8.29 ± 0.02 
L6.37T 8.96 ± 0.05 
V6.40A No detectable signal 
V6.40F 8.09 ± 0.03 
V6.40M 8.34 ± 0.05 
V6.40Y No detectable signal 
W6.48A 7.58 ± 0.09 
W6.48F 7.80 ± 0.05 
W6.48Y 7.83 ± 0.06 
P6.50A 8.08 ± 0.06 
R6.55A No detectable signal 
A204E/R6.55A No detectable signal 
K6.60A 8.83 ± 0.01 
A204E/K6.60A 7.84 ± 0.06 
S7.45A 8.24 ± 0.06 
S7.45N 9.22 ± 0.04 
N7.49A 8.39 ± 0.03 
P7.50A 8.31 ± 0.02 
I7.51A 8.78 ± 0.01 
L7.52A 8.50 ± 0.02 
Y7.53A 8.78 ± 0.06 
K7.58A 8.75 ± 0.05 
K7.59A 9.22 ± 0.10 
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Figure 9.3 Residues mutated in the ghrelin-R as part of this study: schematic representation of the ghrelin-R showing the residues mutated in 
this study (blue). HA-epitope tag introduced at the N-terminus is shown in purple.  
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Figure 9.4 Ghrelin binding affinity: schematic representation of the ghrelin-R summarising the effects of individual alanine substitutions on 
ghrelin binding affinity. See Table 9.1 for colour code. HA-epitope tag introduced at the N-terminus is shown in purple.    
 
„WT-like‟ ghrelin binding affinity 
Residue not mutated to alanine in this study 
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Figure 9.5 Ghrelin potency: schematic representation of the ghrelin-R summarising the effects of individual alanine substitutions on ghrelin 
potency. See Table 9.1 for colour code. HA-epitope tag introduced at the N-terminus is shown in purple.   
 
„WT-like‟ ghrelin potency 
Residue not mutated to alanine in this study 
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Figure 9.6 Ghrelin-R basal activity: schematic representation of the ghrelin-R summarising the effects of individual alanine substitutions on 
basal signalling. See Table 9.1 for colour code. HA-epitope tag introduced at the N-terminus is shown in purple.   
 
„WT-like‟ basal activity 
Residue not mutated to alanine in this study 
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Figure 9.7 Ghrelin efficacy: schematic representation of the ghrelin-R summarising the effects of individual alanine substitutions on ghrelin 
efficacy. See Table 9.1 for colour code. HA-epitope tag introduced at the N-terminus is shown in purple.    
 
„WT-like‟ ghrelin efficacy 
Residue not mutated to alanine in this study 
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Figure 9.8 Receptor cell-surface expression: schematic representation of the ghrelin-R summarising the effects of individual alanine 
substitutions on receptor cell-surface expression. See Table 9.1 for colour code.  HA-epitope tag introduced at the N-terminus is shown in 
purple.   
„WT-like‟ cell-surface expression 
Residue not mutated to alanine in this study 
